<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>NYSE_EVDY_2014</title><style type="text/css"> * {margin:0; padding:0; text-indent:0; }
 .s1 { color: #BFD730; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 50.5pt; }
 .s3 { color: #F99B1E; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 89pt; }
 .s4 { color: #72915D; font-family:"Times New Roman", serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 61pt; }
 .s7 { color: #313F52; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 47pt; }
 .s8 { color: #9599B1; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 47pt; }
 .s9 { color: #636466; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 10pt; }
 .s10 { color: #636466; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s11 { color: #4BC0AF; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 20pt; }
 .s12 { color: #808285; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 16pt; }
 .s13 { color: #93C43F; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 20pt; }
 .s14 { color: #F99B1E; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 10pt; }
 .s15 { color: #636466; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 .s16 { color: #F99B1E; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 50pt; }
 .s17 { color: #A7A9AC; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 .s18 { color: #4BC0AF; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 9pt; }
 .s19 { color: #808285; font-family:Arial, sans-serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 10pt; }
 h3 { color: #F99B1E; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 20pt; }
 .s20 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 8pt; }
 .s21 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 11pt; }
 h4 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 16.5pt; }
 .s22 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; vertical-align: 2pt; }
 .s23 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 13pt; }
 .s24 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 5.5pt; }
 .s25 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 10pt; }
 .s26 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7pt; }
 .s27 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10.5pt; vertical-align: -1pt; }
 .s28 { color: #4670B1; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 4pt; }
 .s29 { color: #8C8EA5; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5pt; }
 .s30 { color: #41B1DD; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6.5pt; }
 .s31 { color: #8C8EA5; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 4.5pt; }
 .s32 { color: #8C8EA5; font-family:"Times New Roman", serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 4pt; }
 .s33 { color: #757795; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5.5pt; }
 .p, p { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; margin:0pt; }
 .h1 { color: #282A28; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 52pt; }
 .h2 { color: #282A28; font-family:"Times New Roman", serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 43pt; }
 .s34 { color: #9EA1A3; font-family:"Times New Roman", serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 43pt; }
 .s35 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 18pt; }
 .s36 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12pt; }
 .s37 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 20pt; }
 .s38 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 12pt; }
 .s39 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s40 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: underline; font-size: 8pt; }
 .s41 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 .s42 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 .s43 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s44 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: underline; font-size: 8pt; }
 .s45 { color: black; font-family:"Times New Roman", serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .a, a { color: black; font-family:"Times New Roman", serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s46 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s47 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 12pt; }
 .s48 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 8pt; }
 .s49 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: bold; text-decoration: none; font-size: 9pt; }
 .s50 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s51 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: underline; font-size: 10pt; }
 .s52 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 1pt; }
 .s54 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s55 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; vertical-align: 3pt; }
 .s56 { color: black; font-family:"Times New Roman", serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s57 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 1pt; }
 .s58 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 .s59 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: underline; font-size: 9pt; }
 .s60 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7pt; }
 .s61 { color: black; font-family:"Times New Roman", serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s62 { color: #93C43F; font-family:Arial, sans-serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 28pt; }
 .s63 { color: #4BC0AF; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 13pt; }
 .s64 { color: #636466; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s65 { color: #636466; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5.5pt; vertical-align: 3pt; }
 .s66 { color: #636466; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s67 { color: #F99B1E; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 13pt; }
 .s68 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 22pt; }
 .s69 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 11pt; }
 .s70 { color: #FFF; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 li {display: block; }
 #l1 {padding-left: 0pt;counter-reset: c1 21; }
 #l1> li:before {counter-increment: c1; content: counter(c1, upper-latin)" "; color: black; font-style: normal; font-weight: normal; text-decoration: none; }
 #l1> li:first-child:before {counter-increment: c1 0;  }
 #l2 {padding-left: 0pt; }
 #l2> li:before {content: "• "; color: black; font-style: normal; font-weight: normal; text-decoration: none; }
 li {display: block; }
 #l3 {padding-left: 0pt;counter-reset: d1 21; }
 #l3> li:before {counter-increment: d1; content: counter(d1, upper-latin)" "; color: black; font-style: normal; font-weight: normal; text-decoration: none; }
 #l3> li:first-child:before {counter-increment: d1 0;  }
 #l4 {padding-left: 0pt; }
 #l4> li:before {content: "• "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l5 {padding-left: 0pt; }
 #l5> li:before {content: "• "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 li {display: block; }
 #l6 {padding-left: 0pt; }
 #l6> li:before {content: "• "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 li {display: block; }
 #l7 {padding-left: 0pt;counter-reset: f1 21; }
 #l7> li:before {counter-increment: f1; content: counter(f1, upper-latin)" "; color: black; font-style: normal; font-weight: normal; text-decoration: none; }
 #l7> li:first-child:before {counter-increment: f1 0;  }
 #l8 {padding-left: 0pt; }
 #l8> li:before {content: "• "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 li {display: block; }
 #l9 {padding-left: 0pt;counter-reset: g1 1; }
 #l9> li:before {counter-increment: g1; content: "("counter(g1, decimal)") "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l9> li:first-child:before {counter-increment: g1 0;  }
 #l10 {padding-left: 0pt; }
 #l10> li:before {content: "• "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 li {display: block; }
 #l11 {padding-left: 0pt;counter-reset: h1 1; }
 #l11> li:before {counter-increment: h1; content: "("counter(h1, decimal)") "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l11> li:first-child:before {counter-increment: h1 0;  }
 li {display: block; }
 #l12 {padding-left: 0pt;counter-reset: i1 1; }
 #l12> li:before {counter-increment: i1; content: counter(i1, decimal)". "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l12> li:first-child:before {counter-increment: i1 0;  }
 #l13 {padding-left: 0pt;counter-reset: j1 2; }
 #l13> li:before {counter-increment: j1; content: "("counter(j1, lower-roman)") "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l13> li:first-child:before {counter-increment: j1 0;  }
 li {display: block; }
 #l14 {padding-left: 0pt;counter-reset: k1 18; }
 #l14> li:before {counter-increment: k1; content: counter(k1, decimal)". "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l14> li:first-child:before {counter-increment: k1 0;  }
 #l15 {padding-left: 0pt;counter-reset: k2 1; }
 #l15> li:before {counter-increment: k2; content: "("counter(k2, decimal)") "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l15> li:first-child:before {counter-increment: k2 0;  }
 li {display: block; }
 #l16 {padding-left: 0pt;counter-reset: l1 1; }
 #l16> li:before {counter-increment: l1; content: "("counter(l1, decimal)") "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l16> li:first-child:before {counter-increment: l1 0;  }
 li {display: block; }
 #l17 {padding-left: 0pt;counter-reset: m1 1; }
 #l17> li:before {counter-increment: m1; content: "("counter(m1, decimal)") "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l17> li:first-child:before {counter-increment: m1 0;  }
 li {display: block; }
 #l18 {padding-left: 0pt;counter-reset: n1 1; }
 #l18> li:before {counter-increment: n1; content: "("counter(n1, lower-latin)") "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l18> li:first-child:before {counter-increment: n1 0;  }
 #l19 {padding-left: 0pt;counter-reset: n2 1; }
 #l19> li:before {counter-increment: n2; content: "("counter(n2, decimal)") "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l19> li:first-child:before {counter-increment: n2 0;  }
 li {display: block; }
 #l20 {padding-left: 0pt;counter-reset: o1 31; }
 #l20> li:before {counter-increment: o1; content: counter(o1, decimal)" "; color: black; font-style: normal; font-weight: normal; text-decoration: none; }
 #l20> li:first-child:before {counter-increment: o1 0;  }
 #l21 {padding-left: 0pt;counter-reset: o2 1; }
 #l21> li:before {counter-increment: o2; content: counter(o1, decimal)"."counter(o2, decimal)" "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 #l21> li:first-child:before {counter-increment: o2 0;  }
 li {display: block; }
 #l22 {padding-left: 0pt;counter-reset: p1 32; }
 #l22> li:before {counter-increment: p1; content: counter(p1, decimal)" "; color: black; font-style: normal; font-weight: normal; text-decoration: none; }
 #l22> li:first-child:before {counter-increment: p1 0;  }
 #l23 {padding-left: 0pt;counter-reset: p2 1; }
 #l23> li:before {counter-increment: p2; content: counter(p1, decimal)"."counter(p2, decimal)" "; color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 #l23> li:first-child:before {counter-increment: p2 0;  }
</style></head><body><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="27" height="29" alt="image" src="NYSE_EVDY_2014/Image_001.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="27" height="29" alt="image" src="NYSE_EVDY_2014/Image_002.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="51" height="25" alt="image" src="NYSE_EVDY_2014/Image_003.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="117" height="41" alt="image" src="NYSE_EVDY_2014/Image_004.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="103" height="71" alt="image" src="NYSE_EVDY_2014/Image_005.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="76" height="57" alt="image" src="NYSE_EVDY_2014/Image_006.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="31" height="39" alt="image" src="NYSE_EVDY_2014/Image_007.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="24" height="39" alt="image" src="NYSE_EVDY_2014/Image_008.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="34" height="39" alt="image" src="NYSE_EVDY_2014/Image_009.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="58" height="39" alt="image" src="NYSE_EVDY_2014/Image_010.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="31" height="39" alt="image" src="NYSE_EVDY_2014/Image_011.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="11" height="11" alt="image" src="NYSE_EVDY_2014/Image_012.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="1" height="202" alt="image" src="NYSE_EVDY_2014/Image_013.png"/></span></p><p class="s1" style="padding-top: 17pt;padding-left: 292pt;text-indent: 3pt;line-height: 79%;text-align: center;">ANNUAL <span style=" color: #4BC0AF;">REPORT</span></p><p class="s3" style="padding-left: 288pt;text-indent: 0pt;line-height: 82pt;text-align: center;">2O14</p><p style="text-indent: 0pt;text-align: left;"><span><img width="794" height="1044" alt="image" src="NYSE_EVDY_2014/Image_014.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s4" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">, <span style=" color: #9A496B;">&#39;&#39; </span><span style=" color: #313F52;">everyday </span><span class="s7">HEALT H </span><span class="s8">&#39;</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="157" height="221" alt="image" src="NYSE_EVDY_2014/Image_015.png"/></span></p><p class="s9" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Ben Wolin</p><p class="s10" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Chief Executive Officer and Co-Founder</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 37pt;text-indent: 0pt;text-align: left;"><span><img width="72" height="72" alt="image" src="NYSE_EVDY_2014/Image_016.png"/></span></p><p class="s11" style="padding-top: 4pt;padding-left: 45pt;text-indent: 0pt;line-height: 21pt;text-align: left;">51M</p><p class="s12" style="padding-left: 25pt;text-indent: 0pt;line-height: 87%;text-align: center;">monthly consumers</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 37pt;text-indent: 0pt;text-align: left;"><span><img width="72" height="72" alt="image" src="NYSE_EVDY_2014/Image_017.png"/></span></p><p class="s13" style="padding-top: 5pt;padding-left: 192pt;text-indent: 0pt;line-height: 21pt;text-align: center;">2/3</p><p class="s12" style="padding-left: 192pt;text-indent: 0pt;line-height: 16pt;text-align: center;">of practicing</p><p class="s12" style="padding-left: 12pt;text-indent: 0pt;line-height: 17pt;text-align: left;">U.S. physicians</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s14" style="padding-left: 49pt;text-indent: 0pt;line-height: 123%;text-align: left;">veryday HealtH enjoyed a very successful year in 2014. <span class="s15">We completed our initial public offering around the end of the first quarter, achieved strong revenue and adjusted EBITDA growth every quarter, and made</span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="1" height="746" alt="image" src="NYSE_EVDY_2014/Image_018.png"/></span></p><p class="s16" style="text-indent: 0pt;line-height: 54pt;text-align: left;">E</p><p style="text-indent: 0pt;text-align: left;"/><p class="s15" style="padding-left: 24pt;text-indent: 0pt;line-height: 126%;text-align: left;">important investments to take advantage of our great opportunity in the large and fast-changing digital health market.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s15" style="padding-left: 24pt;text-indent: 0pt;text-align: left;">Throughout 2014, we articulated a very clear three-part strategy for success:</p><p class="s17" style="padding-top: 6pt;padding-left: 45pt;text-indent: -9pt;line-height: 126%;text-align: left;">l <span style=" color: #636466;">Deeper engagement with our large and growing audience of consumers and healthcare professionals;</span></p><p class="s17" style="padding-top: 3pt;padding-left: 36pt;text-indent: 0pt;text-align: left;">l <span style=" color: #636466;">Deeper engagement with our customers; and</span></p><p class="s17" style="padding-top: 6pt;padding-left: 45pt;text-indent: -9pt;line-height: 126%;text-align: left;">l <span style=" color: #636466;">Using our existing platform to identify new revenue opportunities across the broader healthcare landscape.</span></p><p class="s15" style="padding-top: 3pt;padding-left: 24pt;text-indent: 0pt;line-height: 126%;text-align: left;">Our performance in 2014 has confirmed for us that this is the right growth strategy for Everyday Health, and executing on this strategy will remain our focus throughout 2015.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s18" style="padding-left: 24pt;text-indent: 0pt;line-height: 126%;text-align: left;">these are exciting times in the digital health sector, and there are also very clear trends that are driving the success of our business. <span class="s15">Digital technology is providing new avenues for consumers to manage their health and for healthcare professionals to stay informed and treat patients. Marketers are increasingly taking advantage of the benefits of digital technology to more efficiently reach and engage their targeted audience, as well as better measure the effectiveness of their marketing dollars. This is especially important for the pharmaceutical industry – our biggest customer category – which has dramatically reduced the sales personnel that directly market their products and has shifted its focus to specialty products for smaller patient populations. Lastly, health insurance companies and hospitals now need to directly engage with consumers in various new ways to recruit customers, improve care and lower costs. These trends, which seem here to stay, are highlighting the importance of the digital health communications platform we have been building since I co-founded the company in a Brooklyn kitchen in 2002.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s18" style="padding-left: 24pt;text-indent: 0pt;line-height: 126%;text-align: left;">We are very pleased with our success in 2014 in driving deeper engagement with our consumers and healthcare professionals – part one of our strategy. <span class="s15">We are humbled by the fact that we can reach around 51 million consumers and two-thirds of all practicing U.S. physicians each month to make better health and wellness decisions.</span></p><p class="s15" style="padding-left: 24pt;text-indent: 0pt;line-height: 126%;text-align: left;">Visits to our flagship properties – Everyday Health, MedPage Today and What to Expect – grew 33% from 2013 to 2014, and our audience spent over one million hours in 2014 engaging with the patient education centers on these flagship sites, up approximately 100% from 2013. This success is rooted in our commitment to providing highly-personalized and engaging content and tools that are trusted, innovative and actionable. Health audiences clearly crave an experience tailored to their individual needs and interests – more than five million people registered with us during 2014 and voluntarily provided us with valuable demographic information and health-related</p><p class="s19" style="text-indent: 0pt;line-height: 11pt;text-align: right;">continued</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 37pt;text-indent: 0pt;text-align: left;"><span><img width="72" height="72" alt="image" src="NYSE_EVDY_2014/Image_019.png"/></span></p><h3 style="padding-top: 4pt;padding-left: 38pt;text-indent: 0pt;line-height: 21pt;text-align: left;">65M+</h3><p class="s12" style="padding-left: 193pt;text-indent: 0pt;line-height: 87%;text-align: center;">registered users</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;line-height: 10pt;text-align: left;"><span><img width="157" height="14" alt="image" src="NYSE_EVDY_2014/Image_020.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;text-align: left;"><span><img width="157" height="30" alt="image" src="NYSE_EVDY_2014/Image_021.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s15" style="padding-left: 25pt;text-indent: 0pt;line-height: 126%;text-align: left;">interests, taking us over 65 million registered users since our inception. We expect 2015 to be another year of unrelenting focus on providing the best suite of digital health content and tools across the industry.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="1" height="746" alt="image" src="NYSE_EVDY_2014/Image_022.png"/></span></p><p class="s18" style="padding-left: 25pt;text-indent: 0pt;line-height: 126%;text-align: left;">Deeper engagement with our customers – the second part of our strategy – was a clear highlight of 2014. <span class="s15">Our innovative and data-driven marketing programs have proven to be very effective and increasingly help drive the success of our customers. We focus heavily on deepening our partnerships with our largest customers – as these pharmaceutical and consumer-packaged-goods customers are some of the</span></p><p class="s15" style="padding-left: 25pt;text-indent: 0pt;line-height: 126%;text-align: left;">largest companies in the world, have hundreds of brands to market and represent the majority of marketing dollars in our category. In 2014, our top 30 strategic customers increased their spend with us 29% over 2013, representing 74% of our total advertising and sponsorship revenue in 2014. We expect more of the same in 2015 as dollars continue to shift to digital and away from TV advertising and direct pharma sales- forces – larger and more strategic partnerships with the leading pharmaceutical and health-focused companies in the world.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s18" style="padding-left: 25pt;text-indent: 0pt;line-height: 126%;text-align: left;">We made significant strides in 2014 to extend our existing platform to focus on new revenue opportunities across the broader healthcare landscape – part three of our strategy. <span class="s15">We are confident that, given the dramatic changes in the way healthcare is delivered and paid for in the U.S., we have a large opportunity to utilize our audience, content and data assets to address the important business challenges for health insurers and hospitals. During 2014, we took the important first steps of establishing a dedicated unit to focus on this area and hiring experienced personnel who will define the priorities and execute the strategy in this growth area in the coming years.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s15" style="padding-left: 25pt;text-indent: 0pt;line-height: 126%;text-align: left;">Identifying financially prudent acquisition opportunities that advance our three- pronged strategy may also continue to be an important element of our growth plans. In November 2014, we acquired DoctorDirectory.com – which provides direct to physician multi-channel marketing solutions for late-stage pharmaceutical brands – to accelerate our growth in the large healthcare professional sector. The total amount spent on marketing to healthcare professionals is more than double the amount spent targeting consumers, and we have a lot of running room to increase our direct to physician pharmaceutical revenues in the coming years.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s15" style="padding-left: 25pt;text-indent: 0pt;line-height: 126%;text-align: left;">In March 2015, we acquired Cambridge BioMarketing – the leader in strategic marketing solutions for orphan and rare disease products. Products for orphan and rare diseases are an important growth area across the pharmaceutical industry, and we plan to use the Everyday Health audience, content and data assets to enhance the market-leading marketing solutions offered by Cambridge BioMarketing. We believe the DoctorDirectory.com and Cambridge BioMarketing acquisitions make us the premier digital partner for the leading pharmaceutical companies across their</p><p class="s15" style="padding-left: 25pt;text-indent: 0pt;line-height: 10pt;text-align: left;">entire portfolio. We can now service these pharmaceutical partners across the entire</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s15" style="padding-top: 5pt;padding-left: 6pt;text-indent: 0pt;line-height: 126%;text-align: left;">spectrum of their therapeutic areas – orphan, specialty and mass market brands – and across the entire lifecycle of pharmaceutical marketing – from pre-launch, throughout the growth years and even beyond patent exclusivity.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s15" style="padding-left: 6pt;text-indent: 0pt;line-height: 126%;text-align: left;">Our strong financial results in 2014 are perhaps the best indicator that our strategy is working. Our advertising and sponsorship revenue grew 23% in 2014, while total revenue growth was approximately 18%. Significantly, mobile continues to be a successful delivery channel for our advertising and sponsorship programs. Our mobile revenue grew 82% in 2014, representing 37% of our total revenue in 2014. This solid revenue growth was accompanied by an even larger improvement in our adjusted EBITDA – which increased 66% in 2014. As we said throughout 2014, we</p><p class="s15" style="padding-left: 6pt;text-indent: 0pt;line-height: 126%;text-align: left;">are committed to driving profitable growth and we are confident that we can achieve our long-term adjusted EBITDA margin goals of 30% to 35%.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s18" style="padding-left: 6pt;text-indent: 0pt;line-height: 126%;text-align: left;">Our first year as a publicly-traded company was an outstanding year for Everyday Health, and we finished the year with solid momentum across the business.</p><p class="s15" style="padding-left: 6pt;text-indent: 0pt;line-height: 126%;text-align: left;">With the acquisition of Cambridge BioMarketing, 2015 is also off to a great start. We expect another year of strong revenue growth, expanding adjusted EBITDA margins and continued investment in our future growth. Our success continues to be driven by the dedication and perseverance of our 650 employees, and I would like to recognize the entire Everyday Health team for their contributions to an excellent year and a very bright future.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s15" style="padding-left: 6pt;text-indent: 0pt;line-height: 126%;text-align: left;">As we continue on our journey, all of us at Everyday Health are thankful for your ongoing confidence.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 63pt;text-indent: 0pt;text-align: left;"><span><img width="210" height="46" alt="image" src="NYSE_EVDY_2014/Image_023.jpg"/></span></p><p class="s9" style="padding-top: 2pt;padding-left: 78pt;text-indent: 0pt;text-align: left;">Ben Wolin</p><p class="s10" style="padding-top: 1pt;padding-left: 78pt;text-indent: 0pt;text-align: left;">Chief Executive Officer and Co-Founder</p><p class="s12" style="padding-top: 5pt;padding-left: 19pt;text-indent: 20pt;line-height: 87%;text-align: left;">Advertising and Sponsorship</p><p style="text-indent: 0pt;text-align: left;"><span><img width="1" height="746" alt="image" src="NYSE_EVDY_2014/Image_024.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="162" height="173" alt="image" src="NYSE_EVDY_2014/Image_025.png"/></span></p><p class="s12" style="padding-left: 200pt;text-indent: 0pt;line-height: 16pt;text-align: center;">Revenue</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s20" style="padding-left: 200pt;text-indent: 0pt;line-height: 8pt;text-align: center;">2012-2014</p><p class="s21" style="padding-left: 200pt;text-indent: 0pt;line-height: 11pt;text-align: center;">CAGR</p><h4 style="padding-left: 200pt;text-indent: 0pt;line-height: 18pt;text-align: center;">20%</h4><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-left: 1pt;text-indent: 0pt;line-height: 14pt;text-align: left;">$<span class="s23">115</span></p><p class="s24" style="padding-left: 2pt;text-indent: 0pt;line-height: 6pt;text-align: left;">MILLION</p><p class="s22" style="padding-left: 1pt;text-indent: 0pt;line-height: 14pt;text-align: left;">$<span class="s23">135</span></p><p class="s24" style="padding-left: 2pt;text-indent: 0pt;line-height: 6pt;text-align: left;">MILLION</p><p class="s22" style="padding-left: 1pt;text-indent: 0pt;line-height: 14pt;text-align: left;">$<span class="s23">166</span></p><p class="s24" style="padding-left: 2pt;text-indent: 0pt;line-height: 6pt;text-align: left;">MILLION</p><p style="padding-left: 28pt;text-indent: 0pt;text-align: left;">  </p><p class="s25" style="padding-left: 7pt;text-indent: 0pt;line-height: 11pt;text-align: left;">2012 2013 2014</p><p style="padding-left: 21pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="162" height="173" alt="image" src="NYSE_EVDY_2014/Image_026.png"/></span></p><p class="s12" style="padding-left: 200pt;text-indent: 0pt;line-height: 87%;text-align: center;">Adjusted EBITDA</p><p class="s20" style="padding-top: 13pt;padding-left: 199pt;text-indent: 0pt;line-height: 8pt;text-align: center;">2012-2014</p><p class="s21" style="padding-left: 199pt;text-indent: 0pt;line-height: 11pt;text-align: center;">CAGR</p><p class="s25" style="padding-left: 7pt;text-indent: 0pt;line-height: 11pt;text-align: left;">2012 2013 2014</p><p style="text-indent: 0pt;text-align: left;"/><p class="s26" style="padding-left: 1pt;text-indent: 0pt;line-height: 10pt;text-align: center;">$<span class="s27">7</span></p><p class="s24" style="padding-left: 1pt;text-indent: 0pt;line-height: 5pt;text-align: center;">MILLION</p><p style="text-indent: 0pt;text-align: left;"/><h4 style="padding-bottom: 3pt;padding-left: 199pt;text-indent: 0pt;line-height: 18pt;text-align: center;">120%</h4><p class="s22" style="padding-left: 4pt;text-indent: 0pt;line-height: 14pt;text-align: left;">$<span class="s23">22</span></p><p class="s24" style="padding-left: 2pt;text-indent: 0pt;line-height: 6pt;text-align: left;">MILLION</p><p class="s22" style="padding-left: 4pt;text-indent: 0pt;line-height: 14pt;text-align: left;">$<span class="s23">36</span></p><p class="s24" style="padding-left: 2pt;text-indent: 0pt;line-height: 6pt;text-align: left;">MILLION</p><p style="padding-left: 65pt;text-indent: 0pt;text-align: left;"> </p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="655" height="517" alt="image" src="NYSE_EVDY_2014/Image_027.png"/></span></p><p class="s28" style="padding-left: 131pt;text-indent: 0pt;line-height: 5pt;text-align: left;">0 <span class="s29">a.lNttShodc.,,_</span></p><p class="s31" style="padding-left: 131pt;text-indent: 0pt;line-height: 6pt;text-align: left;"><span class="s30">o </span>Out <span class="s32">o( </span>HCV Thmpy</p><ol id="l1"><ul id="l2"><li style="padding-top: 2pt;padding-left: 196pt;text-indent: -65pt;text-align: left;"><p class="s33" style="display: inline;">IIGIIIWllllllll</p></li></ul></ol><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 17pt;text-indent: 0pt;text-align: left;"><span><img width="63" height="60" alt="image" src="NYSE_EVDY_2014/Image_028.jpg"/></span>    <span class="h1">everyday </span><span class="h2">H EA LTH</span><span class="s34">®</span></p><p style="padding-left: 7pt;text-indent: 0pt;line-height: 4pt;text-align: left;"><span><img width="670" height="5" alt="image" src="NYSE_EVDY_2014/Image_029.png"/></span></p><p class="s35" style="padding-top: 3pt;padding-left: 32pt;text-indent: 0pt;line-height: 19pt;text-align: center;">UNITED STATES</p><p class="s35" style="padding-left: 32pt;text-indent: 0pt;line-height: 19pt;text-align: center;">SECURITIES AND EXCHANGE  COMMISSION</p><p class="s36" style="padding-bottom: 2pt;padding-left: 32pt;text-indent: 0pt;line-height: 13pt;text-align: center;">Washington,  D.C. 20549</p><p style="padding-left: 210pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="128" height="1" alt="image" src="NYSE_EVDY_2014/Image_030.png"/></span></p><p class="s37" style="padding-top: 1pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">FORM 10-K</p><p style="padding-left: 7pt;text-indent: 0pt;line-height: 12pt;text-align: left;">(Mark One)</p><p class="s38" style="padding-left: 31pt;text-indent: -23pt;text-align: left;">� <span class="s36">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><p style="padding-left: 158pt;text-indent: 0pt;line-height: 112%;text-align: center;">For the fiscal year ended December 31, 2014 or</p><p class="s38" style="padding-left: 7pt;text-indent: 0pt;line-height: 13pt;text-align: left;">□ <span class="s36">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE</span></p><p class="s36" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">SECURITIES EXCHANGE ACT OF 1934</p><p style="padding-bottom: 1pt;padding-left: 179pt;text-indent: -58pt;line-height: 112%;text-align: left;">For the transition period from to Commission file number: 001-36371</p><p style="padding-left: 210pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="128" height="1" alt="image" src="NYSE_EVDY_2014/Image_031.png"/></span></p><p class="s35" style="padding-top: 3pt;padding-left: 32pt;text-indent: 0pt;line-height: 20pt;text-align: center;">Everyday  Health, Inc.</p><p class="s39" style="padding-left: 32pt;text-indent: 0pt;line-height: 8pt;text-align: center;">(Exact name of registrant as specified in its charter)</p><p style="padding-top: 3pt;padding-left: 108pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Delaware</p><p class="s39" style="padding-left: 100pt;text-indent: 0pt;line-height: 87%;text-align: center;">(State or other jurisdiction of incorporation or organization)</p><p style="padding-top: 2pt;padding-left: 100pt;text-indent: 0pt;text-align: center;">345 Hudson Street, 16th Floor New York, NY</p><p class="s39" style="padding-left: 100pt;text-indent: 0pt;line-height: 9pt;text-align: center;">(Address of principal executive  offices)</p><p style="padding-top: 3pt;padding-left: 32pt;text-indent: 0pt;line-height: 11pt;text-align: center;">80-0036062</p><p class="s39" style="padding-left: 32pt;text-indent: 0pt;line-height: 9pt;text-align: center;">(I.R.S. Employer Identification  No.)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 32pt;text-indent: 0pt;line-height: 11pt;text-align: center;">10014</p><p class="s39" style="padding-left: 32pt;text-indent: 0pt;line-height: 9pt;text-align: center;">(Zip Code)</p><p class="s39" style="padding-top: 3pt;padding-left: 32pt;text-indent: 0pt;line-height: 9pt;text-align: center;">Registrant’s telephone number, including area code: (646) 728-9500</p><p class="s39" style="padding-left: 32pt;text-indent: 0pt;line-height: 9pt;text-align: center;">Securities registered pursuant to Section 12(b) of the Act:</p><p class="s40" style="padding-top: 2pt;padding-left: 107pt;text-indent: 0pt;text-align: left;">Title of class<span class="s39"> </span>Name of each exchange on which registered</p><p style="padding-top: 5pt;padding-left: 10pt;text-indent: 0pt;text-align: center;">Common  Stock,  $0.01  par  value  per  share                               New  York  Stock  Exchange</p><p style="padding-top: 3pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">Securities registered pursuant to Section 12(g) of the Act:</p><p style="padding-bottom: 2pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">None</p><p style="padding-left: 210pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="128" height="1" alt="image" src="NYSE_EVDY_2014/Image_032.png"/></span></p><p class="s41" style="padding-top: 4pt;padding-left: 7pt;text-indent: 17pt;text-align: left;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES <span class="s42">□ </span>NO <span class="s42">�</span></p><p class="s41" style="padding-left: 7pt;text-indent: 17pt;text-align: left;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES <span class="s42">□ </span>NO <span class="s42">�</span></p><p class="s41" style="padding-left: 7pt;text-indent: 17pt;text-align: justify;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES <span class="s42">� </span>NO <span class="s42">□</span></p><p class="s41" style="padding-left: 7pt;text-indent: 17pt;text-align: left;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES <span class="s42">� </span>NO <span class="s42">□</span></p><p class="s41" style="padding-left: 7pt;text-indent: 17pt;text-align: justify;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. <span class="s42">�</span></p><p class="s41" style="padding-left: 7pt;text-indent: 17pt;text-align: left;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.</p><p class="s41" style="padding-top: 2pt;padding-left: 7pt;text-indent: 0pt;text-align: left;">Large accelerated filer <span class="s42">□ </span>Accelerated filer <span class="s42">□</span></p><p class="s41" style="padding-top: 1pt;padding-left: 7pt;text-indent: 0pt;text-align: left;">Non-accelerated filer <span class="s42">� </span>(Do not check if smaller reporting company) Smaller reporting company <span class="s42">□</span></p><p class="s41" style="padding-left: 7pt;text-indent: 17pt;text-align: left;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES <span class="s42">□ </span>NO <span class="s42">�</span></p><p class="s41" style="padding-left: 7pt;text-indent: 17pt;text-align: left;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $330.0 million as of the last business day of the registrant’s most recently completed second fiscal quarter, based upon the closing price on the New York Stock Exchange reported for such date. Excludes an aggregate of 12,522,930 shares of the registrant’s common stock held as of such date by officers, directors and stockholders that the registrant has concluded are or were affiliates of the registrant. Exclusion of such shares should not be construed to indicate that the holder of any such shares possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.</p><p class="s41" style="padding-bottom: 4pt;padding-left: 25pt;text-indent: 0pt;text-align: left;">There were 31,526,949 shares of the registrant’s common stock issued and outstanding as of February 27, 2015.</p><p style="padding-left: 210pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="128" height="1" alt="image" src="NYSE_EVDY_2014/Image_033.png"/></span></p><p class="s41" style="padding-top: 7pt;padding-left: 146pt;text-indent: 0pt;text-align: left;">DOCUMENTS INCORPORATED BY REFERENCE</p><p class="s41" style="padding-bottom: 4pt;padding-left: 7pt;text-indent: 17pt;text-align: left;">Part III incorporates information by reference from the registrant’s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, in connection with the Registrant’s 2015 Annual Meeting of Stockholders.</p><p style="padding-left: 7pt;text-indent: 0pt;line-height: 4pt;text-align: left;"><span><img width="670" height="5" alt="image" src="NYSE_EVDY_2014/Image_034.png"/></span></p><table style="border-collapse:collapse;margin-left:28.8255pt" cellspacing="0"><tr style="height:75pt"><td style="width:48pt" rowspan="3"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:387pt"><p class="s43" style="padding-left: 69pt;padding-right: 92pt;text-indent: 0pt;line-height: 10pt;text-align: center;">EVERYDAY HEALTH, INC.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-left: 69pt;padding-right: 92pt;text-indent: 0pt;text-align: center;">FORM 10-K</p><p class="s43" style="padding-left: 69pt;padding-right: 92pt;text-indent: 0pt;text-align: center;">FOR THE YEAR ENDED DECEMBER 31, 2014</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-left: 69pt;padding-right: 92pt;text-indent: 0pt;text-align: center;">TABLE  OF CONTENTS</p></td><td style="width:24pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:387pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:24pt"><p class="s44" style="padding-top: 3pt;padding-right: 2pt;text-indent: 0pt;text-align: right;">Page</p></td></tr><tr style="height:17pt"><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-left: 69pt;padding-right: 69pt;text-indent: 0pt;text-align: center;">PART I</p></td><td style="width:24pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:16pt"><td style="width:48pt"><p class="s43" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 1.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-right: 4pt;text-indent: 0pt;text-align: right;">Business..... ......... ......... ......... .......... ......... ......... ......... ........ </p></td><td style="width:24pt"><p class="s43" style="padding-top: 1pt;padding-right: 3pt;text-indent: 0pt;text-align: right;">3</p></td></tr><tr style="height:16pt"><td style="width:48pt"><p class="s43" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 1A.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-right: 4pt;text-indent: 0pt;text-align: right;">Risk Factors ......... ......... ......... .......... ......... ......... ......... ........ </p></td><td style="width:24pt"><p class="s43" style="padding-top: 1pt;padding-right: 3pt;text-indent: 0pt;text-align: right;">24</p></td></tr><tr style="height:16pt"><td style="width:48pt"><p class="s43" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 1B.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-right: 4pt;text-indent: 0pt;text-align: right;">Unresolved Staff Comments. . . ......... .......... ......... ......... ......... ........ </p></td><td style="width:24pt"><p class="s43" style="padding-top: 1pt;padding-right: 3pt;text-indent: 0pt;text-align: right;">46</p></td></tr><tr style="height:16pt"><td style="width:48pt"><p class="s43" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 2.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-right: 4pt;text-indent: 0pt;text-align: right;">Properties . . . ......... ......... ......... .......... ......... ......... ......... ........ </p></td><td style="width:24pt"><p class="s43" style="padding-top: 1pt;padding-right: 3pt;text-indent: 0pt;text-align: right;">46</p></td></tr><tr style="height:16pt"><td style="width:48pt"><p class="s43" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 3.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-right: 4pt;text-indent: 0pt;text-align: right;">Legal Proceedings.... ......... ......... .......... ......... ......... ......... ........ </p></td><td style="width:24pt"><p class="s43" style="padding-top: 1pt;padding-right: 3pt;text-indent: 0pt;text-align: right;">46</p></td></tr><tr style="height:18pt"><td style="width:48pt"><p class="s43" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 4.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-right: 4pt;text-indent: 0pt;text-align: right;">Mine Safety Disclosures....... ......... .......... ......... ......... ......... ........ </p></td><td style="width:24pt"><p class="s43" style="padding-top: 1pt;padding-right: 3pt;text-indent: 0pt;text-align: right;">46</p></td></tr><tr style="height:20pt"><td style="width:48pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:387pt"><p class="s43" style="padding-top: 3pt;padding-left: 69pt;padding-right: 69pt;text-indent: 0pt;text-align: center;">PART II</p></td><td style="width:24pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:30pt"><td style="width:48pt"><p class="s43" style="padding-top: 3pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 5.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 3pt;padding-left: 16pt;text-indent: -9pt;text-align: left;">Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities ....... .......... ......... ......... ......... ........ </p></td><td style="width:24pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">47</p></td></tr><tr style="height:16pt"><td style="width:48pt"><p class="s43" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 6.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-right: 4pt;text-indent: 0pt;text-align: right;">Selected Consolidated Financial Data . . .......... ......... ......... ......... ........ </p></td><td style="width:24pt"><p class="s43" style="padding-top: 1pt;padding-right: 3pt;text-indent: 0pt;text-align: right;">49</p></td></tr><tr style="height:28pt"><td style="width:48pt"><p class="s43" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 7.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-left: 16pt;padding-right: 5pt;text-indent: -9pt;text-align: left;">Management’s Discussion and Analysis of Financial Condition and Results of Operations ......... ......... ......... .......... ......... ......... ......... ........ </p></td><td style="width:24pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">52</p></td></tr><tr style="height:16pt"><td style="width:48pt"><p class="s43" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 7A.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-right: 4pt;text-indent: 0pt;text-align: right;">Quantitative and Qualitative Disclosures About Market Risk ...... ......... ........ </p></td><td style="width:24pt"><p class="s43" style="padding-top: 1pt;padding-right: 3pt;text-indent: 0pt;text-align: right;">69</p></td></tr><tr style="height:16pt"><td style="width:48pt"><p class="s43" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 8.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-right: 4pt;text-indent: 0pt;text-align: right;">Financial Statements and Supplementary Data . . . ......... ......... ......... ........ </p></td><td style="width:24pt"><p class="s43" style="padding-top: 1pt;padding-right: 3pt;text-indent: 0pt;text-align: right;">71</p></td></tr><tr style="height:28pt"><td style="width:48pt"><p class="s43" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 9.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-left: 16pt;padding-right: 5pt;text-indent: -9pt;text-align: left;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure ......... ......... ......... .......... ......... ......... ......... ........ </p></td><td style="width:24pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">104</p></td></tr><tr style="height:16pt"><td style="width:48pt"><p class="s43" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 9A.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-right: 4pt;text-indent: 0pt;text-align: right;">Controls and Procedures ...... ......... .......... ......... ......... ......... ........ </p></td><td style="width:24pt"><p class="s43" style="padding-top: 1pt;padding-right: 3pt;text-indent: 0pt;text-align: right;">104</p></td></tr><tr style="height:18pt"><td style="width:48pt"><p class="s43" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 9B.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-right: 4pt;text-indent: 0pt;text-align: right;">Other Information . . . ......... ......... .......... ......... ......... ......... ........ </p></td><td style="width:24pt"><p class="s43" style="padding-top: 1pt;padding-right: 3pt;text-indent: 0pt;text-align: right;">104</p></td></tr><tr style="height:20pt"><td style="width:48pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:387pt"><p class="s43" style="padding-top: 3pt;padding-left: 69pt;padding-right: 69pt;text-indent: 0pt;text-align: center;">PART III</p></td><td style="width:24pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:18pt"><td style="width:48pt"><p class="s43" style="padding-top: 3pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 10.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 3pt;padding-right: 4pt;text-indent: 0pt;text-align: right;">Directors, Executive Officers and Corporate Governance . ......... ......... ........ </p></td><td style="width:24pt"><p class="s43" style="padding-top: 3pt;padding-right: 3pt;text-indent: 0pt;text-align: right;">105</p></td></tr><tr style="height:16pt"><td style="width:48pt"><p class="s43" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 11.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-right: 4pt;text-indent: 0pt;text-align: right;">Executive Compensation ...... ......... .......... ......... ......... ......... ........ </p></td><td style="width:24pt"><p class="s43" style="padding-top: 1pt;padding-right: 3pt;text-indent: 0pt;text-align: right;">105</p></td></tr><tr style="height:28pt"><td style="width:48pt"><p class="s43" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 12.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-left: 16pt;text-indent: -9pt;text-align: left;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters ........ ......... .......... ......... ......... ......... ........ </p></td><td style="width:24pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">105</p></td></tr><tr style="height:16pt"><td style="width:48pt"><p class="s43" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 13.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-right: 4pt;text-indent: 0pt;text-align: right;">Certain Relationships and Related Transactions, and Director Independence ....... </p></td><td style="width:24pt"><p class="s43" style="padding-top: 1pt;padding-right: 3pt;text-indent: 0pt;text-align: right;">105</p></td></tr><tr style="height:18pt"><td style="width:48pt"><p class="s43" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 14.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-right: 4pt;text-indent: 0pt;text-align: right;">Principal Accounting Fees and Services .......... ......... ......... ......... ........ </p></td><td style="width:24pt"><p class="s43" style="padding-top: 1pt;padding-right: 3pt;text-indent: 0pt;text-align: right;">105</p></td></tr><tr style="height:20pt"><td style="width:48pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:387pt"><p class="s43" style="padding-top: 3pt;padding-left: 69pt;padding-right: 69pt;text-indent: 0pt;text-align: center;">PART IV</p></td><td style="width:24pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:18pt"><td style="width:48pt"><p class="s43" style="padding-top: 3pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Item 15.</p></td><td style="width:387pt"><p class="s43" style="padding-top: 3pt;padding-right: 4pt;text-indent: 0pt;text-align: right;">Exhibits, Financial Statement Schedules.......... ......... ......... ......... ........ </p></td><td style="width:24pt"><p class="s43" style="padding-top: 3pt;padding-right: 3pt;text-indent: 0pt;text-align: right;">106</p></td></tr><tr style="height:13pt"><td style="width:48pt"><p class="s43" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Signatures</p></td><td style="width:387pt"><p class="s43" style="padding-top: 1pt;padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">...... ......... ......... ......... ......... .......... ......... ......... ......... ........ </p></td><td style="width:24pt"><p class="s43" style="padding-top: 1pt;padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: right;">110</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Except as otherwise indicated herein or as the context otherwise requires, references in this Annual Report on Form 10-K to “Everyday Health,” “the company,” “we,” “us,” “our” and similar references refer to Everyday Health, Inc. and, where appropriate, our subsidiaries. This report contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing in this report are the property of their respective holders.</p><p style="padding-top: 2pt;padding-left: 239pt;text-indent: 0pt;text-align: left;">PART I</p><p class="s45" style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. All statements other than statements of historical facts are “forward-looking statements” for purposes of these provisions, including those relating to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend” or “continue,” the negative of terms like these or other comparable terminology, and other words or terms of similar meaning in connection with any discussion of future operating or financial performance. These statements are only predictions. All forward-looking statements included in this Annual Report on Form 10-K are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. Any or all of our forward- looking statements in this document may turn out to be wrong. Actual events or results may differ materially. Our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks, uncertainties and other factors. We discuss many of these risks, uncertainties and other factors in this Annual Report on Form 10-K in greater detail under the heading “Item 1A—Risk Factors.” We caution investors that our business and financial performance are subject to substantial risks and uncertainties.</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;line-height: 24pt;text-align: left;">Item 1. Business.</p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 24pt;text-align: left;">Mission</p><p style="padding-top: 5pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Everyday Health empowers and inspires consumers and healthcare professionals to make better health and wellness decisions.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Overview</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We are a leading provider of digital health and wellness solutions. We combine premier digital content from leading health brands with sophisticated data and analytics technology to provide a highly personalized and differentiated content experience to our users. In December 2014, we estimate that 47 million consumers and approximately two-thirds of all practicing physicians in the</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">U.S. engaged with our health and wellness properties across multiple channels, including the web, mobile devices, video and social media. Our content portfolio and data and analytics expertise provide marketers with a compelling platform to promote their products and services in a highly targeted and measurable manner, influence purchase decisions and drive better health compliance. We believe that we are well positioned to capitalize on new revenue opportunities presented by the growing importance of consumer engagement, data and analytics and digital technologies in the rapidly evolving health and wellness industries. We have begun to utilize our existing content, large audience and sophisticated technology platform to enable healthcare payors, providers and employers to drive consumer engagement, improve health outcomes and reduce healthcare costs.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We provide consumers and healthcare professionals with a multi-brand, multi-channel content experience that can be accessed anytime and anywhere a health-related decision is made. The <i>Everyday Health </i>portfolio of properties currently consists of approximately 25 websites, 21 mobile applications and a number of social media destinations. Our portfolio includes leading brands such as <i>Everyday Health</i>, <i>MedPage Today</i>, <i>DoctorDirectory.com</i>, <i>What to Expect</i>, <i>Jillian Michaels </i>and <i>The South Beach Diet</i>, and incorporates content from highly respected health authorities such as Dr.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Sanjay Gupta. The <i>Everyday Health </i>portfolio also includes properties that we do not own or operate, such as <i>MayoClinic.org </i>and <i>Drugstore.com</i>, but that we help monetize by selling advertisements and sponsorships. Consumers use our content, interactive tools and mobile applications to manage a broad array of health and wellness needs on a daily basis, including weight loss, exercise, healthy pregnancy, diet and nutrition and medical conditions. We also provide</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">healthcare professionals with news, tools and information needed to stay abreast of industry, legislative and regulatory developments in major medical specialties. Because consumers and healthcare professionals increasingly access our content through mobile devices, we have optimized our platform for mobile access. We currently offer 21 mobile applications, which have been downloaded over 18 million times.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our premium content has enabled us to aggregate a large and engaged audience of consumers and healthcare professionals. Since our inception, over 65 million consumers have registered with us and voluntarily provided us with valuable data, including demographic information and health- related interests. We augment our user profiles by collecting behavioral data through engagement with our properties and appending data from third party sources. Our proprietary technology utilizes the data we collect to provide a highly personalized experience for our users, including customized content, to drive better health outcomes and to connect users looking for support. For example, during 2014, approximately two million expectant mothers created a customized pregnancy calendar on our <i>What to Expect </i>property. In addition, users logged approximately 1.8 billion total calories and lost approximately 4.2 million pounds on the <i>Everyday Health </i>portfolio as part of customized diet and fitness programs in 2014.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We derive a significant majority of our revenues from the sale of advertising, sponsorships and other marketing solutions that engage consumers and healthcare professionals. We have developed strong relationships with marketers across a variety of health and wellness categories, including pharmaceuticals, over-the-counter products, food, retail and lifestyle. For example, during 2014, our customers included six of the top ten global advertisers in 2013, as compiled by Advertising Age, and 23 of the top 25 global pharmaceutical companies ranked by 2013 revenue. We specialize in providing these marketers with highly-customized, data-driven marketing solutions that can precisely target niche health audiences, and which are designed to be effective on a desktop or mobile device. Our innovative programs, which utilize sophisticated campaign analytics to measure and maximize a marketer’s return on investment, or ROI, have been instrumental in significantly growing our revenue among our largest customers. We believe our customers view our data-driven marketing solutions as both superior to traditional media channels, which lack interactivity and the ability to measure and optimize ROI in real time, and superior to other online media channels, which lack the data or technology to target the desired audience or measure the effectiveness of the campaign.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Industry Dynamics</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The U.S. healthcare industry is undergoing a profound transformation whereby consumers will likely be more directly engaged in managing their health and making health-related purchase decisions. At the same time, digital technology is providing new avenues for consumers to manage their health, healthcare professionals to stay informed and treat patients, marketers to reach and influence customers, and payors to improve care and lower cost.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Growth in Digital Marketing</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Marketers increasingly view digital marketing as providing significant advantages over traditional marketing channels through improved reach and more precise targeting for their campaigns, as well as the ability to maximize ROI in a more measurable and data-driven manner. We believe the benefits of digital marketing will continue to change the way advertisers plan and buy media and cause them to shift more of their budgets away from traditional media. According to published reports, digital advertising is projected to grow from 22.3% of all U.S. media advertising spend in 2012 to 37.3% in 2018, at which time digital advertising is projected to become the largest individual advertising medium.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: justify;">Health and wellness advertisers are likewise expected to increase their digital marketing spending. According to published reports, digital media spending by the U.S. healthcare and pharmaceutical industry will more than double between 2012 and 2018.</p><p class="s45" style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Rising Importance of the Health Consumer</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Internet has fundamentally altered the consumer health market, as more consumers use digital media as a convenient resource for obtaining critical information, making health and lifestyle decisions and using decision-support tools. During 2014, on average, approximately 181 million unique visitors accessed health-related websites per month in the U.S., according to comScore.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The widespread adoption of mobile devices is further accelerating the usage of the Internet and other digital services to manage a healthy lifestyle. Mobile devices make health-related information easy to access anytime and anywhere, and an increasing number of mobile applications and digitally- connected devices are allowing consumers to directly manage and monitor their health in unprecedented ways. For example, consumers are using mobile technology to track caloric intake and fitness performance, seek information about medical symptoms and conditions, communicate with healthcare professionals, and measure vital signs.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Significant changes in the delivery and reimbursement of healthcare are going to substantially increase the number of healthcare consumers and their level of personal investment in healthcare spending. According to the U.S. Department of Health and Human Services, more than eight million new consumers selected an insurance plan through the Affordable Care Act’s health insurance marketplace in the first enrollment period. In addition, consumers are being forced to bear more of their healthcare costs as a result of the changes caused by the Affordable Care Act as well as payors seeking to link healthcare coverage to personal behavioral and health characteristics. As a result, more consumers will be incentivized to take a greater interest in the price of healthcare, understanding their treatment options and improving their overall health.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Challenges for the Pharmaceutical Industry</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The pharmaceutical industry is facing a number of key challenges that we believe will dramatically increase the need for these companies to interact with consumers and physicians more directly through digital channels.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The research and development pipelines of large global pharmaceutical companies have significantly changed over the past decade. The patent terms of many of the mass-market medicines, the so-called blockbuster drugs, have expired or will expire in the next five years. In response, pharmaceutical companies have shifted their focus from blockbuster drugs to developing and commercializing profitable specialty products for smaller patient populations generally defined by chronic illness. According to published reports, specialty drugs are forecasted to be 50% of all U.S. drug expenditures in 2018, an increase from 20% in 2009. We believe it is difficult to reach smaller, discrete patient populations through traditional advertising channels and, as a result, pharmaceutical companies will increasingly utilize digital channels to better target consumers and physicians.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Moreover, pharmaceutical companies are increasingly changing their traditional sales model and replacing in-person interactions with technology and interactive services that facilitate direct interaction with physicians and consumers. The number of sales representatives employed by pharmaceutical and medical device companies marketing to physicians has declined dramatically in recent years. At the same time, sales representatives are also finding it more difficult to spend meaningful time with physicians as an increasing number of physicians have requested sales representatives refrain from contacting them for marketing purposes.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Healthcare Trends Impacting Physicians and Payors</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">The changing healthcare landscape is presenting new and complex challenges for physicians.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Physicians are seeking ways to address growing administrative complexities, increasing reimbursement pressures, time constraints and a constantly changing regulatory environment. Under developing payment models, physicians are increasingly incentivized to improve their patients’ healthcare outcomes as opposed to being reimbursed solely based on services provided. Physicians are also overburdened with information and challenged with keeping current on medical</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">developments and news. As a result, physicians are increasingly utilizing digital and mobile solutions to meet these challenges, improve practice efficiencies and patient care and keep current on medical developments and news. For example, physicians need access to relevant and reliable clinical information at the point-of-care to help make informed decisions. We believe that physicians will increasingly rely on the Internet and digital technologies to stay better informed on medical developments, provide better care for their patients and more efficiently manage their medical practices.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The changes in the payment models for healthcare costs are forcing payors, providers and employers to significantly alter the way they manage their businesses. For example, payors seeking to recruit new consumers, better manage their health outcomes and drive down overall healthcare costs will need to market health insurance products directly to consumers through the recently introduced healthcare exchanges. These payors will need a better understanding of who the consumer is, what they want and what they can afford, which are challenges that these entities have not historically addressed. Likewise, providers will seek to develop long-term relationships with consumers in order to retain them and improve their long-term health. Lastly, employers will need to more directly engage their employees in managing their health in order to lower the employers’ long-term healthcare costs and improve productivity.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">The Everyday Health Solution</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We have attracted a large and engaged user base of consumers and healthcare professionals to our premium health and wellness properties and utilize our data and analytics expertise to deliver highly personalized user experiences and efficient and effective marketing and engagement solutions.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The combination of our large and registered user base, premier health and wellness brands, content and tools, and proprietary data assets and personalization technology, creates a unique health engagement platform that we can monetize to address the varied business needs of constituencies across the health and wellness landscape. Our key competitive advantages include the following:</p><ol id="l3"><ul id="l4"><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p class="s45" style="display: inline;">Portfolio Management. <span class="p">Our ability to curate and cross-promote a broad array of premier content across the </span>Everyday Health <span class="p">portfolio, which includes many of the most trusted brands in health and wellness, has allowed us to aggregate a highly engaged audience of consumers and healthcare professionals through online and mobile channels.</span></p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p class="s45" style="display: inline;">Proprietary Data and Analytics Expertise. <span class="p">Our robust data assets and our expertise in managing large amounts of internal and external data enable us to offer a superior experience for our users and marketers. Our sophisticated data and analytics capabilities allow us to personalize our content offerings, optimize advertising performance in real time and provide marketers with targeted solutions for their campaigns.</span></p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p class="s45" style="display: inline;">Measurable ROI for Marketers. <span class="p">We have developed a differentiated process to prove ROI for our clients by working closely with third party vendors, such as IMS and Crossix, to independently measure the impact of our programs, including measuring increases in brand awareness and sales. This research allows us to optimize our campaigns and demonstrate a positive ROI for our customers.</span></p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p class="s45" style="display: inline;">Strategic Relationships with Brand Advertisers. <span class="p">We have built deep relationships with many leading brand advertisers and advertising agencies that view us as a strategic and trusted partner for complex digital marketing initiatives that target specific population sets with personalized content and messaging.</span></p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p class="s45" style="display: inline;">Powerful Network Effects. <span class="p">Our content personalization capabilities and ability to develop sophisticated marketing programs continuously improve as our database expands. This self- reinforcing network effect helps enhance our brand, improves user engagement and attracts new users to our properties.</span></p><p class="s45" style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Benefits to Consumers</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We believe that the depth, breadth and quality of our content, combined with our ability to provide a highly personalized experience across multiple channels, enable consumers to better manage their health and wellness needs.</p><p class="s45" style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Broad Portfolio of Trusted Websites. <span class="p">We have designed the </span>Everyday Health <span class="p">portfolio, which includes premier brands and digital properties, to provide multiple sources of reliable and personalized content to satisfy the diverse needs of our consumer audience. Our portfolio of owned or operated properties includes </span>Everyday Health, What to Expect, Dr. Sanjay Gupta, DoctorDirectory.com <span class="p">and </span>Jillian Michaels. <span class="p">These owned or operated properties account for the majority of the consumer traffic to our portfolio. Our portfolio also includes properties that we do not own or operate, such as </span>MayoClinic.org <span class="p">and </span>Drugstore.com. <span class="p">We cross-promote our content on different properties and allow consumers to search for the most relevant content across the entire portfolio. Our ability to cross-promote our content in this manner enables our consumers to benefit from the full spectrum of content across the portfolio.</span></p><p class="s45" style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Engaging Content and Community Features. <span class="p">We have devoted significant resources to developing engaging content, interactive tools and community features that allow consumers to readily access health and wellness content to help manage their daily lives and address specific concerns. For example, in 2014, users spent over one million hours in our online patient education centers. In addition, we actively utilize video and social media channels to engage our consumers in new ways and to promote our content more broadly. We also have created numerous community environments that empower consumers to share information and interact with each other. During 2014, our users posted over nine million comments in community forums on our </span>What to Expect <span class="p">property.</span></p><p class="s45" style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Personalization of the Content Experience. <span class="p">Since our inception, over 65 million consumers have voluntarily registered with us, and we have separately developed over 235 million anonymous health consumer profiles that have been used to personalize content for our unregistered consumers. We utilize this information, as well as proprietary predictive modeling, to provide consumers with more specific content, features and tools that are intended to better meet their needs. For example, consumers can research specific symptoms and create personalized tools, including pregnancy calendars, calorie counters, meal plans and drug alerts. During 2014, more than two million consumers utilized our various diet and fitness tools and we distributed over 200 million opt-in newsletters per month with content specifically tailored to the consumers’ individual interests. The data we gather from each incremental engagement with our properties by a user, whether or not registered, enhances our ability to personalize content we deliver to our users. We believe our data- driven approach to delivering a more personalized user experience is a key differentiator between us and our competitors.</span></p><p class="s45" style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Multi-Channel Approach. <span class="p">We develop our health and wellness content to be distributed across multiple channels and to be accessible anytime and anywhere. In addition to the many websites we operate within the </span>Everyday Health <span class="p">portfolio, we offer 18 consumer mobile applications that are available for use on the iPhone, iPad, Android and Android Tablet. Our mobile applications provide a broad array of features, including customized exercise programs, tailored meal recommendations, video tutorials and tools to track daily performance against goals, which enable our consumers to manage their health and wellness needs throughout the day. We continually seek to build our brands and promote our content in innovative ways that are designed to expand our footprint, including through video and social media channels.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Benefits to Healthcare Professionals</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We believe that we offer healthcare professionals compelling solutions that enable them to stay better informed of medical information and to practice more efficiently.</p><p class="s45" style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Premier Content. <span class="p">We provide premier content that enables healthcare professionals to stay abreast of clinical, industry, legislative and regulatory developments across all major medical</span></p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">specialties. Our flagship professional property, <i>MedPage Today, </i>employs a dedicated team of 35 journalists, including editors, reporters and videographers, and provides relevant clinical news based on research findings published in peer-reviewed medical journals as well as research reported at numerous medical conferences around the world. <i>MedPage Today </i>delivers breaking medical news in over 30 specialties and major public policy developments at the state and federal levels seven days a week. We also partner with prominent healthcare professionals, including Dr. Sanjay Gupta,</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Dr. Kevin Pho and Dr. David Nash, to provide expert commentary and perspectives on important medical developments.</p><p class="s45" style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Practice Tools and Access. <span class="p">We have designed our content offerings to be utilized by healthcare professionals at the point-of-care. Our two </span>MedPage Today <span class="p">mobile applications, which are offered on the Apple and Android platforms and have generated over 800,000 downloads, include breaking medical news, comprehensive reference information and regulatory alerts and announcements. Our healthcare professionals are highly engaged with our mobile applications. For example, in 2014, our </span>MedPage Today <span class="p">properties received an average of 2.5 million visits per month and approximately 55% of the visits to </span>MedPage Today <span class="p">occurred during the practice hours of 8 a.m. through 6 p.m. In addition to our point-of-care tools, through our partnership with Projects In Knowledge, a provider of continuing medical education programs, we offer physicians the ability to satisfy their continuing medical education, or CME, requirements for maintenance of licensure and maintenance of certification through engagement with our news content. Furthermore, in November 2014, we acquired DoctorDirectory.com, which provides healthcare professionals the opportunity to participate in market research and other programs that help shape the healthcare industry, as well as request samples online.</span></p><p class="s45" style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Multiple Distribution Channels. <span class="p">We facilitate access to our high quality news content through various channels. In addition to our </span>MedPage Today <span class="p">properties, we distribute our content through partnerships with premier medical associations, including the American College of Cardiology, the American Heart Association, the American Academy of Neurology and The Endocrine Society. We also syndicate our content to numerous hospitals across the U.S. These affiliations and syndication arrangements have resulted in significant growth in our audience and engagement with our content. For example, annual visits by healthcare professionals to </span>MedPage Today <span class="p">increased approximately 41% from 2013 to 2014.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Benefits to Marketers</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We believe our portfolio of premier health and wellness content and data and analytics capabilities enable our advertising customers to efficiently and effectively reach and engage with their target audience.</p><p class="s45" style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Large and Engaged Audience. <span class="p">Our </span>Everyday Health <span class="p">portfolio attracts a large number of visitors, making it attractive to advertisers in light of the highly fragmented nature of the online health and wellness market. We believe that the overall size, scale and composition of the </span>Everyday Health <span class="p">portfolio, as well as the discrete categories within the portfolio, provide advertisers with significant flexibility to undertake multiple advertising strategies through a single platform, whether focused on a national, regional or local audience. In December 2014, we estimate that 47 million consumers and approximately two-thirds of all practicing physicians in the U.S. interacted with our health and wellness properties. Based on a survey we conducted in 2014, approximately 83% of our consumer audience visited a physician in the last six months and approximately 48% expected to visit a physician within one month.</span></p><p class="s45" style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">High Quality and Trusted Portfolio. <span class="p">Most marketers are highly sensitive to promoting their products and services in an environment that will not diminish the value of their brand. The </span>Everyday Health <span class="p">portfolio provides marketers with a trusted platform to promote their offerings, including a suite of customized marketing solutions, such as targeted display advertising, interactive brand sponsorships, custom e-mail campaigns, lead generation or customer acquisition initiatives.</span></p><p class="s45" style="padding-top: 2pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Targeted and Innovative Solutions. <span class="p">Our portfolio provides marketers with a compelling opportunity to reach consumers and healthcare professionals in a contextually-relevant environment. Our focus on customized offerings, combined with our engaged user base, allows advertisers to effectively target their desired audience through highly immersive interactive campaigns. Our database of information voluntarily provided by millions of registered users facilitates marketing campaigns directed at specific geographic areas, demographic groups, interests, issues or user communities. We believe our recent acquisition of DoctorDirectory.com will further improve our ability to target healthcare professionals, specifically those healthcare professionals not being covered by a pharmaceutical sales representative, and offer our customers marketing solutions that reach their widest target audience and best drive their overall results. In addition, through our </span>Health Reach <span class="p">marketing programs, we utilize our data assets and predictive modeling expertise to design marketing campaigns that retarget our audience beyond the </span>Everyday Health <span class="p">portfolio. As a result, we are able to deliver efficient campaigns for mass and niche target audiences across the entire health and wellness spectrum both on and off our portfolio.</span></p><p class="s45" style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Measurable ROI. <span class="p">We believe a key differentiator of our business is our ability to use our extensive data assets to provide marketers with more significant and measurable ROI relative to offline and other online channels. We provide our marketers with detailed post-campaign reporting that allows them to measure and evaluate the effectiveness of their campaigns. Many of our large advertising campaigns also include specific ROI goals which we are able to effectively measure due to our large opt-in registration database. By virtue of our DoctorDirectory.com acquisition, we now conduct certain marketing campaigns that provide for revenues based entirely upon the ROI we deliver for our customers. By partnering with industry-leading data companies that anonymously match a user’s online campaign exposure to their offline purchase decisions, we can further provide a demonstrable and third-party verified ROI measurement that reflects sales impact.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Benefits to Payors, Providers and Employers</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: justify;">We are developing various products and services for payors, providers and employers to utilize our scaled and targeted database of consumers and customized engagement solutions, enabling such constituents to attract and retain consumers and influence their behavior in order to improve health outcomes and reduce the cost of care.</p><p class="s45" style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Innovative Consumer Engagement Platform. <span class="p">Payors, providers and employers will likely need to more directly engage consumers as the enactment of the Affordable Care Act, increased availability of healthcare data and changes to reimbursement models have put a greater emphasis on health outcomes and costs. Our trusted health and wellness content, tools and community features, which are tailored to meet our consumers’ interests and needs, generate high levels of engagement. This consumer engagement is valuable to payors, providers and employers that are increasingly seeking digital solutions for targeted populations to make more informed health decisions and better manage medical conditions and their daily health across areas such as nutrition, stress, physical activity and weight loss. Lowering healthcare costs is a critical area of focus for these entities and driving better health compliance is an important avenue for achieving this goal.</span></p><p class="s45" style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Efficient Consumer Acquisition Vehicle. <span class="p">As payors increasingly need to market their products and services more directly to consumers, the ability to efficiently market to targeted consumer populations is critical for a wide variety of insurance companies and other payors. For example, payors are increasingly marketing health insurance products directly to consumers through the recently introduced healthcare exchanges or as part of Medicare Advantage. We believe payors will increasingly seek access to our large and engaged user base, proprietary personalization technology and predictive modeling tools to recruit consumers and efficiently manage their marketing spend. As a result, we believe that our platform will be an attractive recruitment vehicle for payors to engage with the right consumer set through innovative digital solutions both on and off our portfolio.</span></p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Our Portfolio and Content</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Our Portfolio</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The properties in the <i>Everyday Health </i>portfolio, which include websites, mobile applications and social media assets, are designed to provide consumers and healthcare professionals with access to the most trusted health and wellness content tailored to meet their daily needs. These properties fall into one of the following categories: (i) properties that we own; (ii) properties that we operate in partnership with leading offline providers of health content or prominent health and wellness experts and personalities; and (iii) properties where we manage and sell advertising opportunities on behalf of partners. Our portfolio currently consists of approximately 25 websites. Between 2010 and 2014, visits to <i>Everyday Health</i>, our flagship consumer property, have increased approximately 26% on a compounded annual basis and visits to <i>MedPage Today</i>, our flagship professional property, have increased approximately 41% on a compounded annual basis. We also have devoted significant resources to developing our mobile applications. We currently offer 21 mobile applications, which have been downloaded more than 18 million times. During 2014, we averaged 49 million monthly visits to the mobile properties we operate. The <i>Everyday Health </i>portfolio also includes a number of social media destinations.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The properties that we own and operate include, among others, <i>Everyday Health</i>, <i>MedPage Today </i>and <i>DoctorDirectory.com. </i>The following table lists some of the properties that we own and operate.</p><p class="s40" style="padding-top: 8pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Brand<span class="s39"> </span>Description                                                                                          </p><p class="s45" style="padding-top: 5pt;padding-left: 264pt;text-indent: -233pt;text-align: left;">Everyday Health Everyday Health <a href="http://www.EverydayHealth.com/" class="s46" target="_blank">is our flagship brand. </a>www.EverydayHealth.com <span class="p">is a broad-based health information website targeting a consumer audience and offering content created by experienced health writers. The content and tools, including the related mobile applications, provide consumers with deep and rich health information intended to empower users to better manage their health and wellness on a daily basis.</span></p><p class="s45" style="padding-top: 8pt;padding-left: 264pt;text-indent: -233pt;text-align: left;"><a href="http://www.MedPageToday.com/" class="a" target="_blank">MedPage Today </a>www.MedPageToday.com <span class="p">provides physicians and other healthcare professionals with peer- reviewed breaking medical news across all key</span></p><p style="padding-left: 264pt;text-indent: 0pt;text-align: left;">medical practice areas, as well as the opportunity to receive free CME credits. Our <i>MedPage Today </i>mobile applications enable physicians to access critical practice information at the point- of-care.</p><p class="s45" style="padding-top: 7pt;padding-left: 264pt;text-indent: -233pt;text-align: left;"><a href="http://www.DoctorDirectory.com/" class="a" target="_blank">DoctorDirectory.com </a>www.DoctorDirectory.com <span class="p">provides healthcare professionals with a suite of content and tools, including </span>MedPage Today <span class="p">news, continuing medical education, market research opportunities and the ability to request samples online.</span></p><p class="s45" style="padding-top: 7pt;padding-left: 264pt;text-indent: -233pt;text-align: left;"><a href="http://www.CarePages.com/" class="a" target="_blank">CarePages </a>www.CarePages.com <span class="p">is a social support website for families experiencing critical care events. The website is an important tool for hospitals that want to provide additional emotional support for patients and their families.</span></p><p class="s45" style="padding-top: 4pt;padding-left: 264pt;text-indent: -233pt;text-align: left;"><a href="http://www.My-Calorie-Counter.com/" class="a" target="_blank">My Calorie Counter </a>www.My-Calorie-Counter.com <span class="p">and the related mobile application contain a suite of calorie and nutrition tools that provide consumers with the ability to easily track food and nutrient intake and calorie burn based on a large database of commonly consumed foods.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 19pt;text-align: left;">We also partner with leading health, diet and fitness experts, personalities and brands to provide our users with access to trusted and reliable content across the health spectrum. These partners include, among others, <i>What to Expect</i>, <i>Jillian Michaels</i>, <i>The South Beach Diet, the Mayo Clinic Diet </i>and <i>Dr. Sanjay Gupta. </i>With respect to these brands, we typically license the exclusive digital rights to their proprietary content and develop digital properties utilizing such content that we then monetize at our discretion either through subscriptions and/or advertising models. Since inception, over two million consumers have purchased subscriptions to one of our health, diet and fitness properties. The following table lists some of the brands we operate in partnerships with leading providers of health content.</p><p class="s40" style="padding-top: 8pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Brand<span class="s39"> </span>Description                                                                                          </p><p class="s45" style="padding-top: 5pt;padding-left: 264pt;text-indent: -233pt;text-align: left;">What to Expect <span class="p">Based on the best-selling pregnancy book, </span>What to Expect When You’re Expecting<a href="http://www.WhattoExpect.com/" class="s46" target="_blank">, by author Heidi Murkoff, </a>www.WhattoExpect.com <span class="p">contains content written by Ms. Murkoff on conception planning and pregnancy, as well as information on newborns and toddlers. The </span>What to Expect <span class="p">Pregnancy Tracker is currently one of the most popular pregnancy mobile applications.</span></p><p class="s45" style="padding-top: 7pt;padding-left: 264pt;text-indent: -233pt;text-align: left;">Jillian Michaels <a href="http://www.JillianMichaels.com/" class="s46" target="_blank">Jillian Michaels is a bestselling author, Daytime Emmy nominated television personality, entrepreneur, and a leading health and wellness experts. Subscribers to </a>www.JillianMichaels.com <span class="p">get access to Ms. Michaels’ program for healthy weight loss, which includes a fitness program, menus and meal plans, videos and interactive tools.</span></p><p class="s45" style="padding-top: 8pt;padding-left: 264pt;text-indent: -233pt;text-align: left;">South Beach Diet <a href="http://www.SouthBeachDiet.com/" class="s46" target="_blank">Based on the best-selling diet book written by South Beach preventive cardiologist, Arthur Agatston, </a>www.SouthBeachDiet.com <span class="p">contains multiple tools for managing diet and measuring weight loss.</span></p><p class="s45" style="padding-top: 7pt;padding-left: 264pt;text-indent: -233pt;text-align: left;">Dr. Sanjay Gupta <a href="http://www.EverydayHealth.com/" class="s46" target="_blank">Dr. Sanjay Gupta, chief medical correspondent for CNN and contributor to “60 Minutes,” contributes real-life perspective and advice on health and condition news aimed at consumers on </a>www.EverydayHealth.com. <a href="http://www.MedPageToday.com/" class="s46" target="_blank">Dr. Gupta also provides healthcare professionals with his perspectives on critical medical news and developments on </a><a href="http://www.MedPageToday.com/" target="_blank">www.MedPageToday.com.</a></p><p class="s45" style="padding-top: 4pt;padding-left: 264pt;text-indent: -233pt;text-align: left;">Mayo Clinic Diet <a href="http://www.Diet.MayoClinic.org/" class="s46" target="_blank">The Mayo Clinic Diet is a plan for weight loss, and ultimately better health, developed by the weight loss experts at Mayo Clinic. Based on the bestselling book by the same name, The Mayo Clinic Diet online program at </a>www.Diet.MayoClinic.org <span class="p">lays out a step-by-step program to jump-start quick weight loss, achieve a goal weight and maintain it for life.</span></p><p class="s45" style="padding-top: 7pt;padding-left: 264pt;text-indent: -233pt;text-align: left;">Meredith Vieira <a href="http://www.EverydayHealth.com/" class="s46" target="_blank">Meredith Vieira, journalist and host of The Meredith Vieira Show, leads conversations about health and wellness aimed at consumers on </a>www.EverydayHealth.com. <span class="p">Ms. Vieira focuses on topics ranging from stress management and healthy eating, to caring for a loved one with a chronic condition or dealing with a serious diagnosis.</span></p><p class="s45" style="padding-top: 7pt;padding-left: 264pt;text-indent: -233pt;text-align: left;">Randy Jackson <span class="p">Randy Jackson, music industry veteran and diabetes advocate, mentors and inspires people living with diabetes through blogs and videos on the </span>Everyday Health <span class="p">portfolio. As part of the “Diabetes Step-by-Step” initiative, Mr. Jackson has created a multimedia platform that provides education and support for people living with diabetes.</span></p><p class="s45" style="padding-top: 8pt;padding-left: 264pt;text-indent: -233pt;text-align: left;">Physicians’ Desk Reference <a href="http://www.PDRHealth.com/" class="s46" target="_blank">As the consumer web portal of the PDR Network, which includes the Physicians’ Desk Reference, </a>www.PDRHealth.com <span class="p">offers consumer-friendly explanations of disease states and conditions, as well as the safe and effective use of prescription drugs, non-prescription drugs and herbal medicines.</span></p><p class="s45" style="padding-top: 7pt;padding-left: 264pt;text-indent: -233pt;text-align: left;">Suzanne Somers’ Sexy Forever <a href="http://www.SexyForever.com/" class="s46" target="_blank">Suzanne Somers’ </a>www.SexyForever.com <span class="p">provides users with tools and tips to uncover and overcome obstacles to losing weight.</span></p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The <i>Everyday Health </i>portfolio also includes properties that we do not own or operate, but rather with whom we partner to manage and sell advertising opportunities. These properties, which include <i>MayoClinic.org </i>and <i>Drugstore.com</i>, among others, provide our users with access to a broader array of in-depth health information and services while broadening the audience for our advertising customers. The following table lists some of the brands with whom we have such partnering relationships.</p><p class="s45" style="padding-top: 4pt;padding-left: 264pt;text-indent: -233pt;text-align: left;">Mayo Clinic <a href="http://www.MayoClinic.org/" class="s46" target="_blank">Produced by a team of Mayo Clinic experts, </a>www.MayoClinic.org <span class="p">gives users access to the expertise and knowledge of thousands of Mayo Clinic physicians and scientists and offers health information to help users assess symptoms, understand their diagnosis and manage their health.</span></p><p class="s45" style="padding-top: 7pt;padding-left: 264pt;text-indent: -233pt;text-align: left;"><a href="http://www.Drugstore.com/" class="a" target="_blank">Drugstore </a>www.Drugstore.com <span class="p">is a leading e-commerce provider of health, beauty, vision and pharmacy products.</span></p><p class="s45" style="padding-top: 7pt;padding-left: 264pt;text-indent: -233pt;text-align: left;">KevinMD <a href="http://www.KevinMD.com/" class="s46" target="_blank">Founded by Kevin Pho, MD, </a>www.KevinMD.com <span class="p">is a leading destination for physician insight on breaking medical news. This website, in partnership with our </span>MedPage Today <span class="p">property, provides Dr. Pho’s unique perspective as a practicing physician.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Our Content</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We place great emphasis on providing trusted and high quality content and tools for our users, as well as vibrant digital communities in which our users can engage directly with each other on specific health topics. To personalize the user experience, our users are encouraged to voluntarily provide us with demographic and other personal information so we can tailor the content and functionality that they receive from us. We believe that our focus on personalization has been critical in fostering a highly engaged user base.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our editorial and product teams are responsible for creating original content and/or licensing third-party content to support the offerings (other than user-generated content) that are available on the properties that we operate. Our proprietary content is created by experienced health and medical writers, editors, videographers, designers and product specialists who create original articles and columns, videos, slideshows, quizzes and interactive graphics across the portfolio. Our innovative content offerings, including a variety of fitness and health tracking tools, interactive slideshows, health assessments, pregnancy calendars and meal planners, are designed to leverage the interactive capabilities of the Internet and allow for dynamic personalization. Our clinical content on <i>MedPage Today</i>, which provides breaking medical news to physicians and other healthcare professionals, is reviewed and approved by a team of physicians under the direction of Projects In Knowledge. We have also embraced social media as an increasingly valuable channel in which to engage our users on a real-time basis.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In addition, in 2013, we expanded our content offerings by partnering with the Mayo Clinic to develop an online health management platform that provides health assessment tools, lifestyle education, health coaching and wellness information to employers and healthcare providers. This platform is designed to support current healthcare initiatives by empowering users to understand their health risks, focus on health and disease prevention, make incremental behavior changes for a healthier lifestyle and find reliable answers to health-related questions.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We believe that our large and highly engaged audience, premier portfolio of brands and data and analytics expertise will allow us to continue to provide highly personalized health and wellness content offerings to our users wherever and however they want it.</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The following table outlines certain of the key content offerings available on our operated properties:</p><p class="s40" style="padding-top: 8pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Content Offering<span class="s39"> </span>Description                                                                                             </p><p style="padding-top: 5pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Everyday Health/Healthy Living Content Original daily and weekly content, which is</p><p style="padding-left: 258pt;text-indent: 0pt;text-align: left;">medically reviewed where appropriate, that offers information, advice and inspiration for those seeking to live healthier lives or who face medical challenges. Content includes relevant, consumer- focused coverage of research published in peer- reviewed medical journals or presented at major medical conferences.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Health Condition and Drug Encyclopedia Wellness and prevention information and advice</p><p style="padding-left: 258pt;text-indent: 0pt;text-align: left;">from leading fitness experts, as well as condition definitions, symptom lists, common treatments and drug information from healthcare authorities.</p><p style="padding-top: 7pt;padding-left: 258pt;text-indent: -227pt;text-align: left;">Health News Coverage of major public health, regulatory and consumer health stories designed to separate fact from fiction and offer actionable messages to health and condition audiences.</p><p style="padding-top: 7pt;padding-left: 258pt;text-indent: -227pt;text-align: left;">Original Video Health videos that focus on people living active, healthy lives, as well as those coping with chronic conditions. Programming that offers expert insight into emerging health trends and important research.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Interactive Slideshows and Graphics Original health content presented in high impact</p><p style="padding-left: 258pt;text-indent: 0pt;text-align: left;">graphical formats, including sequenced photo galleries where consumers may explore wellness trends, health conditions or medical news.</p><p style="padding-top: 7pt;padding-left: 258pt;text-indent: -227pt;text-align: left;">Expert and Patient Perspective Columns and Q&amp;As by leading experts and patient advocates that provide explanation and perspective on condition and wellness topics, including heart disease, depression, psoriasis, multiple sclerosis and cancer, as well as nutrition, weight loss, fitness and longevity.</p><p style="padding-top: 7pt;padding-left: 258pt;text-indent: -227pt;text-align: left;">Health Assessments Quizzes and algorithmic-based intake exams designed to help users assess their risk of developing particular conditions, or the likelihood that they need to seek health care for particular symptoms.</p><p style="padding-top: 7pt;padding-left: 258pt;text-indent: -227pt;text-align: left;">Health Tools Tools that offer users actionable information and/or allow them to track their progress in meeting health challenges and goals over time. Our tools include:</p><p class="s40" style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Content Offering<span class="s39"> </span>Description                                                                                             </p><ul id="l5"><li style="padding-top: 5pt;padding-left: 270pt;text-indent: -11pt;text-align: left;"><p style="display: inline;">The Symptom Checker, which offers a symptom triage tool featuring a board certified</p><p style="padding-left: 270pt;text-indent: 0pt;text-align: left;">emergency room physician who through a series of recorded video segments questions users about their medical history and symptoms and provides care recommendations and action plans.</p></li><li style="padding-top: 7pt;padding-left: 270pt;text-indent: -11pt;text-align: left;"><p style="display: inline;">The Pregnancy Tracker, which provides week- by-week information on fetal development and changes to the woman’s body as the pregnancy progresses. This tool provides content related to each week of a pregnancy.</p></li><li style="padding-top: 7pt;padding-left: 270pt;text-indent: -11pt;text-align: left;"><p style="display: inline;">The Meal Planner, which produces healthy menu recommendations, including nutrient and calorie information, based on user food preferences and dietary restrictions.</p><p style="padding-top: 7pt;padding-left: 258pt;text-indent: -227pt;text-align: left;">Community Forums where consumers can share health goals and experiences.</p><p style="padding-top: 7pt;padding-left: 258pt;text-indent: -227pt;text-align: left;">Healthy Recipes Thousands of recipes across a variety of categories, including low fat, diabetes friendly, low carb, low calorie, low sodium and gluten free.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Advertising and Sponsorship Sales</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We offer innovative marketing solutions to a growing and diverse customer base across a variety of health and wellness categories, including pharmaceuticals, over-the-counter products, food, retail. lifestyle, as well as healthcare providers, such as hospitals, dentists and doctors. During 2014, our customers included six of the top ten global advertisers in 2013, as compiled by Advertising Age, and 23 of the top 25 global pharmaceutical companies ranked by 2013 revenue. Many of our customers promote a variety of different brands and products on the <i>Everyday Health </i>portfolio.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We sell our advertising-based services primarily through our direct sales force. Our sales personnel are located in New York, New York, Asheville, North Carolina, Chicago, Illinois and other areas throughout the U.S., and they are responsible for maintaining direct relationships with our customers and their advertising agencies.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We leverage our large database of user information and preferences to develop innovative solutions for our marketers to engage with their target audience. These marketing solutions have received positive market recognition in recent years, including Effie Awards, Web Health Awards and awards from Medical Marketing and Media. Our solutions take a multi-platform approach and incorporate:</p></li></ul></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">advertisements targeted to consumer and healthcare professionals on websites, newsletters, video, social media outlets and mobile applications;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">interactive brand sponsorships, which consist of custom-created marketing programs featuring content from leading health experts, video, interactive tools and other programs;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">sponsorship of targeted stand-alone e-mails to consumers who have opted to receive such e- mails, whom we refer to as opt-in consumers;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">customer acquisition, or lead generation, campaigns designed to deliver qualified consumers through the registration process; and</p></li><li style="padding-top: 4pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">opportunities for connecting advertisers to consumers through interactive social networking communities.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We also partner with third parties to expand our reach and increase the diversity of our audience. For example, we manage and sell advertising opportunities on websites that are owned and operated by our partners, such as <i>MayoClinic.org </i>and <i>Drugstore.com. </i>Additionally, our <i>Health Reach </i>media product enables marketers to reach our audience and their look-alikes on third party websites, mobile devices, social channels and video outlets. <i>Health Reach </i>leverages our data assets and advertising buying platform to help our customers access the most relevant consumers for their campaigns across advertising exchanges and more effectively optimize their marketing spend. Lastly, we are also able to reach a wide audience of physicians and other healthcare professionals by partnering with medical societies and other organizations to provide medical conference coverage, co-branded newsletters and other professional content.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">An important aspect of our sales model is our emphasis on conducting detailed research to measure the effectiveness or specific ROI of our programs and providing our customers with valuable real-time feedback on campaign efficacy and detailed post-campaign reporting. We work closely with third party vendors, such as IMS and Crossix, to measure the impact of our programs, including measuring increases in brand awareness and product purchases. This research allows us to optimize our campaigns and demonstrate a positive ROI for our customers. By virtue of our DoctorDirectory.com acquisition, we now conduct certain marketing campaigns that provide for revenues based entirely upon the ROI we deliver for our customers.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We expect that our ability to provide our marketers with targeted solutions across a large and contextually immersed audience, together with our result-focused tools that measure a customer’s ROI, will enable us to grow and strengthen our customer relationships, while competing favorably against online and offline publishers in the health and wellness category.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Marketing</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Our marketing efforts are focused on the following objectives:</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">increasing traffic to the properties we operate in the <i>Everyday Health </i>portfolio; and</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">recruiting users to register with or subscribe to our properties and subscription-based premium services.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We utilize a variety of marketing programs across different media channels to achieve these objectives. Our marketing programs include:</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">online display advertising;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">paid search advertising;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">e-mail advertising; and</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">television, print and radio advertising.</p></li></ul></ol><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our in-house marketing and design teams create our marketing campaigns and programs, which are then implemented by our technical and operations personnel and by third-party service providers. We actively and continuously manage our media mix to maximize the efficiency of our marketing investment. Our marketing personnel also focus directly on improving search engine optimization for the properties we operate. Search engine optimization is the process of improving the volume or quality of traffic to a specific property from search engines through unpaid search results, which is otherwise commonly referred to as natural or organic search traffic. Improving the natural search traffic to the properties we operate will allow us to be more efficient with the marketing dollars we deploy to increase traffic across the <i>Everyday Health </i>portfolio.</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Data and Analytics</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We collect and use data from various sources to optimize our content offerings for our audience and the performance of our customers’ advertising and sponsorship campaigns. We have high quality data assets consisting of billions of valuable data points, including up to 5,000 trackable attributes per user, gathered from (i) user profiles generated from data voluntarily submitted by over</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">65 million users since our inception and data aggregated from over 235 million anonymous health consumer profiles we have built since our inception; (ii) data collected from our users’ interactions with one or more of our properties and with other websites through the use of cookies and similar tracking technologies; (iii) the proprietary knowledge we have extracted throughout our operating history of delivering health and wellness content; and (iv) third-party data. We leverage these data assets through our proprietary personalization technology and sophisticated analytics and predictive modeling tools which enable us to increase the likelihood that our users will be exposed to content that is most relevant to them and that our marketers will be able to engage with the right target audience through advertisements and promotions that are most relevant to that user.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our proprietary technology consists of sophisticated analytics tools, predictive modeling and content management systems that enhance our users’ experience and our offerings to our marketers. This technology allows us to provide a personalized experience for our users by providing us with visibility into all user interactions across our portfolio, including content consumption, advertising clicks, activity with our tools, groups and forums, and search behavior. We monitor and analyze how users respond to specific content offerings and continuously improve the quality of our offerings by adapting the content distributed to users based on their previous interactions. For example, during 2014, we distributed over 200 million opt-in newsletters per month with content specifically tailored to the users’ individual interests. We believe that our ability to personalize the content we offer to each particular user, and adapt our offerings to the changing demands of our users, has resulted in increased user satisfaction and engagement with our portfolio of properties.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our proprietary technology also (i) optimizes the relevancy of advertisements and promotions placed across our portfolio and outside of our portfolio to deliver marketing messages that users are most likely to engage with and (ii) tracks and measures the effectiveness of our customers’ advertising campaigns. For example, through the use of our data assets, we are able to attribute revenue to specific marketing spend, gain visibility into the lifetime performance of users and ultimately assess and improve a campaign’s ROI. This ability to measure and improve upon the effectiveness of our marketers’ advertising and promotional campaigns has in part contributed to the growth in the number of our advertising customers and our average advertising and sponsorship revenues per advertiser.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Technology</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our technology infrastructure provides for continuous availability of our content offerings and advertising-based services. Currently, our websites are hosted on infrastructure located in a third- party data center located in Carlstadt, New Jersey with a back-up data center located in Scottsdale, Arizona. Our operations are dependent in part on our ability, and that of our hosting providers, to maintain our computer and telecommunications systems in effective working order and to protect our systems against damage from fire, theft, natural disaster, power loss, telecommunications failure, hacker attacks, computer viruses and other events beyond our control. We back up our data using a combination of the secondary data center, electronic vaulting and tape storage to offsite storage facilities on a daily basis, operate intrusion detection systems and perform regular log reviews for malicious activity. We operate our database in a multi-node platform using a technology designed to support large data sets and transaction volumes. Our technology allows us to aggregate, store and process large amounts of data while maintaining high application availability and responsiveness.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our systems are designed to have no single point of failure, other than the data center itself, and have redundancy at the network, power, firewall, load balancer, application server, database and storage levels. We maintain operational flexibility, which allows us to allocate resources to or from applications based on demand. We continually add and refine functionality for our portfolio,</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">ensuring that each modification is carefully tested and deployed before being moved into production by following a strict change management process. We have access to bandwidth on demand and additional physical capacity in each of our data centers to react to increased volume on our websites. We monitor systems continuously using automated tools and services. Emergency response teams provide full time coverage to respond to any issues affecting user functionality or performance.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We employ several layers of security, including encryption, secure transmission protocols and strict access controls, to ensure privacy, integrity and availability of our data. We utilize additional levels of security for e-commerce transactions, specifically when credit-card processing is required, including background checks of relevant employees and regular third-party security scans. We have contracted with an outside party to independently monitor our properties and ensure that our properties are in compliance with appropriate industry security requirements.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The key components of our software have primarily been designed, developed and deployed by our internal technology group. However, we also license database management software, outsource video delivery for our properties and otherwise use external sources for technological purposes when appropriate. We select external technology partners according to stability, reputation, performance and proven service levels.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Competition</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We face competition for consumers, healthcare professionals and advertising customers from a variety of online and offline companies, government agencies and other organizations that provide content, tools and applications to consumers and healthcare professionals interested in health-related information. Our ability to compete successfully against these entities depends on many factors, including:</p><ul id="l6"><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">the quality, timeliness and reliability of our offerings;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">the effectiveness of our sales and marketing efforts;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">our ability to keep pace with technological advances and trends; and</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">the brand recognition of <i>Everyday Health </i>and the websites, tools and applications in our portfolio.</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">We face competition from the following:</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">websites that provide online consumer health and wellness information, such as</p><p class="s45" style="padding-left: 60pt;text-indent: 0pt;text-align: left;">www.webmd.com<span class="p">;</span></p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p class="s45" style="display: inline;"><a href="http://www.yahoo.com/" class="s46" target="_blank">general interest consumer websites or search engines that offer specialized health sub-channels or functions, such as </a>www.yahoo.com <span class="p">and </span>www.google.com<span class="p">;</span></p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">websites, mobile applications, digital devices and other products and services directed at consumers relating to specific conditions, programs or other specific types of health, wellness and lifestyle content;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p class="s45" style="display: inline;"><a href="http://www.medscape.com/" class="s46" target="_blank">websites, mobile applications and other products and services that target healthcare professionals, including websites such as </a>www.medscape.com <span class="p">(owned by WebMD) and mobile applications offered by Epocrates;</span></p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">other high-traffic websites that include both health-related and non-health-related content and services, including social media websites, such as <i>www.facebook.com</i>; and</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">non-profit and governmental websites that provide consumer health information, such as</p><p class="s45" style="padding-left: 60pt;text-indent: 0pt;text-align: left;"><a href="http://www.fda.gov/" class="a" target="_blank">www.fda.gov</a><a href="http://www.cdc.gov/" class="s46" target="_blank">, </a>www.cdc.gov <a href="http://www.health.nih.gov/" class="s46" target="_blank">and </a><a href="http://www.health.nih.gov/" target="_blank">www.health.nih.gov.</a></p><p class="s45" style="padding-top: 2pt;padding-left: 31pt;text-indent: 19pt;text-align: left;"><a href="http://www.advertising.com/" class="s46" target="_blank">In addition, we face competition from advertising networks that aggregate traffic from multiple online websites or target advertisements to health-related consumers, such as </a>www.advertising.com <a href="http://www.valueclick.com/" class="s46" target="_blank">and </a>www.valueclick.com. <span class="p">We also face competition from a number of companies that provide consumer and professional health-oriented content through traditional offline media. These competitors include magazine and book publishers, such as Time Warner Inc. and Rodale Inc., medical content publishers and distributors of television and video programming.</span></p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We are also developing various products and services for payors, providers and employers. This is a highly competitive market consisting of large, well-established companies as well as smaller companies and start-up entities that are specifically focused on payors, providers and/or employers.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Intellectual Property</p><p class="s45" style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;"><span class="p">We currently own approximately 60 registered trademarks around the world, including </span>Everyday Health<span class="p">, </span>MedPage Today <span class="p">and </span>DoctorDirectory.com. <a href="http://www.EverydayHealth.com/" class="s46" target="_blank">In addition, we own three patents. Our success depends upon our ability to protect our core technology and intellectual property. To accomplish this, we rely on a combination of intellectual property rights, including trade secrets, trademarks, copyrights and patents, as well as contractual restrictions. We enter into confidentiality and proprietary rights agreements with our employees, consultants and business partners, and we control access to and distribution of our proprietary information. In addition, we have registered various domain names, including </a><a href="http://www.EverydayHealth.com/" class="a" target="_blank">www.EverydayHealth.com</a><a href="http://www.MedPageToday.com/" class="s46" target="_blank">, </a>www.MedPageToday.com <span class="p">and </span>www.DoctorDirectory.com<span class="p">, which are critical to the operation of our business and the properties in the </span>Everyday Health <span class="p">portfolio.</span></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">However, not all of our intellectual property is protected by registered copyrights or other registered intellectual property or statutory rights. For example, some of our content is protected by user agreements that limit access to and use of such content.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In addition to the technology and intellectual property that we own, we also license key health- related content and tools from third parties that we distribute on the properties that we operate. We also license software and technology products that are important to our ability to manage and deliver content and market and sell our products and services.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our ability to operate some of our properties is governed by licensing agreements with the owners of the offline brands and associated content, including Heidi Murkoff, author of the best- selling book <i>What to Expect When You’re Expecting</i>, Jillian Michaels, Suzanne Somers, the Mayo Clinic Diet and the South Beach Diet Corp., among others. These licensing agreements provide us with the exclusive rights, subject to limited exceptions, to use and market the brand and associated content online, as well as to determine the precise methods for monetizing the content online. In exchange for these rights, our partners receive specified royalties based on the revenues generated from our operation of the applicable website and related services, such as e-mail newsletters and product sales. We may also create new content in conjunction with these partners. However, pursuant to our agreements with these partners, we may not own the intellectual property rights to this new content or any related user-generated content.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Industry Standards and Government Regulation</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">This section describes the key laws, regulations and industry standards that affect our business.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Some of the aspects described below, such as those surrounding consumer protection, affect us directly. Other aspects do not apply to us directly, but may have a significant effect on the way our partners and customers can operate.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Consumer Protection</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our business is subject to federal and state consumer protection laws that regulate unfair and deceptive practices. The laws that most directly affect our business are those related to the use and protection of consumer information and those related to advertising and marketing.</p><p class="s45" style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Privacy</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our collection, storage and sharing of information regarding consumers, including visitors to our properties, is governed by various U.S. federal and state laws, regulations and standards.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Enforcement by regulators, including the Federal Trade Commission, or the FTC, requires us to provide consumers with notice, choice, security and access with respect to such information.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Behavioral Advertising</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">New laws and regulations may be adopted in the U.S. and internationally, or existing laws and regulations may be interpreted in new ways that would affect our business, particularly with regard to collection or use of data to target advertisements to consumers. A number of U.S. states have proposed bills that contain provisions that would regulate how companies can use cookies and other tracking technologies to collect and use information about individuals and their online behaviors.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We participate in the Digital Advertising Alliance, or DAA, self-regulatory program under which, we provide consumers with notice about our use of cookies and our collection and use of data in connection with the delivery of targeted advertising. In February 2012, President Obama announced that a group of leading Internet companies and online advertising networks agreed to move forward on developing a “Do Not Track” program to allow users to opt-out of having companies collect information about their online actions and the World Wide Web Consortium is currently working to develop such a program. In addition, the DAA and The National Telecommunication and Information Association have developed principles and guidelines for providing users disclosures regarding the use of consumer data on mobile platforms.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Consumers can currently opt out of the placement or use of our cookies for online targeted advertising purposes by either deleting or disabling cookies on their browsers, visiting websites that allow consumers to place an opt-out cookie on their browsers, or by downloading browser plug-ins and other tools that can be set to identify cookies and other tracking technologies and/or block the delivery of online advertisements on websites and applications. In addition, the default settings of consumer devices and software, including web browsers, may be set to prevent the placement of cookies unless the consumer actively elects to allow them.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Data Protection Regulation</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Many states have passed laws regulating the actions that a business must take if it experiences a data breach. Compromised companies must promptly disclose breaches to customers. Congress has also contemplated similar federal legislation relating to data breaches and the Health Information for Economic and Clinical Health Act of 2009, or HITECH, requires breaches of certain unsecured,</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">individually identifiable health information to be reported. In the past, the FTC has prosecuted some data breach cases as unfair and deceptive acts or practices under the Federal Trade Commission Act. We intend to continue to protect all consumer data and to comply with all applicable laws regarding the protection of customer data.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">CAN-SPAM Act</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The CAN-SPAM Act regulates commercial e-mails, provides a right on the part of the recipient to request the sender to stop sending messages, and establishes penalties for the sending of e-mail messages that are intended to deceive the recipient as to source or content. Recipients must be furnished with an electronic method of informing the sender of the recipient’s decision to not receive further commercial e-mails. We are applying the CAN-SPAM requirements to our e-mail communications, and believe that our practices comply with the requirements of the CAN-SPAM Act. In addition, actions could be brought against us under various state spam laws, which are not entirely preempted by CAN-SPAM.</p><p class="s45" style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">COPPA</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Children’s Online Privacy Protection Act, or COPPA, applies to operators of commercial websites and online services, including mobile applications, directed to U.S. children under the age of 13 that collect personal information from children, and to operators of general audience websites with actual knowledge that they are collecting information from U.S. children under the age of 13. In April 2013, the FTC updated its COPPA regulations to specify that the law applies to using cookies for behavioral targeting, device IDs, location data, video and photos for children under 13. Our websites and mobile applications are not directed at children under the age of 13, and our registration process utilizes age screening in order to prevent the under-age registrations. We believe that we are in compliance with COPPA.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Marketing</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The marketing of our services and some of the marketing services we provide to our customers are subject to federal and state consumer protection laws that regulate unfair and deceptive practices. For example, in October 2009, the FTC published Guides Concerning the Use of Endorsements and Testimonials in Advertising, or the Guides. Under the Guides, “material connections,” such as payments or free products, between advertisers and endorsers, such as celebrities and bloggers, must be disclosed. In addition, advertisements that feature a consumer and convey his or her experience with a product or service as typical when that is not the case are required to clearly disclose the results that consumers can generally expect to receive from the advertised product or service.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Regulation of Contests and Sweepstakes</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In order to promote our properties and advertisers, we conduct contests and sweepstakes. Many states have prize, gift or sweepstakes statutes that apply to these promotions. We strive to comply with all applicable laws and regulations when we run these promotions.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Healthcare-Related Regulation</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Regulation of Drug and Medical Device Advertising and Promotion</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Information on our properties that promotes the use of pharmaceutical products or medical devices is subject to U.S. Food and Drug Administration, or FDA, and FTC requirements, and information regarding other products and services is subject to FTC requirements. The Federal Food, Drug, and Cosmetic Act, or FDC Act, requires that prescription drugs, including biological products, be approved by the FDA prior to marketing. The FDA allows for exchange of scientific</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">information prior to approval, provided it is non-promotional in nature and does not draw explicit or implied conclusions regarding the ultimate safety or effectiveness of the unapproved drug. Upon approval, prescription drugs may be promoted and advertised only for uses reviewed and approved by the FDA. In addition, the labeling and advertising can be neither false nor misleading, and must present all material information, including potential risks, in a clear, conspicuous and neutral</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">manner. There are also requirements for specified information to be part of labeling and advertising. Labeling and advertising that violate these legal standards are subject to FDA enforcement action and the FDA may impose administrative, civil and criminal sanctions for violations of the FDC Act or FDA regulations. State attorneys general have similar investigative tools and sanctions available to them.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The FDA also regulates the safety, effectiveness, and labeling of over-the-counter, or OTC, drugs under the FDC Act either through specific product approvals or through regulations that define approved claims for specific categories of such products. The FTC regulates the advertising of OTC drugs under the section of the Federal Trade Commission Act that prohibits unfair or deceptive trade practices. The FDA and FTC regulatory framework requires that OTC drugs be labeled in accordance with FDA approvals or regulations and promoted in a manner that is truthful, adequately substantiated, and consistent with the labeled uses. OTC drugs that do not meet these</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">requirements are subject to FDA or FTC enforcement action depending on the nature of the violation. In addition, state attorneys general may bring enforcement actions for alleged unfair or deceptive advertising.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Companies may now advertise prescription drugs to consumers in any medium, provided that they satisfy FDA requirements. However, legislators, physician groups and others have called for restrictions on advertising of prescription drugs to consumers and increased FDA enforcement.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Congress and the FDA have shown interest in these issues, as well. To date, the FDA has not promulgated any discrete guidance or guidelines for direct to consumer, or DTC, advertising of prescription drugs or medical devices.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Industry trade groups, such as the Pharmaceuticals Research and Manufacturers of America, or PhRMA, have implemented voluntary guidelines for DTC advertising in response to public concerns. The PhRMA Guiding Principles for Direct to Consumer Advertisement of Prescription Medicines address various aspects of DTC advertising, including: balancing presentation of benefits and risks; the timing of DTC campaigns, including allowing for a period for education of healthcare professionals prior to launching a branded DTC campaign; use of healthcare professionals and celebrities in DTC advertisements; and timing and placement of advertisements with adult-oriented content.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">HIPAA Privacy Standards and Security Standards</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Privacy Standards and Security Standards under the Health Insurance Portability and Accountability Act of 1996, or HIPAA, establish a set of basic national privacy and security standards for the protection of certain individually identifiable health information by health plans, healthcare clearinghouses and healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services. HITECH makes certain of HIPAA’s privacy and security standards also directly applicable to covered entities’ business associates. As a result, business associates are now subject to significant civil and criminal penalties for failure to comply with applicable privacy and security rule requirements. Moreover, HITECH creates a new requirement to report certain breaches of unsecured, individually identifiable health information and imposes penalties on entities that fail to do so. Additionally, certain states have adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Licensed Professional Regulation</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The practice of most healthcare professions requires licensing under applicable state law. In addition, the laws in some states prohibit business entities from practicing medicine. Similar state prohibitions may exist with respect to other licensed professions. We do not believe that we engage in the practice of medicine or any other licensed healthcare profession, and we have attempted to structure our websites, tools, partner relationships and other operations to avoid violating these state licensing and professional practice laws. We do not believe that we provide professional medical advice, diagnosis, treatment, or other advice that is tailored in such a way as to implicate state licensing or professional practice laws. We employ and contract with physicians, nutritionists and fitness instructors who provide only medical, nutrition and fitness information to consumers.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Anti-Kickback Laws</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">There are federal and state laws that govern patient referrals, physician financial relationships and inducements to healthcare providers and patients. The federal healthcare program’s anti- kickback law prohibits any person or entity from offering, paying, soliciting or receiving anything of value, directly or indirectly, for the referral of patients covered by Medicare, Medicaid and other federal healthcare programs. Many states also have similar anti-kickback laws that are not necessarily limited to items or services for which payment is made by a federal healthcare program. In 2002, the Office of the Inspector General of the U.S. Department of Health and Human Services, the federal government agency responsible for interpreting the federal anti-kickback law, issued an</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">advisory opinion that concluded that the sale of advertising and sponsorships to healthcare providers and vendors by web-based information services implicates the federal anti-kickback law. However, the advisory opinion suggests that enforcement action will not result if the fees paid represent fair market value for the advertising or sponsorship arrangements, the fees do not vary based on the volume or value of business generated by the advertising, and the advertising and sponsorship relationships are clearly identified as such to users. We carefully review our practices to ensure that we comply with all applicable laws.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Employees</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">As of December 31, 2014, we had approximately 560 employees. None of our employees is represented by a labor union or is subject to a collective bargaining agreement. We have not experienced an employment-related work stoppage and consider relations with our employees to be good.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Information about Segment and Geographic Revenue</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Information about segment and geographic revenue is set forth in Note 2 of the notes to the consolidated financial statements under Item 8 of this Annual Report on Form 10-K.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Corporate History</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We were incorporated in Delaware in January 2002 as Agora Media Inc. We changed our name to Waterfront Media Inc. in January 2004. In January 2010, to better align our corporate identity with the <i>Everyday Health </i>brand, we changed our name to Everyday Health, Inc.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our principal executive office is located at 345 Hudson Street, 16th Floor, New York, NY 10014, and our telephone number is (646) 728-9500.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We completed our initial public offering in March 2014 and our common stock is listed on the New York Stock Exchange under the symbol “EVDY.”</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The names <i>Everyday Health</i>, <i>MedPage Today </i>and <i>DoctorDirectory.com </i>and our logos are trademarks, service marks or trade names owned by us. All other trademarks, service marks or trade names appearing in this Annual Report on Form 10-K are owned by their respective holders.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Available Information</p><p class="s45" style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;"><a href="http://www.EverydayHealth.com/" class="s46" target="_blank">Our website is located at </a><a href="http://www.EverydayHealth.com/" class="a" target="_blank">www.EverydayHealth.com</a><a href="http://ir.everydayhealth.com/" class="s46" target="_blank">, and our investor relations website is located at </a>http://ir.everydayhealth.com/. <a href="http://www.sec.gov/" class="s46" target="_blank">Copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to these reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available, free of charge, on our investor relations website as soon as reasonably practicable after we file such material electronically with or furnish it to the Securities and Exchange Commission, or the SEC. The SEC also maintains a website that contains our SEC filings. The address of the website is </a>www.sec.gov. <span class="p">Further, a copy of this Annual Report on Form 10-K is located at the SEC’s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549.</span></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Information on the operation of the Public Reference Room can be obtained by calling the SEC at 1-800-SEC-0330. The information on, or that can be accessed through, any property in the <i>Everyday Health </i>portfolio is not incorporated by reference into this Annual Report on Form 10-K and inclusion of the website addresses of the properties in the <i>Everyday Health </i>portfolio in this Annual Report on Form 10-K are inactive textual references only.</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Item 1A. Risk Factors.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">You should carefully consider the following risk factors, in addition to the other information contained in this Annual Report on Form 10-K and the information incorporated by reference herein. If any of the events described in the following risk factors occurs, our business, operating results and financial condition could be seriously harmed.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward- looking statements as a result of factors that are described below and elsewhere in this Annual Report on Form 10-K.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Risks Related to Our Business</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">We have incurred significant losses since our inception and expect to incur losses in the future.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We have accumulated significant losses since our inception. As of December 31, 2014, our accumulated deficit was $119.1 million. We expect to continue to incur significant operating expenses and, as a result, we will need to generate significant revenues to achieve or sustain profitability. We may not be able to achieve or sustain profitability on a quarterly or annual basis in the future.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">If we are unable to provide content and services that attract users to the Everyday Health portfolio on a consistent basis, our advertising and sponsorship revenues could be reduced.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our users have numerous other online and offline sources of health and wellness related information and product offerings. Our ability to compete for user traffic depends upon our ability to provide compelling and trusted health and wellness content, tools, mobile applications and other services that meet the needs of a variety of types of users, including consumers, physicians and other healthcare professionals. Our ability to do so depends, in turn, on:</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">our ability to develop innovative tools and mobile applications, as well as implement new and updated features and services for existing tools and applications;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">our ability to hire and retain qualified authors, journalists and independent writers;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">our ability to license quality content from third parties; and</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">our ability to monitor and respond to increases and decreases in user interest in specific topics.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">If users do not perceive our content, mobile applications and tools to be useful, reliable and trustworthy, we may not be able to attract or retain users or otherwise maintain or increase the frequency and duration of their visits to our portfolio. We cannot assure you that we will be able to continue to develop or acquire needed content, applications and tools at a reasonable cost or on a timely basis. The revenue opportunities generated from these efforts may fail to justify the amounts spent.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In addition, since users may be attracted to properties within the <i>Everyday Health </i>portfolio as a result of a specific condition or for a specific purpose, it is difficult for us to predict the rate at which such users will return to these properties. Because we generate revenues by, among other things, selling sponsorships in the <i>Everyday Health </i>portfolio, a decline in user traffic levels or a reduction in the number of pages viewed by users could cause our revenues to decrease and could have a material adverse effect on our results of operations.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Our failure to attract and retain users in a cost-effective manner could compromise our ability to grow our revenues and become profitable.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our continued success is highly dependent on our ability to attract and retain consumers, physicians and other healthcare professionals in a cost-effective manner. In order to attract users to</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">the <i>Everyday Health </i>portfolio, we must expend considerable amounts of money and resources for advertising and marketing. We use a diverse mix of marketing and advertising programs to promote our portfolio, and we have spent, and expect to continue to spend, significant amounts of money on these initiatives. Significant increases in the pricing of one or more of these initiatives will result in higher marketing costs. Our failure to attract and acquire new, and retain existing, users in a cost- effective manner would make it more difficult to maintain and grow our revenues and ultimately to achieve profitability.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Increasingly, individuals are using mobile devices to access online content, applications and services and, if we fail to capture a significant share of this growing market opportunity or fail to generate revenues from it, our business could be adversely affected.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The number of individuals, including physicians and other healthcare professionals, who access online content, applications and services through smartphones, tablets and other mobile devices has increased dramatically in the past few years. Accordingly, the portion of our page views from mobile devices has increased rapidly and is expected to continue to increase in the foreseeable future. To compete in this area, we must develop content, applications and tools for mobile devices that:</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">users find engaging;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">work with a variety of mobile operating systems and networks; and</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">achieve a high level of market acceptance.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">If we fail to capture a significant share of this increasingly important portion of the market, it could adversely affect our business. As mobile technology continues to evolve, it is difficult to predict the problems we may encounter in developing and maintaining a robust mobile offering and we may need to devote additional resources to the creation, maintenance and support of our mobile offerings. Even if demand for our mobile applications continues to grow and we achieve a significant share of this market, we cannot assure you that we will be able to achieve significant revenues or profits from these efforts. If we are unable to successfully implement monetization strategies for our mobile offerings, our revenues and financial results may be negatively affected.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">If we are unable to prove that our advertising and sponsorship offerings provide a good return on investment for our customers, our financial results could be harmed.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our ability to grow our advertising and sponsorship revenues will be dependent on our ability to demonstrate to marketers that their marketing campaigns in the <i>Everyday Health </i>portfolio provide a meaningful ROI relative to offline and other online opportunities. In fact, certain of our marketing campaigns are designed such that the revenues we receive are based entirely upon the ROI we deliver for our customers. We have invested significant resources in developing our research, analytics and campaign effectiveness capabilities and expect to continue to do so in the future. Our ability, however, to demonstrate the value of advertising and sponsorship in the <i>Everyday Health </i>portfolio will depend, in part, on the sophistication of our analytics and measurement capabilities, the actions taken by our competitors to enhance their offerings, whether we meet the ROI expectations of our customers and a number of other factors. If we are unable to maintain sophisticated advertising offerings that provide value to our customers or demonstrate our ability to provide such value to our customers, our financial results will be harmed.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Our advertising and sponsorship revenues are frequently derived from short-term contracts that may not be renewed.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Many of our advertising and sponsorship contracts are short-term commitments and are subject to termination by the customer. Despite the short-term nature of these commitments, we typically expend significant resources over a lengthy sales cycle to obtain these contracts. Moreover, the time between the execution of a contract with the advertiser or sponsor for a program and the delivery of our services may be longer than expected, especially for larger contracts, and may be subject to</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">delays over which we have little or no control. Our current customers may not fulfill their obligations under their existing contracts or continue to advertise with us beyond the terms of their existing contracts. If a significant number of advertisers, or a few large advertisers, decide to reduce their expenditures with us or to discontinue advertising with us, we could experience a material decline in our revenues.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Our advertising and sponsorship revenues are subject to fluctuations due to a number of factors that are beyond our control, including the timing and amount of expenditures by our customers.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Advertising and sponsorship revenues comprise a significant component of our revenues. Our advertising and sponsorship revenues accounted for approximately 90.3% and 86.6% of our total revenues for the years ended December 31, 2014 and 2013, respectively. Advertising spending in the markets in which we compete can fluctuate significantly as a result of a variety of factors, many of which are outside of our control. These factors include:</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">variations in expenditures by advertisers due to budgetary constraints;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">the cancellation, non-renewal or delay of campaigns;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">advertisers’ internal review process;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">the cyclical and discretionary nature of advertising spending;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">the timing of FDA approvals of prescription drugs and medical devices;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">regulatory changes affecting advertising and promotion of prescription drugs and medical devices;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">seasonal factors relating to the prevalence of specific health conditions and other seasonal factors that affect the promotion of specific products; and</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">general economic conditions, including those specific to the Internet and media industries.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Our quarterly revenues and operating results are subject to significant fluctuations, and these fluctuations may adversely affect the trading price of our common stock.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We have experienced, and expect to continue to experience, significant fluctuations in our quarterly revenues and operating results. Our quarterly revenues and operating results may fluctuate significantly due to a number of factors, many of which are outside of our control. These factors include:</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">traffic levels to the properties in our portfolio;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">our ability to introduce new and appealing content, applications and tools that will drive the growth of our user base;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">the spending priorities and advertising budget cycles of specific advertisers;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">the addition or loss of advertisers;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">the addition of new websites, mobile applications and services by us or our competitors;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">changes in our pricing policies or those of our competitors; and</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">costs relating to our ongoing efforts to improve our content and advertising-based service offerings.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In addition, seasonal factors can also affect our operating results. For example, we have historically experienced an increase in new subscriptions in the first calendar quarter. This increase typically coincides with the general trend towards making healthy lifestyle choices at the beginning of the new year.</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">As a result of these seasonal and quarterly fluctuations, we believe that comparisons of our quarterly results of operations are not necessarily meaningful and that these comparisons are not reliable as indicators of our future performance. In addition, these fluctuations could result in volatility in our operating results and may adversely affect our cash flows. As our business grows, these seasonal fluctuations may become more pronounced. Any seasonal or quarterly fluctuations that we report in the future may differ from the expectations of securities analysts and investors. This could cause the price of our common stock to decline.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Our inability to sustain or grow our advertising rates, or our inability to manage the pace of change in the advertising technology industry, could adversely affect our operating results.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The rates charged for advertising on the Internet, particularly in the consumer health sector, have fluctuated over the past few years due to a variety of factors, including the growth in use of search engines, the increase in the use of automated or programmatic advertising buying, growth of the mobile advertising market, general economic conditions and competitive offerings. We have committed significant resources to delivering content and advertising-based services designed to appeal to our customers by engaging users in a more interactive and personalized manner and seeking to provide a higher return on our customers’ advertising expenditures. However, our customers may not perceive our content offerings and advertising-based services as sufficiently valuable to justify the payment of our rates. Moreover, given the inherent difficulties in delivering a rich advertisement on mobile channels, the increasing reliance of our customers on automated or programmatic advertising buying networks and the focus by advertisers on enforcing viewability requirements for their advertising impressions, we may encounter difficulties in obtaining the prices that we seek for our advertising solutions. If we are unable to maintain our historical, or grow to anticipated, pricing levels for advertising, we will experience difficulties in maintaining or growing our revenues. As the advertising industry develops new concepts and technology to deliver and price advertising inventory, we may also incur additional costs to keep pace with these changes and to implement more effective products and services.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">A significant portion of the traffic to the Everyday Health portfolio is directed to us through algorithmic search results on Internet search engines and, if we are listed less prominently in search result listings, our business and operating results could be harmed.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">A significant portion of the traffic to the <i>Everyday Health </i>portfolio is directed to us through the algorithmic search results on Internet search engines such as Google. Algorithms are used by search engines to determine search result listings, and the order of such listings, displayed in response to specific searches. Accordingly, in addition to providing quality content and tools, we seek to design our properties to deliver that content and tools in ways that will cause them to rank well in algorithmic search engine results, which makes it more likely that search engine users will visit our properties. This is commonly referred to as search engine optimization, or SEO. However, there can be no assurance that our SEO efforts will succeed in improving the ranking of our content or, even if they do result in such improvement, that the improved ranking will result in increased numbers of users and page views for our properties. In addition, search engines frequently change the criteria that determine site rankings in their search results, and our SEO efforts will not be successful if we do not respond to those changes appropriately and on a timely basis. Search engine providers may also prioritize search results generated by certain types of queries, including health queries, based on criteria they select or may otherwise intermediate in the search results generated, which could, in some circumstances, reduce the ranking that would otherwise be provided to our properties and increase the ranking of other properties. If we are unable to respond effectively to changes made by search engine providers in their algorithms and other processes, a substantial decrease in traffic to the <i>Everyday Health </i>portfolio could occur, which could cause our revenues to decrease and have a material adverse effect on our results of operations.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The properties in our portfolio may also become listed less prominently in unpaid search results for other reasons, such as search engine technical difficulties, search engine technical changes and changes we make to our properties. In addition, search engines have deemed the practices of some</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">companies to be inconsistent with search engine guidelines and have decided not to list their websites in search result listings at all. If listed less prominently or not at all in search result listings for any reason, the traffic to the <i>Everyday Health </i>portfolio would likely decline, which could harm our operating results. If we decide to attempt to replace this traffic, we may be required to increase our marketing expenditures, which could also harm our operating results.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">If we are unsuccessful at pursuing adjacent opportunities in the broader health and wellness sectors, we may not be able to achieve our growth and business objectives.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">To date, we have principally focused on providing health and wellness content to consumers and healthcare professionals and providing marketing solutions to our customers. However, an important component of our growth strategy involves leveraging our core assets to pursue adjacent opportunities in the broader health and wellness sectors. We believe that our large audience, sophisticated interactive tools and our ability to drive better health outcomes will open up new revenue opportunities for us in the broader health and wellness industries. For example, we have recently created a healthcare solutions division which will leverage our existing core assets to offer payors, providers and employers various marketing and other products and services. However, our experience in developing new products and services, and marketing to new potential customers, in these areas is limited. Therefore, we may need to make additional investments in product development and sales and marketing in order to effectively pursue such opportunities. If we are unable to successfully develop new offerings to pursue such opportunities or we are unable to successfully market our offerings to payors, providers and employers or other potential customers in adjacent markets, we may not be able to achieve our growth and business objectives.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 51pt;text-indent: -20pt;text-align: left;">Failure to maintain and enhance our brands could have a material adverse effect on our business.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We believe that our brand identity is critical to the success of our business and in maintaining our reputation as a trusted source of health and wellness information. We also believe that maintaining and enhancing our brands are vital to expanding our user base and growing our relationships with advertisers. We believe that the importance of brand recognition and user loyalty will only increase in light of increasing competition in our markets. Some of our existing and potential competitors, including search engines, media companies and other online content providers, have well established brands with greater recognition and market penetration. We have expended considerable resources on establishing and enhancing the <i>Everyday Health </i>brand and the other brands in the <i>Everyday Health </i>portfolio. We have developed policies and procedures that are intended to preserve and enhance these brands, including editorial procedures designed to control the quality of our content. We expect to continue to devote significant additional resources and efforts to enhance our brands. However, we may not be able to successfully maintain or enhance awareness of our brands, and events outside of our control may have a negative effect on our brands.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Our inability to enter into new, or otherwise extend our existing, partnership arrangements or the decline in the popularity of our partners would adversely affect our ability to grow our business and revenues.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We depend on partnership arrangements under which we license content from third parties, including <i>The South Beach Diet</i>, <i>Jillian Michaels </i>and <i>What to Expect, </i>to attract and retain consumers to the <i>Everyday Health </i>portfolio. We believe that such content is an important element of our business and helps to differentiate us from our competitors. We have also entered into agreements with entities such as the <i>Mayo Clinic </i>and <i>Drugstore.com </i>to monetize their properties by selling advertising and sponsorships. Our partnership arrangements have varying duration, renewal terms and termination rights. Our inability to renew our existing partnership arrangements, or to otherwise enter into new arrangements, in each case on commercially favorable terms, could adversely affect the appeal of our portfolio to our users, advertisers and partners.</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In addition, we rely on the popularity and credibility of partners that are associated with certain properties in the <i>Everyday Health </i>portfolio. These partners may not retain their current appeal or may become subject to negative publicity. The popularity and credibility of the properties associated with these partners also depend on the quality and acceptance of competing content released into the marketplace at or near the same time, the availability of alternative sources for the information, general economic conditions and other tangible and intangible factors, all of which are difficult to predict. Consumer preferences change frequently, and it is a challenge to anticipate what offerings will be successful at a certain point in time. Any decline in the popularity of the content offerings, or any negative publicity, whether individually or with respect to the content offerings associated with the properties associated with these partners, may have an adverse impact on our business and revenues.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Significant declines in our premium subscription-based business could adversely affect our operating results.</p><p class="s45" style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;"><a href="http://www.JillianMichaels.com/" class="s46" target="_blank">Our premium services consist primarily of subscriptions sold to users who purchase access to one or more of the properties in our portfolio or to a specific interactive service or application, including </a><a href="http://www.SouthBeachDiet.com/" class="a" target="_blank">www.JillianMichaels.com, </a>www.SouthBeachDiet.com <a href="http://www.Diet.MayoClinic.org/" class="s46" target="_blank">or </a>www.Diet.MayoClinic.org. <span class="p">As our growth strategy has evolved to focus primarily on advertising and sponsorship services, we have experienced a decline in the number of paid subscribers to our premium services in recent years and a decline in our overall subscription revenues. Subscribers may choose not to renew their subscriptions for many reasons at any time prior to the renewal date, including:</span></p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">a desire to reduce discretionary spending;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">a perception that they do not use the service sufficiently;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">a belief that the service is a poor value or that competitive services provide a better value or experience; or</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">a feeling that subscriber service issues are not satisfactorily resolved.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We expect the decline in our subscription revenues to continue. However, if we are unable to add a sufficient number of new subscribers or if our existing subscribers cancel at a more rapid rate than anticipated, our financial results could be negatively impacted.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Future acquisitions could disrupt our business and harm our financial condition and operating results.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Since our inception, we have acquired a number of complementary businesses, products and technologies. Most recently, in November 2014, we acquired DoctorDirectory.com, which provided pharmaceutical companies with multi-channel interactive marketing services that target healthcare professionals. We intend to continue to seek other complementary acquisitions in the future, particularly with respect to growing our product and service offerings for payors and providers.</p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Acquisitions and investments involve numerous risks, including:</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">potential negative impact on our financial results because they may require us to incur charges and substantial debt or liabilities, may require us to amortize, write down or record</p><p style="padding-left: 60pt;text-indent: 0pt;text-align: left;">impairment of amounts related to deferred compensation, goodwill and other intangible assets, or may cause adverse tax consequences, substantial depreciation or deferred compensation charges;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">difficulty in assimilating the operations and personnel of acquired businesses and/or unexpected expenses in connection therewith;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">potential disruption of our ongoing businesses and distraction of our management and the management of acquired companies;</p></li><li style="padding-top: 4pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">potential loss of key personnel, customers or users from either our current business or an acquired company’s business;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">unanticipated expenses relating to implementing or improving internal controls, procedures and policies appropriate for a public company of a business that prior to the acquisition lacked these controls, procedures and policies;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">potential litigation resulting from our business combinations or acquisition activities; and</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">potential unknown liabilities associated with the acquired businesses.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our inability to integrate any acquired business successfully or the failure to achieve any expected synergies could result in increased expenses and a reduction in expected revenues or revenue growth. In addition, we may not be able to identify or consummate any future acquisition on favorable terms, or at all. If we do pursue an acquisition, it is possible that we may not realize the anticipated benefits from the acquisition or that the financial markets or investors will negatively view the acquisition. As a result, our stock price could fluctuate or decline.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">The costs associated with potential acquisitions or strategic partnerships could dilute your investment or adversely affect our results of operations.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In order to finance acquisitions, investments or strategic partnerships, we may use equity securities, debt, cash or a combination of the foregoing. Any issuance of equity securities or securities convertible into equity may result in substantial dilution to our existing stockholders, reduce the market price of our common stock or both. Any debt financing is likely to increase our interest expense and include financial and other covenants that could have an adverse impact on our business. In addition, an acquisition may involve non-recurring charges, including write-downs of significant amounts of intangible assets or goodwill. The related increases in expenses could adversely affect our results of operations. Any such acquisitions or strategic alliances may require us to obtain additional equity or debt financing, which may not be available on commercially acceptable terms, or at all. We do not intend to seek security holder approval for any such acquisition or security issuance unless required by applicable law, regulation or the terms of our existing securities.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Our growth could strain our personnel, technology and infrastructure resources. If we are unable to implement appropriate controls and procedures to manage our growth, we may not be able to successfully implement our business plan.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our growth in our business and operations, including the integration of a number of acquisitions, has placed a significant strain on our management, administrative, technological, operational and financial infrastructure. Anticipated future growth, including growth related to the broadening of our content offerings and advertising-based services and our expansion into new product offerings and geographic areas, will continue to place similar strains on our management, technology and infrastructure. Our success will depend in part upon our ability to manage our growth. To manage the expected growth of our business and operations, we will need to continue to improve our operational, financial, technological and management controls and our reporting systems and procedures. The resulting additional capital investments will increase our costs, which will make it more difficult for us to offset any future revenue shortfalls by offsetting cost reductions in the short term.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">We face significant competition in attracting both users and customers.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The markets for healthcare information products and services are intensely competitive, continually evolving and, in some cases, subject to rapid change. Our properties face competition from numerous other companies, both in attracting users and in generating revenue from advertisers. We compete for users and advertisers with the following:</p></li><li style="padding-top: 4pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">websites, mobile applications and other products and services that provide online health and wellness information directed at consumers and/or healthcare professionals, including both commercial websites and non-profit and governmental websites;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">general interest consumer websites that offer specialized health sub-channels or functions;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">search engines that provide specialized health search and other high-traffic websites that include both health-related and non-health-related content and services, including social media websites;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">advertising networks that aggregate traffic from multiple websites; and</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">offline publications and information services.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">As we continue to diversify the breadth of our content offerings and advertising-based services and expand internationally, we expect our competitors to further expand as well. Our current and future competitors may offer new categories of content, products or services before we do, which may give them a competitive advantage when trying to attract consumers or advertisers. Moreover, both existing and potential users may perceive our competitors’ offerings to be superior to ours.</p><p style="padding-top: 7pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Moreover, we are developing various products and services for payors, providers and employers.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">The market for providing products and services to payors, providers and employers is highly competitive and we do not have experience competing against these types of companies.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Many of our current and potential competitors have longer operating histories, larger customer bases, greater brand recognition and significantly greater financial, marketing and other resources than we do. As a result, we could lose market share to our competitors, and our revenues could decline.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">There are a number of risks associated with expansion of our business internationally.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Although currently our international operations are not material, expansion into international markets is one of the elements of our long-term growth strategy. In addition to facing many of the same challenges we face domestically, there are additional risks and costs inherent in expanding our business in international markets. These include:</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">strong local competitors that are better attuned to the local culture and preferences;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">the need to adapt the content and advertising programs on our properties to meet local needs and to comply with local legal and regulatory requirements;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">limitations on our activities in foreign countries;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">more restrictive data protection regulation, which may vary by country;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">difficulties in staffing and managing multinational operations;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">foreign political and economic uncertainty;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">currency exchange-rate fluctuations; and</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">potential adverse tax requirements.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We have limited experience in managing international operations. As a result, we may face difficulties and unforeseen expenses in expanding our business internationally, and even if we attempt to do so, we may be unsuccessful.</p><p class="s45" style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">We may not be able to attract, hire and retain qualified personnel in a cost-effective manner, which could impact the quality of our products and services and the effectiveness of our management, resulting in increased costs and lower revenues.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our success depends on our ability to attract, hire and retain, at commercially reasonable rates, qualified editorial, sales and marketing, data sciences, customer support, technical, financial and accounting, legal and other managerial personnel. The competition for personnel in the industries in which we operate is intense and our personnel are often presented with compelling new opportunities. Our personnel may terminate their employment at any time for any reason, and in the recent past, a number of our talented personnel have terminated their employment with us to seek other opportunities. Loss of personnel may result in increased costs for replacement hiring and training. If we fail to attract and hire new personnel, or retain and motivate our current personnel, we may not be able to operate our businesses effectively, serve our users and customers properly or maintain the quality of our products and services.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Given the tenure and experience of our Chief Executive Officer, and his guiding role in developing our business and growth strategy since our inception, our growth may be inhibited, or our operations may be impaired, if we were to lose his services.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our growth and success depends to a significant extent on our ability to retain Benjamin Wolin, our Chief Executive Officer, who co-founded our company and has led the growth and management of our business since its inception. The loss of the services of Mr. Wolin could result in our inability to manage our operations effectively and to implement our business strategy. This may cause our stock price to fluctuate or decline. Further, we cannot assure you that we would be able to successfully integrate a newly-hired chief executive officer with our existing management team.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Risks Related to Our Intellectual Property and Technology Platform</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">If our intellectual property and technologies are not adequately protected to prevent use or misappropriation by our competitors, the value of our brand and other intangible assets may be diminished, and our business may be adversely affected.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our future success and competitive position depend in part on our ability to protect our proprietary technologies and intellectual property both in the U.S. and in foreign countries. We rely, and expect to continue to rely, on a combination of confidentiality and licensing agreements with</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">our employees, consultants and third parties with whom we have relationships, along with trademark, copyright, patent and trade secret protection laws, to protect our proprietary technologies and intellectual property. These measures and agreements may not effectively prevent disclosure of confidential information, including trade secrets, and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. We could potentially lose future intellectual property protection if any unauthorized disclosure of such information occurs.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We rely on our trademarks, trade names and brand names to distinguish our products and services from the products and services of our competitors, and have registered or applied to register many of these trademarks. We cannot assure you that our trademark applications will be approved. Third parties may also oppose our trademark applications, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we may be forced to rebrand our products and services, which could result in a loss of brand recognition, and could require us to devote resources to advertising and marketing new brands.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We also possess intellectual property rights in aspects of our content, search technology, software products and other processes. However, we do not register copyrights in most of our content. Copyrights of U.S. origin must be registered before the copyright owner may bring an infringement suit in the U.S. If one of our unregistered copyrights of U.S. origin is infringed by a third party, we will need to register the copyright before we can file an infringement suit in the U.S., and our remedies in any such infringement suit may be limited. Typically, our content is primarily protected by user agreements that limit access to and use of our content. Compliance with</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">use restrictions is difficult to monitor, and our copyright rights may be more difficult to enforce than other forms of intellectual property rights.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We have applied for patent protection in the U.S. relating to certain products, processes and services. We may also rely on unpatented proprietary technology. We cannot assure you that the steps we take will be adequate to protect our technologies and intellectual property, that our patent applications will lead to issued patents, that others will not develop or patent similar or superior technologies, products or services, that our patents and other intellectual property will not be challenged, invalidated or circumvented by others or that the patents that we own will be of sufficient scope or strength to provide us with any meaningful protection or commercial advantage.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The legal standards relating to the validity, enforceability and scope of protection of intellectual property rights in Internet-related industries are uncertain and still evolving. If the protection of our technologies and intellectual property is inadequate to prevent use or appropriation by third parties, the value of our brand and other intangible assets may diminish. In addition, third parties may knowingly or unknowingly infringe our patents, copyrights, trademarks and other intellectual property rights, and litigation may be necessary to protect and enforce our intellectual property rights. Any such litigation could be costly and divert management’s attention and resources away from our business. We also expect that the more successful we are, the more likely that competitors will claim that we infringe on their intellectual property or proprietary rights. Even if these claims do not result in liability to us, we could incur significant costs in investigating and defending against these claims.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Our ability to deliver personalized content and to measure the performance of advertising campaigns depends on our ability to collect and use data, and any limitations on the collection and use of this data could significantly diminish the value of our solutions.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our ability to deliver personalized content and measure and optimize the performance of marketing campaigns depends on our ability to utilize the data we collect directly from our users, data we collect from user engagement with the <i>Everyday Health </i>portfolio and data we obtain from third parties. Our users voluntarily provide us with demographic and other information when they register for one of our websites or mobile applications. We also employ cookies and other personal identifiers to personalize content and advertising. Cookies are small files placed on an Internet user’s computer that are used to collect information related to the user, such as the history of the user’s interactions with our properties or third-party websites. Lastly, we purchase data from third party sources to augment our user profiles so we are better able to personalize content and better target our marketing programs.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">If changes in user sentiment regarding the sharing of information results in a significant number of visitors to our websites and applications refusing to provide us with demographic information or information about their specific health interests, our ability to personalize content for our users and provide targeted marketing solutions would be impaired. Likewise, if our users choose to opt-out of having their data used for behavioral targeting, it would be more difficult for us to offer targeted marketing programs to our customers. In addition, a material increase in the number of users who either opt out of accepting cookies or who use browsers, devices or applications that limit the use of cookies or other tracking technologies could negatively impact our ability to collect valuable data and provide advertising solutions to our clients.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We append data from third party sources to augment our user profiles. If we are unable to acquire data from third party sources for whatever reason, or if there is a marked increase in the cost of obtaining such data, our ability to personalize content and provide targeted marketing solutions could be negatively impacted.</p><p class="s45" style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Our possession and use of personal information presents risks that could harm our business. Unauthorized disclosure or manipulation of such data, whether through breach of our network security or otherwise, could expose us to costly litigation and damage our reputation.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our operations are dependent in part on our ability, and that of our hosting providers, to maintain our computer and telecommunications systems in effective working order and to protect our systems against damage from fire, theft, natural disaster, power loss, telecommunications failure, hacker attacks, computer viruses and other events beyond our control. Maintaining our network security is of critical importance because we use and store confidential user, employee and other sensitive data, such as names, addresses, credit card numbers and other personal information, including information about a user’s health interests.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We and our vendors use commercially available encryption technology when transmitting sensitive personal information over public networks. We also use security and business controls to limit access to, and use of, personal information. Third parties may be able to circumvent these security and business measures by developing and deploying viruses, worms and other malicious software programs that are designed to attack or infiltrate our systems and networks. In addition, employee error, malfeasance or other errors in the storage, use or transmission of personal information could result in a breach of registered user or employee privacy.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">If third parties improperly obtain and use the personal information of our registered users or employees, we may be required to expend significant resources to resolve these problems. A major breach of our network security and systems could have serious negative consequences for our businesses, including:</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">possible fines, penalties and damages;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">class action lawsuits;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">reduced demand for our content offerings and advertising-based services;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">an unwillingness of users to provide us with their credit card or payment information;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">an unwillingness of registered users to provide us with personal information; and</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">harm to our reputation and brand.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Finally, privacy concerns in general may cause visitors to avoid online websites that collect information and may indirectly inhibit market acceptance of our products and services. In addition, if our privacy practices are deemed unacceptable by watchdog groups or privacy advocates, such groups may attempt to block access to our properties or disparage our reputation and business.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">As a creator and a distributor of content over the Internet, we face potential liability for legal claims based on the nature and content of the materials that we create or distribute.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Users access health-related content through our portfolio, including information regarding particular medical conditions, diagnosis and treatment and possible adverse reactions or side effects from medications. If our content, or content we obtain from third parties, contains inaccuracies, it is possible that consumers who rely on that content or others may make claims against us with various causes of action. Although the properties in our portfolio contain terms and conditions, including disclaimers of liability, that are intended to reduce or eliminate our liability, third parties may claim that these online agreements are unenforceable. The law governing the validity and enforceability of online agreements is still evolving and subject to uncertainty. A finding by a court that these agreements are invalid and that we are subject to liability could harm our business and require us to make costly changes to our properties and related content policies.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: justify;">We have editorial procedures in place to control the quality of our content offerings. However, our editorial and other quality control procedures may not be sufficient to ensure that there are no errors or omissions in our content offerings or to prevent such errors and omissions in content that</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">is controlled by our partners. Even if potential claims do not result in liability to us, investigating and defending against these claims could be expensive and time consuming and could divert management’s attention away from our operations.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">If we become subject to these types of claims and are not successful in our defense, we may be forced to pay substantial damages. Our insurance may not adequately protect us against these claims. The filing of these claims may result in negative publicity and also damage our reputation as a high quality and trusted provider of health and wellness content and services.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Intellectual property claims against us could be costly and result in the loss of significant rights related to, among other things, our properties and advertising and marketing activities.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">From time to time, third parties may allege that we have violated their intellectual property rights. If we are forced to defend ourselves against intellectual property infringement claims, regardless of the merit or ultimate result of such claims, we may face costly litigation, diversion of technical and management personnel, limitations on our ability to use our current properties or inability to market or provide our content offerings or advertising-based services. As a result of any such dispute, we may have to:</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">develop new non-infringing technology;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">pay damages;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">enter into royalty or licensing agreements;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">cease providing certain content or advertising-based services; or</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">take other actions to resolve the claims.</p></li></ul><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">These actions, if required, may be costly, time-consuming or unavailable on terms acceptable to us, if at all. In addition, many of our partnering agreements require us to indemnify our partners for third-party intellectual property infringement claims, which could increase the cost to us of an adverse ruling in such an action.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Furthermore, we face potential suits and liability for negligence, copyright, patent or trademark infringement or other claims based on the nature of our content. These claims could potentially arise with respect to owned, licensed or user-provided content. Litigation to defend these claims could be costly, and any other liabilities we incur in connection with the claims could be significant.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In addition, we could be exposed to liability in connection with material posted to the properties in our portfolio and on social media websites by our employees and our users. Many of the properties in our portfolio offer consumers an opportunity to post comments and opinions and we may share such content on social media websites. Some of this user-provided content may infringe on third-party intellectual property rights or privacy rights or may otherwise be subject to challenge under copyright laws. Moreover, we could face claims for making such user-provided content available on our properties if users rely on such information to their detriment, particularly if the information relates to medical diagnosis and treatment. Such claims could divert management’s time and attention away from our business and result in significant costs to us, regardless of the merit of these claims.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">If we cannot protect our domain names, our ability to successfully promote our brands will be impaired.</p><p class="s45" style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;"><a href="http://www.EverydayHealth.com/" class="s46" target="_blank">We currently own various web domain names, including </a>www.EverydayHealth.com <a href="http://www.MedPageToday.com/" class="s46" target="_blank">and </a><a href="http://www.MedPageToday.com/" class="a" target="_blank">www.MedPageToday.com</a><span class="p">, that are critical to the operation of our business. The acquisition and maintenance of domain names, or Internet addresses, is generally regulated by governmental agencies and domain name registrars. The regulation of domain names in the U.S. and in foreign countries is subject to change. Governing bodies may establish additional top-level domains, appoint additional domain name registrars or modify the requirements for holding domain names. As a</span></p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">result, we may be unable to acquire or maintain relevant domain names in all countries in which we conduct business. We may be unable to prevent third parties from acquiring domain names that are similar to, infringe upon or otherwise decrease the value of our trademarks and other proprietary rights. We may not be able to successfully implement our business strategy of establishing a strong brand for <i>Everyday Health </i>if we cannot prevent others from using similar domain names. This failure could impair our ability to increase market share and revenues.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Interruption or failure of our information technology and communications systems could impair our ability to effectively deliver our services, which could negatively impact our operating results.</p><p style="padding-top: 7pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Our business depends on the continuing operation of our technology infrastructure and systems.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Any damage to or failure of our systems could result in interruptions in our ability to deliver offerings quickly and accurately and/or process visitors’ responses emanating from our various properties. Interruptions in our service could disrupt our business, result in the disclosure or misuse of confidential or proprietary information, reduce our revenues and profits, and damage our reputation if people believe our systems are unreliable. Our systems and operations are vulnerable to damage or interruption from earthquakes, terrorist and/or cyber attacks, floods, fires, power loss, break-ins, security breaches, hardware or software failures, telecommunications failures, computer viruses or other attempts to harm our systems and similar events.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We rely on third-party vendors, including data center and Internet bandwidth providers. Any disruption in the network access or co-location services provided by these third-party providers or any failure of these third-party providers to handle current or higher volumes of use could significantly harm our business. We may not maintain redundant systems or facilities for some of these services. In the event of a catastrophic event with respect to one or more of these systems or facilities, we may experience an extended period of system unavailability, which could negatively impact our relationship with our users. In addition, system failures may result in loss of data, including user registration data, business intelligence data, content, and other data critical to the operation of our online services, which could cause significant harm to our business and our reputation. Any financial or other difficulties our providers face may have negative effects on our business, the nature and extent of which we cannot predict.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In addition, as the number of properties in our portfolio and users who access our portfolio increases, our technology infrastructure may not be able to meet the increased demand. A sudden and unexpected increase in the volume of usage could strain the capacity of our technology infrastructure. Any capacity constraints we experience could lead to slower response times or system failures and adversely affect the availability of properties and the level of consumer usage, which could result in the loss of customers or revenue or harm to our business and results of operations.</p><p style="padding-top: 7pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Any unscheduled interruption in our service would result in an immediate loss of revenue.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Frequent or persistent system failures that result in the unavailability of any of the properties in our portfolio or slower response times could reduce the number of users accessing our properties, impair our delivery of advertisements and harm the perception of our portfolio as reliable, trustworthy and consistent sources of information. Our insurance policies provide only limited coverage for service interruptions and may not adequately compensate us for any losses that may occur due to any failures or interruptions in our systems.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Risks Related to Regulation of Our Industry</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Laws and standards relating to data collection and use practices and the privacy of Internet users and other individuals could impair our efforts to maintain and grow our audience, thereby decreasing our advertising and sponsorship revenues.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We collect information from users who register to access certain content on our portfolio, as well as from third party sources of data. Subject to the ability of our users to decline, we may use this information to provide our users content and advertising that may be of interest to them. We may also share information about registered users with our advertisers. Internet user privacy and the</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">use of our users’ information to track online activities are issues that are subject to rigorous regulatory discussions and analysis both in the U.S. and abroad. We have privacy policies posted on our properties that we believe comply with laws applicable to us requiring notice about our information collection, use and disclosure practices. The U.S. federal and various state governments have adopted or proposed limitations on the collection, distribution and use of personal information of Internet users. Several foreign jurisdictions, including the European Union and Canada, have adopted legislation, including directives or regulations, that may limit our collection and use of information from Internet users in these jurisdictions. Enforcement by regulators, including the FTC, requires us to provide consumers with notice, choice, security and access with respect to such information. The standards are subject to interpretation by courts and other governmental authorities. We cannot assure you that the privacy policies and other statements we provide to users of properties in our portfolio, or our practices with respect to these matters, will be found sufficient to protect us from liability or adverse publicity in this area. A determination by a government agency, court or other governmental authority that any of our practices do not meet applicable standards or regulations, or the implementation of new standards or requirements, could result in liability and adversely affect our business. In addition, inquiries or proceedings involving foreign or</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">U.S. data protection authorities may be expensive or time consuming, and their outcome is uncertain. Furthermore, we cannot assure you that our advertisers are currently in compliance, or will remain in compliance, with their own privacy policies, regulations governing consumer privacy or other applicable legal requirements.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In addition, growing public concern about privacy, data security and the collection, distribution and use of personal information has led to self-regulation of these practices by the Internet advertising and direct marketing industry. We participate in the DAA self-regulatory program under which we provide consumers with notice about our use of cookies and our collection and use of data in connection with the delivery of targeted advertising. Ensuring compliance with these industry standards could negatively impact our revenues or result in increased costs. Failure to comply with current or new industry standards could create liability for us, damage our reputation and result in a loss of users and advertisers.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We also may be subject to COPPA, which applies to operators of commercial websites and online services directed to U.S. children under the age of 13 that collect personal information from children, and to operators of general audience websites with actual knowledge that they are collecting information from U.S. children under the age of 13. Our properties are not directed at children under the age of 13, and our registration process utilizes age screening in order to prevent under-age registrations. We believe that we are in compliance with COPPA. COPPA, however, is subject to interpretation by courts and other governmental authorities. The failure to accurately anticipate the application, interpretation or legislative expansion of this law could create liability for us, result in adverse publicity and negatively affect our business.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Additionally, more burdensome laws or regulations, including consumer privacy and data security laws, could be enacted or applied to us or our advertising customers. Such laws or regulations could impair our ability to collect user information that helps us to provide more targeted advertising to our users, thereby impairing our ability to maintain and grow our audience and maximize advertising and sponsorship revenues from our customers.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">We face potential liability related to the privacy and security of health-related information we collect from or on behalf of our consumers.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: justify;">The privacy and security of information about the physical or mental health or condition of an individual is an area of significant focus in the U.S. because of heightened privacy concerns and the potential for significant consumer harm from the misuse of such sensitive data. We have procedures and technology in place intended to safeguard the information we receive from users of our services from unauthorized access or use.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Privacy Standards and Security Standards under HIPAA establish a set of basic national privacy and security standards for the protection of individually identifiable health information by</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services. Notably, whereas HIPAA previously directly regulated only these covered entities, HITECH makes certain of HIPAA’s Privacy and Security Standards directly applicable to covered entities’ business associates. As a result, business associates are now subject to significant civil and criminal penalties for failure to comply with applicable Privacy and Security Standards. Moreover, HITECH creates a new requirement to report certain breaches of unsecured, individually identifiable health information and imposes penalties on entities that fail to do so. Additionally, certain states have adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Some of our current or future products and services may involve the collection of individually identifiable health information for HIPAA covered entities. In addition, we may sign business associate agreements in connection with the provision of the products and services developed for other third parties. If our data practices do not comply with the requirements of HIPAA or HITECH, we may be directly subject to liability. In addition, if our security practices do not comply with our contractual obligations, we may be subject to liability for breach of those obligations.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">HITECH also creates obligations for us to report any unauthorized use or disclosure of protected health information to our covered entity clients. The 2013 final HITECH omnibus rule modifies the breach reporting standard in a manner that will likely make more data security incidents qualify as reportable breaches. Any liability from a failure to comply with the requirements of HIPAA or HITECH, to the extent such requirements are deemed to apply to our operations, or contractual obligations, could subject us to significant civil or criminal penalties and adversely affect our financial condition. The costs of complying with privacy and security related legal and regulatory requirements are burdensome and could have a material adverse effect on our results of operations. These new provisions, as modified, will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us, as well as our clients and strategic partners. In addition, we are unable to predict what changes to the HIPAA Privacy Standards and Security Standards might be made in the future or how those changes could affect our business. Any new legislation or regulation in the area of privacy and security of personal information, including personal health information, could also adversely affect our business operations.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Developments in the healthcare industry could adversely affect our business.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">A significant portion of our advertising and sponsorship revenues is derived from the healthcare industry, including pharmaceutical, over-the-counter and consumer-packaged-goods companies, and could be affected by changes affecting healthcare spending. Likewise, we intend to grow our product and service offerings to payors, providers and employers and industry changes affecting healthcare spending could impact the market for these offerings. General reductions in expenditures by healthcare industry participants could result from, among other things:</p><ol id="l7"><ul id="l8"><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">government regulation or private initiatives that affect the manner in which healthcare industry participants interact with consumers and the general public;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">consolidation of healthcare industry participants;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">reductions in governmental funding for healthcare; and</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">adverse changes in business or economic conditions affecting pharmaceutical companies or other healthcare industry participants.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Even if general expenditures by industry participants remain the same or increase, developments in the healthcare industry may result in reduced spending in some or all of the specific market segments that we serve now or in the future. For example, use of our content offerings and the sale of our products and services could be affected by:</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">changes in the design and provision of health insurance plans;</p></li><li style="padding-top: 4pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">a decrease in the number of new drugs or pharmaceutical products coming to market; and</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: justify;"><p style="display: inline;">decreases in marketing expenditures by pharmaceutical companies as a result of governmental regulation or private initiatives that discourage or prohibit advertising or sponsorship activities by pharmaceutical companies.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In addition, our advertising customers’ expectations regarding pending or potential industry developments may also affect their budgeting processes and spending plans with us.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The healthcare industry has changed significantly in recent years. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or, collectively, PPACA, was signed into law in March 2010 and makes extensive changes to the system of healthcare insurance and benefits in the U.S. In general, PPACA seeks to reduce healthcare costs and decrease the number of uninsured legal U.S. residents by, among other things, requiring individuals to carry, and certain employers to offer, health insurance or be subject to penalties.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">PPACA also imposes new regulations on health insurers, including guaranteed coverage requirements, prohibitions on certain annual and all lifetime limits on amounts paid on behalf of or to plan members, increased restrictions on rescinding coverage, establishment of minimum medical loss ratio requirements, a requirement to cover certain preventive services on a first dollar basis, the establishment of state insurance exchanges and essential benefit packages, and greater limitations on how health insurers price certain of their products. PPACA also enhances remedies against fraud and abuse and contains provisions that will affect the revenues and profits of pharmaceutical and medical device companies, including new taxes on certain sales of their products. In addition, other legislative changes have been proposed and adopted since PPACA was enacted. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and accordingly, our financial operations.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We expect that significant changes to the healthcare industry will continue to occur. However, the timing and impact of developments in the healthcare industry are difficult to predict. We cannot assure you that the demand for our offerings will continue to exist at current levels or that we will have adequate technical, financial and marketing resources to react to changes in the healthcare industry. However, we believe that certain aspects of PPACA and future implementing regulations and other healthcare reform initiatives that seek to reduce healthcare costs may create opportunities for our company, including with respect to our health tools and, more generally, with respect to our capabilities in providing health and wellness information and education. However, we cannot yet determine the scope of any such opportunities or what competition we may face in our efforts to pursue such opportunities.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Government regulation of healthcare creates risks and challenges with respect to our compliance efforts and our business strategies.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The healthcare industry is highly regulated and subject to changing political, legislative, regulatory and other influences. Existing and future laws and regulations affecting the healthcare industry could create unexpected liabilities for us, cause us to incur additional costs and restrict our operations. Many healthcare laws are complex, and their application may not be clear. Our failure to accurately anticipate the application of these laws and regulations, or other failure to comply with such laws and regulations, could create liability for us. Even in areas where we are not subject to healthcare regulation directly, we may become involved in governmental actions or investigations through our relationships with customers that are regulated, and participation in such actions or investigations, even if we are not a party and not the subject of an investigation, may cause us to incur significant expenses.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">For example, there are federal and state laws that govern patient referrals, physician financial relationships and inducements to healthcare providers and patients. The federal healthcare programs’ anti-kickback law prohibits any person or entity from willingly offering, paying, soliciting or receiving anything of value, directly or indirectly, to induce or reward, or in return for either the referral of patients covered by Medicare, Medicaid and other federal healthcare programs or the</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">leasing, purchasing, ordering or arranging for or recommending the lease, purchase or order of any item, good, facility or service covered by these programs. Many states also have similar anti-kickback laws that are not necessarily limited to items or services for which payment is made by a federal healthcare program. Our sale of advertising and sponsorships to healthcare providers implicates these laws. However, we review our practices to ensure that we comply with all applicable laws. The laws in this area are broad and we cannot determine precisely how the laws will be applied to our business practices. Any determination by a state or federal regulatory agency that any of our practices violate any of these laws could subject us to liability and require us to change or terminate some portions of our business.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Further, we derive revenues from the sale of advertising and promotion of prescription and over-the-counter drugs. If the FDA or the FTC finds that any of the information provided on our portfolio of websites violates FDA or FTC regulations, they may take regulatory or judicial action against us and/or the advertiser of that information. State attorneys general may also take similar action based on their state’s consumer protection statutes. Any increase or change in regulation of advertising and promotion in the healthcare industry could make it more difficult for us to generate and grow our advertising and sponsorship revenues.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In addition, the practice of most healthcare professions requires licensing under applicable state law and state laws may further prohibit business entities from practicing medicine, which is referred to as the prohibition against the corporate practice of medicine. Similar state prohibitions may exist with respect to other licensed professions. We believe that we do not engage in the practice of medicine or any other licensed healthcare profession, or provide, through our portfolio of websites, professional medical advice, diagnosis, treatment or other advice that is tailored in such a way as to implicate state licensing or professional practice laws. However, a state may determine that some portion of our business violates these laws and may seek to have us discontinue those portions or subject us to penalties or licensure requirements. Any determination that we are a healthcare provider and acted improperly as a healthcare provider may result in liability to us.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We believe that none of our existing online services and mobile applications is subject to regulation as a medical device under applicable FDA regulations. However, it is possible that products and services that we may offer in the future could subject us to such regulation or that current rules could change or be interpreted to apply to some of our existing online services or mobile applications. Complying with such regulations could be burdensome and costly and could delay our introduction or new services or applications.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Changes in regulations could hurt our business and financial results.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">It is possible that new laws and regulations or new interpretations of existing laws and regulations in the U.S. and elsewhere will be adopted covering issues affecting our business, including:</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">privacy, data security and use of personally identifiable information;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">copyrights, trademarks and domain names; and</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">marketing practices, such as e-mail or direct marketing.</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Increased government regulation, or the application of existing laws to online activities, could:</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">decrease the growth rate of the Internet;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">negatively impact our ability to generate revenues;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">increase our operating expenses; or</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">expose us to significant liabilities.</p><p class="s45" style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Our business could be harmed if we are unable to correspond with existing and potential consumers by e-mail.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We use e-mail as a significant means of communicating with our existing and potential consumers and healthcare professionals. The laws and regulations governing the use of e-mail for marketing purposes continue to evolve, and the growth and development of the market for commerce over the Internet may lead to the adoption of additional legislation or changes to existing laws. Such laws may impose additional restrictions on our ability to send e-mail to our users or potential users.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Notably, the CAN-SPAM Act regulates commercial e-mails, provides a right on the part of the recipient to request the sender to stop sending messages, and establishes penalties for the sending of e-mail messages that are intended to deceive the recipient as to source or content. An action alleging our failure to comply with the CAN-SPAM Act and the adverse publicity associated with any such action could result in less user participation and lead to reduced revenues from advertisers. If we were found to be in violation of the CAN-SPAM Act, applicable state laws not preempted by the CAN-SPAM Act, or foreign laws regulating the distribution of e-mail, whether as a result of violations by our partners or if we were deemed to be directly subject to and in violation of these requirements, we could be exposed to damages or penalties.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In addition to legal restrictions on the use of e-mail, Internet service providers and others typically attempt to block the transmission of unsolicited e-mail, commonly known as spam. If an Internet service provider or software program identifies e-mail from us as spam, we could be placed on a restricted list that would block our e-mail to consumers or potential consumers who maintain e- mail accounts with these Internet service providers or who use these software programs.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Failure to maintain CME accreditation could adversely affect our ability to provide online CME as part of our MedPage Today offering.</p><p class="s45" style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;"><a href="http://www.MedPageToday.com/" class="s46" target="_blank">Physicians utilize </a>www.MedPageToday.com <span class="p">to fulfill their continuing medical education, or CME, obligations. Our CME activities, which are conducted as part of our </span>MedPage Today <span class="p">offering, are planned and implemented in accordance with the current Essential Areas and Elements and the Policies of the Accreditation Council for Continuing Medical Education, or ACCME, which oversees providers of CME credit, and other applicable accreditation standards. We currently rely on Projects In Knowledge as our ACCME-accredited provider in connection with our CME offering. ACCME’s standards for commercial support of CME are intended to assure, among other things, that CME activities of ACCME-accredited providers, such as Projects In Knowledge, are independent of “commercial interests,” which are defined as entities that produce, market, re-sell or distribute healthcare goods and services, excluding certain organizations. “Commercial interests,” and entities owned or controlled by “commercial interests,” are ineligible for accreditation by the ACCME.</span></p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">CME activities may be subject to government oversight or regulation by Congress, the FDA, the U.S. Department of Health and Human Services, and state regulatory agencies. Educational activities, including CME, directed at physicians have been subject to increased governmental</p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;"><a href="http://www.MedPageToday.com/" class="s46" target="_blank">scrutiny to ensure that sponsors do not influence or control the content of the activities. In the event that these regulatory challenges inhibit our ability to provide CME, or if Projects In Knowledge, our ACCME-accredited partner, elects to terminate its relationship with us and we are unable to identify a suitable replacement partner, our ability to continue to attract physicians to </a>www.MedPageToday.com <span class="p">may suffer.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Risks Related to Ownership of Our Common Stock</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Our share price may be volatile, which could result in substantial losses for investors.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The market price of shares of our common stock may be subject to wide fluctuations. For example, since our initial public offering, or IPO, in March 2014, our common stock has traded at prices as high as $19.89 per share and as low as $10.86 per share. The market price of our common</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">stock may continue to fluctuate in response to the many risk factors listed in this section and other factors beyond our control, including:</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">actual or anticipated fluctuations in our key operating metrics, financial condition and operating results;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">issuance of new or updated research or reports by securities analysts;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">our announcement of actual results for a fiscal period that are higher or lower than projected or expected results, or our announcement of revenues or earnings guidance that is higher or lower than expected;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">sales or expected sales of additional common stock;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">announcements from, or operating results of, our competitors; or</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">general economic and market conditions.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Furthermore, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations,</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">may cause our common stock price to decline. As a result, you may lose some or all of your investment in our common stock. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">If we fail to maintain proper and effective internal and disclosure controls, our ability to produce accurate financial statements and other disclosures on a timely basis could be impaired.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. Commencing with the fiscal year ending December 31, 2015, we must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting in our Form 10-K for that year, as required by Section 404 of the Sarbanes-Oxley Act. For as long as we remain an “emerging growth company” under the Jumpstart Our Business Startups, or JOBS Act, we expect to avail ourselves of the exemption from the requirement that our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Compliance with the Sarbanes-Oxley Act will require that we incur substantial additional professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. If we or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, or if we are unable to comply with the requirements of Section 404 in a timely manner or assert that our internal control over financial reporting is effective, the market price of our stock could decline and we could be subject to sanctions or investigations by the New York Stock Exchange, the SEC or other regulatory authorities.</p><p class="s45" style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">As an “emerging growth company” under the JOBS Act we are permitted to, and intend to, rely on exemptions from certain disclosure requirements.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We are an “emerging growth company” and, for as long as we continue to be an “emerging growth company,” we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies including, but not limited to, not being required to have our independent registered public accounting firm audit our internal control over financial reporting as required by Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and not being required to hold a nonbinding advisory vote on executive compensation or obtain stockholder approval of “golden parachute” payments. We could be an “emerging growth company” for up to five years, although, if we have more than $1.0 billion in annual revenue, the market value of our common stock that is held by non-affiliates exceeds $700 million as of June 30 of any year, or we issue more than $1.0 billion of non-convertible debt over a three-year period before the end of that five-year period, we would cease to be an “emerging growth company” as of the December 31 following such occurrence. Investors may find our common stock less attractive if we choose to rely on these exemptions, in which case the price of our common stock may suffer or there may be a less active trading market for our common stock and our stock price may be more volatile.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Our reported financial results may be adversely affected by changes in accounting principles applicable to us.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Generally accepted accounting principles in the U.S. are subject to interpretation by the Financial Accounting Standards Board, the American Institute of Certified Public Accountants, the SEC and various bodies formed to promulgate and interpret appropriate accounting principles. A change in these principles or interpretations could have a significant effect on our reported financial results, and could affect the reporting of transactions completed before the announcement of a change. In addition, the SEC has announced a multi-year plan that could ultimately lead to the use of International Financial Reporting Standards by U.S. issuers in their SEC filings. Any such change could have a significant effect on our reported financial results.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Our ability to raise capital in the future may be limited.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our business and operations may consume resources faster than we anticipate. In the future, we may need to raise additional funds through the issuance of new equity securities, debt or a combination of both. Additional financing may not be available on favorable terms, or at all. If adequate funds are not available on acceptable terms, we may be unable to fund our capital requirements. If we issue new debt securities, the debt holders would have rights senior to common stockholders to make claims on our assets, and the terms of any debt could restrict our operations, including our ability to pay dividends on our common stock. If we issue additional equity securities, existing stockholders will experience dilution, and the new equity securities could have rights senior to those of our common stock. Because our decision to issue securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings. Thus, our stockholders bear the risk of our future securities offerings reducing the market price of our common stock and diluting their interest.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Covenants in our credit facility restrict our operational flexibility.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The agreement governing our credit facility contains usual and customary restrictive covenants relating to our management and the operation of our business, including the following:</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">incurring additional indebtedness;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">making certain investments;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">disposing of assets;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">paying dividends and making other distributions to our stockholders;</p></li><li style="padding-top: 4pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">engaging in mergers and acquisitions; and</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">granting liens on our assets.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our credit facility also requires us to maintain specified financial ratios. Our ability to meet the financial covenants could be affected by events beyond our control. Failure to comply with any of the operational or financial covenants under our credit facility could result in a default, which could cause our lenders to accelerate the timing of payments and exercise their liens on substantially all of our assets, which would have a material adverse effect on our business, operating results and financial condition.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">We have significant debt service obligations as a result of our outstanding long-term indebtedness.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">As of December 31, 2014, we had $90.0 million of outstanding borrowings pursuant to our credit facility. Under the terms of this credit facility, as amended, we are required to make principal and interest payments on these borrowings through the maturity date of this facility in November 2019. As a result, we must use a significant portion of cash generated by our operations to satisfy our ongoing debt service obligations. Additionally, we will be required to repay, extend or refinance these borrowings when they become due, and there is no guarantee that we will be able to do so on reasonable terms or at all. If we are unable to meet our debt service obligations or to satisfy our obligations when they mature, our creditors could among other things, declare a default and accelerate the timing of payments and exercise their liens on substantially all of our assets, which would have a material adverse effect on our business, operating results and financial condition.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Provisions of our certificate of incorporation, bylaws and Delaware law could deter takeover attempts.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Various provisions in our certificate of incorporation and bylaws could delay, prevent or make more difficult a merger, tender offer, proxy contest or other attempt to acquire control of our company. Our stockholders might view any transaction of this type as being in their best interest since the transaction could result in a higher stock price than the then-current market price for our common stock. Among other things, our certificate of incorporation and bylaws:</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">authorize our Board of Directors to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">divide our Board of Directors into three classes so that only approximately one-third of the total number of directors is elected each year;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">permit directors to be removed only for cause and then only by a two-thirds vote of our stockholders;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">prohibit stockholders from calling a special meeting of stockholders;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">prohibit action by written consent of our stockholders; and</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">specify advance notice requirements for stockholder proposals and director nominations.</p></li></ul></ol><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We are subject to the provisions of Section 203 of the Delaware General Corporation Law regulating corporate takeovers and which has an anti-takeover effect with respect to transactions not approved in advance by our Board of Directors, including discouraging takeover attempts that might result in a premium over the market price for shares of our common stock. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of, and do not currently intend to opt out of, this provision.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders,</p><p class="s45" style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Pursuant to our amended and restated certificate of incorporation, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or (iv) any action asserting a claim governed by the internal affairs doctrine. Our amended and restated certificate of incorporation further provides that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provision. The forum selection clause in our amended and restated certificate of incorporation may limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Future sales of shares of our common stock by existing stockholders could depress the market price of our common stock.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. As of February 27, 2015, we had approximately 31.5 million shares of our common stock outstanding. The majority of these shares were acquired prior to our IPO and were subject to lock-up agreements prohibiting holders of these shares from selling any of their shares for a period of 180 days following our IPO. These lock-up agreements have expired and, as a result, a substantial number of our shares are now generally freely tradable, subject, in the case of sales by our affiliates, to the volume limitations and other provisions of Rule 144 under the Securities Act of 1933, as amended, or the Securities Act. If holders of these shares sell, or indicate an intent to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline significantly. In addition, certain holders of shares of our common stock, including certain holders of our existing warrants, may require us, subject to certain conditions, to prepare and file a registration statement under the Securities Act and are entitled to include their shares in any registration statement we may file for ourselves or other stockholders. If we register the resale of these shares in the future, the holders could sell those shares freely in the public market, without regard to the limitations of Rule 144. Furthermore, shares of our common stock subject to outstanding awards under our 2003 Stock Option Plan and our 2014 Equity Incentive Plan, as well as the shares of our common stock reserved for future issuance under our 2014 Equity Incentive Plan, under our 2014 Employee Stock Purchase Plan and upon exercise of outstanding warrants, will become eligible for sale in the public market in the future, subject to certain legal and contractual limitations. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline substantially.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">If securities or industry analysts change their recommendations regarding our stock adversely or cease coverage of our company, our stock price and trading volume could decline.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock, our stock price would likely decline. If one or more of these analysts ceases coverage of our company or fails to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</p><p class="s45" style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">We do not currently intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend solely on appreciation in the price of our common stock.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We have never declared or paid any cash dividends on our common stock and do not intend to do so for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. In addition, the provisions of our credit facility prohibit us from paying cash dividends without first obtaining the consent of our lenders. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future, and the success of an investment in shares of our common stock will depend upon any future appreciation in their value. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which you purchase your shares.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Item 1B. Unresolved Staff Comments.</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">None.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Item 2. Properties.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: justify;">Our corporate headquarters are currently located in a facility encompassing approximately 87,000 square feet of office space in a building at 345 Hudson Street in New York, New York pursuant to a lease which extends through October 2023.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We also lease office space in North Adams, Massachusetts; Washington, DC; Asheville, North Carolina; North Hollywood, California; Chicago, Illinois; and Mumbai, India; and utilize a third-party data center hosting facility located in Carlstadt, New Jersey and a back-up data center located in Scottsdale, Arizona.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We believe that our current facilities are generally in good operating condition and are sufficient to meet our needs for the foreseeable future.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Item 3. Legal Proceedings.</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">We are not currently subject to any material legal proceedings.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Item 4. Mine Safety Disclosures.</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">None.</p><p style="padding-top: 2pt;padding-left: 238pt;text-indent: 0pt;text-align: left;">PART II</p><p style="padding-top: 8pt;padding-left: 67pt;text-indent: -36pt;text-align: left;">Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Price Range of Our Common Stock</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our common stock has traded on the New York Stock Exchange under the symbol “EVDY” since our initial public offering in March 2014. As of February 27, 2015, there were 31,526,949 shares of our common stock outstanding, which were held by 83 holders of record of our common stock.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Because many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders. As of February 27, 2015, the closing price of our common stock as reported on the New York Stock Exchange was $14.30 per share.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The following table sets forth, for the periods indicated, the reported high and low sales prices per share of our common stock as reported on the New York Stock Exchange:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:68.6785pt" cellspacing="0"><tr style="height:11pt"><td style="width:304pt" colspan="2"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:40pt"><p class="s44" style="padding-left: 11pt;text-indent: 0pt;line-height: 8pt;text-align: left;">High</p></td><td style="width:36pt"><p class="s44" style="padding-left: 4pt;padding-right: 1pt;text-indent: 0pt;line-height: 8pt;text-align: center;">Low</p></td></tr><tr style="height:14pt"><td style="width:22pt"><p class="s43" style="text-indent: 0pt;text-align: right;">2014</p></td><td style="width:282pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:36pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:22pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:282pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: left;">First Quarter (beginning March 28, 2014). .......... ......... .</p></td><td style="width:40pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">$14.75</p></td><td style="width:36pt"><p class="s43" style="padding-left: 4pt;padding-right: 1pt;text-indent: 0pt;line-height: 11pt;text-align: center;">$13.01</p></td></tr><tr style="height:12pt"><td style="width:22pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:282pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: left;">Second Quarter ......... ......... ......... .......... ......... .</p></td><td style="width:40pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">19.89</p></td><td style="width:36pt"><p class="s43" style="padding-left: 9pt;padding-right: 1pt;text-indent: 0pt;line-height: 11pt;text-align: center;">11.84</p></td></tr><tr style="height:12pt"><td style="width:22pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:282pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: left;">Third Quarter. . ......... ......... ......... .......... ......... .</p></td><td style="width:40pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">19.24</p></td><td style="width:36pt"><p class="s43" style="padding-left: 9pt;padding-right: 1pt;text-indent: 0pt;line-height: 11pt;text-align: center;">12.70</p></td></tr><tr style="height:12pt"><td style="width:22pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:282pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: left;">Fourth Quarter ......... ......... ......... .......... ......... .</p></td><td style="width:40pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">15.21</p></td><td style="width:36pt"><p class="s43" style="padding-left: 9pt;padding-right: 1pt;text-indent: 0pt;line-height: 11pt;text-align: center;">10.86</p></td></tr><tr style="height:12pt"><td style="width:22pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: right;">2015</p></td><td style="width:282pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:36pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:22pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:282pt"><p class="s43" style="text-indent: 0pt;line-height: 10pt;text-align: left;">First Quarter (through February 27, 2015) .......... ......... .</p></td><td style="width:40pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 10pt;text-align: right;">$14.93</p></td><td style="width:36pt"><p class="s43" style="padding-left: 4pt;padding-right: 1pt;text-indent: 0pt;line-height: 10pt;text-align: center;">$13.47</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Dividend Policy</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We have never declared or paid any cash dividends on our capital stock, and we do not currently intend to pay any cash dividends on our common stock in the foreseeable future. We expect to retain future earnings, if any, to fund the development and growth of our business. In addition, our credit facility prohibits us from paying dividends on our common stock without first obtaining the consent of our lenders. Any future determination as to the declaration and payment of dividends, if any, will be at the discretion of our Board of Directors and will depend on then existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our Board of Directors may deem relevant.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Stock Performance Graph</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">We show below the cumulative total return to our stockholders during the period from</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">March 28, 2014 through December 31, 2014 in comparison to the cumulative return on the Russell 2000 Index and the Research Data Group (RDG) Internet Composite Index during that same period. The results assume that $100 was invested on March 28, 2014 in our common stock or March 31, 2014 in the indexes listed above, including reinvestment of dividends, if any.</p><p class="s47" style="padding-top: 3pt;padding-left: 87pt;text-indent: 0pt;text-align: left;">COMPARISON OF 9 MONTH CUMULATIVE TOTAL RETURN*</p><p class="s42" style="padding-left: 150pt;text-indent: 0pt;text-align: center;">Among Everyday Health, Inc., the Russell 2000 Index and the RDG Internet Composite Index</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="519" height="255" alt="image" src="NYSE_EVDY_2014/Image_035.png"/></span></p><p class="s48" style="padding-left: 46pt;text-indent: 0pt;text-align: left;">$160</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 46pt;text-indent: 0pt;text-align: left;">$140</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 46pt;text-indent: 0pt;text-align: left;">$120</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 46pt;text-indent: 0pt;text-align: left;">$100</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 51pt;text-indent: 0pt;text-align: left;">$80</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 51pt;text-indent: 0pt;text-align: left;">$60</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 51pt;text-indent: 0pt;text-align: left;">$40</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-left: 51pt;text-indent: 0pt;text-align: left;">$20</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s48" style="padding-top: 4pt;padding-left: 55pt;text-indent: 0pt;text-align: left;">$0</p><p class="s48" style="padding-left: 58pt;text-indent: 0pt;text-align: left;">3/28/14 4/14 5/14 6/14 7/14 8/14 9/14 10/14 11/14 12/14</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="35" height="8" alt="image" src="NYSE_EVDY_2014/Image_036.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="35" height="8" alt="image" src="NYSE_EVDY_2014/Image_037.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="35" height="8" alt="image" src="NYSE_EVDY_2014/Image_038.png"/></span></p><p class="s49" style="padding-left: 84pt;text-indent: 0pt;text-align: left;">Everyday Health, Inc. Russell 2000 RDG Internet Composite</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s50" style="padding-left: 72pt;text-indent: 0pt;text-align: left;">*$100 invested on 3/28/14 in stock or 3/31/14 in index, including reinvestment of dividends.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 19pt;text-align: left;">This information under “Stock Performance Graph” is not deemed filed with the SEC and is not to be incorporated by reference in any of our filings under the Securities Act or the Exchange Act, whether made before or after the date of this Annual Report on Form 10-K and irrespective of any general incorporation language in those filings.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Recent Sales of Unregistered Equity Securities</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">On November 13, 2014, we issued an aggregate of 45,822 shares of our common stock to an accredited investor pursuant to the net exercise, for no additional consideration, of a warrant to purchase 73,345 shares of our common stock at a purchase price of $4.91 per share.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">No underwriters were used in the foregoing transaction. The issuance of securities described in the paragraph above was deemed to be exempt from registration pursuant to an exemption from registration under the Securities Act in reliance upon Section 3(a)(9) of the Securities Act. Such holder received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration or an available exemption from such registration. All of the foregoing securities are deemed restricted securities for the purposes of the Securities Act.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Use of Proceeds</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Not applicable.</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Item 6. Selected Financial Data.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The following selected financial data should be read in conjunction with our consolidated financial statements and notes to our consolidated financial statements and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained elsewhere in this Annual Report on Form 10-K. The selected Consolidated Statements of Operations data for the years ended December 31, 2014, 2013 and 2012 and Consolidated Balance Sheet data as of December 31, 2014 and 2013 have been derived from our audited financial statements appearing elsewhere in this Annual Report on Form 10-K. The selected Consolidated Statements of Operations data for the years ended December 31, 2011 and 2010 and the Consolidated Balance Sheet data as of December 31, 2012, 2011 and 2010 were derived from our audited consolidated financial statements, which are not included in this Annual Report on Form 10-K. Historical results are not necessarily indicative of future results.</p><p class="s40" style="padding-top: 2pt;padding-left: 202pt;text-indent: 0pt;text-align: center;">                                        Year ended December  31,                                        </p><p class="s40" style="padding-top: 1pt;padding-left: 202pt;text-indent: 0pt;text-align: center;">        2014        <span class="s39">   </span>        2013       <span class="s39">   </span>        2012       <span class="s39">   </span>        2011      <span class="s39">  </span>       2010       </p><p class="s39" style="padding-top: 1pt;padding-left: 202pt;text-indent: 0pt;text-align: center;">(In thousands, except share and per share data)</p><p style="padding-top: 1pt;padding-bottom: 1pt;padding-left: 41pt;text-indent: -10pt;line-height: 87%;text-align: left;">Consolidated Statement of Operations Data:</p><table style="border-collapse:collapse;margin-left:28.8234pt" cellspacing="0"><tr style="height:11pt"><td style="width:204pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Revenues:</p></td><td style="width:259pt" colspan="5"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:204pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 10pt;text-align: right;">Advertising and sponsorship revenues . . . .</p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;line-height: 10pt;text-align: left;">$ 166,465</p></td><td style="width:47pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">$ 134,893</p></td><td style="width:51pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">$ 109,956</p></td><td style="width:51pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 10pt;text-align: right;">$ 96,191</p></td><td style="width:54pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 10pt;text-align: right;">$ 75,657</p></td></tr><tr style="height:11pt"><td style="width:204pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 10pt;text-align: right;">Premium services revenues .... ......... .. </p></td><td style="width:56pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 10pt;text-align: left;">17,860</p></td><td style="width:47pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">20,957</p></td><td style="width:51pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">23,536</p></td><td style="width:51pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 10pt;text-align: right;">29,582</p></td><td style="width:54pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 10pt;text-align: right;">35,564</p></td></tr><tr style="height:13pt"><td style="width:204pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 10pt;text-align: right;">Video production fees......... ......... .. </p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;line-height: 10pt;text-align: left;">                —</p></td><td style="width:47pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">              —</p></td><td style="width:51pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">         5,000</p></td><td style="width:51pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">              —</p></td><td style="width:54pt"><p class="s51" style="padding-right: 6pt;text-indent: 0pt;line-height: 10pt;text-align: right;">              —</p></td></tr><tr style="height:12pt"><td style="width:204pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Total revenues ....... ......... ......... .. </p></td><td style="width:56pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">184,325</p></td><td style="width:47pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">155,850</p></td><td style="width:51pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">138,492</p></td><td style="width:51pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: right;">125,773</p></td><td style="width:54pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">111,221</p></td></tr><tr style="height:12pt"><td style="width:204pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Operating expenses:</p></td><td style="width:56pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:47pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:54pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:204pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 9pt;text-align: right;">Cost of revenues ..... ......... ......... .. </p></td><td style="width:56pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 9pt;text-align: left;">49,296</p></td><td style="width:203pt" colspan="4"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 9pt;text-align: left;">43,338 40,543 40,985 45,039</p></td></tr><tr style="height:11pt"><td style="width:204pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 10pt;text-align: right;">Sales and marketing. . ......... ......... .. </p></td><td style="width:56pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 10pt;text-align: left;">48,605</p></td><td style="width:203pt" colspan="4"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 10pt;text-align: left;">44,385 38,603 36,266 26,972</p></td></tr><tr style="height:11pt"><td style="width:204pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 10pt;text-align: right;">Product development. ......... ......... .. </p></td><td style="width:56pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 10pt;text-align: left;">44,541</p></td><td style="width:203pt" colspan="4"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 10pt;text-align: left;">43,759 45,676 36,960 26,172</p></td></tr><tr style="height:13pt"><td style="width:204pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 10pt;text-align: right;">General and administrative.... ......... .. </p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;line-height: 10pt;text-align: left;">         30,041</p></td><td style="width:203pt" colspan="4"><p class="s51" style="text-indent: 0pt;line-height: 10pt;text-align: left;">       27,462 25,874 23,199 19,922</p></td></tr><tr style="height:14pt"><td style="width:204pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">Total operating expenses ...... ......... .. </p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;text-align: left;">       172,483</p></td><td style="width:203pt" colspan="4"><p class="s51" style="text-indent: 0pt;text-align: left;">     158,944 150,696 137,410 118,105</p></td></tr><tr style="height:13pt"><td style="width:204pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Income (loss) from operations. . . ......... .. </p></td><td style="width:56pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">11,842</p></td><td style="width:203pt" colspan="4"><p class="s43" style="padding-left: 18pt;text-indent: 0pt;line-height: 11pt;text-align: left;">(3,094) (12,204) (11,637) (6,884)</p></td></tr><tr style="height:11pt"><td style="width:204pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Interest expense, net . . . ......... ......... .. </p></td><td style="width:56pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(3,711)</p></td><td style="width:203pt" colspan="4"><p class="s43" style="padding-left: 18pt;text-indent: 0pt;line-height: 10pt;text-align: left;">(8,442) (4,898) (1,589) (1,572)</p></td></tr><tr style="height:13pt"><td style="width:204pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Other expense .......... ......... ......... .. </p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;line-height: 10pt;text-align: left;">         (4,114<span class="s43">)</span></p></td><td style="width:203pt" colspan="4"><p class="s51" style="text-indent: 0pt;line-height: 10pt;text-align: left;">          (359<span class="s43">)</span> (1,069<span class="s43">)</span> — (2,881<span class="s43">)</span></p></td></tr><tr style="height:23pt"><td style="width:204pt"><p class="s43" style="padding-top: 1pt;padding-left: 12pt;padding-right: 1pt;text-indent: -10pt;line-height: 10pt;text-align: left;">Income (loss) from continuing operations before provision for income taxes ...... .. </p></td><td style="width:56pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">4,017</p></td><td style="width:203pt" colspan="4"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-left: 13pt;text-indent: 0pt;line-height: 11pt;text-align: left;">(11,895) (18,171) (13,226) (11,337)</p></td></tr><tr style="height:13pt"><td style="width:204pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Benefit (provision) for income taxes...... .. </p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;line-height: 10pt;text-align: left;">           8,666</p></td><td style="width:203pt" colspan="4"><p class="s51" style="text-indent: 0pt;line-height: 10pt;text-align: left;">       (1,102<span class="s43">)</span> (1,026<span class="s43">)</span> 615 1,771</p></td></tr><tr style="height:13pt"><td style="width:204pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Income (loss) from continuing operations . .</p></td><td style="width:56pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">12,683</p></td><td style="width:203pt" colspan="4"><p class="s43" style="padding-left: 13pt;text-indent: 0pt;line-height: 11pt;text-align: left;">(12,997) (19,197) (12,611) (9,566)</p></td></tr><tr style="height:23pt"><td style="width:204pt"><p class="s43" style="padding-left: 12pt;padding-right: 4pt;text-indent: -10pt;line-height: 86%;text-align: left;">Loss from discontinued  operations,  net  of tax ......... .......... ......... ......... .. </p></td><td style="width:56pt"><p class="s51" style="padding-top: 8pt;text-indent: 0pt;text-align: left;">                —</p></td><td style="width:203pt" colspan="4"><p class="s51" style="padding-top: 8pt;text-indent: 0pt;text-align: left;">       (5,239<span class="s43">)</span> (3,257<span class="s43">)</span> (2,590<span class="s43">)</span> —</p></td></tr><tr style="height:14pt"><td style="width:204pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Net income (loss)....... ......... ......... .. </p></td><td style="width:56pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s51" style="text-indent: 0pt;text-align: left;">$ 12,683</p></td><td style="width:203pt" colspan="4"><p class="s51" style="text-indent: 0pt;text-align: left;">$ (18,236<span class="s43">) </span>$ (22,454<span class="s43">) </span>$ (15,201<span class="s43">) </span>$ (9,566<span class="s43">)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s52" style="text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="58" height="1" alt="image" src="NYSE_EVDY_2014/Image_039.png"/></span> <span><img width="58" height="1" alt="image" src="NYSE_EVDY_2014/Image_040.png"/></span> <span><img width="58" height="1" alt="image" src="NYSE_EVDY_2014/Image_041.png"/></span></p></td></tr><tr style="height:13pt"><td style="width:204pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Basic net income (loss) attributable to</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:203pt" colspan="4"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p style="padding-left: 41pt;text-indent: 0pt;line-height: 10pt;text-align: left;">common stockholders per common share:</p><p style="padding-top: 1pt;padding-left: 51pt;text-indent: -10pt;line-height: 86%;text-align: left;">Net income (loss) attributable to common stockholders from continuing</p><p style="padding-left: 51pt;text-indent: 0pt;line-height: 10pt;text-align: left;">operations (1)...... ......... ......... .. $ 0.19 $ (2.55) $ (4.01) $ (2.74) $ (2.16)</p><p style="padding-left: 51pt;text-indent: -10pt;line-height: 87%;text-align: left;">Net loss attributable to common stockholders from discontinued</p><p style="padding-left: 51pt;text-indent: 0pt;line-height: 10pt;text-align: left;">operations, net of tax ....... ......... .. <u>$ —</u> <u>$ (1.03</u>) <u>$ (0.68</u>) <u>$ (0.56</u>) <u>$ —</u></p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Net income (loss) attributable to common</p><p style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">stockholders (1) ...... ......... ......... .. <u>$ 0.19</u> <u>$ (3.57</u>) <u>$ (4.69</u>) <u>$ (3.30</u>) <u>$ (2.16</u>)</p><p style="padding-top: 3pt;padding-left: 41pt;text-indent: -10pt;line-height: 86%;text-align: left;">Diluted net income (loss) attributable to common stockholders per common share:</p><p style="padding-top: 1pt;padding-left: 51pt;text-indent: -10pt;line-height: 86%;text-align: left;">Net income (loss) attributable to common stockholders from continuing</p><p style="padding-left: 51pt;text-indent: 0pt;line-height: 10pt;text-align: left;">operations (1)...... ......... ......... .. $ 0.17 $ (2.55) $ (4.01) $ (2.74) $ (2.16)</p><p style="padding-left: 51pt;text-indent: -10pt;line-height: 87%;text-align: left;">Net loss attributable to common stockholders from discontinued</p><p style="padding-left: 51pt;text-indent: 0pt;line-height: 10pt;text-align: left;">operations, net of tax ....... ......... .. <u>$ —</u> <u>$ (1.03</u>) <u>$ (0.68</u>) <u>$ (0.56</u>) <u>$ —</u></p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Net income (loss) attributable to common</p><p style="padding-left: 41pt;text-indent: 0pt;line-height: 11pt;text-align: left;">stockholders (1) ...... ......... ......... .. <u>$ 0.17</u> <u>$ (3.57</u>) <u>$ (4.69</u>) <u>$ (3.30</u>) <u>$ (2.16</u>)</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Weighted-average common shares</p><table style="border-collapse:collapse;margin-left:38.799pt" cellspacing="0"><tr style="height:11pt"><td style="width:194pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">outstanding:</p></td><td style="width:255pt" colspan="2"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:194pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Basic ....... .......... ......... ......... .. </p></td><td style="width:55pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">24,259,395</p></td><td style="width:200pt"><p class="s43" style="padding-left: 16pt;padding-right: 13pt;text-indent: 0pt;line-height: 10pt;text-align: center;">5,103,351 4,791,474 4,607,675 4,428,478</p></td></tr><tr style="height:11pt"><td style="width:194pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Diluted..... .......... ......... ......... .. </p></td><td style="width:55pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">26,911,782</p></td><td style="width:200pt"><p class="s43" style="padding-left: 16pt;padding-right: 13pt;text-indent: 0pt;line-height: 9pt;text-align: center;">5,103,351 4,791,474 4,607,675 4,428,478</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="63" height="1" alt="image" src="NYSE_EVDY_2014/Image_042.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l9"><li style="padding-left: 49pt;text-indent: -17pt;text-align: left;"><p style="display: inline;">For the year ended December 31, 2014, basic and diluted net income attributable to common stockholders per share includes an $8.1 million deemed dividend from the conversion of our Series G preferred stock on April 2, 2014. Refer to “Note 10—Common Stock and Redeemable Convertible Preferred Stock” in the notes to the consolidated financial statements included in Part II, Item 8 of this Form 10-K.</p><p class="s40" style="padding-top: 2pt;padding-left: 251pt;text-indent: 0pt;text-align: left;">                                         As of December 31,                                         </p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:28.8244pt" cellspacing="0"><tr style="height:10pt"><td style="width:217pt" rowspan="2"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:49pt"><p class="s44" style="padding-right: 5pt;text-indent: 0pt;line-height: 8pt;text-align: right;">     2014     </p></td><td style="width:47pt"><p class="s44" style="padding-left: 5pt;text-indent: 0pt;line-height: 8pt;text-align: left;">     2013     </p></td><td style="width:55pt"><p class="s44" style="padding-left: 7pt;text-indent: 0pt;line-height: 8pt;text-align: left;">     2012     </p></td><td style="width:47pt"><p class="s44" style="padding-left: 2pt;text-indent: 0pt;line-height: 8pt;text-align: left;">     2011     </p></td><td style="width:48pt"><p class="s44" style="padding-left: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">     2010     </p></td></tr><tr style="height:11pt"><td style="width:49pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:47pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:55pt"><p class="s54" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">(in thousands)</p></td><td style="width:47pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:217pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Consolidated Balance Sheet Data:</p></td><td style="width:49pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:47pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:55pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:47pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:217pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Cash and cash equivalents. . . ......... ......... </p></td><td style="width:49pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">$ 50,729</p></td><td style="width:47pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ 16,242</p></td><td style="width:55pt"><p class="s43" style="padding-left: 7pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ 23,888</p></td><td style="width:47pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ 27,238</p></td><td style="width:48pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ 15,405</p></td></tr><tr style="height:12pt"><td style="width:217pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Working capital .... ......... ......... ......... </p></td><td style="width:49pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">82,494</p></td><td style="width:47pt"><p class="s43" style="padding-left: 15pt;text-indent: 0pt;line-height: 11pt;text-align: left;">30,221</p></td><td style="width:55pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">20,617</p></td><td style="width:47pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4,585</p></td><td style="width:48pt"><p class="s43" style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: left;">14,808</p></td></tr><tr style="height:12pt"><td style="width:217pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Total assets......... ......... ......... ......... </p></td><td style="width:49pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">313,491</p></td><td style="width:47pt"><p class="s43" style="padding-left: 10pt;text-indent: 0pt;line-height: 11pt;text-align: left;">192,282</p></td><td style="width:55pt"><p class="s43" style="padding-left: 12pt;text-indent: 0pt;line-height: 11pt;text-align: left;">195,660</p></td><td style="width:47pt"><p class="s43" style="padding-left: 7pt;text-indent: 0pt;line-height: 11pt;text-align: left;">181,817</p></td><td style="width:48pt"><p class="s43" style="padding-left: 9pt;text-indent: 0pt;line-height: 11pt;text-align: left;">154,575</p></td></tr><tr style="height:12pt"><td style="width:217pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Deferred revenue. . . ......... ......... ......... </p></td><td style="width:49pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">6,740</p></td><td style="width:47pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">6,808</p></td><td style="width:55pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 11pt;text-align: right;">6,018</p></td><td style="width:47pt"><p class="s43" style="padding-left: 12pt;text-indent: 0pt;line-height: 11pt;text-align: left;">11,297</p></td><td style="width:48pt"><p class="s43" style="padding-left: 18pt;text-indent: 0pt;line-height: 11pt;text-align: left;">8,361</p></td></tr><tr style="height:12pt"><td style="width:217pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Long-term debt (including current portion) . . .</p></td><td style="width:49pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">90,000</p></td><td style="width:47pt"><p class="s43" style="padding-left: 15pt;text-indent: 0pt;line-height: 11pt;text-align: left;">71,333</p></td><td style="width:55pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">62,666</p></td><td style="width:47pt"><p class="s43" style="padding-left: 12pt;text-indent: 0pt;line-height: 11pt;text-align: left;">40,440</p></td><td style="width:48pt"><p class="s43" style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: left;">18,235</p></td></tr><tr style="height:12pt"><td style="width:217pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Redeemable convertible preferred stock....... </p></td><td style="width:49pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">—</p></td><td style="width:47pt"><p class="s43" style="padding-left: 10pt;text-indent: 0pt;line-height: 11pt;text-align: left;">158,766</p></td><td style="width:55pt"><p class="s43" style="padding-left: 12pt;text-indent: 0pt;line-height: 11pt;text-align: left;">158,766</p></td><td style="width:47pt"><p class="s43" style="padding-left: 7pt;text-indent: 0pt;line-height: 11pt;text-align: left;">158,766</p></td><td style="width:48pt"><p class="s43" style="padding-left: 9pt;text-indent: 0pt;line-height: 11pt;text-align: left;">153,781</p></td></tr><tr style="height:11pt"><td style="width:217pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Stockholders’ equity (deficit) ......... ......... </p></td><td style="width:49pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 10pt;text-align: right;">173,286</p></td><td style="width:47pt"><p class="s43" style="text-indent: 0pt;line-height: 10pt;text-align: right;">(89,969)</p></td><td style="width:55pt"><p class="s43" style="padding-left: 13pt;text-indent: 0pt;line-height: 10pt;text-align: left;">(78,650)</p></td><td style="width:47pt"><p class="s43" style="padding-left: 8pt;text-indent: 0pt;line-height: 10pt;text-align: left;">(64,126)</p></td><td style="width:48pt"><p class="s43" style="padding-left: 10pt;text-indent: 0pt;line-height: 10pt;text-align: left;">(54,197)</p></td></tr></table><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Overview</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We are a leading digital health and wellness company. By combining premium health and wellness content with our sophisticated proprietary data assets and analytics tools, we enable consumers to manage their health, healthcare professionals to stay informed and make better decisions for their patients, and marketers to communicate and engage with consumers and healthcare professionals. Our properties fall into the following categories: (i) properties that we own and/or operate in partnership with leading offline providers of health content or prominent health and wellness experts and personalities, including <i>Everyday Health</i>, <i>MedPage Today</i>, <i>DoctorDirectory.com</i>, <i>What to Expect</i>, <i>Dr. Sanjay Gupta</i>, <i>Jillian Michaels </i>and <i>The South Beach Diet</i>; and (ii) properties where we manage and sell advertising opportunities on behalf of third parties, including <i>MayoClinic.org </i>and <i>Drugstore.com</i>. We utilize our proprietary technology, together with our extensive data assets, to personalize the content experience, empower our users to make more- informed health decisions and drive better health outcomes. We deliver our content and solutions whenever, wherever and however a user makes a health-related decision through multiple channels, including desktop, mobile web, and mobile phone and tablet applications, as well as video and social media.</p><p style="padding-top: 7pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">We also utilize the data we collect to enable health and wellness marketers to:</p><ul id="l10"><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">reach and engage the right audience at the right time;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">influence purchase decisions;</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">drive health compliance and health outcomes; and</p></li><li style="padding-top: 8pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">quantitatively prove the efficacy of the marketing solutions we implement.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We derive a significant majority of our revenues from the sale of advertising, sponsorships and other marketing solutions across a variety of health and wellness categories, including pharmaceuticals, over-the-counter products, food, retail and lifestyle. To a lesser extent, we generate revenues from the sale of our premium services, which consist primarily of subscriptions sold to individuals who purchase access to one or more properties in our portfolio.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In late 2010, we made a strategic decision to expand our business into the market for providing content and marketing solutions targeting healthcare professionals through our acquisition of MedPage Holdings, Inc., or MPT. We believe that the entry into the healthcare professional market provided us with a significant revenue opportunity because pharmaceutical companies spend a larger percentage of their marketing budgets on healthcare professionals as compared to consumers. In addition, the acquisition of MPT enabled us to offer marketers the ability to target both healthcare professionals and consumers with a single marketing solution.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In late 2014, we expanded further into the healthcare professional sector with the acquisition of DoctorDirectory.com, Inc., or DD, a provider of multi-channel marketing solutions for pharmaceutical brands seeking to influence healthcare professionals. We expect that the acquisition of DD will deepen our penetration into the healthcare professional market by significantly increasing our physician reach and enhancing our sophisticated return on investment, or ROI, based marketing solutions that we offer advertisers seeking to engage with healthcare professionals. Following the</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">DD acquisition, we reach more than two-thirds of practicing physicians in the U.S. and expect increased user engagement by offering an expanded suite of content and tools to healthcare professionals.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In late 2014, we also began to focus on leveraging our existing assets to generate revenue from new customer channels across the broader healthcare landscape, particularly payors and providers. Specifically, our Healthcare Solutions unit will focus on utilizing our large, highly-engaged audience, premium content and tools, and advanced data and analytics capabilities to engage and influence consumers on behalf of payors and providers. We may also explore partnering relationships and</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">corporate development opportunities to more effectively execute on our growth strategy in this large market opportunity.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We expect our revenue to increase in 2015. We also expect our operating expenses to increase in 2015, but to decrease as a percentage of revenues. As a result, we expect that our Adjusted EBITDA will improve in 2015, and expect that our capital expenditures will decline as a percentage of revenues over the same period.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Background Information</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Key Trends Affecting Our Business</p><p style="padding-top: 7pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">We believe that the following key trends drive our ability to continue to grow our business:</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">Marketers are allocating an increasing proportion of their advertising spending to online advertising and are seeking solutions that better target their audience and maximize ROI. We believe that the ability to offer complex data-driven solutions that demonstrate ROI will be a key determinant in our success in attracting marketing dollars in the coming years. We also believe that the online percentage of the total health-related advertising market is still relatively small, and that this percentage will increase in the coming years.</p></li><li style="padding-top: 6pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">The Internet and digital and mobile devices have become indispensable for both consumers seeking to take a more active role in managing their diverse health and wellness needs and healthcare professionals striving to provide better care for their patients and manage their practices more efficiently. We believe that individuals will increasingly seek out digital content and solutions, and spend more time interacting with these digital channels, to educate themselves, directly manage and monitor their health and wellness, and make a wide array of other health-related purchase decisions, including purchasing health insurance.</p></li><li style="padding-top: 6pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">The pharmaceutical industry is experiencing a major shift from large mass-market “blockbuster” drugs to niche or specialty medications that target discrete patient populations. At the same time, dramatically-reduced sales forces and other restrictions on interacting directly with physicians have made it more difficult for pharmaceutical companies to efficiently market their products and services. As a result, we believe the need for these companies to interact with consumers and physicians more directly through digital channels will increase significantly.</p></li><li style="padding-top: 6pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">The evolving healthcare environment is forcing many health-related companies to face new challenges and adopt, in many cases for the first time, strategies targeting consumers and healthcare professionals. We believe our large and engaged audience, premium brands and a rich database of user information afford us a significant opportunity to grow our revenues as these entities, including health insurance companies, pharmacy benefit management companies and health information technology vendors, seek new ways to drive down costs, acquire new customers and utilize technology to achieve better health outcomes.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Key Metric</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We use the following key financial metric in measuring the performance of our business, allocating resources and making decisions regarding operating strategies.</p></li><li style="padding-top: 6pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p class="s45" style="display: inline;">Average Advertising and Sponsorship Revenues per Advertiser. <span class="p">Average advertising and sponsorship revenues per advertiser is our advertising and sponsorship revenues from advertisers that marketed their products and services on the </span>Everyday Health <span class="p">portfolio during a specific period divided by the total number of advertisers. We use this metric to assess our success in expanding our advertising and sponsorship relationships and increasing our market share of advertising dollars from each of our customers.</span></p><p style="padding-top: 6pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">The following represents our recent performance with respect to this key metric:</p><p class="s39" style="padding-top: 3pt;text-indent: 0pt;text-align: right;">Year ended December 31,(1)</p><p style="padding-left: 359pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="142" height="1" alt="image" src="NYSE_EVDY_2014/Image_043.png"/></span></p><p class="s40" style="text-indent: 0pt;text-align: right;">   2014 2013 2012   </p><p style="padding-top: 3pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Advertising and sponsorship revenues per advertiser</p><p style="padding-left: 61pt;text-indent: 0pt;line-height: 10pt;text-align: left;">(in thousands) . .......... ......... ......... ......... ......... .... $495.4 $420.2 $324.4</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="64" height="1" alt="image" src="NYSE_EVDY_2014/Image_044.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s55" style="padding-left: 64pt;text-indent: -13pt;text-align: left;">(1) <span class="p">Based on 336, 321 and 339 total advertisers for the years ended December, 2014, 2013 and 2012, respectively.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Revenues</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We generate revenues primarily through advertising and sponsorships, and premium services, including subscriptions and licensing fees.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our advertising and sponsorship revenues, also referred to as marketing solutions revenue, consist primarily of revenues generated from:</p></li><li style="padding-top: 6pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">display advertisements on properties in the <i>Everyday Health </i>portfolio and in our free e-mail newsletters, which are primarily sold based on a cost-per-impression advertising model;</p></li><li style="padding-top: 6pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">customer acquisition marketing programs, which are sold based on the number of qualified potential customers that are provided to our advertisers;</p></li><li style="padding-top: 6pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">our <i>Health Reach </i>marketing programs that allow marketers the opportunity to target specific audiences outside of the <i>Everyday Health </i>portfolio using our audience data and analytics;</p></li><li style="padding-top: 6pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">interactive brand sponsorships, which consist of our integrated database marketing programs and sponsorships within the <i>Everyday Health </i>portfolio, which typically include both components that are sold based on a cost-per-impression basis (in which we are paid based on the number of advertisements we display) and components that are sold based on a cost-per- visitor basis (in which we are paid for delivering a visitor to an advertiser’s website), and sometimes include a production fee; and</p></li><li style="padding-top: 6pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">marketing programs that provide for revenues based upon the ROI we deliver for our customers.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Increasing our advertising and sponsorship revenues attributable to interactive brand sponsorships has been an important focus for us in the past few years. Revenues linked to interactive brand sponsorships exceeded 50% of our advertising and sponsorship revenues in 2014. We expect that revenues linked to interactive brand sponsorships and/or marketing programs where we are paid based upon the ROI we deliver for our customers will exceed 50% of our advertising and sponsorship revenues in 2015.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Although we typically do not distinguish between desktop and mobile channels in the structuring and pricing of our marketing campaigns, mobile channels have become increasingly important in fulfilling these campaigns, including our interactive brand sponsorships. Our advertising and sponsorship revenue delivered via mobile channels increased 81.6% to $67.7 million in 2014 from $37.3 million in 2013.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In addition, by virtue of our recent acquisition of DD, we now conduct certain marketing campaigns that provide for revenues based entirely upon the ROI we deliver for our customers.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: justify;">Our advertisers and sponsors consist primarily of pharmaceutical companies, manufacturers and retailers of over-the-counter products and consumer-packaged-goods, and healthcare providers, such as hospitals and other healthcare professionals.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our premium services revenues consist primarily of revenues generated from subscriptions sold to individuals who purchase access for a defined period of time to one or more of the properties in the <i>Everyday Health </i>portfolio. Our subscription services are designed to provide the consumer with the ability to access consumer health content from well-recognized sources, and to personalize or customize a specific health or wellness program.</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Over the last several years, we have intentionally focused more directly on increasing our advertising and sponsorship revenues, which represents a much larger revenue opportunity than premium services. As a result, the mix of our total revenues from advertising and sponsorship services and premium services has changed. In 2014, our advertising and sponsorship revenues accounted for 90.3% of total revenues, compared to 86.6% in 2013. In 2014, our premium services revenues accounted for 9.7% of total revenues, compared to 13.4% in 2013. We anticipate that revenues derived from advertising and sponsorship services will continue to grow in the future as a percentage of total revenues. Our premium services, however, generate a significant portion of our registered users, and the valuable data that is voluntarily provided to us through our premium services, including demographic information and health-related interests, enables us to grow our advertising and sponsorship revenues. As a result, while we expect that premium services revenues will continue to decrease as a percentage of total revenues, our subscription products will continue to serve as an important source for registered users that will drive our advertising and sponsorship revenues and potentially offset any decline in our direct revenue from premium services. Although to date, revenues from payors, providers and employers have been immaterial, we expect that these revenues will likely increase as we seek to utilize our existing assets to address the consumer engagement needs of these entities. To the extent that our revenues from these sources increase in the future, this may alter the trends described above.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The timing of our revenues is affected by certain seasonal factors. Our advertising and sponsorship revenues are traditionally the lowest in the first quarter of the year, due primarily to the seasonal spend patterns of our advertising customers, and increases throughout the remainder of the year. Conversely, due to high consumer demand for diet and fitness programs at the start of each year associated with annual resolutions to live healthier lifestyles, we traditionally increase our media expenditures in the first calendar quarter to promote properties in the <i>Everyday Health </i>portfolio</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">that focus on diet and fitness. As a result of these trends, our gross margin tends to be lowest in the first quarter of each calendar year, typically increasing with each consecutive quarter. We anticipate that, as our revenues increase, our gross profit will continue to increase while our period-over-period gross margin may not increase commensurately.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Cost of Revenues, Gross Profit and Gross Margin</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The <i>Everyday Health </i>portfolio includes properties that we own, properties that we operate in partnership with leading offline health brands and properties where we manage and sell advertising opportunities on behalf of partners. Cost of revenues consists primarily of the expenses associated with aggregating the total audience across the <i>Everyday Health </i>portfolio or delivering an audience to fulfill a marketing campaign. These costs include:</p></li><li style="padding-top: 6pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">media costs;</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">royalty payments to the <i>Everyday Health </i>portfolio partners; and</p></li><li style="padding-top: 7pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">to a lesser extent, transaction processing costs associated with subscription fees for our premium services, ad serving and other expenses.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Media costs consist primarily of fees paid to online publishers, Internet search companies and other media channels where we advertise our <i>Everyday Health </i>portfolio. These media activities are directly attributable to generating revenue, increasing the audience to the properties we operate, increasing the number of individuals subscribing to our premium services and growing our registered user base. Our partner royalties are generally based on the amount of revenues generated on the particular property. In some cases, we guarantee the partner a minimum annual payment.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We carefully monitor our gross profit and gross margin because they are key indicators of our financial performance and success in aggregating and monetizing our audience across the entire <i>Everyday Health </i>portfolio. Gross profit is defined as total revenues minus cost of revenues. Gross margin is defined as our gross profit as a percentage of our total revenues. While we focus on the growth of both gross profit and gross margin, we may make investments from time to time that will position us for growth at the expense of gross margin.</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Since our operating decisions are based on aggregating and monetizing the <i>Everyday Health </i>portfolio audience as a whole, we believe that our aggregate gross profit is an important measure of our overall performance and do not believe that the gross profit associated with any individual property or category of properties is meaningful to an analysis of our overall operating performance. The gross margin we realize on revenues generated on our owned and our operated properties, however, is generally higher than the gross margin generated from properties within our portfolio that are operated by our partners because we typically pay a higher royalty rate to partners that operate their own properties. At the same time, some of the other costs to operate the properties in the <i>Everyday Health </i>portfolio, such as product development expenses, website hosting and maintenance expenses, are included in operating expenses and not reflected in our cost of revenues. As a result, we also believe that our Adjusted EBITDA is an important metric for measuring our overall financial performance (for a detailed description of Adjusted EBITDA, see “Supplemental Financial Information” below).</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Both our gross profit and gross margin improved for the year ended December 31, 2014, compared to the prior two years, as shown in the table below:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:68.6795pt" cellspacing="0"><tr style="height:10pt"><td style="width:236pt" rowspan="3"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:154pt"><p class="s44" style="padding-left: 5pt;text-indent: 0pt;line-height: 8pt;text-align: left;">           Year ended December 31,          </p></td></tr><tr style="height:11pt"><td style="width:154pt"><p class="s44" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">     2014 2013 2012     </p></td></tr><tr style="height:11pt"><td style="width:154pt"><p class="s54" style="padding-left: 34pt;text-indent: 0pt;text-align: left;">(dollars in thousands)</p></td></tr><tr style="height:12pt"><td style="width:236pt"><p class="s43" style="padding-left: 3pt;padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Revenues ....... .......... ......... ......... ....... </p></td><td style="width:154pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$184,325 $155,850 $138,492</p></td></tr><tr style="height:12pt"><td style="width:236pt"><p class="s43" style="padding-left: 3pt;padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Revenue growth .......... ......... ......... ....... </p></td><td style="width:154pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">18.3% 12.5% 10.1%</p></td></tr><tr style="height:12pt"><td style="width:236pt"><p class="s43" style="padding-left: 3pt;padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Cost of revenues.......... ......... ......... ....... </p></td><td style="width:154pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ 49,296 $ 43,338 $ 40,543</p></td></tr><tr style="height:12pt"><td style="width:236pt"><p class="s43" style="padding-left: 3pt;padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Gross profit..... .......... ......... ......... ....... </p></td><td style="width:154pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$135,029 $112,512 $ 97,949</p></td></tr><tr style="height:11pt"><td style="width:236pt"><p class="s43" style="padding-left: 3pt;padding-right: 5pt;text-indent: 0pt;line-height: 10pt;text-align: center;">Gross margin . . . .......... ......... ......... ....... </p></td><td style="width:154pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">73.3% 72.2% 70.7%</p></td></tr></table><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We expect our gross profit to continue to improve in the near term as we continue to aggregate our audience more efficiently and enhance our monetization capabilities across the entire <i>Everyday Health </i>portfolio. While we expect our cost of revenues to continue to increase on an absolute basis in the foreseeable future, we do not believe that any such increases will negatively impact our gross profit or Adjusted EBITDA since we anticipate that the growth in our total revenues will continue to exceed the increase in our cost of revenues.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Operating Expenses</p><p class="s45" style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Sales and Marketing. <span class="p">Sales and marketing expenses consist primarily of personnel-related costs, including commissions and non-cash stock compensation, for our account management, research, marketing, sales and data analytics and creative design personnel, as well as fees for third-party professional marketing and analytical services and depreciation and amortization expense pertaining to property and equipment. Our sales and marketing departments include data analytics personnel that analyze traffic and advertising ROI data to determine the effectiveness of advertising and marketing campaigns. We expect our sales and marketing expenses to increase in absolute dollars as we increase the number of sales, sales support and analytical personnel, but expect sales and marketing expenses to decrease as a percentage of revenues.</span></p><p class="s45" style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Product Development. <span class="p">Product development expenses consist of costs related to the products and services we provide to our audience, including the costs associated with the operation and maintenance of the properties in the </span>Everyday Health <span class="p">portfolio that we operate. These costs primarily consist of personnel-related expenses, including non-cash stock compensation, for our editorial, product management, technology and customer service personnel. Product development expenses also include fees paid to editorial and technology consultants; other technology costs; and depreciation and amortization expense pertaining to property and equipment, capitalized technology costs, including website and mobile development costs, and video and television production costs.</span></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">We expect our investment in product development to increase in absolute dollars as we continue to increase our editorial, product development and technology personnel, and as we enhance our product offerings by creating and licensing content, tools and applications, including new offerings for payors, providers and employers. However, we expect product development expenses to decrease as a percentage of revenues.</p><p class="s45" style="padding-top: 2pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">General and Administrative. <span class="p">General and administrative expenses consist primarily of personnel- related expenses, including non-cash stock compensation, for our executive, finance, legal, human resources and other administrative personnel, as well as accounting and legal professional fees and other general corporate expenses, including insurance, facilities expenses and depreciation and amortization expense pertaining to property and equipment and amortization of definite-lived intangible assets. We expect our general and administrative expenses, including accounting and legal- related expenses and insurance costs, to increase as we have transitioned to being a public company, but expect general and administrative expenses to decrease as a percentage of revenues.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Interest Expense, Net</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">These amounts consist principally of interest expense partially offset by interest income. Interest expense is primarily related to our credit facilities.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Other Expense</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Other expense consists of certain non-operating expenses, primarily the write-off of unamortized deferred financing costs and prepayment fees incurred in connection with refinancing our credit facilities.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Income Taxes</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We are subject to tax at the federal, state and local level in the U.S. and in one foreign jurisdiction. Earnings from our limited non-U.S. activities are subject to local country income tax and may also be subject to U.S. income tax.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">As of December 31, 2014, we had approximately $107 million of U.S. federal and state net operating loss, or NOL, carryforwards available to offset future taxable income. The U.S. federal NOL carryforwards will expire from 2020 through 2033. The full utilization of these NOL carryforwards in the future will be dependent upon our ability to generate taxable income and could be limited due to ownership changes, as defined under the provisions of Section 382 of the Internal Revenue Code of 1986, as amended. Specifically, Section 382 contains rules that limit the ability of a company that undergoes an ownership change, which is generally any change in ownership of more than 50% of its stock over a three-year period, to use its previously-recognized NOL carryforwards and specified built-in losses in years after the ownership change. We completed an analysis in 2013 to determine the impact that past ownership changes may have on our ability to use our NOL carryforwards and have determined that, through 2012, approximately $0.5 million of the then- existing NOL carryforwards will be limited by Section 382. However, changes in our stock ownership resulting from our initial public offering, or IPO, or other potential future transactions, could result in additional ownership changes under Section 382. Our NOLs may also be limited under similar provisions of state law. The NOL carryforwards at December 31, 2014 include approximately $7.4 million in income tax deductions related to stock options, which will be reflected as a credit to additional paid-in-capital as realized.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Loss From Discontinued Operations</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In November 2013, we sold our Doctor Solutions business, which provided online directories and other marketing services to healthcare professionals. The sale represented a disposal of a component of an entity whose operations and cash flows were eliminated from our ongoing business after the sale. As such, the operating results of this business have been reported as discontinued operations in our consolidated statements of operations.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Results of Operations</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The following table sets forth our consolidated statement of operations data for the periods presented. The period-to-period comparisons of the results are not necessarily indicative of our results for future periods.</p><p class="s40" style="padding-top: 2pt;padding-left: 349pt;text-indent: 0pt;text-align: left;">           Year ended December 31,           </p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:28.8234pt" cellspacing="0"><tr style="height:44pt"><td style="width:321pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-top: 7pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Consolidated Statement of Operations Data:</p><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Revenues:</p></td><td style="width:40pt"><p class="s44" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">     2014     </p></td><td style="width:58pt"><p class="s44" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: center;">     2013     </p><p class="s54" style="padding-top: 1pt;padding-right: 2pt;text-indent: 0pt;text-align: center;">(in thousands)</p></td><td style="width:44pt"><p class="s44" style="text-indent: 0pt;line-height: 8pt;text-align: left;">     2012     </p></td></tr><tr style="height:12pt"><td style="width:321pt"><p class="s43" style="padding-right: 10pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Advertising and sponsorship revenues .... ......... ......... ....... </p></td><td style="width:40pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">$166,465</p></td><td style="width:58pt"><p class="s43" style="padding-left: 9pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$134,893</p></td><td style="width:44pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: left;">$109,956</p></td></tr><tr style="height:12pt"><td style="width:321pt"><p class="s43" style="padding-right: 10pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Premium services revenues ...... ......... ......... ......... ....... </p></td><td style="width:40pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">17,860</p></td><td style="width:58pt"><p class="s43" style="padding-left: 19pt;text-indent: 0pt;line-height: 11pt;text-align: left;">20,957</p></td><td style="width:44pt"><p class="s43" style="padding-left: 10pt;text-indent: 0pt;line-height: 11pt;text-align: left;">23,536</p></td></tr><tr style="height:14pt"><td style="width:321pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Video production fees . . ......... ......... ......... ......... ....... </p></td><td style="width:40pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">           —</p></td><td style="width:58pt"><p class="s51" style="padding-left: 9pt;text-indent: 0pt;line-height: 11pt;text-align: left;">           —</p></td><td style="width:44pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">      5,000</p></td></tr><tr style="height:13pt"><td style="width:321pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Total revenues. ......... ......... ......... ......... ......... ....... </p></td><td style="width:40pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">  184,325</p></td><td style="width:58pt"><p class="s51" style="padding-left: 9pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  155,850</p></td><td style="width:44pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">  138,492</p></td></tr><tr style="height:16pt"><td style="width:321pt"><p class="s43" style="padding-top: 3pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Operating expenses:</p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:58pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:321pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 10pt;text-align: right;">Cost of revenues........ ......... ......... ......... ......... ....... </p></td><td style="width:49pt" colspan="2"><p class="s43" style="padding-left: 9pt;text-indent: 0pt;line-height: 10pt;text-align: left;">49,296</p></td><td style="width:49pt"><p class="s43" style="padding-left: 9pt;text-indent: 0pt;line-height: 10pt;text-align: left;">43,338</p></td><td style="width:44pt"><p class="s43" style="padding-left: 10pt;text-indent: 0pt;line-height: 10pt;text-align: left;">40,543</p></td></tr><tr style="height:12pt"><td style="width:321pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Sales and marketing .... ......... ......... ......... ......... ....... </p></td><td style="width:49pt" colspan="2"><p class="s43" style="padding-left: 9pt;text-indent: 0pt;line-height: 11pt;text-align: left;">48,605</p></td><td style="width:49pt"><p class="s43" style="padding-left: 9pt;text-indent: 0pt;line-height: 11pt;text-align: left;">44,385</p></td><td style="width:44pt"><p class="s43" style="padding-left: 10pt;text-indent: 0pt;line-height: 11pt;text-align: left;">38,603</p></td></tr><tr style="height:12pt"><td style="width:321pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Product development . . . ......... ......... ......... ......... ....... </p></td><td style="width:49pt" colspan="2"><p class="s43" style="padding-left: 9pt;text-indent: 0pt;line-height: 11pt;text-align: left;">44,541</p></td><td style="width:49pt"><p class="s43" style="padding-left: 9pt;text-indent: 0pt;line-height: 11pt;text-align: left;">43,759</p></td><td style="width:44pt"><p class="s43" style="padding-left: 10pt;text-indent: 0pt;line-height: 11pt;text-align: left;">45,676</p></td></tr><tr style="height:14pt"><td style="width:321pt"><p class="s43" style="padding-right: 10pt;text-indent: 0pt;line-height: 11pt;text-align: right;">General and administrative ...... ......... ......... ......... ....... </p></td><td style="width:49pt" colspan="2"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">    30,041</p></td><td style="width:49pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">    27,462</p></td><td style="width:44pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">    25,874</p></td></tr><tr style="height:15pt"><td style="width:321pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;text-align: right;">Total operating expenses ........ ......... ......... ......... ....... </p></td><td style="width:49pt" colspan="2"><p class="s51" style="text-indent: 0pt;text-align: left;">  172,483</p></td><td style="width:49pt"><p class="s51" style="text-indent: 0pt;text-align: left;">  158,944</p></td><td style="width:44pt"><p class="s51" style="text-indent: 0pt;text-align: left;">  150,696</p></td></tr><tr style="height:14pt"><td style="width:321pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Income (loss) from operations ..... ......... ......... ......... ....... </p></td><td style="width:49pt" colspan="2"><p class="s43" style="padding-left: 9pt;text-indent: 0pt;text-align: left;">11,842</p></td><td style="width:49pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;text-align: right;">(3,094)</p></td><td style="width:44pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">(12,204)</p></td></tr><tr style="height:12pt"><td style="width:321pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Interest expense, net ...... ......... ......... ......... ......... ....... </p></td><td style="width:49pt" colspan="2"><p class="s43" style="padding-left: 11pt;text-indent: 0pt;line-height: 11pt;text-align: left;">(3,711)</p></td><td style="width:49pt"><p class="s43" style="padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(8,442)</p></td><td style="width:44pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(4,898)</p></td></tr><tr style="height:14pt"><td style="width:321pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Other expense . . . ......... ......... ......... ......... ......... ....... </p></td><td style="width:49pt" colspan="2"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">    (4,114<span class="s43">)</span></p></td><td style="width:49pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">       (359<span class="s43">)</span></p></td><td style="width:44pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">    (1,069<span class="s43">)</span></p></td></tr><tr style="height:24pt"><td style="width:321pt"><p class="s43" style="padding-top: 2pt;padding-left: 12pt;padding-right: 10pt;text-indent: -10pt;line-height: 87%;text-align: left;">Income (loss)  from  continuing  operations  before  provision  for income taxes. . . ......... ......... ......... ......... ......... ....... </p></td><td style="width:49pt" colspan="2"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-left: 14pt;text-indent: 0pt;text-align: left;">4,017</p></td><td style="width:49pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">(11,895)</p></td><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">(18,171)</p></td></tr><tr style="height:14pt"><td style="width:321pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Benefit (provision) for income taxes ........ ......... ......... ....... </p></td><td style="width:49pt" colspan="2"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">      8,666</p></td><td style="width:49pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">    (1,102<span class="s43">)</span></p></td><td style="width:44pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">    (1,026<span class="s43">)</span></p></td></tr><tr style="height:14pt"><td style="width:321pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Income (loss) from continuing operations . . . ......... ......... ....... </p></td><td style="width:49pt" colspan="2"><p class="s43" style="padding-left: 9pt;text-indent: 0pt;text-align: left;">12,683</p></td><td style="width:49pt"><p class="s43" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">(12,997)</p></td><td style="width:44pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">(19,197)</p></td></tr><tr style="height:14pt"><td style="width:321pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Loss from discontinued operations, net of tax ....... ......... ....... </p></td><td style="width:49pt" colspan="2"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">              -</p></td><td style="width:49pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">    (5,239<span class="s43">)</span></p></td><td style="width:44pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">    (3,257<span class="s43">)</span></p></td></tr><tr style="height:15pt"><td style="width:321pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Net Income (loss)......... ......... ......... ......... ......... ....... </p></td><td style="width:49pt" colspan="2"><p class="s51" style="text-indent: 0pt;text-align: left;">$ 12,683</p></td><td style="width:49pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s51" style="text-indent: 0pt;text-align: left;">$(18,236<span class="s43">)</span></p></td><td style="width:44pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s51" style="text-indent: 0pt;text-align: left;">$(22,454<span class="s43">)</span></p></td></tr><tr style="height:34pt"><td style="width:321pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Comparison of Years ended December 31, 2014 and 2013</p></td><td style="width:49pt" colspan="2"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:44pt;border-top-style:solid;border-top-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:17pt"><td style="width:321pt"><p class="s56" style="padding-top: 4pt;padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Revenues</p></td><td style="width:49pt" colspan="2"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:49pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p style="padding-top: 7pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Our total revenues increased 18.3% to $184.3 million in 2014 from $155.9 million in 2013. The</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">$28.5 million increase in total revenues consisted of a $31.6 million increase in advertising and sponsorship revenues partially offset by a $3.1 million decrease in premium services revenues. No advertiser accounted for 10% or more of total revenues in 2014. In 2013, one advertiser accounted for approximately 12% of total revenues.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Advertising and sponsorship revenues increased 23.4% to $166.5 million in 2014 from $134.9 million in 2013. The $31.6 million increase in advertising and sponsorship revenues was driven by an increase in revenue per advertiser, as compared to 2013, due to expanded relationships with existing advertisers. The increase in advertising and sponsorship revenues was also attributable to an increase in the number of advertisers that marketed their products and services on the <i>Everyday Health </i>portfolio, driven by a continued focus from our sales team on generating new client relationships.</p><p style="padding-top: 6pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Premium services revenues decreased 14.8% to $17.9 million in 2014 from $21.0 million in 2013.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">The decrease was primarily attributable to a $4.1 million decrease in subscription fee revenues to</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">$12.9 million in 2014 from $17.0 million in 2013. The decrease in subscription fee revenues was primarily due to a decrease in our average paid subscribers per month, which resulted from a general decline in the popularity of certain of our brands. This decrease was partially offset by subscription fee revenue from a new subscription brand launched in June 2014, and higher average revenue per paid subscriber per month.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Costs and Expenses</p><p class="s45" style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Cost of Revenues. <span class="p">Cost of revenues increased 13.7% to $49.3 million in 2014 from $43.3 million in 2013. The $6.0 million increase in cost of revenues was primarily attributable to an increase in royalties to our portfolio partners commensurate with the increase in advertising and sponsorship</span></p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">revenues. Cost of revenues as a percentage of total revenues decreased to 26.7% in 2014 from 27.8% in 2013.</p><p class="s45" style="padding-top: 6pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Sales and Marketing. <span class="p">Sales and marketing expenses increased 9.5% to $48.6 million in 2014 from</span></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">$44.4 million in 2013. This $4.2 million increase was primarily due to higher levels of compensation expense, including increased staffing and related cash and non-cash stock compensation expense for the sales development, sales operations and data analytics teams associated with generating and supporting increased advertising and sponsorship revenues in 2014 compared to 2013, partially offset by a $2.1 million decrease in acquisition earn-out expense in 2014 compared to 2013. Sales and marketing expenses as a percentage of total revenues decreased to 26.4% in 2014, as compared to 28.5% in 2013.</p><p class="s45" style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Product Development. <span class="p">Product development expenses increased 1.8% to $44.5 million in 2014 from $43.8 million in 2013. This $0.8 million increase in product development expenses was primarily due to increases in cash and non-cash stock compensation expense, partially offset by a $1.2 million impairment charge in 2013 pertaining to website content and tools which did not recur in 2014.</span></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Product development expenses as a percentage of total revenues decreased to 24.2% in 2014, as compared to 28.1% in 2013.</p><p class="s45" style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">General and Administrative. <span class="p">General and administrative expenses increased 9.4% to $30.0 million in 2014 from $27.5 million in 2013. This $2.6 million increase was primarily due to increases in cash and non-cash stock compensation expense and professional service fee expenses, attributed in part to being public in 2014, partially offset by a $1.1 million decrease in amortization expense related to intangible assets. General and administrative expenses as a percentage of total revenues decreased to 16.3% in 2014, as compared to 17.6% in 2013.</span></p><p class="s45" style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Interest Expense, Net. <span class="p">Interest expense, net, decreased 56.0% to $3.7 million in 2014, compared to $8.4 million in 2013. The $4.7 million decrease in interest expense was primarily due to the refinancing of our credit facility in March 2014 at a lower interest rate in 2014 compared with 2013, and to a net decrease in the weighted-average outstanding borrowings under our credit facilities in 2014 as compared to 2013.</span></p><p class="s45" style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Other Expense. <span class="p">Other expense in 2014 consisted primarily of the write-off of unamortized deferred financing costs totaling $2.8 million and prepayment penalties totaling $1.0 million related to the March 2014 credit facility refinancing, compared with certain non-operating expense charges totaling $0.4 million in 2013.</span></p><p class="s45" style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Provision (Benefit) for Income Taxes. <span class="p">The provision (benefit) for income taxes was approximately $(8.7) million and $1.1 million during the years 2014 and 2013, respectively. For 2014, the benefit for income taxes includes a one-time tax benefit of $10.0 million associated with the remeasurement of the valuation allowances against our deferred tax assets related to the DoctorDirectory.com, Inc. acquisition. The remaining provision in 2014 and 2013 pertains primarily to deferred income taxes related to basis differences in indefinite lived intangible assets that could not be offset by current year deferred tax assets, as well as the current provision for state income taxes.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Comparison of Years ended December 31, 2013 and 2012</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Revenues</p><p style="padding-top: 7pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Our total revenues increased 12.5% to $155.9 million in 2013 from $138.5 million in 2012. The</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">$17.4 million increase in total revenues consisted of a $24.9 million increase in advertising and sponsorship revenues partially offset by a $2.6 million decrease in premium services revenues. Our 2012 revenues also included $5.0 million in non-recurring video production fee revenues in connection with the launch of the <i>Everyday Health </i>YouTube channel. In 2013, one advertiser accounted for approximately 12% of total revenues. No advertiser accounted for 10% or more of total revenues in 2012.</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Advertising and sponsorship revenues increased 22.7% to $134.9 million in 2013 from $110.0 million in 2012. The $24.9 million increase in advertising and sponsorship revenues was driven by an increase in revenue per advertiser, as compared to 2012, due to expanded relationships with existing advertisers. The increase in advertising and sponsorship revenues was also attributable to an increase in the number of consumer advertisers that marketed their products and services on the <i>Everyday Health </i>portfolio, driven by an increased focus from our sales team on generating new client relationships.</p><p style="padding-top: 6pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Premium services revenues decreased 10.9% to $21.0 million in 2013 from $23.5 million in 2012.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">The decrease was primarily attributable to a $2.7 million decrease in subscription fee revenues to</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">$17.0 million in 2013 from $19.7 million in 2012. The decrease in subscription fee revenues was primarily due to a decrease in our average paid subscribers per month, which resulted from a general decline in the popularity of certain of our brands. This decrease was partially offset by higher average revenue per paid subscriber per month, due to slightly increased billing plans and higher renewal rates.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Costs and Expenses</p><p class="s45" style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Cost of Revenues. <span class="p">Cost of revenues increased 6.9% to $43.3 million in 2013 from $40.5 million in 2012. The $2.8 million increase in cost of revenues was primarily attributable to an increase in royalties to our portfolio partners commensurate with the increase in advertising and sponsorship revenues. Cost of revenues as a percentage of total revenues decreased to 27.8% in 2013 from 29.3% in 2012.</span></p><p class="s45" style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Sales and Marketing. <span class="p">Sales and marketing expenses increased 15.0% to $44.4 million in 2013 from $38.6 million in 2012. This $5.8 million increase was primarily due to higher levels of compensation expense, including increased staffing and related compensation for the sales development, sales operations and data analytics teams associated with generating and supporting increased advertising and sponsorship revenues in 2013 compared to 2012. The increase in sales and marketing expenses in 2013 is attributable in part to our September 2012 EQAL acquisition, and includes a $0.8 million increase in accrued acquisition earnout expense. Sales and marketing expenses as a percentage of total revenues increased to 28.5% in 2013, as compared to 27.9% in 2012.</span></p><p class="s45" style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Product Development. <span class="p">Product development expenses decreased 4.2% to $43.8 million in 2013 from $45.7 million in 2012. This $1.9 million decrease in product development expenses was primarily due to a decrease in video and television production cost amortization expense of $5.8 million related to our </span>Everyday Health <span class="p">YouTube channel, partially offset by increases in compensation expense of $2.3 million, a $1.2 million impairment charge pertaining to website content and tools and depreciation and amortization of $0.8 million. Product development expenses as a percentage of total revenues decreased to 28.1% in 2013, as compared to 33.0% in 2012.</span></p><p class="s45" style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">General and Administrative. <span class="p">General and administrative expenses increased 6.2% to $27.5 million in 2013 from $25.9 million in 2012. This $1.6 million increase was primarily due to increases in compensation and facilities expenses, including facilities expenses attributable in part to our September 2012 EQAL acquisition. General and administrative expenses as a percentage of total revenues decreased to 17.6% in 2013, as compared to 18.7% in 2012.</span></p><p class="s45" style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Interest Expense, Net. <span class="p">Interest expense, net, increased 72.4% to $8.4 million in 2013, compared to $4.9 million in 2012. The $3.5 million increase in interest expense was primarily due to an approximate $18.0 million net increase in average outstanding borrowings under our credit facilities in 2013 compared with 2012, and to a lesser extent, a $0.9 million increase in amortization of deferred financing costs relating to our credit facilities borrowings.</span></p><p class="s45" style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Other Expense. <span class="p">Other expense in 2013 consisted of certain non-operating expense charges totaling $0.4 million, compared with the write-off of unamortized deferred financing costs totaling</span></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">$1.1 million in 2012.</p><p class="s45" style="padding-top: 2pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Provision for Income Taxes. <span class="p">The provision for income taxes was approximately $1.1 million and</span></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">$1.0 million during the years 2013 and 2012, respectively. The provision pertains primarily to deferred income taxes related to basis differences in indefinite lived intangible assets that could not be offset by current year deferred tax assets, as well as the current provision for state income taxes.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Loss from Discontinued Operations</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Loss from discontinued operations increased 60.9% from $3.3 million in 2012 to $5.2 million in 2013. The $1.9 million increase was primarily due to the $1.3 million loss on sale, and to a lesser extent a $0.6 million greater operating loss for the Doctor Solutions business in 2013 as compared to 2012. The business was sold in November 2013.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Supplemental Financial Information</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The following discussion provides information regarding Adjusted EBITDA, a performance measure that is not determined in accordance with U.S. generally accepted accounting principles, or GAAP, as well as information regarding certain non-cash operating expenses that are reflected in the Adjusted EBITDA calculation. We use Adjusted EBITDA in conjunction with GAAP operating performance measures as part of our overall assessment of our performance, for planning purposes, including the preparation of our annual operating budget, to evaluate the effectiveness of our business strategies and to communicate with our Board of Directors concerning our financial performance.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We define Adjusted EBITDA as net income (loss) plus: interest expense, net; income tax expense (benefit); depreciation and amortization expense; stock-based compensation expense; compensation expense related to acquisition earnout arrangements; write-offs of unamortized deferred financing and other debt extinguishment costs; reduction in force severance charges; loss from discontinued operations; and certain other non-cash charges such as asset impairment charges and preferred stock warrant mark-to-market adjustments. We believe that Adjusted EBITDA is useful to investors and other users of our financial statements in evaluating our operating performance because it provides them with an additional tool to compare business performance across companies and across periods. Furthermore, we believe that:</p></li><li style="padding-top: 6pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">Adjusted EBITDA provides investors and other users of our financial information consistency and comparability with our past financial performance, facilitates period-to-period comparisons of operations and comparisons with our peer companies, many of which use similar non- GAAP financial measures to supplement their GAAP results; and</p></li><li style="padding-top: 6pt;padding-left: 60pt;text-indent: -9pt;text-align: left;"><p style="display: inline;">It is useful to exclude certain non-cash charges, such as depreciation and amortization and stock-based compensation and non-core operational charges, such as asset impairment charges and write-off of debt extinguishment costs, from Adjusted EBITDA because the amount of such expenses in any specific period may not be directly correlated to the underlying performance of our business operations and these expenses can vary significantly between periods.</p></li></ul></li></ol><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We do not place undue reliance on Adjusted EBITDA as our only measure of operating performance. Adjusted EBITDA should not be considered as a substitute for other measures of financial performance reported in accordance with GAAP. There are limitations to using non-GAAP financial measures, including that other companies may calculate these measures differently than we do, that they do not reflect our capital expenditures or future requirements for capital expenditures and that they do not reflect changes in, or cash requirements for, our working capital.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">As Adjusted EBITDA is a non-GAAP measure, the following table presents a reconciliation of Net income (loss) to Adjusted EBITDA.</p><p class="s40" style="padding-top: 2pt;padding-left: 356pt;text-indent: 0pt;text-align: left;">        Year Ended December 31,        </p><p class="s40" style="padding-top: 1pt;padding-left: 356pt;text-indent: 0pt;text-align: left;">    2014 2013 2012     </p><p class="s39" style="padding-top: 1pt;padding-bottom: 2pt;padding-left: 395pt;text-indent: 0pt;text-align: left;">(in thousands)</p><table style="border-collapse:collapse;margin-left:28.8234pt" cellspacing="0"><tr style="height:11pt"><td style="width:323pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Net Income (Loss) ........ ......... ......... ......... ......... ........ </p></td><td style="width:45pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$12,683</p></td><td style="width:49pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$(18,236)</p></td><td style="width:46pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$(22,454)</p></td></tr><tr style="height:12pt"><td style="width:323pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Add (deduct):</p></td><td style="width:45pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:49pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:46pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:323pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Interest expense, net....... ......... ......... ......... ......... ........ </p></td><td style="width:45pt"><p class="s43" style="padding-left: 15pt;text-indent: 0pt;line-height: 11pt;text-align: left;">3,711</p></td><td style="width:49pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">8,442</p></td><td style="width:46pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4,898</p></td></tr><tr style="height:12pt"><td style="width:323pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Income tax expense (benefit) ....... ......... ......... ......... ........ </p></td><td style="width:45pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(8,666)</p></td><td style="width:49pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">1,102</p></td><td style="width:46pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">1,026</p></td></tr><tr style="height:12pt"><td style="width:323pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Depreciation and amortization expense...... ......... ......... ........ </p></td><td style="width:45pt"><p class="s43" style="padding-left: 10pt;text-indent: 0pt;line-height: 11pt;text-align: left;">14,943</p></td><td style="width:49pt"><p class="s43" style="padding-left: 12pt;text-indent: 0pt;line-height: 11pt;text-align: left;">15,450</p></td><td style="width:46pt"><p class="s43" style="padding-left: 12pt;text-indent: 0pt;line-height: 11pt;text-align: left;">14,602</p></td></tr><tr style="height:12pt"><td style="width:323pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Stock compensation expense........ ......... ......... ......... ........ </p></td><td style="width:45pt"><p class="s43" style="padding-left: 15pt;text-indent: 0pt;line-height: 11pt;text-align: left;">9,100</p></td><td style="width:49pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">2,969</p></td><td style="width:46pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">3,532</p></td></tr><tr style="height:12pt"><td style="width:323pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Warrant mark-to-market adjustment......... ......... ......... ........ </p></td><td style="width:45pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">252</p></td><td style="width:49pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">—</p></td><td style="width:46pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">—</p></td></tr><tr style="height:12pt"><td style="width:323pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Compensation expense related to acquisition earnout ......... ........ </p></td><td style="width:45pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">135</p></td><td style="width:49pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">2,211</p></td><td style="width:46pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">1,428</p></td></tr><tr style="height:12pt"><td style="width:323pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Deferred revenue adjustment related to acquisitions. . ......... ........ </p></td><td style="width:45pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">—</p></td><td style="width:49pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">—</p></td><td style="width:46pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">72</p></td></tr><tr style="height:12pt"><td style="width:323pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Write-off of unamortized deferred financing costs .... ......... ........ </p></td><td style="width:45pt"><p class="s43" style="padding-left: 15pt;text-indent: 0pt;line-height: 11pt;text-align: left;">3,861</p></td><td style="width:49pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">—</p></td><td style="width:46pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">1,069</p></td></tr><tr style="height:12pt"><td style="width:323pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Reduction in force severance charges........ ......... ......... ........ </p></td><td style="width:45pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">—</p></td><td style="width:49pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">3,188</p></td><td style="width:46pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">—</p></td></tr><tr style="height:12pt"><td style="width:323pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Asset impairment charges . ......... ......... ......... ......... ........ </p></td><td style="width:45pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">—</p></td><td style="width:49pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">1,377</p></td><td style="width:46pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">—</p></td></tr><tr style="height:14pt"><td style="width:323pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Loss from discontinued operations. . ......... ......... ......... ........ </p></td><td style="width:45pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">         —</p></td><td style="width:49pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">      5,239</p></td><td style="width:46pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">      3,257</p></td></tr><tr style="height:15pt"><td style="width:323pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Adjusted EBITDA ........ ......... ......... ......... ......... ........ </p></td><td style="width:45pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">$36,019</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="43" height="1" alt="image" src="NYSE_EVDY_2014/Image_045.png"/></span></p></td><td style="width:49pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">$ 21,742</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 4pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="48" height="1" alt="image" src="NYSE_EVDY_2014/Image_046.png"/></span></p></td><td style="width:46pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">      7,430</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 4pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="48" height="1" alt="image" src="NYSE_EVDY_2014/Image_047.png"/></span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 19pt;text-align: left;">The following table summarizes our depreciation and amortization and stock compensation expenses included in the Adjusted EBITDA reconciliation table above and details the breakdown of such expenses in the respective statements of operations line-items.</p><p class="s40" style="padding-top: 7pt;text-indent: 0pt;text-align: right;">                                    Year Ended December 31,                                    </p><p class="s39" style="padding-top: 1pt;text-indent: 0pt;line-height: 9pt;text-align: right;">Depreciation /</p><p class="s40" style="text-indent: 0pt;line-height: 9pt;text-align: right;">                   amortization                   </p><p class="s39" style="padding-top: 1pt;padding-left: 22pt;text-indent: 0pt;line-height: 9pt;text-align: center;">Stock</p><p class="s40" style="text-indent: 0pt;line-height: 9pt;text-align: center;">           compensation (1)           </p><p class="s40" style="padding-top: 1pt;padding-left: 246pt;text-indent: 0pt;text-align: left;">    2014 2013 2012 2014 2013 2012   </p><p class="s39" style="padding-top: 1pt;padding-bottom: 2pt;padding-left: 340pt;text-indent: 0pt;text-align: left;">(in thousands)</p><table style="border-collapse:collapse;margin-left:28.8234pt" cellspacing="0"><tr style="height:11pt"><td style="width:213pt"><p class="s43" style="padding-left: 1pt;padding-right: 3pt;text-indent: 0pt;line-height: 10pt;text-align: center;">Sales and marketing ......... ......... ........ </p></td><td style="width:43pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 10pt;text-align: right;">$ 1,279</p></td><td style="width:44pt"><p class="s43" style="text-indent: 0pt;line-height: 10pt;text-align: center;">$ 1,183</p></td><td style="width:45pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 10pt;text-align: right;">$ 1,065</p></td><td style="width:39pt"><p class="s43" style="text-indent: 0pt;line-height: 10pt;text-align: center;">$2,769</p></td><td style="width:39pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 10pt;text-align: right;">$ 602</p></td><td style="width:36pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">$ 553</p></td></tr><tr style="height:12pt"><td style="width:213pt"><p class="s43" style="padding-left: 1pt;padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Product development ........ ......... ........ </p></td><td style="width:43pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">10,745</p></td><td style="width:44pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: center;">10,325</p></td><td style="width:45pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">9,324</p></td><td style="width:39pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: center;">2,102</p></td><td style="width:39pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">1,091</p></td><td style="width:36pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">791</p></td></tr><tr style="height:14pt"><td style="width:213pt"><p class="s43" style="padding-left: 1pt;padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: center;">General and administrative. . ......... ........ </p></td><td style="width:43pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">    2,919</p></td><td style="width:44pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: center;">    3,942</p></td><td style="width:45pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">    4,213</p></td><td style="width:39pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: center;">  4,229</p></td><td style="width:39pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">  1,276</p></td><td style="width:36pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">  2,188</p></td></tr><tr style="height:15pt"><td style="width:213pt"><p class="s43" style="padding-left: 1pt;padding-right: 3pt;text-indent: 0pt;text-align: center;">Total expense ...... ......... ......... ........ </p></td><td style="width:43pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">$14,943</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="43" height="1" alt="image" src="NYSE_EVDY_2014/Image_048.png"/></span></p></td><td style="width:44pt"><p class="s51" style="text-indent: 0pt;text-align: center;">$15,450</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="43" height="1" alt="image" src="NYSE_EVDY_2014/Image_049.png"/></span></p></td><td style="width:45pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">$14,602</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="43" height="1" alt="image" src="NYSE_EVDY_2014/Image_050.png"/></span></p></td><td style="width:39pt"><p class="s51" style="text-indent: 0pt;text-align: center;">$9,100</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="37" height="1" alt="image" src="NYSE_EVDY_2014/Image_051.png"/></span></p></td><td style="width:39pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">$2,969</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="37" height="1" alt="image" src="NYSE_EVDY_2014/Image_052.png"/></span></p></td><td style="width:36pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">$3,532</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="37" height="1" alt="image" src="NYSE_EVDY_2014/Image_053.png"/></span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="64" height="1" alt="image" src="NYSE_EVDY_2014/Image_054.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 49pt;text-indent: -17pt;text-align: left;">(1) Stock compensation expense includes charges related to our 2014 Employee Stock Purchase Plan beginning in 2014. Refer to “Note 11—Stock-Based Compensation” in the notes to the consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Liquidity and Capital Resources</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Working Capital</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">As of December 31, 2014, we had cash and cash equivalents of $50.7 million and working capital of $82.6 million.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Sources of Liquidity and Long-Term Debt</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our primary sources of cash have historically been proceeds from the issuance of convertible redeemable preferred stock, bank borrowings and our March 2014 IPO. Since the beginning of 2003, we have issued convertible redeemable preferred stock for aggregate net proceeds of $82.0 million. Our IPO resulted in net proceeds of $70.6 million after deducting underwriting discounts and commissions and other offering costs. As of December 31, 2014, we had $90.0 million of borrowings outstanding under our credit facility.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">On November 10, 2014, we refinanced our debt. Under our existing credit facility with Silicon Valley Bank, SunTrust Bank, Stifel Bank &amp; Trust and Comerica Bank, or the Credit Facility, we maintain a revolver, with a maximum borrowing limit of $55.0 million, and also have a $60.0 million term loan. As of December 31, 2014, there was $60.0 million outstanding on the term loan and</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">$30.0 million outstanding on the revolver. The repayment terms for any balance outstanding on the revolver provide for quarterly interest payments, with the principal being due in full in November 2019. The repayment terms for the term loan provide for quarterly interest and principal payments, with a maturity date of November 2019. The interest rate on the revolver and the term loan is equal to the London Inter-Bank Offered Rate, or LIBOR, plus a variable rate ranging from 2.75% to 4.0% depending on our consolidated leverage ratio, as defined in the Credit Facility agreement, and we are charged a commitment fee of 0.50% on the unused portion of the revolver. As of December 31, 2014, the interest rate on our Credit Facility was 3.48%. The Credit Facility contains certain financial and operational covenants with which we must comply, whether or not there are any borrowings outstanding. Such covenants include requirements to maintain a minimum consolidated fixed charge coverage ratio and a maximum consolidated leverage ratio, each as defined in the Credit Facility, as well as restrictions on certain types of dispositions, mergers and acquisitions, indebtedness, investments, liens and capital expenditures, issuance of capital stock and our ability to pay dividends and make other distributions. We were in compliance with the financial and operational covenants of the Credit Facility as of December 31, 2014. The Credit Facility is secured by a first priority security interest in substantially all of our existing and future assets.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Operating and Capital Expenditure Requirements</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our principal uses of cash historically have been to fund operating losses, finance business acquisitions and capital expenditures relating to purchases of property and equipment to support our infrastructure and capitalized product and video/television content development. We currently expect that our existing cash and cash equivalents, together with anticipated cash flows from operations, will be sufficient to fund our anticipated cash needs for at least the next twelve months. Our liquidity could be negatively affected by a decrease in demand for our marketing solutions, including the impact of changes in advertiser spending behavior, and by other factors outside of our control, including general economic conditions, as well as the other risks to our business discussed under “Item 1A—Risk Factors.” Our cash requirements going forward may require us to raise additional funds through borrowing or the issuance of additional equity or equity-linked securities. Any</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">increase in the amount of our borrowings will result in an increase in our interest expense. Future issuance of equity or equity-linked securities will result in dilution to the holders of our common stock. In addition, if the banking system or the financial markets are volatile, our ability to raise additional debt or equity capital could be adversely affected. Additional financing may not be available on commercially reasonable terms or at all.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:28.8234pt" cellspacing="0"><tr style="height:29pt"><td style="width:318pt"><p class="s56" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Components of Liquidity and Capital Resources</p></td><td style="width:145pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s44" style="text-indent: 0pt;text-align: center;">         Year Ended December 31,         </p></td></tr><tr style="height:11pt"><td style="width:318pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:145pt"><p class="s44" style="text-indent: 0pt;text-align: center;">     2014 2013 2012     </p></td></tr><tr style="height:23pt"><td style="width:318pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Net cash provided by (used in) operating activities ......... ......... .</p></td><td style="width:145pt"><p class="s54" style="text-indent: 0pt;text-align: center;">(in thousands)</p><p class="s43" style="padding-left: 3pt;text-indent: 0pt;text-align: center;">$ 20,040 $ 1,672 $ (8,782)</p></td></tr><tr style="height:12pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Net cash used in investing activities ...... ......... ......... ......... .</p></td><td style="width:145pt"><p class="s43" style="padding-left: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">(79,223) (17,507) (15,532)</p></td></tr><tr style="height:12pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Net cash provided by financing activities . ......... ......... ......... .</p></td><td style="width:145pt"><p class="s43" style="padding-left: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">93,670 8,189 20,964</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Net increase (decrease) in cash and cash equivalents ....... ......... .</p></td><td style="width:145pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 10pt;text-align: center;">$ 34,487 $ (7,646) $ (3,350)</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Operating Activities</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">For the year ended December 31, 2014, net cash provided by operating activities was $20.0 million, consisting of net income of $12.7 million, adjusted for non-cash expenses of $19.7 million, including depreciation and amortization, non-cash stock-based compensation expense, amortization and write-off of deferred financing costs, partially offset by a benefit for deferred income taxes.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Additionally, changes in operating assets and liabilities used $12.3 million of cash, which was primarily due to an increase in accounts receivable due to higher advertising and sponsorship revenues and a decrease in accounts payable and accrued expenses due to the timing of vendor payments, partially offset by a decrease in prepaid expenses and other current assets.</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Net cash provided by operating activities was $18.4 million higher in the year ended December 31, 2014 compared to the year ended December 31, 2013, resulting primarily from an increase in net income of $31.1 million, an increase in non-cash stock based compensation of $6.1 million, and a</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">$4.2 million decrease in prepaid expenses and other current assets, partially offset by a $9.5 million decrease in accounts payable and accrued expenses due to the timing of vendor invoice payments and a $10.0 million decrease in the deferred income tax provision due to a one-time, non-cash tax benefit related to the DD acquisition for the year ended December 31, 2014 compared to the same period in 2013.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">For the year ended December 31, 2013, net cash provided by operating activities was $1.7 million, consisting of cash provided by operating activities from continuing operations of $5.9 million offset by cash used in operating activities from discontinued operations of $4.2 million. Net cash provided by operating activities from continuing operations of $5.9 million consisted of a loss from continuing operations of $13.0 million, adjusted for non-cash expenses of $23.0 million, including depreciation and amortization and non-cash stock-based compensation expense. Additionally, changes in operating assets and liabilities used $4.1 million of cash, which was primarily due to increases in accounts receivable due to higher advertising and sponsorship revenues and in prepaid expenses and other current assets, partially offset by an increase in (i) accounts payable and accrued expenses due to the timing of vendor payments and (ii) deferred revenue related to certain marketing campaigns and premium services billed in advance of the services being provided. Net</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: justify;">cash used in operating activities from discontinued operations of $4.2 million consisted of a loss from discontinued operations of $5.2 million adjusted for non-cash items, primarily the write-off of certain assets in connection with the sale.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Net cash provided by operating activities was $10.5 million higher in the year ended December 31, 2013 compared to the year ended December 31, 2012, resulting primarily from a $5.4 million decrease in video and television costs after completion of the <i>Everyday Health </i>YouTube channel in 2012, a $7.6 million increase in accounts payable and accrued expenses due to the timing of vendor invoice payments and a $6.9 million increase in deferred revenue, partially offset by a $7.5 million increase in accounts receivable due to higher advertising and sponsorship revenues and a $2.5 million increase in prepaid expenses and other current assets for the year ended December 31, 2013 compared to the same period in 2012.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">For the year ended December 31, 2012, net cash used in operating activities was $8.8 million, consisting of cash used in operating activities from continuing operations of $5.9 million and cash used in operating activities from discontinued operations of $2.9 million. Net cash used in operating activities from continuing operations of $5.9 million consisted of a loss from continuing operations of</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">$19.2 million, adjusted for non-cash expenses of $27.3 million, including depreciation and amortization and non-cash stock-based compensation expense. Additionally, changes in operating assets and liabilities used $14.0 million of cash, which was primarily due to additions of video and television production costs relating to the <i>Everyday Health </i>YouTube channel, and a decrease in deferred revenue primarily related to the timing of advertising billings in relation to services rendered in advance of the services being provided and an increase in accounts receivable. Net cash used in operating activities from discontinued operations of $2.9 million consisted of the $3.2 million operating loss from discontinued operations, adjusted for non-cash items, for the year ended December 31, 2012.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Investing Activities</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our primary investing activities have historically consisted of additions to property and equipment, including computer hardware and software, leasehold improvements and capitalized video and television production costs and product development costs. Additionally, our investing activities included payments made to acquire businesses.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We used $79.2 million of net cash in investing activities during the year ended December 31, 2014, consisting of $14.8 million of additions to property and equipment and $65.0 million for</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">purchase price payments relating to the DD acquisition. Net cash used in investing activities was</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">$61.7 million higher than in the year ended December 31, 2013.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We used $17.5 million of net cash in investing activities during the year ended December 31, 2013, consisting of $10.7 million of additions to property and equipment, $6.7 million for payments relating to the EQAL acquisition, and $0.7 million in security deposits for additional office space. Net cash used in investing activities was $2.0 million higher than in the year ended December 31, 2012.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We used $15.5 million of net cash in investing activities during the year ended December 31, 2012, primarily for purchases of property and equipment and, to a lesser extent, for a deferred purchase price payment related to a 2011 acquisition.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Financing Activities</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our financing activities have historically consisted primarily of borrowings and repayments under our revolver and term loan credit facilities, and related financing costs, and proceeds from the exercise of stock options. In addition to such activities, in 2014 we received proceeds from our IPO, net of underwriting discounts and commissions and related offering costs.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We generated $93.7 million of net cash in financing activities during the year ended December 31, 2014, primarily from $70.6 million received from the net proceeds upon the closing of our IPO,</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">$7.9 million received upon the exercise of stock option awards and $18.7 million of additional net borrowings under our revolver and term loan credit facilities, partially offset by $2.9 million of related financing costs. Net cash provided by financing activities was $85.5 million higher than in the year ended December 31, 2013.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We generated $8.2 million of net cash in financing activities during the year ended December 31, 2013, primarily from $11.5 million of additional borrowings under our credit facility partially offset by $2.8 million of principal repayments under our term loan credit facility. Net cash provided by financing activities was $12.8 million lower than in the year ended December 31, 2012.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We generated $21.0 million of net cash from financing activities during the year ended December 31, 2012, primarily as a result of the refinancing of our credit facilities during 2012, including the receipt of $35.0 million under a new subordinated facility, repayment of the $15.0 million balance from a former subordinated credit facility, and the payment of $1.3 million in closing costs relating to such refinancing. We also borrowed a net amount of $5.1 million under our revolver facility and repaid $2.8 million under the term loan portion of our credit facility.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Contractual Obligations and Commitments</p><p style="padding-top: 7pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">The following table summarizes our principal contractual obligations as of December 31, 2014:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s40" style="padding-left: 275pt;text-indent: 0pt;text-align: left;">                               Payments due by period                               </p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s40" style="text-indent: 0pt;text-align: right;">     Total     </p><p class="s39" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Less than</p><p class="s40" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">   1 year<span class="s39"> </span>1-3 years 3-5 years </p><p class="s39" style="padding-top: 1pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">(in thousands)</p><p class="s39" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">More than</p><p class="s40" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">   5 years   </p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:28.8242pt" cellspacing="0"><tr style="height:11pt"><td style="width:243pt"><p class="s43" style="padding-left: 2pt;padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: center;">Long-term debt obligations (1) ......... ......... .... </p></td><td style="width:45pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">$ 90,000</p></td><td style="width:41pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">$ 3,000</p></td><td style="width:41pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 10pt;text-align: right;">$12,000</p></td><td style="width:47pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 10pt;text-align: right;">$ 75,000</p></td><td style="width:40pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">$ —</p></td></tr><tr style="height:12pt"><td style="width:243pt"><p class="s43" style="padding-left: 2pt;padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Operating lease obligations .... ......... ......... .... </p></td><td style="width:45pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">33,018</p></td><td style="width:41pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">4,042</p></td><td style="width:41pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: right;">7,314</p></td><td style="width:47pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">6,747</p></td><td style="width:40pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">14,915</p></td></tr><tr style="height:12pt"><td style="width:243pt"><p class="s43" style="padding-left: 1pt;padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Minimum guarantees under royalty agreements (2) . .</p></td><td style="width:45pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">92,632</p></td><td style="width:41pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">19,095</p></td><td style="width:41pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: right;">26,191</p></td><td style="width:47pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">24,457</p></td><td style="width:40pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">22,889</p></td></tr><tr style="height:12pt"><td style="width:243pt"><p class="s43" style="padding-left: 2pt;padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Purchase obligations (3) ....... ......... ......... .... </p></td><td style="width:45pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">21,995</p></td><td style="width:41pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">16,863</p></td><td style="width:41pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: right;">5,132</p></td><td style="width:47pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">—</p></td><td style="width:40pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">—</p></td></tr><tr style="height:22pt"><td style="width:243pt"><p class="s43" style="padding-left: 2pt;padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Total......... ......... ......... ......... ......... .... </p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 2pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="64" height="1" alt="image" src="NYSE_EVDY_2014/Image_055.png"/></span></p></td><td style="width:45pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">$237,645</p></td><td style="width:41pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">$43,000</p></td><td style="width:41pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: right;">$50,637</p></td><td style="width:47pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">$106,204</p></td><td style="width:40pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">$37,804</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l11"><li style="padding-top: 3pt;padding-left: 49pt;text-indent: -17pt;text-align: left;"><p style="display: inline;">In addition to the principal repayments due under our Credit Facility shown above based on outstanding borrowings of $90.0 million as of December 31, 2014, interest payments of $2.7 million are due in less than 1 year, $5.8 million in 1-3 years and $5.2 million in 3-5 years. For a description of our long-term debt obligations, see “Liquidity and Capital Resources—Sources of Liquidity and Long-Term Debt” above.</p></li><li style="padding-top: 1pt;padding-left: 49pt;text-indent: -17pt;text-align: left;"><p style="display: inline;">Some of the minimum guaranteed payments are subject to reductions if specified performance metrics are not achieved by our partners with respect to the non-operated properties in the <i>Everyday Health </i>portfolio.</p></li><li style="padding-top: 6pt;padding-left: 49pt;text-indent: -17pt;text-align: left;"><p style="display: inline;">Purchase obligations pertain primarily to fees for third-party content, technology and other services.</p></li></ol><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Off-Balance Sheet Arrangements</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We do not engage in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, as part of our ongoing business. Accordingly, our operating results, financial condition and cash flows are not subject to off-balance sheet risks.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Critical Accounting Policies and Estimates</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: justify;">Our consolidated financial statements are prepared in accordance with GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, costs and expenses, and related disclosures.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">These estimates and assumptions are often based on judgments that we believe to be reasonable under the circumstances at the time made, but all such estimates and assumptions are inherently uncertain and unpredictable. Actual results may differ from those estimates and assumptions and it is possible that other professionals, applying their own judgment to the same facts and circumstances, could develop and support alternative estimates and assumptions that would result in material changes to our operating results and financial condition. We evaluate our estimates and assumptions on an ongoing basis. Our estimates are based on historical experience and various other assumptions that we believe to be reasonable under the circumstances.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We believe the following reflects our critical accounting policies and our more significant judgments and estimates used in the preparation of our consolidated financial statements. For further information on all of our significant accounting policies, see Note 2 of our accompanying notes to consolidated financial statements included in Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Revenue Recognition and Deferred Revenue</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We generate revenues primarily through advertising and sponsorships, and premium services, including subscriptions and licensing fees, and, to a lesser extent, video production fees.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We recognize advertising revenues in the period in which the advertisement is delivered. Our revenues from sponsorship services is recognized over the period in which we substantially satisfy our contractual obligations set forth in the relevant sponsorship agreements. When contractual arrangements contain multiple elements, revenue is allocated to each element based on its relative fair value determined using prices charged when elements are sold separately. In instances where individual deliverables are not sold separately, or when third-party evidence is not available, fair value is determined based on our best estimate of selling price. Advertising and sponsorship revenues accounted for 90.3%, 86.6% and 79.4% of total revenues for the years ended</p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 11pt;text-align: left;">December 31, 2014, 2013 and 2012, respectively.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We recognize subscription revenues ratably over the relevant subscription periods, which are predominantly quarterly, after deducting refunds and charge-backs. We typically charge each subscriber’s credit card for the full price for their subscription at the commencement of the subscription period and at each subscription renewal date, unless the consumer cancels the subscription prior to the renewal date. When consumers sign up for free-trial subscriptions, we automatically charge their credit card for a subscription at the end of the free-trial period unless they cancel before the trial period ends. Once billed, the revenue is recognized on a straight line basis, ratably over the subscription period. No revenue is recognized or allocated to the free-trial period.</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We generally recognize licensing revenue over the life of the contract. We recognize video production fee revenue as the video content is completed and delivered to the customer.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Deferred revenue consists primarily of (i) subscription fees that we have collected from consumers but for which revenue has not been recognized, and (ii) revenues from advertising and sponsorship services and licensing fees that we have billed in advance of when the revenue is to be earned.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Internal Software and Website Development Cost</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We incur costs to develop software for internal use and for our website applications. In accordance with authoritative accounting guidance, we capitalize costs, consisting principally of payroll and related benefits, third-party consultants and related charges, incurred during the application development phase of a project as well as the costs of content developed for our properties by third-party consultants which is deemed to be reference material in nature and to provide a future economic benefit. Upon completion of a project, the capitalized costs are amortized using the straight-line method over their estimated useful lives, which is typically three years.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Software and website development costs that do not meet the criteria for capitalization are expensed as incurred and are included in product development expenses in the consolidated statements of operations.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Goodwill</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Goodwill resulting from our acquisitions represents the excess cost over fair value of the identifiable net tangible and intangible assets of acquired businesses.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Goodwill is tested for impairment on an annual basis as of October 1, and whenever events or circumstances indicate that the carrying value of the asset may not be recoverable. Application of the impairment test requires judgment and results in impairment being recognized if the carrying value of the asset exceeds its fair value. We operate as one operating segment and one reporting unit.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We perform an initial qualitative analysis to evaluate whether any events and circumstances occurred or exist that provide evidence that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is not more likely than not that the fair value of the reporting unit is less than its carrying value, no further assessment of the reporting unit’s goodwill is necessary. If it is more likely than not that the fair value of the reporting unit is less than its carrying value, then the goodwill must be tested using a two-step quantitative process, and if the carrying value of a reporting unit’s goodwill exceeds its implied fair value, an impairment loss equal to the excess is recorded.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The evaluation of our goodwill annually on October 1 indicated that the carrying value of the asset was less than the fair value and, accordingly, there was no impairment loss recognized for the years ended December 31, 2014, 2013 and 2012.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Long-Lived Assets</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our long-lived assets, in addition to goodwill discussed above, consist of property and equipment and intangible assets with definite lives. These intangible assets resulted from our business acquisitions, and consist of trade names, customer relationships and agreements with certain of our website partners.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The amount assigned to our definite-lived intangible assets is a subjective analysis based on our estimates of the future benefit of these assets using acceptable valuation techniques. The estimated fair values assigned to our trade names and other definite-lived intangible assets are computed based on discounted cash flows using the Relief From Royalty Method and Excess Earnings Method, respectively, which applies various assumptions developed by management, including projected revenues, operating margins, attrition rates, royalty rates and discount rates.</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our property and equipment and definite-lived intangible assets are depreciated and amortized over their estimated useful lives, generally three to five years for property and equipment and three to ten years for definite-lived intangible assets, which are determined based on several factors, primarily the period of time the asset is expected to remain in service and provide benefit to us. We review these definite-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. There were no indicators of impairment of these definite-lived assets during the years ended December 31, 2014 and 2012.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">During the year ended December 31, 2013, we recorded impairment charges of $1.2 million related to certain website costs included in property and equipment.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Stock-Based Compensation</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We account for stock-based compensation expense in accordance with the current authoritative accounting guidance, under which stock-based awards, including stock options, are measured at fair value as of the grant date and recognized as compensation expense over the requisite service period (generally the vesting period), which we have elected to amortize using the graded attribution method.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 23pt;text-align: left;">We use the Black-Scholes option pricing model to estimate the fair value of the stock option and our Employee Stock Purchase Plan (“ESPP”) awards. As there was no public market for our common stock prior to our IPO in March 2014, and therefore a lack of company-specific historical and implied volatility data, we have determined the share price volatility for awards granted based on an analysis of reported data for a peer group of companies that granted awards with substantially similar terms. The expected volatility of awards granted has been determined using an average of the historical realized volatility measures of this peer group of companies for a period of time commensurate with the expected term of the option. We intend to continue to consistently apply this process using the same or similar entities until a sufficient amount of historical information regarding the volatility of our own share price becomes available, or unless circumstances change such that the identified entities are no longer similar to us. In this latter case, more suitable entities whose share prices are publicly available would be utilized in the calculation.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The expected life of options granted has been determined utilizing the simplified method for determining the expected life for options qualifying for treatment due to the limited history we have with option exercise activity. The expected term for ESPP shares is based on the purchase period.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">The risk-free interest rate is based on a U.S. Treasury yield curve for periods equal to the expected term of the awards on the grant date. We have not paid, and do not anticipate paying, cash dividends on our shares of common stock, and the expected dividend yield is, therefore, assumed to be zero.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In addition, forfeitures are estimated at the time of grant, based on our historical forfeiture experience, and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The assumptions used in calculating the fair value of stock-based awards represent our best estimates. These estimates involve inherent uncertainties and the application of management judgment. The assumptions we used in the Black-Scholes pricing model are based on subjective future expectations combined with management judgment. If any of the assumptions used in this pricing model change significantly, stock-based compensation for future awards may differ materially from the awards granted previously. Additionally, the pricing model fair value of the awards is based upon the fair value of our underlying common stock.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Income Taxes</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: justify;">We are subject to income taxes in the United States and one foreign jurisdiction. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the tax and financial statement reporting basis of assets and liabilities, as well as for operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to</p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The components of the deferred tax assets and liabilities are individually classified as current and non-current based on their characteristics. We reduce the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that we will not realize some or all of the deferred tax asset. As a result of our historical operating performance and the cumulative net losses incurred to date, we do not have sufficient objective evidence to support the recovery of the net deferred tax assets. Accordingly, we have established a valuation allowance against net deferred tax assets for financial reporting purposes because we believe it is more likely than not that these deferred tax assets will not be realized.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We account for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is “more-likely-than-not” that the position will be sustained upon examination. Potential interest and penalties associated with unrecognized tax positions are recognized in income tax expense.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Recently Issued and Adopted Accounting Pronouncements</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In July 2013, the Financial Accounting Standards Board, or FASB, issued amended guidance for income taxes. This amendment requires that entities present an unrecognized tax benefit, or portion of an unrecognized tax benefit, as a reduction to a deferred tax asset in the financial statements for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, with certain exceptions. We adopted this amended guidance beginning in the quarter ended March 31, 2014. The adoption of this guidance had no impact on our consolidated financial statements.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In April 2014, the FASB issued amended guidance for reporting discontinued operations. Under the new guidance, only disposals that represent a strategic shift having a material impact on an entity’s operations and financial results shall be reported as discontinued operations, with expanded disclosures. This amendment will be effective for the first annual reporting period beginning after December 15, 2015. We do not expect the impact of the adoption of this guidance to be material to our consolidated financial statements.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In May 2014, the FASB issued amended guidance for revenue recognition. This amendment provides a comprehensive new revenue recognition model. The core principle of the guidance is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. This amendment is effective for fiscal years beginning after December 15, 2016, and for interim periods within those fiscal years. Early adoption is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We have not yet selected a transition method and we are currently evaluating the effect that the new standard will have on our consolidated financial statements and related disclosures.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In June 2014, the FASB issued updated guidance on stock compensation accounting requiring that a performance target that affects vesting and could be achieved after the requisite service period should be treated as a performance condition. Current GAAP does not contain explicit guidance on how to account for such share-based payments. This updated guidance is effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. Early adoption is permitted. We do not expect the impact of the adoption of this guidance to be material to our consolidated financial statements.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We are exposed to market risk related to changes in interest rates, foreign currency exchange rates and inflation. We do not use derivative financial instruments for speculative, hedging or trading purposes, although in the future we may enter into interest rate or exchange rate hedging arrangements to manage the risks described below.</p><p class="s45" style="padding-top: 2pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Interest Rate Risk. <span class="p">Our interest income is primarily generated from interest earned on highly liquid, short-term money market funds. Our exposure to market risks related to interest expense is limited to borrowings under our credit facility. Based on the $90.0 million of borrowings outstanding under our credit facility as of December 31, 2014 and the interest rates in effect at that date, our annual interest expense would amount to $3.1 million. A hypothetical interest rate increase of 1% on our credit facility would increase annual interest expense by $0.9 million. We do not enter into interest rate swaps, caps or collars or other hedging instruments.</span></p><p class="s45" style="padding-top: 6pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Foreign Currency Risk. <span class="p">Substantially all of our revenues and expenses are denominated in</span></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">U.S. dollars and, therefore, our exposure to market risks related to fluctuations in foreign currency exchange rates is not material.</p><p class="s45" style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Inflation Risk. <span class="p">We do not believe that inflation has had a material effect on our business, financial condition or results of operations. Nonetheless, if our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition and results of operations.</span></p><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Item 8. Financial Statements and Supplementary Data.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s36" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">Everyday  Health, Inc.</p><p style="padding-top: 4pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">Index to Consolidated Financial  Statements</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Everyday Health, Inc. Audited Consolidated Financial Statements:</p><p class="s40" style="padding-top: 3pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">Page</p><p style="padding-top: 4pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Report of independent registered public accounting firm 72</p><p style="padding-top: 4pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Consolidated balance sheets as of December 31, 2014 and 2013 73</p><p style="padding-top: 4pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Consolidated statements of operations for the years ended December 31, 2014, 2013 and 2012 74</p><p style="padding-top: 4pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Consolidated statements of redeemable convertible preferred stock and stockholders’ equity</p><p style="padding-left: 7pt;text-indent: 0pt;text-align: center;">(deficit)  for  the  years  ended  December  31,  2014,  2013  and  2012                                              75</p><p style="padding-top: 4pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Consolidated statements of cash flows for the years ended December 31, 2014, 2013 and 2012 76</p><p style="padding-top: 4pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Notes to consolidated financial statements 77</p><p class="s36" style="padding-top: 1pt;padding-left: 107pt;text-indent: 0pt;text-align: left;">Report of independent registered public accounting firm</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">The Board of Directors and Stockholders of Everyday Health, Inc.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We have audited the consolidated balance sheets of Everyday Health, Inc. (the Company) as of December 31, 2014 and 2013, and the related consolidated statements of operations, redeemable convertible preferred stock and stockholders’ equity (deficit), and cash flows for each of the three years in the period ended December 31, 2014. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company’s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Everyday Health, Inc. at December 31, 2014 and 2013, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2014, in conformity with U.S. generally accepted accounting principles.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="205" height="1" alt="image" src="NYSE_EVDY_2014/Image_056.png"/></span></p><p style="padding-left: 51pt;text-indent: 0pt;text-align: left;">/s/ Ernst &amp; Young LLP New York, New York March 5, 2015</p><p style="padding-top: 3pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">Consolidated  Balance Sheets</p><p class="s39" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">(in thousands, except share and per share data)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s40" style="padding-top: 3pt;text-indent: 0pt;text-align: right;">           December 31,           </p><p class="s40" style="padding-top: 1pt;text-indent: 0pt;text-align: right;">      2014 2013      </p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Assets</p><p style="padding-bottom: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Current assets:</p><table style="border-collapse:collapse;margin-left:28.8254pt" cellspacing="0"><tr style="height:11pt"><td style="width:357pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 10pt;text-align: right;">Cash and cash equivalents . ......... ......... ......... .......... ......... .</p></td><td style="width:53pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 10pt;text-align: right;">$ 50,729</p></td><td style="width:49pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">$ 16,242</p></td></tr><tr style="height:22pt"><td style="width:357pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Accounts receivable, net of allowance for doubtful accounts of $637 and</p><p class="s43" style="padding-left: 32pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$530 as of December 31, 2014 and 2013, respectively......... ......... .</p></td><td style="width:53pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">68,007</p></td><td style="width:49pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">49,373</p></td></tr><tr style="height:12pt"><td style="width:357pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Deferred tax asset ......... ......... ......... ......... .......... ......... .</p></td><td style="width:53pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">656</p></td><td style="width:49pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">133</p></td></tr><tr style="height:14pt"><td style="width:357pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Prepaid expenses and other current assets . . . ......... .......... ......... .</p></td><td style="width:53pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">        5,529</p></td><td style="width:49pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">        7,822</p></td></tr><tr style="height:14pt"><td style="width:357pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">Total current assets ........ ......... ......... ......... .......... ......... .</p></td><td style="width:53pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">124,921</p></td><td style="width:49pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">73,570</p></td></tr><tr style="height:12pt"><td style="width:357pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Property and equipment, net . . . ......... ......... ......... .......... ......... .</p></td><td style="width:53pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">25,502</p></td><td style="width:49pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">21,095</p></td></tr><tr style="height:12pt"><td style="width:357pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Goodwill ..... ......... ......... ......... ......... ......... .......... ......... .</p></td><td style="width:53pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">127,115</p></td><td style="width:49pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">82,153</p></td></tr><tr style="height:12pt"><td style="width:357pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Intangible assets, net . . ......... ......... ......... ......... .......... ......... .</p></td><td style="width:53pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">30,716</p></td><td style="width:49pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">9,735</p></td></tr><tr style="height:14pt"><td style="width:357pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Other assets . . ......... ......... ......... ......... ......... .......... ......... .</p></td><td style="width:53pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">        5,237</p></td><td style="width:49pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">        5,729</p></td></tr><tr style="height:15pt"><td style="width:357pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">Total assets ....... ......... ......... ......... ......... .......... ......... .</p></td><td style="width:53pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">$ 313,491</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="55" height="1" alt="image" src="NYSE_EVDY_2014/Image_057.png"/></span></p></td><td style="width:49pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">$ 192,282</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="55" height="1" alt="image" src="NYSE_EVDY_2014/Image_058.png"/></span></p></td></tr></table><p style="padding-top: 4pt;padding-left: 41pt;text-indent: -10pt;line-height: 87%;text-align: left;">Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)</p><p style="padding-bottom: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Current liabilities:</p><table style="border-collapse:collapse;margin-left:28.8244pt" cellspacing="0"><tr style="height:11pt"><td style="width:357pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 10pt;text-align: right;">Accounts payable and accrued expenses ..... ......... .......... ......... .</p></td><td style="width:55pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$ 31,722</p></td><td style="width:51pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$ 34,378</p></td></tr><tr style="height:12pt"><td style="width:357pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Deferred revenue . ......... ......... ......... ......... .......... ......... .</p></td><td style="width:55pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">6,740</p></td><td style="width:51pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">6,808</p></td></tr><tr style="height:12pt"><td style="width:357pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Current portion of long-term debt . . ......... ......... .......... ......... .</p></td><td style="width:55pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">3,000</p></td><td style="width:51pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">1,333</p></td></tr><tr style="height:14pt"><td style="width:357pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Other current liabilities .... ......... ......... ......... .......... ......... .</p></td><td style="width:55pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">           965</p></td><td style="width:51pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">           830</p></td></tr><tr style="height:14pt"><td style="width:357pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">Total current liabilities..... ......... ......... ......... .......... ......... .</p></td><td style="width:55pt"><p class="s43" style="padding-left: 19pt;text-indent: 0pt;text-align: left;">42,427</p></td><td style="width:51pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;text-align: left;">43,349</p></td></tr><tr style="height:12pt"><td style="width:357pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Long-term debt........ ......... ......... ......... ......... .......... ......... .</p></td><td style="width:55pt"><p class="s43" style="padding-left: 19pt;text-indent: 0pt;line-height: 11pt;text-align: left;">87,000</p></td><td style="width:51pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">70,000</p></td></tr><tr style="height:12pt"><td style="width:357pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Deferred tax liabilities. ......... ......... ......... ......... .......... ......... .</p></td><td style="width:55pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">6,673</p></td><td style="width:51pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">5,199</p></td></tr><tr style="height:12pt"><td style="width:357pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Other long-term liabilities ...... ......... ......... ......... .......... ......... .</p></td><td style="width:55pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">4,105</p></td><td style="width:51pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">4,937</p></td></tr><tr style="height:12pt"><td style="width:357pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Commitments and contingencies <i>(Note 13)</i></p></td><td style="width:55pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:41pt"><td style="width:357pt"><p class="s43" style="padding-left: 12pt;padding-right: 5pt;text-indent: -10pt;line-height: 10pt;text-align: left;">Redeemable convertible preferred stock (Series A-G),  net  of  expenses,  $0.01 par value: 10,000,000 and 27,204,144 shares  authorized  at  December  31, 2014 and 2013, respectively; no shares and 26,820,270 shares issued and outstanding at December 31, 2014 and 2013, respectively ......... ......... .</p></td><td style="width:55pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-top: 6pt;padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">—</p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-top: 6pt;padding-left: 12pt;text-indent: 0pt;line-height: 11pt;text-align: left;">158,766</p></td></tr><tr style="height:55pt"><td style="width:357pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Stockholders’ equity (deficit):</p><p class="s43" style="padding-top: 1pt;padding-left: 32pt;padding-right: 5pt;text-indent: -10pt;line-height: 87%;text-align: left;">Common stock, $0.01 par value: 90,000,000 and 45,000,000 shares authorized at December 31,  2014  and  2013,  respectively;  31,489,196 and 5,366,478 shares issued and outstanding at December 31, 2014 and 2013, respectively ........ ......... ......... ......... .......... ......... .</p></td><td style="width:55pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-top: 7pt;padding-right: 7pt;text-indent: 0pt;text-align: right;">314</p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-top: 7pt;padding-right: 6pt;text-indent: 0pt;text-align: right;">54</p></td></tr><tr style="height:12pt"><td style="width:357pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Treasury stock .... ......... ......... ......... ......... .......... ......... .</p></td><td style="width:55pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(55)</p></td><td style="width:51pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(55)</p></td></tr><tr style="height:12pt"><td style="width:357pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Additional paid-in capital . . ......... ......... ......... .......... ......... .</p></td><td style="width:55pt"><p class="s43" style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: left;">292,117</p></td><td style="width:51pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">33,726</p></td></tr><tr style="height:14pt"><td style="width:357pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Accumulated deficit........ ......... ......... ......... .......... ......... .</p></td><td style="width:55pt"><p class="s51" style="padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: right;">  (119,090<span class="s43">)</span></p></td><td style="width:51pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  (123,694<span class="s43">)</span></p></td></tr><tr style="height:15pt"><td style="width:357pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">Total stockholders’ equity (deficit). . ......... ......... .......... ......... .</p></td><td style="width:55pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">    173,286</p></td><td style="width:51pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">    (89,969<span class="s43">)</span></p></td></tr><tr style="height:25pt"><td style="width:357pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Total liabilities, redeemable convertible preferred stock and</p><p class="s43" style="padding-left: 32pt;text-indent: 0pt;line-height: 11pt;text-align: left;">stockholders’ equity (deficit)...... ......... ......... .......... ......... .</p></td><td style="width:55pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s51" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">$ 313,491</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="54" height="1" alt="image" src="NYSE_EVDY_2014/Image_059.png"/></span></p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s51" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">$ 192,282</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 4pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="54" height="1" alt="image" src="NYSE_EVDY_2014/Image_060.png"/></span></p></td></tr></table><p style="padding-top: 3pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">Consolidated Statements Of  Operations</p><p class="s39" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">(in thousands, except share and per share data)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s40" style="padding-top: 3pt;padding-left: 322pt;text-indent: 0pt;text-align: left;">                 Year ended December 31,                 </p><p class="s40" style="padding-top: 1pt;padding-left: 322pt;text-indent: 0pt;text-align: left;">        2014 2013 2012       </p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-bottom: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Revenues</p><table style="border-collapse:collapse;margin-left:28.8234pt" cellspacing="0"><tr style="height:11pt"><td style="width:293pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 10pt;text-align: right;">Advertising and sponsorship revenues........ ......... .... </p></td><td style="width:62pt"><p class="s43" style="text-indent: 0pt;line-height: 10pt;text-align: left;">$ 166,465</p></td><td style="width:57pt"><p class="s43" style="text-indent: 0pt;line-height: 10pt;text-align: left;">$ 134,893</p></td><td style="width:51pt"><p class="s43" style="text-indent: 0pt;line-height: 10pt;text-align: left;">$ 109,956</p></td></tr><tr style="height:12pt"><td style="width:293pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Premium services revenues. ......... ......... ......... .... </p></td><td style="width:62pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">17,860</p></td><td style="width:57pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">20,957</p></td><td style="width:51pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">23,536</p></td></tr><tr style="height:14pt"><td style="width:293pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Video production fees...... ......... ......... ......... .... </p></td><td style="width:62pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">                —</p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">              —</p></td><td style="width:51pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">         5,000</p></td></tr><tr style="height:13pt"><td style="width:293pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Total revenues .... ......... ......... ......... ......... .... </p></td><td style="width:62pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">       184,325</p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">     155,850</p></td><td style="width:51pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">     138,492</p></td></tr><tr style="height:16pt"><td style="width:293pt"><p class="s43" style="padding-top: 3pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Operating expenses:</p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:293pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 10pt;text-align: right;">Cost of revenues . . ......... ......... ......... ......... .... </p></td><td style="width:62pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 10pt;text-align: left;">49,296</p></td><td style="width:57pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 10pt;text-align: left;">43,338</p></td><td style="width:51pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 10pt;text-align: left;">40,543</p></td></tr><tr style="height:12pt"><td style="width:293pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Sales and marketing........ ......... ......... ......... .... </p></td><td style="width:62pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">48,605</p></td><td style="width:57pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">44,385</p></td><td style="width:51pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">38,603</p></td></tr><tr style="height:12pt"><td style="width:293pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Product development....... ......... ......... ......... .... </p></td><td style="width:62pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">44,541</p></td><td style="width:57pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">43,759</p></td><td style="width:51pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">45,676</p></td></tr><tr style="height:14pt"><td style="width:293pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 11pt;text-align: right;">General and administrative ......... ......... ......... .... </p></td><td style="width:62pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">         30,041</p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">       27,462</p></td><td style="width:51pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">       25,874</p></td></tr><tr style="height:14pt"><td style="width:293pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;text-align: right;">Total operating expenses. . . ......... ......... ......... .... </p></td><td style="width:62pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;text-align: left;">172,483</p></td><td style="width:57pt"><p class="s43" style="padding-left: 12pt;text-indent: 0pt;text-align: left;">158,944</p></td><td style="width:51pt"><p class="s43" style="padding-left: 12pt;text-indent: 0pt;text-align: left;">150,696</p></td></tr><tr style="height:12pt"><td style="width:293pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Income (loss) from  operations . . ......... ......... ......... .... </p></td><td style="width:62pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">11,842</p></td><td style="width:57pt"><p class="s43" style="padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(3,094)</p></td><td style="width:51pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(12,204)</p></td></tr><tr style="height:12pt"><td style="width:293pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Interest expense, net. . . ......... ......... ......... ......... .... </p></td><td style="width:62pt"><p class="s43" style="padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(3,711)</p></td><td style="width:57pt"><p class="s43" style="padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(8,442)</p></td><td style="width:51pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(4,898)</p></td></tr><tr style="height:14pt"><td style="width:293pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Other expense ......... ......... ......... ......... ......... .... </p></td><td style="width:62pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">         (4,114<span class="s43">)</span></p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">          (359<span class="s43">)</span></p></td><td style="width:51pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">       (1,069<span class="s43">)</span></p></td></tr><tr style="height:24pt"><td style="width:293pt"><p class="s43" style="padding-top: 2pt;padding-left: 12pt;padding-right: 11pt;text-indent: -10pt;line-height: 87%;text-align: left;">Income (loss) from continuing operations before provision for income taxes ........ ......... ......... ......... ......... .... </p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 11pt;text-indent: 0pt;text-align: right;">4,017</p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">(11,895)</p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">(18,171)</p></td></tr><tr style="height:14pt"><td style="width:293pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Benefit (provision) for income taxes..... ......... ......... .... </p></td><td style="width:62pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">           8,666</p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">       (1,102<span class="s43">)</span></p></td><td style="width:51pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">       (1,026<span class="s43">)</span></p></td></tr><tr style="height:14pt"><td style="width:293pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Income (loss) from continuing operations......... ......... .... </p></td><td style="width:62pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;text-align: left;">12,683</p></td><td style="width:57pt"><p class="s43" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">(12,997)</p></td><td style="width:51pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">(19,197)</p></td></tr><tr style="height:14pt"><td style="width:293pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Loss from discontinued operations, net of tax .... ......... .... </p></td><td style="width:62pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">                —</p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">       (5,239<span class="s43">)</span></p></td><td style="width:51pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">       (3,257<span class="s43">)</span></p></td></tr><tr style="height:14pt"><td style="width:293pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Net income (loss)...... ......... ......... ......... ......... .... </p></td><td style="width:62pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;text-align: left;">12,683</p></td><td style="width:57pt"><p class="s43" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">(18,236)</p></td><td style="width:51pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">(22,454)</p></td></tr><tr style="height:14pt"><td style="width:293pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Series G preferred stock deemed dividend........ ......... .... </p></td><td style="width:62pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">         (8,079<span class="s43">)</span></p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">              —</p></td><td style="width:51pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">              —</p></td></tr><tr style="height:15pt"><td style="width:293pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Net income (loss) attributable to common stockholders . . . .... </p></td><td style="width:62pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s51" style="text-indent: 0pt;text-align: left;">$ 4,604</p></td><td style="width:57pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s51" style="text-indent: 0pt;text-align: left;">$ (18,236<span class="s43">)</span></p></td><td style="width:51pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s51" style="text-indent: 0pt;text-align: left;">$ (22,454<span class="s43">)</span></p></td></tr><tr style="height:37pt"><td style="width:293pt"><p class="s43" style="padding-top: 4pt;padding-left: 12pt;padding-right: 11pt;text-indent: -10pt;line-height: 86%;text-align: left;">Basic net income (loss) attributable to common stockholders per common share:</p><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Net income (loss) attributable to common stockholders</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt;border-top-style:solid;border-top-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt;border-top-style:solid;border-top-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:293pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 9pt;text-align: right;">from continuing operations ....... ......... ......... .... </p></td><td style="width:62pt"><p class="s43" style="text-indent: 0pt;line-height: 9pt;text-align: left;">$ 0.19</p></td><td style="width:57pt"><p class="s43" style="text-indent: 0pt;line-height: 9pt;text-align: left;">$ (2.55)</p></td><td style="width:51pt"><p class="s43" style="text-indent: 0pt;line-height: 9pt;text-align: left;">$ (4.01)</p></td></tr><tr style="height:12pt"><td style="width:293pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Net loss attributable to common stockholders from</p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:293pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 10pt;text-align: right;">discontinued operations, net of tax ........ ......... .... </p></td><td style="width:62pt"><p class="s51" style="text-indent: 0pt;line-height: 10pt;text-align: left;">                —</p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 10pt;text-align: left;">         (1.03<span class="s43">)</span></p></td><td style="width:51pt"><p class="s51" style="text-indent: 0pt;line-height: 10pt;text-align: left;">         (0.68<span class="s43">)</span></p></td></tr><tr style="height:15pt"><td style="width:293pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Net income (loss) attributable to common stockholders . . . .... </p></td><td style="width:62pt"><p class="s51" style="text-indent: 0pt;text-align: left;">$ 0.19</p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;text-align: left;">$ (3.57<span class="s43">)</span></p></td><td style="width:51pt"><p class="s51" style="text-indent: 0pt;text-align: left;">$ (4.69<span class="s43">)</span></p></td></tr><tr style="height:35pt"><td style="width:293pt"><p class="s43" style="padding-top: 2pt;padding-left: 12pt;padding-right: 19pt;text-indent: -10pt;line-height: 87%;text-align: left;">Diluted net income (loss) attributable to common stockholders per common share:</p><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Net income (loss) attributable to common stockholders</p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:293pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 9pt;text-align: right;">from continuing operations ....... ......... ......... .... </p></td><td style="width:62pt"><p class="s43" style="text-indent: 0pt;line-height: 9pt;text-align: left;">$ 0.17</p></td><td style="width:57pt"><p class="s43" style="text-indent: 0pt;line-height: 9pt;text-align: left;">$ (2.55)</p></td><td style="width:51pt"><p class="s43" style="text-indent: 0pt;line-height: 9pt;text-align: left;">$ (4.01)</p></td></tr><tr style="height:12pt"><td style="width:293pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Net loss attributable to common stockholders from</p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:293pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 10pt;text-align: right;">discontinued operations, net of tax ........ ......... .... </p></td><td style="width:62pt"><p class="s51" style="text-indent: 0pt;line-height: 10pt;text-align: left;">                —</p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 10pt;text-align: left;">         (1.03<span class="s43">)</span></p></td><td style="width:51pt"><p class="s51" style="text-indent: 0pt;line-height: 10pt;text-align: left;">         (0.68<span class="s43">)</span></p></td></tr><tr style="height:15pt"><td style="width:293pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Net income (loss) attributable to common stockholders . . . .... </p></td><td style="width:62pt"><p class="s51" style="text-indent: 0pt;text-align: left;">$ 0.17</p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;text-align: left;">$ (3.57<span class="s43">)</span></p></td><td style="width:51pt"><p class="s51" style="text-indent: 0pt;text-align: left;">$ (4.69<span class="s43">)</span></p></td></tr><tr style="height:14pt"><td style="width:293pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Weighted-average common shares outstanding:</p></td><td style="width:62pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:293pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Basic ........ .......... ......... ......... ......... ......... .... </p></td><td style="width:62pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">24,259,395</p></td><td style="width:57pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">5,103,351</p></td><td style="width:51pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4,791,474</p></td></tr><tr style="height:11pt"><td style="width:293pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Diluted ...... .......... ......... ......... ......... ......... .... </p></td><td style="width:62pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">26,911,782</p></td><td style="width:57pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">5,103,351</p></td><td style="width:51pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">4,791,474</p></td></tr></table><p style="padding-top: 3pt;padding-left: 104pt;text-indent: 0pt;text-align: center;">Consolidated Statements Of Redeemable Convertible Preferred Stock And Stockholders’ Equity (Deficit)</p><p class="s39" style="padding-left: 32pt;text-indent: 0pt;line-height: 9pt;text-align: center;">(in thousands, except share  data)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="51" height="755" alt="image" src="NYSE_EVDY_2014/Image_061.png"/></span></p><p class="s39" style="padding-top: 4pt;padding-left: 158pt;text-indent: -2pt;line-height: 87%;text-align: left;">Redeemable convertible</p><p class="s40" style="padding-left: 138pt;text-indent: 0pt;line-height: 8pt;text-align: left;">      preferred stock Common stock    </p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s39" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Treasury</p><p class="s40" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">   stock   </p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s39" style="padding-top: 6pt;padding-left: 10pt;text-indent: -6pt;line-height: 87%;text-align: left;">Additional paid in</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s39" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">Accumulated</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s39" style="padding-top: 6pt;padding-left: 7pt;text-indent: 13pt;line-height: 87%;text-align: left;">Total stockholders’</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s39" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Balance at December 31,</p><p class="s40" style="padding-left: 15pt;text-indent: 0pt;line-height: 8pt;text-align: left;">    Shares Amount Shares<span class="s39"> </span>Amount Amount</p><p class="s40" style="padding-left: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">    capital    </p><p class="s40" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">      deficit      </p><p class="s40" style="padding-left: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">equity (deficit)</p><p class="s39" style="padding-left: 39pt;text-indent: 0pt;line-height: 9pt;text-align: left;">2011 . . . . . . . . . . . . . . . .... ... 26,820,270 $ 158,766 4,709,010 $ 47 $ — $ 18,831 $ (83,004) $(64,126)</p><p class="s39" style="padding-top: 1pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Exercise of stock options . . . — — 46,505 1 — 167 — 168</p><p class="s39" style="padding-top: 1pt;padding-bottom: 1pt;padding-left: 39pt;text-indent: -8pt;text-align: left;">Warrant issued in connection with credit</p><table style="border-collapse:collapse;margin-left:28.8234pt" cellspacing="0"><tr style="height:10pt"><td style="width:108pt"><p class="s54" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">facility . . . . . . . . . . . . . .... ... </p></td><td style="width:128pt" colspan="3"><p class="s54" style="padding-left: 33pt;text-indent: 0pt;line-height: 8pt;text-align: left;">— — —</p></td><td style="width:33pt"><p class="s54" style="padding-right: 10pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:83pt" colspan="2"><p class="s54" style="padding-left: 17pt;text-indent: 0pt;line-height: 8pt;text-align: left;">— 3,452</p></td><td style="width:99pt" colspan="2"><p class="s54" style="padding-left: 31pt;text-indent: 0pt;line-height: 8pt;text-align: left;">— 3,452</p></td></tr><tr style="height:11pt"><td style="width:108pt"><p class="s54" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Issuance of common stock . .</p></td><td style="width:128pt" colspan="3"><p class="s54" style="padding-left: 33pt;text-indent: 0pt;text-align: left;">— — 105,340</p></td><td style="width:33pt"><p class="s54" style="padding-right: 10pt;text-indent: 0pt;text-align: right;">1</p></td><td style="width:83pt" colspan="2"><p class="s54" style="padding-left: 17pt;text-indent: 0pt;text-align: left;">— 699</p></td><td style="width:99pt" colspan="2"><p class="s54" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">— 700</p></td></tr><tr style="height:20pt"><td style="width:108pt"><p class="s54" style="padding-left: 10pt;text-indent: -8pt;text-align: left;">Stock-based compensation expense related to</p></td><td style="width:128pt" colspan="3"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:33pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:83pt" colspan="2"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:99pt" colspan="2"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:108pt"><p class="s54" style="padding-right: 3pt;text-indent: 0pt;line-height: 8pt;text-align: right;">employee stock options . . .</p></td><td style="width:44pt"><p class="s54" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:40pt"><p class="s54" style="padding-right: 4pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:44pt"><p class="s54" style="padding-right: 6pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:33pt"><p class="s54" style="padding-right: 10pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:35pt"><p class="s54" style="padding-left: 17pt;text-indent: 0pt;line-height: 8pt;text-align: left;">—</p></td><td style="width:48pt"><p class="s54" style="padding-left: 19pt;text-indent: 0pt;line-height: 8pt;text-align: left;">3,610</p></td><td style="width:53pt"><p class="s54" style="padding-right: 13pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:46pt"><p class="s54" style="padding-right: 5pt;text-indent: 0pt;line-height: 8pt;text-align: right;">3,610</p></td></tr><tr style="height:13pt"><td style="width:108pt"><p class="s54" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Net loss . . . . . . . . . . . . . . .... ... </p></td><td style="width:44pt"><p class="s44" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">               —</p></td><td style="width:40pt"><p class="s44" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">             —</p></td><td style="width:44pt"><p class="s44" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">              —</p></td><td style="width:33pt"><p class="s44" style="padding-right: 10pt;text-indent: 0pt;text-align: right;">    —</p></td><td style="width:35pt"><p class="s44" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">    —</p></td><td style="width:48pt"><p class="s44" style="padding-left: 7pt;text-indent: 0pt;text-align: left;">           —</p></td><td style="width:53pt"><p class="s44" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">    (22,454<span class="s54">)</span></p></td><td style="width:46pt"><p class="s44" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">  (22,454<span class="s54">)</span></p></td></tr><tr style="height:12pt"><td style="width:108pt"><p class="s54" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Balance at December 31,</p></td><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:33pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:35pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:53pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:46pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:108pt"><p class="s54" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">2012 . . . . . . . . . . . . . . . .... ... </p></td><td style="width:44pt"><p class="s54" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">26,820,270</p></td><td style="width:40pt"><p class="s54" style="padding-right: 4pt;text-indent: 0pt;line-height: 8pt;text-align: right;">158,766</p></td><td style="width:44pt"><p class="s54" style="padding-right: 6pt;text-indent: 0pt;line-height: 8pt;text-align: right;">4,860,855</p></td><td style="width:33pt"><p class="s54" style="padding-right: 10pt;text-indent: 0pt;line-height: 8pt;text-align: right;">49</p></td><td style="width:35pt"><p class="s54" style="padding-left: 17pt;text-indent: 0pt;line-height: 8pt;text-align: left;">—</p></td><td style="width:48pt"><p class="s54" style="padding-left: 15pt;text-indent: 0pt;line-height: 8pt;text-align: left;">26,759</p></td><td style="width:53pt"><p class="s54" style="padding-right: 10pt;text-indent: 0pt;line-height: 8pt;text-align: right;">(105,458)</p></td><td style="width:46pt"><p class="s54" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">(78,650)</p></td></tr><tr style="height:10pt"><td style="width:108pt"><p class="s54" style="padding-left: 2pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Exercise of stock options . . .</p></td><td style="width:44pt"><p class="s54" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:40pt"><p class="s54" style="padding-right: 4pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:44pt"><p class="s54" style="padding-right: 6pt;text-indent: 0pt;line-height: 8pt;text-align: right;">183,501</p></td><td style="width:33pt"><p class="s54" style="padding-right: 10pt;text-indent: 0pt;line-height: 8pt;text-align: right;">2</p></td><td style="width:35pt"><p class="s54" style="padding-left: 17pt;text-indent: 0pt;line-height: 8pt;text-align: left;">—</p></td><td style="width:48pt"><p class="s54" style="padding-left: 25pt;text-indent: 0pt;line-height: 8pt;text-align: left;">787</p></td><td style="width:53pt"><p class="s54" style="padding-right: 13pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:46pt"><p class="s54" style="padding-right: 5pt;text-indent: 0pt;line-height: 8pt;text-align: right;">789</p></td></tr><tr style="height:72pt"><td style="width:192pt" colspan="3"><p class="s54" style="padding-top: 1pt;padding-left: 10pt;padding-right: 102pt;text-indent: -8pt;text-align: left;">Warrant issued in connection with credit</p><p class="s54" style="padding-left: 10pt;text-indent: 0pt;line-height: 9pt;text-align: left;">facility . . . . . . . . . . . . . .... ... — —</p><p class="s54" style="padding-top: 1pt;padding-left: 2pt;padding-right: 4pt;text-indent: 0pt;line-height: 119%;text-align: left;">Issuance of  common stock . .        —         — Purchase of treasury stock . . — —</p><p class="s54" style="padding-left: 10pt;padding-right: 93pt;text-indent: -8pt;text-align: left;">Stock-based compensation expense related to</p></td><td style="width:259pt" colspan="6"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s54" style="padding-left: 62pt;padding-right: 38pt;text-indent: 0pt;text-align: center;">— — — 149 — 149</p><p class="s54" style="padding-top: 1pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">330,022 3 — 2,992 — 2,995</p><p class="s54" style="padding-top: 1pt;padding-left: 62pt;padding-right: 48pt;text-indent: 0pt;text-align: center;">(7,900) — (55) — — (55)</p></td></tr><tr style="height:10pt"><td style="width:108pt"><p class="s54" style="padding-right: 3pt;text-indent: 0pt;line-height: 8pt;text-align: right;">employee stock options . . .</p></td><td style="width:44pt"><p class="s54" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:40pt"><p class="s54" style="padding-right: 4pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:44pt"><p class="s54" style="padding-right: 6pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:33pt"><p class="s54" style="padding-right: 10pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:35pt"><p class="s54" style="padding-left: 17pt;text-indent: 0pt;line-height: 8pt;text-align: left;">—</p></td><td style="width:48pt"><p class="s54" style="padding-left: 19pt;text-indent: 0pt;line-height: 8pt;text-align: left;">3,039</p></td><td style="width:53pt"><p class="s54" style="padding-right: 13pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:46pt"><p class="s54" style="padding-right: 5pt;text-indent: 0pt;line-height: 8pt;text-align: right;">3,039</p></td></tr><tr style="height:13pt"><td style="width:108pt"><p class="s54" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Net loss . . . . . . . . . . . . . . .... ... </p></td><td style="width:44pt"><p class="s44" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">               —</p></td><td style="width:40pt"><p class="s44" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">             —</p></td><td style="width:44pt"><p class="s44" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">              —</p></td><td style="width:33pt"><p class="s44" style="padding-right: 10pt;text-indent: 0pt;text-align: right;">    —</p></td><td style="width:35pt"><p class="s44" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">    —</p></td><td style="width:48pt"><p class="s44" style="padding-left: 7pt;text-indent: 0pt;text-align: left;">           —</p></td><td style="width:53pt"><p class="s44" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">    (18,236<span class="s54">)</span></p></td><td style="width:46pt"><p class="s44" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">  (18,236<span class="s54">)</span></p></td></tr><tr style="height:12pt"><td style="width:108pt"><p class="s54" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Balance at December 31,</p></td><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:33pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:35pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:53pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:46pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:108pt"><p class="s54" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">2013 . . . . . . . . . . . . . . . .... ... </p></td><td style="width:44pt"><p class="s54" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">26,820,270</p></td><td style="width:40pt"><p class="s54" style="padding-right: 4pt;text-indent: 0pt;line-height: 8pt;text-align: right;">158,766</p></td><td style="width:44pt"><p class="s54" style="padding-right: 6pt;text-indent: 0pt;line-height: 8pt;text-align: right;">5,366,478</p></td><td style="width:33pt"><p class="s54" style="padding-right: 10pt;text-indent: 0pt;line-height: 8pt;text-align: right;">54</p></td><td style="width:35pt"><p class="s54" style="padding-right: 7pt;text-indent: 0pt;line-height: 8pt;text-align: right;">(55)</p></td><td style="width:48pt"><p class="s54" style="padding-left: 15pt;text-indent: 0pt;line-height: 8pt;text-align: left;">33,726</p></td><td style="width:53pt"><p class="s54" style="padding-right: 10pt;text-indent: 0pt;line-height: 8pt;text-align: right;">(123,694)</p></td><td style="width:46pt"><p class="s54" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">(89,969)</p></td></tr><tr style="height:10pt"><td style="width:108pt"><p class="s54" style="padding-left: 2pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Exercise of stock options . . .</p></td><td style="width:44pt"><p class="s54" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:40pt"><p class="s54" style="padding-right: 4pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:44pt"><p class="s54" style="padding-right: 6pt;text-indent: 0pt;line-height: 8pt;text-align: right;">1,139,891</p></td><td style="width:33pt"><p class="s54" style="padding-right: 10pt;text-indent: 0pt;line-height: 8pt;text-align: right;">11</p></td><td style="width:35pt"><p class="s54" style="padding-left: 17pt;text-indent: 0pt;line-height: 8pt;text-align: left;">—</p></td><td style="width:48pt"><p class="s54" style="padding-left: 19pt;text-indent: 0pt;line-height: 8pt;text-align: left;">7,291</p></td><td style="width:53pt"><p class="s54" style="padding-right: 13pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:46pt"><p class="s54" style="padding-right: 5pt;text-indent: 0pt;line-height: 8pt;text-align: right;">7,302</p></td></tr><tr style="height:206pt"><td style="width:192pt" colspan="3"><p class="s54" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Issuance of common stock</p><p class="s54" style="padding-left: 10pt;text-indent: 0pt;line-height: 9pt;text-align: left;">for acquired business . . . . . — —</p><p class="s54" style="padding-top: 2pt;padding-left: 10pt;padding-right: 93pt;text-indent: -8pt;text-align: left;">Issuance of common stock in connection with employee stock purchase</p><p class="s54" style="padding-left: 10pt;text-indent: 0pt;line-height: 9pt;text-align: left;">plan . . . . . . . . . . . . . . . .... ... — —</p><p class="s54" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Stock-based compensation</p><p class="s54" style="padding-left: 10pt;text-indent: 0pt;line-height: 9pt;text-align: left;">expense. . . . . . . . . . . . .... ... — —</p><p class="s54" style="padding-top: 2pt;padding-left: 10pt;padding-right: 94pt;text-indent: -8pt;text-align: left;">Warrant issued in connection with website</p><p class="s54" style="padding-left: 10pt;text-indent: 0pt;line-height: 9pt;text-align: left;">partner agreement . .... ... — —</p><p class="s54" style="padding-top: 1pt;padding-left: 10pt;padding-right: 95pt;text-indent: -8pt;text-align: justify;">Issuance of common stock in connection with IPO, net of $8,848 issuance</p><p class="s54" style="padding-left: 10pt;text-indent: 0pt;line-height: 9pt;text-align: left;">costs . . . . . . . . . . . . . . . .... ... — —</p><p class="s54" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Conversion of preferred</p><p class="s54" style="padding-left: 10pt;text-indent: 0pt;line-height: 9pt;text-align: left;">stock. . . . . . . . . . . . . . . .... ... (26,820,270) (158,766)</p><p class="s54" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Series G preferred stock</p><p class="s54" style="padding-left: 10pt;text-indent: 0pt;line-height: 9pt;text-align: left;">deemed dividend . . .... ... — —</p><p class="s54" style="padding-top: 1pt;padding-left: 10pt;padding-right: 65pt;text-indent: -8pt;text-align: left;">Reclassification of liability warrants to equity</p></td><td style="width:259pt" colspan="6"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s54" style="padding-left: 62pt;padding-right: 52pt;text-indent: 0pt;text-align: center;">65,710 1 — 918 — 919</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s54" style="padding-left: 62pt;padding-right: 56pt;text-indent: 0pt;text-align: center;">138,184 1 — 1,591 — 1,592</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s54" style="padding-left: 29pt;text-indent: 0pt;text-align: left;">— — — 9,100 — 9,100</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s54" style="padding-left: 29pt;text-indent: 0pt;text-align: left;">— — — 1,131 — 1,131</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s54" style="padding-left: 62pt;padding-right: 62pt;text-indent: 0pt;text-align: center;">5,676,414 57 — 70,565 — 70,622</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s54" style="padding-left: 62pt;padding-right: 66pt;text-indent: 0pt;text-align: center;">18,457,235 184 — 158,582 — 158,766</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s54" style="padding-left: 29pt;text-indent: 0pt;text-align: left;">— — — 8,079 (8,079) —</p></td></tr><tr style="height:10pt"><td style="width:108pt"><p class="s54" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">warrants . . . . . . . . . . . .... ... </p></td><td style="width:44pt"><p class="s54" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:40pt"><p class="s54" style="padding-right: 4pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:44pt"><p class="s54" style="padding-right: 6pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:33pt"><p class="s54" style="padding-right: 10pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:35pt"><p class="s54" style="padding-left: 17pt;text-indent: 0pt;line-height: 8pt;text-align: left;">—</p></td><td style="width:48pt"><p class="s54" style="padding-left: 19pt;text-indent: 0pt;line-height: 8pt;text-align: left;">1,140</p></td><td style="width:53pt"><p class="s54" style="padding-right: 13pt;text-indent: 0pt;line-height: 8pt;text-align: right;">—</p></td><td style="width:46pt"><p class="s54" style="padding-right: 5pt;text-indent: 0pt;line-height: 8pt;text-align: right;">1,140</p></td></tr><tr style="height:11pt"><td style="width:108pt"><p class="s54" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Exercise of warrants . .... ... </p></td><td style="width:44pt"><p class="s54" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">—</p></td><td style="width:40pt"><p class="s54" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">—</p></td><td style="width:44pt"><p class="s54" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">645,284</p></td><td style="width:33pt"><p class="s54" style="padding-right: 10pt;text-indent: 0pt;text-align: right;">6</p></td><td style="width:35pt"><p class="s54" style="padding-left: 17pt;text-indent: 0pt;text-align: left;">—</p></td><td style="width:48pt"><p class="s54" style="padding-left: 30pt;text-indent: 0pt;text-align: left;">(6)</p></td><td style="width:53pt"><p class="s54" style="padding-right: 13pt;text-indent: 0pt;text-align: right;">—</p></td><td style="width:46pt"><p class="s54" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">—</p></td></tr><tr style="height:13pt"><td style="width:108pt"><p class="s54" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Net income . . . . . . . . . . .... ... </p></td><td style="width:44pt"><p class="s44" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">               —</p></td><td style="width:40pt"><p class="s44" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">             —</p></td><td style="width:44pt"><p class="s44" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">              —</p></td><td style="width:33pt"><p class="s44" style="padding-right: 10pt;text-indent: 0pt;text-align: right;">    —</p></td><td style="width:35pt"><p class="s44" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">    —</p></td><td style="width:48pt"><p class="s44" style="padding-left: 7pt;text-indent: 0pt;text-align: left;">           —</p></td><td style="width:53pt"><p class="s44" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">      12,683</p></td><td style="width:46pt"><p class="s44" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">    12,683</p></td></tr><tr style="height:12pt"><td style="width:108pt"><p class="s54" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Balance at December 31,</p></td><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:44pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:33pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:35pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:48pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:53pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:46pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:108pt"><p class="s54" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">2014 . . . . . . . . . . . . . . . .... ... </p></td><td style="width:44pt"><p class="s44" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">               —</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 2pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="51" height="1" alt="image" src="NYSE_EVDY_2014/Image_062.png"/></span></p></td><td style="width:40pt"><p class="s44" style="padding-right: 4pt;text-indent: 0pt;line-height: 8pt;text-align: right;">$ —</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 3pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="44" height="1" alt="image" src="NYSE_EVDY_2014/Image_063.png"/></span></p></td><td style="width:44pt"><p class="s44" style="padding-right: 6pt;text-indent: 0pt;line-height: 8pt;text-align: right;">31,489,196</p></td><td style="width:33pt"><p class="s44" style="padding-right: 10pt;text-indent: 0pt;line-height: 8pt;text-align: right;">$314</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="21" height="1" alt="image" src="NYSE_EVDY_2014/Image_064.png"/></span></p></td><td style="width:35pt"><p class="s44" style="padding-right: 7pt;text-indent: 0pt;line-height: 8pt;text-align: right;">$(55<span class="s54">)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="20" height="1" alt="image" src="NYSE_EVDY_2014/Image_065.png"/></span></p></td><td style="width:48pt"><p class="s44" style="padding-left: 7pt;text-indent: 0pt;line-height: 8pt;text-align: left;">$292,117</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 7pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="39" height="1" alt="image" src="NYSE_EVDY_2014/Image_066.png"/></span></p></td><td style="width:53pt"><p class="s44" style="padding-left: 6pt;text-indent: 0pt;line-height: 8pt;text-align: left;">$(119,090<span class="s54">)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="44" height="1" alt="image" src="NYSE_EVDY_2014/Image_067.png"/></span></p></td><td style="width:46pt"><p class="s44" style="padding-left: 10pt;text-indent: 0pt;line-height: 8pt;text-align: left;">$173,286</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="40" height="1" alt="image" src="NYSE_EVDY_2014/Image_068.png"/></span></p></td></tr></table><p style="padding-top: 3pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">Consolidated Statements Of Cash  Flows</p><p class="s39" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">(in thousands)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s40" style="text-indent: 0pt;text-align: right;">         Year Ended December 31,         </p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:28.8223pt" cellspacing="0"><tr style="height:24pt"><td style="width:318pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Cash flows from operating activities</p></td><td style="width:50pt"><p class="s44" style="padding-left: 5pt;text-indent: 0pt;line-height: 8pt;text-align: left;">     2014     </p></td><td style="width:49pt"><p class="s44" style="padding-left: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">     2013     </p></td><td style="width:46pt"><p class="s44" style="padding-left: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">     2012     </p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Net income (loss)...... .......... ......... ......... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$ 12,683</p></td><td style="width:49pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$(18,236)</p></td><td style="width:46pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$(22,454)</p></td></tr><tr style="height:13pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Less loss from discontinued operations, net of tax . ......... ......... .</p></td><td style="width:50pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">           —</p></td><td style="width:49pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">    (5,239<span class="s43">)</span></p></td><td style="width:46pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">    (3,257<span class="s43">)</span></p></td></tr><tr style="height:13pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Income (loss) from continuing operations. ......... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: left;">12,683</p></td><td style="width:49pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(12,997)</p></td><td style="width:46pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(19,197)</p></td></tr><tr style="height:21pt"><td style="width:318pt"><p class="s43" style="padding-left: 12pt;padding-right: 13pt;text-indent: -10pt;line-height: 10pt;text-align: left;">Adjustments to reconcile income (loss) from continuing operations to net cash provided by (used in) operating activities:</p></td><td style="width:50pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:49pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:46pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Depreciation and amortization. . . ......... ......... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-left: 14pt;text-indent: 0pt;line-height: 10pt;text-align: left;">14,943</p></td><td style="width:49pt"><p class="s43" style="padding-left: 12pt;text-indent: 0pt;line-height: 10pt;text-align: left;">15,450</p></td><td style="width:46pt"><p class="s43" style="padding-left: 12pt;text-indent: 0pt;line-height: 10pt;text-align: left;">14,602</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Amortization of video and television costs......... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">—</p></td><td style="width:49pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">632</p></td><td style="width:46pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 10pt;text-align: left;">6,430</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Provision for doubtful accounts . . ......... ......... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">315</p></td><td style="width:49pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">62</p></td><td style="width:46pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 10pt;text-align: right;">69</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Stock-based compensation ....... ......... ......... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-left: 19pt;text-indent: 0pt;line-height: 10pt;text-align: left;">9,100</p></td><td style="width:49pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 10pt;text-align: left;">2,969</p></td><td style="width:46pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 10pt;text-align: left;">3,532</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Amortization and write-off of deferred financing costs ..... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-left: 19pt;text-indent: 0pt;line-height: 10pt;text-align: left;">4,389</p></td><td style="width:49pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 10pt;text-align: left;">1,646</p></td><td style="width:46pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 10pt;text-align: left;">1,756</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Loss on disposals of property and equipment...... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">—</p></td><td style="width:49pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 10pt;text-align: left;">1,261</p></td><td style="width:46pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 10pt;text-align: right;">—</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">(Benefit) provision for deferred income taxes ..... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(9,071)</p></td><td style="width:49pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">962</p></td><td style="width:46pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 10pt;text-align: right;">931</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Changes in operating assets and liabilities:</p></td><td style="width:50pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:49pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:46pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Accounts receivable . . . .......... ......... ......... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(12,437)</p></td><td style="width:49pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(10,683)</p></td><td style="width:46pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(3,200)</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Prepaid expenses and other current assets ......... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-left: 19pt;text-indent: 0pt;line-height: 10pt;text-align: left;">1,489</p></td><td style="width:49pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(2,725)</p></td><td style="width:46pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(246)</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Additions to video and television costs . . . ......... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">—</p></td><td style="width:49pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(453)</p></td><td style="width:46pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(5,876)</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Accounts payable and accrued expenses . . ......... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(1,942)</p></td><td style="width:49pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 10pt;text-align: left;">7,529</p></td><td style="width:46pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(28)</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Deferred revenue ...... .......... ......... ......... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(68)</p></td><td style="width:49pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 10pt;text-align: left;">1,744</p></td><td style="width:46pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(5,171)</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Other current liabilities .......... ......... ......... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">58</p></td><td style="width:49pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(426)</p></td><td style="width:46pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 10pt;text-align: right;">171</p></td></tr><tr style="height:13pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Other long-term liabilities ....... ......... ......... ......... ......... .</p></td><td style="width:50pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">         581</p></td><td style="width:49pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">         951</p></td><td style="width:46pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">         364</p></td></tr><tr style="height:23pt"><td style="width:318pt"><p class="s43" style="padding-top: 1pt;padding-left: 12pt;text-indent: -10pt;line-height: 10pt;text-align: left;">Net cash provided by (used in) operating activities from continuing operations . . ......... .......... ......... ......... ......... ......... .</p></td><td style="width:50pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: left;">20,040</p></td><td style="width:49pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">5,922</p></td><td style="width:46pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(5,863)</p></td></tr><tr style="height:13pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Net cash used in operating activities from discontinued operations . . .</p></td><td style="width:50pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">           —</p></td><td style="width:49pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">    (4,250<span class="s43">)</span></p></td><td style="width:46pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">    (2,919<span class="s43">)</span></p></td></tr><tr style="height:13pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Net cash provided by (used in) operating activities ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: left;">20,040</p></td><td style="width:49pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">1,672</p></td><td style="width:46pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(8,782)</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Cash flows from investing activities</p></td><td style="width:50pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:49pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:46pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Additions to property and equipment, net ......... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(14,754)</p></td><td style="width:49pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(10,654)</p></td><td style="width:46pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(12,909)</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Proceeds from sale of business . . ......... ......... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">400</p></td><td style="width:49pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">600</p></td><td style="width:46pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 10pt;text-align: right;">—</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Payment for business purchased, net of cash acquired ...... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(65,000)</p></td><td style="width:49pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(6,736)</p></td><td style="width:46pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(2,627)</p></td></tr><tr style="height:13pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Payment of security deposits and other assets ..... ......... ......... .</p></td><td style="width:50pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">         131</p></td><td style="width:49pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">       (717<span class="s43">)</span></p></td><td style="width:46pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">            4</p></td></tr><tr style="height:13pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Net cash used in investing activities ...... ......... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(79,223)</p></td><td style="width:49pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(17,507)</p></td><td style="width:46pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(15,532)</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Cash flows from financing activities</p></td><td style="width:50pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:49pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:46pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Net proceeds from common stock issuance ........ ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-left: 14pt;text-indent: 0pt;line-height: 10pt;text-align: left;">70,622</p></td><td style="width:49pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">—</p></td><td style="width:46pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 10pt;text-align: right;">—</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Proceeds from the exercise of stock options ....... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-left: 19pt;text-indent: 0pt;line-height: 10pt;text-align: left;">7,939</p></td><td style="width:49pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">101</p></td><td style="width:46pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 10pt;text-align: right;">168</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Repayments of principal under former revolver credit facility ....... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(30,000)</p></td><td style="width:49pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(850)</p></td><td style="width:46pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(1,500)</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Borrowings under former revolver credit facility. . . ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">—</p></td><td style="width:49pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 10pt;text-align: left;">7,350</p></td><td style="width:46pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 10pt;text-align: left;">6,560</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Repayment of principal under former term loan facility .... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(41,333)</p></td><td style="width:49pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(2,833)</p></td><td style="width:46pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(17,833)</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Borrowings under former term loan facility........ ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">—</p></td><td style="width:49pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 10pt;text-align: left;">5,000</p></td><td style="width:46pt"><p class="s43" style="padding-left: 12pt;text-indent: 0pt;line-height: 10pt;text-align: left;">35,000</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Borrowings under revolver credit facility . ......... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-left: 14pt;text-indent: 0pt;line-height: 10pt;text-align: left;">62,300</p></td><td style="width:49pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">—</p></td><td style="width:46pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 10pt;text-align: right;">—</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Repayment of principal under revolver credit facility....... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(32,300)</p></td><td style="width:49pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">—</p></td><td style="width:46pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 10pt;text-align: right;">—</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Borrowings under term loan facility ...... ......... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-left: 14pt;text-indent: 0pt;line-height: 10pt;text-align: left;">61,000</p></td><td style="width:49pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">—</p></td><td style="width:46pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 10pt;text-align: right;">—</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Repayment of principal under term loan facility. . . ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(1,000)</p></td><td style="width:49pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">—</p></td><td style="width:46pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 10pt;text-align: right;">—</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Principal payments on capital lease obligations .... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(659)</p></td><td style="width:49pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(456)</p></td><td style="width:46pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(86)</p></td></tr><tr style="height:11pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Payments of credit facility financing costs ......... ......... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(2,899)</p></td><td style="width:49pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(68)</p></td><td style="width:46pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">(1,345)</p></td></tr><tr style="height:13pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Payment for purchase of treasury stock. . . ......... ......... ......... .</p></td><td style="width:50pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">           —</p></td><td style="width:49pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">         (55<span class="s43">)</span></p></td><td style="width:46pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">           —</p></td></tr><tr style="height:14pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Net cash provided by financing activities . ......... ......... ......... .</p></td><td style="width:50pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">    93,670</p></td><td style="width:49pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">      8,189</p></td><td style="width:46pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">    20,964</p></td></tr><tr style="height:13pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Net increase (decrease) in cash and cash equivalents ....... ......... .</p></td><td style="width:50pt"><p class="s43" style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: left;">34,487</p></td><td style="width:49pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(7,646)</p></td><td style="width:46pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(3,350)</p></td></tr><tr style="height:13pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Cash and cash equivalents, beginning of year...... ......... ......... .</p></td><td style="width:50pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">    16,242</p></td><td style="width:49pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">    23,888</p></td><td style="width:46pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">    27,238</p></td></tr><tr style="height:15pt"><td style="width:318pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Cash and cash equivalents, end of year. . . ......... ......... ......... .</p></td><td style="width:50pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">$ 50,729</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="47" height="1" alt="image" src="NYSE_EVDY_2014/Image_069.png"/></span></p></td><td style="width:49pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">$ 16,242</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 4pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="47" height="1" alt="image" src="NYSE_EVDY_2014/Image_070.png"/></span></p></td><td style="width:46pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">$ 23,888</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 4pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="47" height="1" alt="image" src="NYSE_EVDY_2014/Image_071.png"/></span></p></td></tr></table><p style="padding-top: 3pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">Notes to Consolidated Financial  Statements</p><p class="s39" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">(in thousands, except share and per share data)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l12"><li style="padding-top: 3pt;padding-left: 42pt;text-indent: -11pt;text-align: left;"><p style="display: inline;">Business</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Everyday Health, Inc. (the “Company”) operates a portfolio of health and wellness websites and mobile applications that provides consumers, healthcare professionals, advertisers and partners with content and advertising-based services. The Company was incorporated in the State of Delaware in January 2002 as Agora Media Inc., and changed its name to Waterfront Media Inc. in January 2004. In January 2010, the Company changed its name to Everyday Health, Inc. to better align its corporate identity with the <i>Everyday Health </i>brand.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li style="padding-left: 42pt;text-indent: -11pt;text-align: left;"><p style="display: inline;">Significant Accounting Policies</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Principles of Consolidation</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries. The results of operations for companies acquired are included in the consolidated financial statements from the effective date of the acquisition. All significant intercompany accounts and transactions have been eliminated in consolidation.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Use of Estimates</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience, current business factors and other available information. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition and deferred revenue, allowance for doubtful accounts, internal software development costs and website development costs, valuation of long-lived assets, goodwill and other intangible assets, income taxes and stock-based compensation.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Reclassifications</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Certain reclassifications have been made to the prior year financial statements to conform to the December 31, 2014 presentation.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Initial Public Offering</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">On April 2, 2014, the Company closed its initial public offering of common stock (“IPO”). The IPO, including the additional shares issued and sold on April 30, 2014 pursuant to the underwriters’ exercise of their over-allotment option, resulted in net proceeds of $70,622, after deducting underwriting discounts and commissions and offering costs borne by the Company totaling $8,848. As a result of the IPO, the Company’s common stock, redeemable convertible preferred stock, additional paid-in capital, and stock options and warrants to purchase stock changed as follows (collectively, the “IPO-Related Transactions”): (i) the Company issued and sold 5,676,414 shares of common stock at a public offering price of $14.00 per share, (ii) all of the Company’s redeemable convertible preferred stock outstanding automatically converted into an aggregate of 18,457,235 shares of common stock, including 577,055 additional shares of common stock related to the Series G redeemable convertible preferred stock ratchet provision (refer to Note 10), (iii) certain selling stockholders exercised stock options and warrants for an aggregate of 339,053 shares of common stock, (iv) 149,839 shares of common stock were issued upon the automatic net exercise of a warrant, and (v) outstanding warrants to purchase 222,977 shares of redeemable convertible preferred stock automatically converted into warrants to purchase an aggregate of 148,650 shares of</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">common stock, which resulted in the reclassification of the preferred stock warrant liability of $1,140 to additional paid-in capital.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Cash and Cash Equivalents</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash equivalents principally consist of the Company’s investment in U.S. Treasury securities and other money market funds. The fair value of these investment funds is based on quoted market prices, which are Level 1 inputs, pursuant to the fair value accounting standard, which establishes a framework for measuring fair value and requires disclosures about fair value measurements by establishing a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Property and Equipment</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, ranging from three to five years. Amortization of leasehold improvements is computed using the straight-line method over the shorter of the lease term or the estimated useful life of the improvement.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Video and Television Costs</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company entered into agreements during 2011 and 2012 for the creation and production of a health/wellness television series, a recipe/food television series and a YouTube health channel.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Video and television costs related to these productions are stated at the lower of cost, less accumulated amortization, or fair value in the consolidated balance sheets. The amount of capitalized video and television costs recognized in operating expense for a given period is determined using the film forecast computation method. Under this method, the amortization of capitalized costs is based on the proportion of the production’s revenues recognized for such period to the production’s estimated remaining ultimate revenues. All video and television costs relating to these productions were fully amortized as of December 31, 2013. Amortization expense of video and television costs, aggregating $632 and $6,430 for the years ended December 31, 2013 and 2012, respectively, is included in product development expense in the consolidated statements of operations.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Internal Software Development Costs</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company incurs costs to develop software for internal use. The Company expenses all costs that relate to the planning and post-implementation phases of development as product development expense. Costs incurred in the application development phase, consisting principally of payroll and related benefits, are capitalized. Upon completion, the capitalized costs are amortized using the straight-line method over their estimated useful lives, which is generally three years.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Website Development Costs</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company incurs costs to develop its website applications. The Company expenses all costs that relate to the planning and post-implementation phases of website development as product development expense. Costs incurred in the application development phase, consisting principally of third-party consultants and related charges, and the costs of content determined to provide a future economic benefit, are capitalized. Upon completion, the capitalized costs are amortized using the straight-line method over their estimated useful lives, which is generally three years.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Goodwill</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Goodwill represents the excess cost over fair value of the identifiable net assets of acquired businesses.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Goodwill is tested for impairment on an annual basis as of October 1, and whenever events or circumstances indicate that the carrying value of the asset may not be recoverable.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">An initial qualitative analysis is performed evaluating whether any events and circumstances occurred or exist that provide evidence that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, based on this analysis, indicators deem it more likely than not that the fair value of the reporting unit is less than its carrying amount, then the two-step quantitative impairment test is performed; otherwise, no further step is required.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">If and when needed to complete the two-step quantitative assessment, the fair value of goodwill is estimated using a combination of an income approach based on the present value of estimated future cash flows, and a market approach examining transactions in the marketplace involving the sale of stocks of similar publicly traded companies, or the sale of entire companies engaged in operations similar to those of the Company. As the Company has one operating segment and one reporting unit, the first step of the impairment test requires a comparison of the fair value of the reporting unit, or business enterprise value as a whole, to the carrying value of the Company’s invested capital. If the carrying amount exceeds the fair value, there is indication that an impairment may exist, and a second step must be performed. If the carrying amount is less than the fair value, no indication of impairment exists, and a second step is not performed.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The evaluation of the Company’s goodwill indicated that the carrying value of the asset was less than the fair value and, accordingly, there was no impairment loss recognized for the years ended December 31, 2014, 2013 and 2012.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Long-Lived Assets</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company reviews long-lived assets, including property and equipment and intangible assets with definite lives, for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. The intangible assets with definite lives consist principally of trade names, customer relationships and agreements with certain of the Company’s website partners. Definite-lived intangible assets are amortized over their estimated useful lives, ranging from three to ten years, using the straight-line method which approximates the pattern in which economic benefits are consumed. In accordance with its policy, the Company reviews the estimated useful lives of its intangible assets on an ongoing basis. There were no indicators of impairment of the Company’s long-lived assets during the year ended December 31, 2014. During the year ended December 31, 2013, the Company recorded impairment charges of $1,190 related to the consolidation and reorganization of certain website content and tools. This $1,190 charge is included in product development expense in the accompanying consolidated statements of operations. There were no indicators of impairment of the Company’s long-lived assets during the year ended December 31, 2012.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Revenue Recognition and Deferred Revenue</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company generates its revenue from advertising and sponsorships, premium services, including subscriptions and licensing fees, and, to a lesser extent, video production fees. Advertising revenue is recognized in the period in which the advertisement is delivered. Revenue from sponsorships is recognized over the period the Company substantially satisfies its contractual obligations as required under the respective sponsorship agreements. When contractual arrangements</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">contain multiple elements, revenue is allocated to each element based on its relative fair value determined using prices charged when elements are sold separately. In instances where individual deliverables are not sold separately, or when third-party evidence is not available, fair value is determined based on management’s best estimate of selling price.</p><p style="padding-top: 7pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Subscriptions are generally paid in advance on a monthly, quarterly or annual basis.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Subscription revenue, after deducting refunds and charge-backs, is recognized on a straight-line basis ratably over the subscription periods. Licensing revenue is generally recognized over the life of the contract. Video production fee revenue is recognized as the video content is completed and delivered to the customer.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Deferred revenue relates to: (i) subscription fees for which amounts have been collected but for which revenue has not been recognized, and (ii) advertising and sponsorship fees and licensing fees billed in advance of when the revenue is to be earned.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Cost of Revenues</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Cost of revenues consists principally of the expenses associated with aggregating the total audience across the Company’s portfolio of websites, including (i) royalty expenses for licensing content for certain websites within the portfolio and for the portion of advertising revenue the Company pays to the owners of certain other websites within the portfolio, and (ii) media costs associated with audience aggregation activities. Cost of revenues also includes credit card fees and service charges associated with subscription fees for the Company’s premium services.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Royalty expense amounted to $20,937, $18,673 and $12,898 for the years ended December 31, 2014, 2013 and 2012, respectively.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Media costs consist primarily of fees paid to online publishers, Internet search companies and other media channels for search engine and database marketing, and display and television advertising. These media activities are attributable to revenue-generating and audience aggregation events, designed to increase the audience to the websites the Company operates, increase the number of subscribers to premium services and grow the Company’s registered user base. Media costs totaled $24,973, $22,437 and $23,841 for the years ended December 31, 2014, 2013 and 2012, respectively.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Other Expense</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In connection with the refinancing of its credit facilities in 2014, the Company wrote-off unamortized deferred financing costs totaling $2,845 and incurred prepayment fees of $1,016, which, together with the mark-to-market adjustment on certain preferred stock warrants of $253, is reflected as other expense in the accompanying consolidated statements of operations for the year ended December 31, 2014. In connection with the refinancing of its credit facilities in 2012, the Company wrote-off unamortized deferred financing costs totaling $1,069, which is reflected as other expense in the accompanying consolidated statements of operations for the year ended December 31, 2012.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Income Taxes</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: justify;">The Company accounts for taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the tax and financial statement reporting basis of assets and liabilities.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">settled. The Company reduces the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that the Company will not realize some or all of the deferred tax asset. As a result of the Company’s historical operating performance and the cumulative net losses incurred to date, the Company does not have sufficient objective evidence to support the recovery of the net deferred tax assets. Accordingly, the Company has established a valuation allowance against net deferred tax assets for financial reporting purposes to the extent it is determined that such deferred tax assets are not more likely than not to be realized.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company accounts for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is “more likely than not” that the position will be sustained upon examination. Potential interest and penalties associated with unrecognized tax positions are recognized in income tax expense.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Comprehensive Income (Loss)</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Other than the Series G preferred stock deemed dividend reflected in the accompanying statement of operations for the year end December 31, 2014 (see Note 10), the Company has no items of other comprehensive income (loss).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Fair Value of Financial Instruments</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Due to their short-term maturities, the carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, approximate fair value. Cash equivalents principally consist of the Company’s investment in U.S. Treasury securities and other highly liquid money market funds. The fair value of these investment funds is based on quoted market prices, which are Level 1 inputs, pursuant to the fair value accounting standard, which establishes a framework for measuring fair value and requires disclosures about fair value measurements by establishing a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of the Company’s debt approximates the recorded amounts as the interest rates on the credit facilities are based on market interest rates.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Stock-Based Compensation</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company accounts for all share-based payments, including grants of employee stock options, based on the fair value of the award measured at the grant date. The Company uses the Black-Scholes option pricing model to estimate the fair value of the stock option awards. Stock- based compensation expense is recognized over the period during which the recipient provides services, generally the vesting period.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Business Concentrations, Accounts Receivable and Credit Risk</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Financial instruments which potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and accounts receivable.</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Cash and cash equivalents includes U.S. Treasury securities and other money market funds.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Concentration of credit risk with respect to accounts receivable is limited due to the large number of customers comprising the Company’s customer base and the ongoing credit evaluation of its customers.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">For the year ended December 31, 2014, no advertising customer accounted for greater than 10% of total revenues. For the year ended December 31, 2013, one advertising customer accounted for 12% of total revenues. For the year ended December 31, 2012, no advertising customer accounted</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">for greater than 10% of total revenues. As of December 31, 2014, no advertising customers accounted for greater than 10% of total accounts receivable. As of December 31, 2013, one advertising customer accounted for 16% of accounts receivable. As many of the Company’s advertising customers work through the same advertising agencies, the Company also monitors the concentration of accounts receivable at the agency level. As of December 31, 2014, no advertising agency accounted for greater than 10% of accounts receivable. As of December 31, 2013, three advertising agencies accounted for 14%, 11% and 11% of accounts receivable, respectively.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company’s accounts receivable balance of $68,007 and $49,373 reflected in the accompanying balance sheets as of December 31, 2014 and 2013, respectively, include unbilled accounts receivable of $7,064 as of December 31, 2014 and $290 as of December 31, 2013. The</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">$7,064 consists of $4,482 of unbilled accounts receivable relating to DoctorDirectory.com, Inc. contracts (see Note 3) for which billings were not issued as of December 31, 2014, and $2,582 of revenue earned on the Company’s advertising and sponsorship contracts which were not contractually billable as of such date.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">An allowance for doubtful accounts is established with respect to accounts receivable that the Company has determined to be doubtful of collection, based upon factors surrounding the credit risk of customers, historical experience and other information.</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">The following table summarizes the activity of the allowance for doubtful accounts:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s40" style="padding-top: 3pt;text-indent: 0pt;text-align: right;">Year Ended December 31<span class="s39">,</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:48.7803pt" cellspacing="0"><tr style="height:11pt"><td style="width:317pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:36pt"><p class="s44" style="padding-left: 5pt;text-indent: 0pt;line-height: 8pt;text-align: left;">  2014  </p></td><td style="width:36pt"><p class="s44" style="padding-left: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">  2013  </p></td><td style="width:34pt"><p class="s44" style="padding-left: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">  2012  </p></td></tr><tr style="height:14pt"><td style="width:317pt"><p class="s43" style="padding-left: 36pt;padding-right: 39pt;text-indent: 0pt;text-align: center;">Balance at beginning of year........ ......... ......... ......... ...... </p></td><td style="width:36pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">$ 530</p></td><td style="width:36pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">$ 651</p></td><td style="width:34pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">$ 835</p></td></tr><tr style="height:12pt"><td style="width:317pt"><p class="s43" style="padding-left: 36pt;padding-right: 39pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Bad debt provision......... ......... ......... ......... ......... ...... </p></td><td style="width:36pt"><p class="s43" style="padding-left: 13pt;text-indent: 0pt;line-height: 11pt;text-align: left;">384</p></td><td style="width:36pt"><p class="s43" style="padding-left: 12pt;text-indent: 0pt;line-height: 11pt;text-align: left;">251</p></td><td style="width:34pt"><p class="s43" style="padding-left: 12pt;text-indent: 0pt;line-height: 11pt;text-align: left;">501</p></td></tr><tr style="height:14pt"><td style="width:317pt"><p class="s43" style="padding-left: 36pt;padding-right: 39pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Write-offs ......... ......... ......... ......... ......... ......... ...... </p></td><td style="width:36pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  (277<span class="s43">)</span></p></td><td style="width:36pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  (372<span class="s43">)</span></p></td><td style="width:34pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  (685<span class="s43">)</span></p></td></tr><tr style="height:15pt"><td style="width:317pt"><p class="s43" style="padding-left: 36pt;padding-right: 39pt;text-indent: 0pt;text-align: center;">Balance at end  of year ..... ......... ......... ......... ......... ...... </p></td><td style="width:36pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">$ 637</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="32" height="1" alt="image" src="NYSE_EVDY_2014/Image_072.png"/></span></p></td><td style="width:36pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">$ 530</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 4pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="32" height="1" alt="image" src="NYSE_EVDY_2014/Image_073.png"/></span></p></td><td style="width:34pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">$ 651</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 4pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="32" height="1" alt="image" src="NYSE_EVDY_2014/Image_074.png"/></span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Business Combinations</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed and intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. During the measurement period, which is up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, based on additional information impacting the assigned estimated fair values.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Segment Information</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company and its subsidiaries are organized in a single operating segment, providing online health solutions, and the Company also has one reportable segment. Substantially all of the Company’s revenues are derived from U.S. sources.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Net Income (Loss) Attributable to Common Stockholders per Common Share</p><p style="padding-top: 5pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Basic net income (loss) attributable to common stockholders per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period.</p><p style="padding-top: 4pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Diluted net income (loss) attributable to common stockholders per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">of shares of common stock outstanding for the period, adjusted to reflect potentially dilutive securities. Potentially dilutive securities consist of incremental shares issuable upon the assumed exercise of stock options and warrants using the treasury stock method, convertible preferred shares using the “if-converted” method, and employee withholdings to purchase common stock under the Company’s 2014 Employee Stock Purchase Plan, or ESPP. For the years ended December 31, 2013 and 2012, the Company had outstanding options, warrants and convertible preferred stock which were not included in the computation of diluted net loss per common share because the effect would have been anti-dilutive.</p><p style="padding-top: 5pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The basic and diluted net income (loss) attributable to common stockholders per common share is calculated as follows for the periods presented:</p><p class="s40" style="padding-top: 5pt;padding-left: 322pt;text-indent: 0pt;text-align: left;">                 Year Ended December 31,                 </p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:28.8244pt" cellspacing="0"><tr style="height:24pt"><td style="width:288pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s51" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Numerator:</p></td><td style="width:63pt"><p class="s44" style="padding-left: 5pt;text-indent: 0pt;line-height: 8pt;text-align: left;">        2014        </p></td><td style="width:57pt"><p class="s44" style="padding-left: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">       2013       </p></td><td style="width:55pt"><p class="s44" style="padding-left: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">       2012       </p></td></tr><tr style="height:12pt"><td style="width:288pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Income (loss) from continuing operations......... ......... .... </p></td><td style="width:63pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ 12,683</p></td><td style="width:57pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ (12,997)</p></td><td style="width:55pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ (19,197)</p></td></tr><tr style="height:14pt"><td style="width:288pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Loss from discontinued operations, net of tax .... ......... .... </p></td><td style="width:63pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">                —</p></td><td style="width:57pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">       (5,239<span class="s43">)</span></p></td><td style="width:55pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">       (3,257<span class="s43">)</span></p></td></tr><tr style="height:14pt"><td style="width:288pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Net income (loss)...... ......... ......... ......... ......... .... </p></td><td style="width:63pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;text-align: right;">12,683</p></td><td style="width:57pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">(18,236)</p></td><td style="width:55pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">(22,454)</p></td></tr><tr style="height:14pt"><td style="width:288pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Series G preferred stock deemed dividend........ ......... .... </p></td><td style="width:63pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">         (8,079<span class="s43">)</span></p></td><td style="width:57pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">              —</p></td><td style="width:55pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">              —</p></td></tr><tr style="height:15pt"><td style="width:288pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Net income (loss) attributable to common stockholders . . . .... </p></td><td style="width:63pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">$ 4,604</p></td><td style="width:57pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">$ (18,236<span class="s43">)</span></p></td><td style="width:55pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">$ (22,454<span class="s43">)</span></p></td></tr><tr style="height:14pt"><td style="width:288pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Denominator:</p></td><td style="width:63pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:55pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:34pt"><td style="width:288pt"><p class="s43" style="padding-left: 12pt;text-indent: -10pt;line-height: 86%;text-align: left;">Weighted-average number of common shares outstanding for basic net income (loss) attributable to common</p><p class="s43" style="padding-left: 12pt;text-indent: 0pt;line-height: 10pt;text-align: left;">stockholders per common share ....... ......... ......... .... </p></td><td style="width:63pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s51" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">  24,259,395</p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s51" style="padding-top: 7pt;padding-left: 4pt;text-indent: 0pt;text-align: left;">  5,103,351</p></td><td style="width:55pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s51" style="padding-top: 7pt;padding-left: 4pt;text-indent: 0pt;text-align: left;">  4,791,474</p></td></tr><tr style="height:14pt"><td style="width:288pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Dilutive securities:</p></td><td style="width:63pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:55pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:288pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Stock option awards (1) ........ ......... ......... ......... .... </p></td><td style="width:63pt"><p class="s43" style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: left;">2,235,059</p></td><td style="width:57pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">—</p></td><td style="width:55pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">—</p></td></tr><tr style="height:12pt"><td style="width:288pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Warrants to purchase common stock .... ......... ......... .... </p></td><td style="width:63pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">412,305</p></td><td style="width:57pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">—</p></td><td style="width:55pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">—</p></td></tr><tr style="height:14pt"><td style="width:288pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Employee stock purchase plan. . ......... ......... ......... .... </p></td><td style="width:63pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">           5,023</p></td><td style="width:57pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">              —</p></td><td style="width:55pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">              —</p></td></tr><tr style="height:17pt"><td style="width:288pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Total weighted-average diluted shares . . . ......... ......... .... </p></td><td style="width:63pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">  26,911,782</p></td><td style="width:57pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">  5,103,351</p></td><td style="width:55pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">  4,791,474</p></td></tr><tr style="height:26pt"><td style="width:288pt"><p class="s43" style="padding-top: 4pt;padding-left: 12pt;padding-right: 14pt;text-indent: -10pt;line-height: 87%;text-align: left;">Basic net income (loss) attributable to common stockholders per common share:</p></td><td style="width:63pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:55pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:288pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">Income (loss) from continuing operations ...... ......... .... </p></td><td style="width:63pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$ 0.19</p></td><td style="width:57pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$ (2.55)</p></td><td style="width:55pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$ (4.01)</p></td></tr><tr style="height:14pt"><td style="width:288pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Loss from discontinued operations, net of tax . . ......... .... </p></td><td style="width:63pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">                —</p></td><td style="width:57pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">         (1.03<span class="s43">)</span></p></td><td style="width:55pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">         (0.68<span class="s43">)</span></p></td></tr><tr style="height:13pt"><td style="width:288pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Net income (loss) attributable to common stockholders . .... </p></td><td style="width:63pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ 0.19</p></td><td style="width:57pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ (3.57<span class="s43">)</span></p></td><td style="width:55pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ (4.69<span class="s43">)</span></p></td></tr><tr style="height:30pt"><td style="width:288pt"><p class="s43" style="padding-top: 8pt;padding-left: 12pt;padding-right: 14pt;text-indent: -10pt;line-height: 86%;text-align: left;">Diluted net income (loss) attributable to common stockholders per common share:</p></td><td style="width:63pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:55pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:288pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Income (loss) from continuing operations ...... ......... .... </p></td><td style="width:63pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ 0.17</p></td><td style="width:57pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ (2.55)</p></td><td style="width:55pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ (4.01)</p></td></tr><tr style="height:14pt"><td style="width:288pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Loss from discontinued operations, net of tax . . ......... .... </p></td><td style="width:63pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">                —</p></td><td style="width:57pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">         (1.03<span class="s43">)</span></p></td><td style="width:55pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">         (0.68<span class="s43">)</span></p></td></tr><tr style="height:13pt"><td style="width:288pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Net income (loss) attributable to common stockholders . .... </p></td><td style="width:63pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ 0.17</p></td><td style="width:57pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ (3.57<span class="s43">)</span></p></td><td style="width:55pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ (4.69<span class="s43">)</span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="64" height="1" alt="image" src="NYSE_EVDY_2014/Image_075.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 49pt;text-indent: -17pt;text-align: left;">(1) The weighted-average diluted shares for the year ended December 31, 2014 excludes a weighted- average number of stock options of 1,337,766 which were anti-dilutive.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Foreign Currency</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The financial statements and transactions of the Company’s foreign subsidiary are maintained in its local currency. The translation of foreign currencies into United States dollars is performed for balance sheet accounts using current exchange rates in effect at the balance sheet date, and for revenue and expense accounts using average exchange rates during the year. Foreign currency gains</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">or losses are included in the consolidated statements of operations and were not material in any of the periods presented.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Recently Issued and Adopted Accounting Standards</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In July 2013, the Financial Accounting Standards Board (“FASB”) issued amended guidance for income taxes. This amendment requires that entities present an unrecognized tax benefit, or portion of an unrecognized tax benefit, as a reduction to a deferred tax asset in the financial statements for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, with certain exceptions. The Company adopted this amended guidance beginning in the quarter ended March 31, 2014. The adoption of this guidance had no impact on the Company’s consolidated financial statements.</p><p style="padding-top: 5pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In April 2014, the FASB issued amended guidance for reporting discontinued operations. Under the new guidance, only disposals that represent a strategic shift having a material impact on an entity’s operations and financial results shall be reported as discontinued operations, with expanded disclosures. This amendment will be effective for the first annual reporting period beginning after December 15, 2015. The Company does not expect the impact of the adoption of this guidance to be material to the consolidated financial statements.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In May 2014, the FASB issued amended guidance for revenue recognition. This amendment provides a comprehensive new revenue recognition model. The core principle of the guidance is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. This amendment is effective for fiscal years beginning after December 15, 2016, and for interim periods within those fiscal years. Early adoption is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company has not yet selected a transition method and is currently evaluating the effect that the new standard will have on the consolidated financial statements and related disclosures.</p><p style="padding-top: 5pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In June 2014, the FASB issued updated guidance on stock compensation accounting requiring that a performance target that affects vesting and could be achieved after the requisite service period should be treated as a performance condition. Current GAAP does not contain explicit guidance on how to account for such share-based payments. This updated guidance is effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. Early adoption is permitted. The Company does not expect the impact of the adoption of this guidance to be material to the consolidated financial statements.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li style="padding-left: 42pt;text-indent: -11pt;text-align: left;"><p style="display: inline;">Acquisitions</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In November 2014, the Company acquired all of the outstanding equity of DoctorDirectory.com, Inc., a South Carolina corporation (“DD”), which provided pharmaceutical companies with multi- channel interactive marketing services that target healthcare professionals, for a cash purchase price of $65,000. The Company expects that the DD acquisition will enable the Company to significantly increase the number of healthcare professionals it reaches, deepen and broaden its relationships with pharmaceutical companies, gain valuable expertise across sales, marketing and data and analytics, and introduce new products and services to healthcare professionals. As of December 31, 2014, all purchase price obligations were settled, subject to any working capital adjustments that may arise.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">For the year ended December 31, 2014, acquisition-related costs of $183 are included in general and administrative expenses in the accompanying consolidated statement of operations. The acquisition was accounted for as a business combination and, accordingly, the purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed on the basis of their</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">respective fair values. The results of operations of DD have been included in the consolidated financial statements of the Company from November 12, 2014, the closing date of the acquisition.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The following table summarizes the preliminary allocation of the assets acquired and liabilities assumed based on their fair values on the acquisition date. The fair values presented are based on a preliminary valuation and are subject to adjustment during a measurement period of up to one year from the acquisition date. The measurement period provides the Company with the ability to adjust the fair values of acquired assets for new information that is obtained about circumstances that existed as of the acquisition date.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:68.6798pt" cellspacing="0"><tr style="height:11pt"><td style="width:336pt"><p class="s43" style="padding-left: 3pt;padding-right: 5pt;text-indent: 0pt;line-height: 10pt;text-align: center;">Accounts receivable . . ......... ......... ......... ......... .......... ...... </p></td><td style="width:47pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$ 6,513</p></td></tr><tr style="height:12pt"><td style="width:336pt"><p class="s43" style="padding-left: 3pt;padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Deferred tax asset .... ......... ......... ......... ......... .......... ...... </p></td><td style="width:47pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">81</p></td></tr><tr style="height:12pt"><td style="width:336pt"><p class="s43" style="padding-left: 3pt;padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Other current assets . . ......... ......... ......... ......... .......... ...... </p></td><td style="width:47pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">232</p></td></tr><tr style="height:12pt"><td style="width:336pt"><p class="s43" style="padding-left: 3pt;padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Property and equipment ....... ......... ......... ......... .......... ...... </p></td><td style="width:47pt"><p class="s43" style="padding-left: 18pt;text-indent: 0pt;line-height: 11pt;text-align: left;">1,612</p></td></tr><tr style="height:12pt"><td style="width:336pt"><p class="s43" style="padding-left: 3pt;padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Goodwill .... ......... ......... ......... ......... ......... .......... ...... </p></td><td style="width:47pt"><p class="s43" style="padding-left: 13pt;text-indent: 0pt;line-height: 11pt;text-align: left;">44,962</p></td></tr><tr style="height:12pt"><td style="width:336pt"><p class="s43" style="padding-left: 3pt;padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Intangible assets ...... ......... ......... ......... ......... .......... ...... </p></td><td style="width:47pt"><p class="s43" style="padding-left: 13pt;text-indent: 0pt;line-height: 11pt;text-align: left;">23,500</p></td></tr><tr style="height:12pt"><td style="width:336pt"><p class="s43" style="padding-left: 3pt;padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Accounts payable and accrued expenses......... ......... .......... ...... </p></td><td style="width:47pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(1,798)</p></td></tr><tr style="height:14pt"><td style="width:336pt"><p class="s43" style="padding-left: 3pt;padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Deferred tax liability . ......... ......... ......... ......... .......... ...... </p></td><td style="width:47pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  (10,102<span class="s43">)</span></p></td></tr><tr style="height:15pt"><td style="width:336pt"><p class="s43" style="padding-left: 3pt;padding-right: 5pt;text-indent: 0pt;text-align: center;">Total consideration paid ....... ......... ......... ......... .......... ...... </p></td><td style="width:47pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">$ 65,000</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="48" height="1" alt="image" src="NYSE_EVDY_2014/Image_076.png"/></span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 19pt;text-align: left;">The following table presents the Company’s pro forma consolidated revenues and net income (loss) for the years ended December 31, 2014 and 2013. The unaudited pro forma results include the historical consolidated statements of operations of the Company and DD, giving effect to the DD acquisition, and related financing transactions, as if they had occurred at the beginning of the earliest period presented.</p><p class="s39" style="padding-top: 6pt;padding-left: 399pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Unaudited</p><p class="s39" style="padding-left: 370pt;text-indent: 14pt;line-height: 86%;text-align: left;">Pro Forma Results <u>Year Ended December 31</u>,</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:48.7803pt" cellspacing="0"><tr style="height:11pt"><td style="width:312pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p class="s44" style="text-indent: 0pt;line-height: 8pt;text-align: center;">     2014     </p></td><td style="width:54pt"><p class="s44" style="padding-left: 10pt;text-indent: 0pt;line-height: 8pt;text-align: left;">     2013     </p></td></tr><tr style="height:14pt"><td style="width:312pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Revenues ..... ......... ......... ......... ......... ......... ........ </p></td><td style="width:57pt"><p class="s43" style="text-indent: 0pt;text-align: center;">$201,335</p></td><td style="width:54pt"><p class="s43" style="padding-left: 10pt;text-indent: 0pt;text-align: left;">$172,877</p></td></tr><tr style="height:11pt"><td style="width:312pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Net income (loss) ...... ......... ......... ......... ......... ........ </p></td><td style="width:57pt"><p class="s43" style="text-indent: 0pt;line-height: 10pt;text-align: center;">$ 4,640</p></td><td style="width:54pt"><p class="s43" style="padding-left: 10pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$(12,425)</p></td></tr></table><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The unaudited pro forma results include: (i) amortization expense associated with acquired intangible and technology assets; (ii) incremental interest expense related to additional borrowings on the Company’s Credit Facility in connection with financing the DD acquisition, and amortization of related deferred financing costs (see Note 9); (iii) elimination of stock-based compensation expenses related to the pre-acquisition period; (iv) elimination of transaction costs incurred related to the acquisition; and (v) elimination of DD’s historical federal tax provision for the year ended December 31, 2013, as the combined entity would have a loss before provision for income taxes for the year. Additionally, the unaudited pro forma combined net income for the year ended December 31, 2014 includes a pro forma adjustment to eliminate a one-time benefit recorded to the provision for income taxes of $10,033 (see Note 12) which resulted from reducing the deferred tax valuation allowance related to acquired intangible and other assets. The benefit is excluded from the unaudited pro forma results as it will not have a continuing impact on the combined results.</p><p style="padding-top: 5pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The unaudited pro forma results give effect to pro forma events that are (1) directly attributable to the assumed acquisition, (2) factually supportable, and (3) with respect to the combined statements of operations, expected to have a continuing impact on the combined results.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Additionally, the unaudited pro forma adjustments are not necessarily indicative of or intended to represent the results that would have been achieved had the transaction been consummated as of the date indicated or that may be achieved in the future. The actual results reported by the combined company in periods following the acquisition may differ significantly from those reflected</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">in the pro forma results for a number of reasons, including cost saving synergies from operating efficiencies and the effect of the incremental costs incurred to integrate the two companies.</p><p style="padding-top: 6pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In September 2012, the Company acquired all of the outstanding equity of EQAL, Inc., a Delaware corporation (“EQ”), which managed digital media properties for various brands and celebrities. The EQ acquisition enabled the Company to expand its core lifestyle offerings by exploiting EQ’s expertise in branded digital content, scripted video, social marketing and celebrity influence. The purchase price was valued at $9,657, consisting of $6,736 in cash and shares of common stock valued at $2,921. The cash and stock amounts due to the former EQ stockholders were payable in installments during 2013. As of December 31, 2013, all such purchase price obligations were settled.</p><p style="padding-top: 5pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">For the year ended December 31, 2012, acquisition-related costs of $89 are included in general and administrative expenses in the accompanying consolidated statement of operations. The acquisition was accounted for as a business combination and, accordingly, the purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed on the basis of their respective fair values. The results of operations of EQ have been included in the consolidated financial statements of the Company from September 21, 2012, the closing date of the acquisition. Pro forma consolidated results of operations giving effect to this acquisition would not vary materially from historical results.</p><p style="padding-top: 5pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The following table summarizes the tangible and intangible assets acquired, the liabilities assumed and the consideration paid:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:68.6798pt" cellspacing="0"><tr style="height:11pt"><td style="width:341pt"><p class="s43" style="padding-left: 36pt;padding-right: 39pt;text-indent: 0pt;line-height: 10pt;text-align: center;">Cash . . ......... ......... ......... ......... .......... ......... ......... ..... </p></td><td style="width:42pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$ 174</p></td></tr><tr style="height:12pt"><td style="width:341pt"><p class="s43" style="padding-left: 36pt;padding-right: 39pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Accounts receivable .... ......... ......... .......... ......... ......... ..... </p></td><td style="width:42pt"><p class="s43" style="padding-left: 13pt;text-indent: 0pt;line-height: 11pt;text-align: left;">1,167</p></td></tr><tr style="height:12pt"><td style="width:341pt"><p class="s43" style="padding-left: 36pt;padding-right: 39pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Other current assets .... ......... ......... .......... ......... ......... ..... </p></td><td style="width:42pt"><p class="s43" style="padding-left: 21pt;text-indent: 0pt;line-height: 11pt;text-align: left;">237</p></td></tr><tr style="height:12pt"><td style="width:341pt"><p class="s43" style="padding-left: 36pt;padding-right: 39pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Property and equipment ......... ......... .......... ......... ......... ..... </p></td><td style="width:42pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">18</p></td></tr><tr style="height:12pt"><td style="width:341pt"><p class="s43" style="padding-left: 36pt;padding-right: 39pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Goodwill. ...... ......... ......... ......... .......... ......... ......... ..... </p></td><td style="width:42pt"><p class="s43" style="padding-left: 13pt;text-indent: 0pt;line-height: 11pt;text-align: left;">9,904</p></td></tr><tr style="height:12pt"><td style="width:341pt"><p class="s43" style="padding-left: 36pt;padding-right: 39pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Intangible assets ........ ......... ......... .......... ......... ......... ..... </p></td><td style="width:42pt"><p class="s43" style="padding-left: 13pt;text-indent: 0pt;line-height: 11pt;text-align: left;">1,130</p></td></tr><tr style="height:12pt"><td style="width:341pt"><p class="s43" style="padding-left: 36pt;padding-right: 39pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Other assets . . . ......... ......... ......... .......... ......... ......... ..... </p></td><td style="width:42pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">26</p></td></tr><tr style="height:12pt"><td style="width:341pt"><p class="s43" style="padding-left: 36pt;padding-right: 39pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Accounts payable and accrued expenses . . .......... ......... ......... ..... </p></td><td style="width:42pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(1,819)</p></td></tr><tr style="height:12pt"><td style="width:341pt"><p class="s43" style="padding-left: 36pt;padding-right: 39pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Deferred revenue....... ......... ......... .......... ......... ......... ..... </p></td><td style="width:42pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(625)</p></td></tr><tr style="height:14pt"><td style="width:341pt"><p class="s43" style="padding-left: 36pt;padding-right: 39pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Other current liabilities . ......... ......... .......... ......... ......... ..... </p></td><td style="width:42pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">     (555<span class="s43">)</span></p></td></tr><tr style="height:15pt"><td style="width:341pt"><p class="s43" style="padding-left: 36pt;padding-right: 39pt;text-indent: 0pt;text-align: center;">Total consideration paid ......... ......... .......... ......... ......... ..... </p></td><td style="width:42pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">$ 9,657</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="41" height="1" alt="image" src="NYSE_EVDY_2014/Image_077.png"/></span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 19pt;text-align: left;">During 2013, the merger agreement with EQ was amended with respect to the contingent earn- out provisions. Pursuant to the amendments, the former stockholders and founders of EQ were eligible to receive up to $5,000 based on the Company’s achievement of certain revenue and operating income targets during 2013. The Company records any such earn-outs as compensation expense for the applicable periods. For the year ended December 31, 2013, the Company incurred</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">$2,211 of such expense, which is included in sales and marketing expense in the accompanying consolidated statements of operations. The earn-out payment, which was payable in cash and shares of the Company’s common stock, was settled in full during the year ended December 31, 2014.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li style="padding-left: 42pt;text-indent: -11pt;text-align: left;"><p style="display: inline;">Discontinued Operations</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In November 2013, the Board of Directors approved a plan to sell the Doctor Solutions business, which provided online directories and other marketing services to healthcare professionals. By the end of 2013, the Company identified a buyer and completed the sale, at a price of $1,000.</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">The sale represented a disposal of a component of an entity whose operations and cash flows were eliminated from the Company’s ongoing business after the sale. As such, the operating results, along</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">with the loss on sale, have been reported as discontinued operations in the consolidated statements of operations for the years ended December 31, 2013 and 2012. As the sale was completed during 2013, there were no results from discontinued operations to report for the year ended December 31, 2014. The loss from discontinued operations was comprised of the following:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s39" style="padding-left: 407pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Year ended</p><p class="s40" style="padding-left: 391pt;text-indent: 0pt;line-height: 9pt;text-align: left;">      December 31,      </p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:48.7803pt" cellspacing="0"><tr style="height:11pt"><td style="width:337pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:45pt"><p class="s44" style="padding-left: 5pt;text-indent: 0pt;line-height: 8pt;text-align: left;">    2013    </p></td><td style="width:41pt"><p class="s44" style="padding-left: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">    2012    </p></td></tr><tr style="height:14pt"><td style="width:337pt"><p class="s43" style="padding-left: 2pt;padding-right: 5pt;text-indent: 0pt;text-align: center;">Revenues ......... ......... ......... ......... ......... .......... ......... .</p></td><td style="width:45pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">$ 7,116</p></td><td style="width:41pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">$ 7,794</p></td></tr><tr style="height:12pt"><td style="width:337pt"><p class="s43" style="padding-left: 2pt;padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Loss from operations ...... ......... ......... ......... .......... ......... .</p></td><td style="width:45pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: right;">$(3,971)</p></td><td style="width:41pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$(3,257)</p></td></tr><tr style="height:14pt"><td style="width:337pt"><p class="s43" style="padding-left: 2pt;padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Loss on sale ...... ......... ......... ......... ......... .......... ......... .</p></td><td style="width:45pt"><p class="s51" style="padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: right;">  (1,268<span class="s43">)</span></p></td><td style="width:41pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">         —</p></td></tr><tr style="height:14pt"><td style="width:337pt"><p class="s43" style="padding-left: 2pt;padding-right: 5pt;text-indent: 0pt;text-align: center;">Loss from discontinued operations before tax......... .......... ......... .</p></td><td style="width:45pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">(5,239)</p></td><td style="width:41pt"><p class="s43" style="padding-left: 9pt;text-indent: 0pt;text-align: left;">(3,257)</p></td></tr><tr style="height:14pt"><td style="width:337pt"><p class="s43" style="padding-left: 2pt;padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Income tax (provision) benefit ...... ......... ......... .......... ......... .</p></td><td style="width:45pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">         —</p></td><td style="width:41pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">         —</p></td></tr><tr style="height:15pt"><td style="width:337pt"><p class="s43" style="padding-left: 2pt;padding-right: 5pt;text-indent: 0pt;text-align: center;">Net loss from discontinued operations ....... ......... .......... ......... .</p></td><td style="width:45pt"><p class="s51" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">$(5,239<span class="s43">)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="42" height="1" alt="image" src="NYSE_EVDY_2014/Image_078.png"/></span></p></td><td style="width:41pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">$(3,257<span class="s43">)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 4pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="42" height="1" alt="image" src="NYSE_EVDY_2014/Image_079.png"/></span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 19pt;text-align: left;">No benefit for income taxes was provided as the Company recorded a full valuation allowance against the NOLs generated by the discontinued operations.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li style="padding-left: 42pt;text-indent: -11pt;text-align: left;"><p style="display: inline;">Prepaid Expenses and Other Current Assets</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Prepaid expenses and other current assets consist of the following:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s40" style="padding-top: 3pt;text-indent: 0pt;text-align: right;">    December 31,    </p><p class="s40" style="padding-top: 1pt;text-indent: 0pt;text-align: right;">   2014 2013   </p><p style="padding-top: 3pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Prepaid royalties......... ......... ......... ......... ......... ......... ...... $1,225 $1,195</p><p style="padding-left: 51pt;text-indent: 0pt;text-align: left;">Initial public offering costs ....... ......... ......... ......... ......... ...... — 1,083</p><p style="padding-left: 51pt;text-indent: 0pt;text-align: left;">Prepaid marketing ....... ......... ......... ......... ......... ......... ...... 422 714</p><p style="padding-left: 51pt;text-indent: 0pt;text-align: left;">Amount due from buyer of business....... ......... ......... ......... ...... — 400</p><p style="padding-left: 51pt;text-indent: 0pt;text-align: left;">Restricted cash . ......... ......... ......... ......... ......... ......... ...... — 500</p><p style="padding-left: 51pt;text-indent: 0pt;text-align: left;">Other. . ......... ......... ......... ......... ......... ......... ......... ......<u> 3,882 3,930</u></p><p style="padding-top: 3pt;padding-bottom: 2pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Total . . ......... ......... ......... ......... ......... ......... ......... ...... <u>$5,529</u> <u>$7,822</u></p><p class="s57" style="padding-left: 398pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="37" height="1" alt="image" src="NYSE_EVDY_2014/Image_080.png"/></span>	<span><img width="37" height="1" alt="image" src="NYSE_EVDY_2014/Image_081.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li style="padding-left: 42pt;text-indent: -11pt;text-align: left;"><p style="display: inline;">Property and Equipment</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Property and equipment consist of the following:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s40" style="padding-top: 3pt;text-indent: 0pt;text-align: right;">         December 31,         </p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:48.7793pt" cellspacing="0"><tr style="height:11pt"><td style="width:328pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:49pt"><p class="s44" style="padding-left: 5pt;text-indent: 0pt;line-height: 8pt;text-align: left;">     2014     </p></td><td style="width:46pt"><p class="s44" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">     2013     </p></td></tr><tr style="height:14pt"><td style="width:328pt"><p class="s43" style="padding-left: 23pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">Computer equipment and purchased software .... ......... ......... .... </p></td><td style="width:49pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">$ 12,402</p></td><td style="width:46pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">$ 10,529</p></td></tr><tr style="height:12pt"><td style="width:328pt"><p class="s43" style="padding-left: 23pt;padding-right: 25pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Internally developed software. . . ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s43" style="padding-left: 13pt;text-indent: 0pt;line-height: 11pt;text-align: left;">37,226</p></td><td style="width:46pt"><p class="s43" style="padding-left: 12pt;text-indent: 0pt;line-height: 11pt;text-align: left;">28,486</p></td></tr><tr style="height:12pt"><td style="width:328pt"><p class="s43" style="padding-left: 23pt;padding-right: 25pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Acquired technology. . . ......... ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s43" style="padding-left: 18pt;text-indent: 0pt;line-height: 11pt;text-align: left;">1,957</p></td><td style="width:46pt"><p class="s43" style="padding-left: 25pt;text-indent: 0pt;line-height: 11pt;text-align: left;">927</p></td></tr><tr style="height:12pt"><td style="width:328pt"><p class="s43" style="padding-left: 23pt;padding-right: 25pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Furniture, fixtures and office equipment. ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s43" style="padding-left: 18pt;text-indent: 0pt;line-height: 11pt;text-align: left;">2,978</p></td><td style="width:46pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">2,858</p></td></tr><tr style="height:12pt"><td style="width:328pt"><p class="s43" style="padding-left: 23pt;padding-right: 25pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Leasehold improvements ....... ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s43" style="padding-left: 18pt;text-indent: 0pt;line-height: 11pt;text-align: left;">6,381</p></td><td style="width:46pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">6,296</p></td></tr><tr style="height:14pt"><td style="width:328pt"><p class="s43" style="padding-left: 23pt;padding-right: 25pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Website development costs ..... ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">    25,292</p></td><td style="width:46pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">    20,425</p></td></tr><tr style="height:14pt"><td style="width:328pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:49pt"><p class="s43" style="padding-left: 13pt;text-indent: 0pt;text-align: left;">86,236</p></td><td style="width:46pt"><p class="s43" style="padding-left: 12pt;text-indent: 0pt;text-align: left;">69,521</p></td></tr><tr style="height:14pt"><td style="width:328pt"><p class="s43" style="padding-left: 23pt;padding-right: 25pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Less accumulated depreciation and amortization. . ......... ......... .... </p></td><td style="width:49pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  (60,734<span class="s43">)</span></p></td><td style="width:46pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  (48,426<span class="s43">)</span></p></td></tr><tr style="height:15pt"><td style="width:328pt"><p class="s43" style="padding-left: 23pt;padding-right: 25pt;text-indent: 0pt;text-align: center;">Total ......... ......... ......... ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">$ 25,502</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="48" height="1" alt="image" src="NYSE_EVDY_2014/Image_082.png"/></span></p></td><td style="width:46pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">$ 21,095</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 3pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="48" height="1" alt="image" src="NYSE_EVDY_2014/Image_083.png"/></span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: right;">During the years ended December 31, 2014, 2013 and 2012, the Company capitalized $8,870,</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">$7,416 and $7,279, respectively, of internally developed software costs. Unamortized internally</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">developed software was $13,078 and $10,882 as of December 31, 2014 and 2013, respectively. Amortization expense of internally developed software was $6,583, $5,198 and $4,196 for the years ended December 31, 2014, 2013 and 2012, respectively.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Depreciation and amortization expense related to property and equipment is classified as follows in the accompanying consolidated statements of operations:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s40" style="text-indent: 0pt;text-align: right;">      Year Ended December 31,      </p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:48.7803pt" cellspacing="0"><tr style="height:11pt"><td style="width:291pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:43pt"><p class="s44" style="padding-right: 5pt;text-indent: 0pt;line-height: 8pt;text-align: right;">    2014    </p></td><td style="width:45pt"><p class="s44" style="padding-right: 5pt;text-indent: 0pt;line-height: 8pt;text-align: right;">    2013    </p></td><td style="width:40pt"><p class="s44" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">    2012    </p></td></tr><tr style="height:14pt"><td style="width:291pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Sales and marketing......... ......... ......... ......... ........ </p></td><td style="width:43pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">$ 1,286</p></td><td style="width:45pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">$ 1,183</p></td><td style="width:40pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">$ 1,065</p></td></tr><tr style="height:12pt"><td style="width:291pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Product development........ ......... ......... ......... ........ </p></td><td style="width:43pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">10,811</p></td><td style="width:45pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">10,325</p></td><td style="width:40pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">9,324</p></td></tr><tr style="height:14pt"><td style="width:291pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">General and administrative. . ......... ......... ......... ........ </p></td><td style="width:43pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">       327</p></td><td style="width:45pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">       350</p></td><td style="width:40pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">       423</p></td></tr><tr style="height:15pt"><td style="width:291pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Total depreciation and amortization. . ......... ......... ........ </p></td><td style="width:43pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">$12,424</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="43" height="1" alt="image" src="NYSE_EVDY_2014/Image_084.png"/></span></p></td><td style="width:45pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">$11,858</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="43" height="1" alt="image" src="NYSE_EVDY_2014/Image_085.png"/></span></p></td><td style="width:40pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">$10,812</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="43" height="1" alt="image" src="NYSE_EVDY_2014/Image_086.png"/></span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li style="padding-left: 42pt;text-indent: -11pt;text-align: left;"><p style="display: inline;">Goodwill and Other Intangible Assets</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">During the year ended December 31, 2014, goodwill of $44,962 and definite-lived intangible assets of $23,500 were recorded in connection with the DD acquisition (see Note 3). Included in the goodwill is $10,033 recorded in connection with a deferred tax liability recognized upon acquisition, related to basis differences in acquired intangible assets (see Note 12). Intangible assets acquired in connection with the DD acquisition consist of customer relationships of $15,390 and trade names of</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">$8,110, which have estimated useful lives of 10 years and 7 years, respectively.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">During the year ended December 31, 2013, goodwill increased by $321 during the subsequent measurement period from purchase price adjustments related to the EQ acquisition. In connection with the sale of the Doctor Solutions business in 2013, goodwill of $235 and intangible assets with an unamortized balance on the date of sale of $1,547 were written off as part of the loss on sale of discontinued operations (see Note 4).</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">During the year ended December 31, 2012, goodwill of $9,583 and definite-lived intangible assets of $1,130 were recorded in connection with the EQ acquisition (see Note 3).</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Intangible assets consist of the following:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s40" style="padding-top: 3pt;padding-left: 166pt;text-indent: 0pt;text-align: left;">                       December 31, 2014 December 31, 2013                      </p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s39" style="text-indent: 0pt;text-align: right;">Gross</p><p class="s39" style="padding-top: 2pt;padding-left: 138pt;text-indent: 0pt;line-height: 87%;text-align: center;">Weighted- average remaining</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s39" style="padding-left: 8pt;text-indent: 0pt;text-align: left;">Gross</p><p class="s39" style="padding-top: 2pt;padding-left: 104pt;text-indent: 0pt;line-height: 87%;text-align: center;">Weighted- average remaining</p><table style="border-collapse:collapse;margin-left:28.8244pt" cellspacing="0"><tr style="height:16pt"><td style="width:134pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:36pt"><p class="s54" style="padding-left: 3pt;text-indent: 0pt;line-height: 7pt;text-align: left;">carrying</p><p class="s44" style="padding-left: 2pt;text-indent: 0pt;line-height: 8pt;text-align: left;"> amount</p></td><td style="width:52pt"><p class="s54" style="padding-left: 2pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Accumulated</p><p class="s44" style="padding-left: 2pt;text-indent: 0pt;line-height: 8pt;text-align: left;"> amortization</p></td><td style="width:38pt"><p class="s44" style="padding-top: 6pt;padding-right: 5pt;text-indent: 0pt;line-height: 8pt;text-align: right;">    Net    </p></td><td style="width:36pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s54" style="padding-left: 7pt;text-indent: 0pt;line-height: 7pt;text-align: left;">useful</p><p class="s54" style="padding-left: 9pt;text-indent: 0pt;line-height: 8pt;text-align: left;">life(a)</p></td><td style="width:39pt"><p class="s54" style="padding-left: 6pt;text-indent: 0pt;line-height: 7pt;text-align: left;">carrying</p><p class="s44" style="padding-left: 5pt;text-indent: 0pt;line-height: 8pt;text-align: left;"> amount</p></td><td style="width:52pt"><p class="s54" style="padding-left: 2pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Accumulated</p><p class="s44" style="padding-left: 2pt;text-indent: 0pt;line-height: 8pt;text-align: left;"> amortization</p></td><td style="width:34pt"><p class="s44" style="padding-top: 6pt;padding-right: 6pt;text-indent: 0pt;line-height: 8pt;text-align: right;">   Net   </p></td><td style="width:36pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s54" style="padding-left: 7pt;text-indent: 0pt;line-height: 7pt;text-align: left;">useful</p><p class="s54" style="padding-left: 9pt;text-indent: 0pt;line-height: 8pt;text-align: left;">life(a)</p></td></tr><tr style="height:17pt"><td style="width:134pt"><p class="s58" style="padding-top: 4pt;padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">Customer relationships . . . . . . . . .</p></td><td style="width:36pt"><p class="s58" style="padding-top: 4pt;padding-right: 2pt;text-indent: 0pt;text-align: right;">$27,300</p></td><td style="width:52pt"><p class="s58" style="padding-top: 4pt;padding-right: 6pt;text-indent: 0pt;text-align: right;">$(11,247)</p></td><td style="width:38pt"><p class="s58" style="padding-top: 4pt;padding-right: 6pt;text-indent: 0pt;text-align: right;">$16,053</p></td><td style="width:36pt;border-top-style:solid;border-top-width:1pt"><p class="s58" style="padding-top: 4pt;padding-left: 11pt;padding-right: 11pt;text-indent: 0pt;text-align: center;">9.5</p></td><td style="width:39pt"><p class="s58" style="padding-top: 4pt;padding-right: 3pt;text-indent: 0pt;text-align: right;">$11,910</p></td><td style="width:52pt"><p class="s58" style="padding-top: 4pt;padding-right: 6pt;text-indent: 0pt;text-align: right;">$(10,481)</p></td><td style="width:34pt"><p class="s58" style="padding-top: 4pt;padding-right: 6pt;text-indent: 0pt;text-align: right;">$1,429</p></td><td style="width:36pt;border-top-style:solid;border-top-width:1pt"><p class="s58" style="padding-top: 4pt;padding-left: 11pt;padding-right: 11pt;text-indent: 0pt;text-align: center;">2.9</p></td></tr><tr style="height:13pt"><td style="width:134pt"><p class="s58" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">Other intangibles . . . . . . . . . . . . . . .</p></td><td style="width:36pt"><p class="s58" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">3,900</p></td><td style="width:52pt"><p class="s58" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">(3,482)</p></td><td style="width:38pt"><p class="s58" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">418</p></td><td style="width:36pt"><p class="s58" style="padding-left: 11pt;padding-right: 11pt;text-indent: 0pt;text-align: center;">0.7</p></td><td style="width:39pt"><p class="s58" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">3,900</p></td><td style="width:52pt"><p class="s58" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">(2,925)</p></td><td style="width:34pt"><p class="s58" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">975</p></td><td style="width:36pt"><p class="s58" style="padding-left: 11pt;padding-right: 11pt;text-indent: 0pt;text-align: center;">1.7</p></td></tr><tr style="height:15pt"><td style="width:134pt"><p class="s58" style="padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">Trade names. . . . . . . . . . . . . . . . . . . .</p></td><td style="width:36pt"><p class="s59" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">  18,615</p></td><td style="width:52pt"><p class="s59" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">    (4,370<span class="s58">)</span></p></td><td style="width:38pt"><p class="s59" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">  14,245</p></td><td style="width:36pt"><p class="s58" style="padding-left: 11pt;padding-right: 11pt;text-indent: 0pt;text-align: center;">6.5</p></td><td style="width:39pt"><p class="s59" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">  10,505</p></td><td style="width:52pt"><p class="s59" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">    (3,174<span class="s58">)</span></p></td><td style="width:34pt"><p class="s59" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">  7,331</p></td><td style="width:36pt"><p class="s58" style="padding-left: 11pt;padding-right: 11pt;text-indent: 0pt;text-align: center;">7.0</p></td></tr><tr style="height:16pt"><td style="width:134pt"><p class="s58" style="padding-top: 1pt;padding-left: 1pt;padding-right: 1pt;text-indent: 0pt;text-align: center;">Total . . . . . . . . . . . . . . . . . . . . . . . . . . .</p></td><td style="width:36pt"><p class="s59" style="padding-top: 1pt;padding-right: 2pt;text-indent: 0pt;text-align: right;">$49,815</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 2pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="39" height="1" alt="image" src="NYSE_EVDY_2014/Image_087.png"/></span></p></td><td style="width:52pt"><p class="s59" style="padding-top: 1pt;padding-right: 6pt;text-indent: 0pt;text-align: right;">$(19,099<span class="s58">)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 9pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="44" height="1" alt="image" src="NYSE_EVDY_2014/Image_088.png"/></span></p></td><td style="width:38pt"><p class="s59" style="padding-top: 1pt;padding-right: 6pt;text-indent: 0pt;text-align: right;">$30,716</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 2pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="39" height="1" alt="image" src="NYSE_EVDY_2014/Image_089.png"/></span></p></td><td style="width:36pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:39pt"><p class="s59" style="padding-top: 1pt;padding-right: 3pt;text-indent: 0pt;text-align: right;">$26,315</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="39" height="1" alt="image" src="NYSE_EVDY_2014/Image_090.png"/></span></p></td><td style="width:52pt"><p class="s59" style="padding-top: 1pt;padding-right: 6pt;text-indent: 0pt;text-align: right;">$(16,580<span class="s58">)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 9pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="44" height="1" alt="image" src="NYSE_EVDY_2014/Image_091.png"/></span></p></td><td style="width:34pt"><p class="s59" style="padding-top: 1pt;padding-right: 6pt;text-indent: 0pt;text-align: right;">$9,735</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 2pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="33" height="1" alt="image" src="NYSE_EVDY_2014/Image_092.png"/></span></p></td><td style="width:36pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="64" height="1" alt="image" src="NYSE_EVDY_2014/Image_093.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s55" style="padding-top: 3pt;padding-left: 44pt;text-indent: -13pt;text-align: justify;">(a) <span class="p">The calculation of the weighted-average remaining useful life is based on weighting the net book value of each asset in its group, and applying the weight to its respective remaining amortization period.</span></p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Amortization expense relating to the definite-lived intangible assets totaled $2,519, $3,592 and</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">$3,790 for the years ended December 31, 2014, 2013 and 2012, respectively, and is included in general and administrative expense in the accompanying consolidated statements of operations.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 51pt;text-indent: 0pt;line-height: 173%;text-align: left;">Future amortization expense of the intangible assets is estimated to be as follows: Year ending December 31:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:68.6796pt" cellspacing="0"><tr style="height:11pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 10pt;text-align: center;">2015 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">$ 4,635</p></td></tr><tr style="height:12pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">2016 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">3,945</p></td></tr><tr style="height:12pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">2017 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">3,937</p></td></tr><tr style="height:12pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">2018 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">3,748</p></td></tr><tr style="height:12pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">2019 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">3,748</p></td></tr><tr style="height:14pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Thereafter ...... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">  10,703</p></td></tr><tr style="height:15pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;text-align: center;">Total . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">$30,716</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="43" height="1" alt="image" src="NYSE_EVDY_2014/Image_094.png"/></span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li style="padding-left: 42pt;text-indent: -11pt;text-align: left;"><p style="display: inline;">Accounts Payable and Accrued Expenses</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Accounts payable and accrued expenses consist of the following:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s40" style="padding-top: 3pt;text-indent: 0pt;text-align: right;">       December 31,       </p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:48.7803pt" cellspacing="0"><tr style="height:11pt"><td style="width:335pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:44pt"><p class="s44" style="padding-right: 5pt;text-indent: 0pt;line-height: 8pt;text-align: right;">    2014    </p></td><td style="width:41pt"><p class="s44" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">    2013    </p></td></tr><tr style="height:14pt"><td style="width:335pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Accounts payable . . . ......... ......... ......... ......... ......... ........ </p></td><td style="width:44pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">$ 8,563</p></td><td style="width:41pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">$ 8,459</p></td></tr><tr style="height:12pt"><td style="width:335pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Accrued compensation ....... ......... ......... ......... ......... ........ </p></td><td style="width:44pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">8,260</p></td><td style="width:41pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">8,282</p></td></tr><tr style="height:12pt"><td style="width:335pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Accrued acquisition earn-outs ......... ......... ......... ......... ........ </p></td><td style="width:44pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">1,425</p></td><td style="width:41pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">3,639</p></td></tr><tr style="height:12pt"><td style="width:335pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Accrued royalties.... ......... ......... ......... ......... ......... ........ </p></td><td style="width:44pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">5,991</p></td><td style="width:41pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">6,589</p></td></tr><tr style="height:12pt"><td style="width:335pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Accrued media and licensed content . . ......... ......... ......... ........ </p></td><td style="width:44pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">3,716</p></td><td style="width:41pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">3,178</p></td></tr><tr style="height:12pt"><td style="width:335pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Accrued interest..... ......... ......... ......... ......... ......... ........ </p></td><td style="width:44pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">408</p></td><td style="width:41pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">943</p></td></tr><tr style="height:12pt"><td style="width:335pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Accrued professional fees .... ......... ......... ......... ......... ........ </p></td><td style="width:44pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">718</p></td><td style="width:41pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">872</p></td></tr><tr style="height:14pt"><td style="width:335pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Other accrued expenses ...... ......... ......... ......... ......... ........ </p></td><td style="width:44pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">    2,641</p></td><td style="width:41pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">    2,416</p></td></tr><tr style="height:15pt"><td style="width:335pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Total ...... .......... ......... ......... ......... ......... ......... ........ </p></td><td style="width:44pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">$31,722</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="43" height="1" alt="image" src="NYSE_EVDY_2014/Image_095.png"/></span></p></td><td style="width:41pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">$34,378</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="43" height="1" alt="image" src="NYSE_EVDY_2014/Image_096.png"/></span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li style="padding-left: 42pt;text-indent: -11pt;text-align: left;"><p style="display: inline;">Long-Term Debt</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company entered into a credit facility agreement with a syndicated bank group in March 2014, which replaced its then-existing credit facility as described further below. The credit facility consisted of a revolver (“Revolver”) with a maximum borrowing limit of $35,000 and a term loan (“Term Loan”) of $40,000. In November 2014, in connection with the DD acquisition (see Note 3), the credit facility was amended and restated (as amended and restated, the “Credit Facility”), which, among other things, (i) increased the maximum borrowing limit of the Revolver from $35,000 to</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">$55,000; (ii) increased the Term Loan from $39,000 outstanding as of such date to $60,000; (iii) extended the maturity date of the Term Loan and the due date of principal on the Revolver from March 2019 to November 2019; and (iv) effected certain modifications to the covenants and terms as set forth in the Credit Facility agreement.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The repayment terms of the Revolver provide for quarterly interest payments, with the principal being due in full in November 2019. The repayment terms of the Term Loan provide for quarterly interest and principal payments, with a maturity date of November 2019. The interest rate on the Credit Facility is equal to the London Inter-Bank Offered Rate, or LIBOR, plus a variable rate ranging from 2.75% to 4.0% depending on the Company’s consolidated leverage ratio, as defined in the Credit Facility agreement, and there is a 0.50% commitment fee on the unused portion of the Revolver. As of December 31, 2014, the interest rate on the Credit Facility was 3.48%. As of December 31, 2014, there was $60,000 outstanding on the Term Loan and $30,000 outstanding on the Revolver.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Credit Facility contains certain financial and operational covenants, including requirements to maintain a minimum consolidated fixed charge coverage ratio and a maximum consolidated leverage ratio, each as defined in the Credit Facility agreement, as well as restrictions on certain types of dispositions, mergers and acquisitions, indebtedness, investments, liens and capital expenditures, issuance of capital stock and the Company’s ability to pay dividends. The Credit Facility is secured by a first priority security interest in substantially all of the Company’s existing and future assets. The Company was in compliance with the financial and operational covenants of the Credit Facility as of December 31, 2014.</p><p style="padding-top: 7pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">Maturities of debt outstanding as of December 31, 2014 are as follows:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:68.6796pt" cellspacing="0"><tr style="height:11pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 10pt;text-align: center;">2015 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 10pt;text-align: right;">$ 3,000</p></td></tr><tr style="height:12pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">2016 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">6,000</p></td></tr><tr style="height:12pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">2017 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">6,000</p></td></tr><tr style="height:12pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">2018 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">6,000</p></td></tr><tr style="height:14pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">2019 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">  69,000</p></td></tr><tr style="height:15pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;text-align: center;">Total . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">$90,000</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="43" height="1" alt="image" src="NYSE_EVDY_2014/Image_097.png"/></span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 19pt;text-align: left;">In connection with the credit facility financing in March 2014 discussed above, the Company repaid all outstanding borrowings under its former credit facilities, and such credit facilities were terminated. In March 2014, the Company wrote-off unamortized deferred financing costs of $2,845 and prepayment fees of $1,016 related to the former credit facilities, which is reflected in other expense in the accompanying consolidated statement of operations for the year ended December 31, 2014.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Prior to termination of the former credit facilities, the Company maintained a credit facility, which was entered into in September 2010 and was amended in 2011, 2012 and 2013. This former credit facility (as amended, the “Former Credit Facility”) consisted of a revolving facility and a term loan. Under the Former Credit Facility, the maximum amount that could be outstanding under the revolver was the lesser of $30,000 and 80% of eligible accounts receivable. The maximum amount that could be outstanding under the term loan was $8,500. The repayment terms of the revolver, as amended, provided for monthly interest payments, with the principal being due in September 2015. The repayment terms for the term loan, as amended, provided for monthly interest payments, with principal payments commencing in April 2011 and ending in December 2014.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">At December 31, 2013, the outstanding borrowings under the revolver and term loan components of the Former Credit Facility amounted to $30,000 and $1,333, respectively. At December 31, 2013, the interest rate on the revolver was Wall Street Journal Prime Rate (“WSJ Prime rate”) plus 2.0%, or 5.25%. At December 31, 2013, the interest rate on the term loan was the WSJ Prime rate plus 3.25%, or 6.50%.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In addition to the Former Credit Facility, the Company also previously maintained a subordinated credit facility, consisting of a 54-month term loan (the “Initial Subordinated Facility”). Under the Initial Subordinated Facility, the maximum amount that could be outstanding was</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">$15,000, and the interest rate was 13.0%. In October 2012, the Company entered into a new subordinated facility with the lender of the Former Credit Facility and an unrelated third party (the “Subordinated Facility”), and repaid all outstanding borrowings under the Initial Subordinated Facility, and such facility was terminated.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Subordinated Facility consisted of a 36-month $35,000 term loan. The repayment terms for the Subordinated Facility provided for monthly interest payments commencing in November 2012</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">and ending in November 2015. The principal amount was payable in full in October 2015. The interest rate for the Subordinated Facility was 14.0%.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">During the year ended December 31, 2013, the Company entered into a loan modification to the Subordinated Facility, which consisted of a $5,000 increase to the term loan, with such additional amount being payable in full in November 2016. At December 31, 2013, outstanding borrowings under the Subordinated Facility, as amended, amounted to $40,000.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Former Credit Facility and Subordinated Facility contained certain financial and operational covenants, including restrictions on certain types of dispositions, mergers and acquisitions, indebtedness, investments, liens and capital expenditures, issuance of capital stock and the ability of the Company to pay dividends and make other distributions. The Company was in compliance with the financial and operational covenants of the Former Credit Facility and Subordinated Facility as of December 31, 2013 and 2012.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In connection with the credit facilities that were in place prior to 2014, the Company issued to the lenders warrants to purchase a total of: (i) 592,501 shares of common stock at $0.015 per share,</p><ol id="l13"><li style="padding-left: 48pt;text-indent: -17pt;text-align: left;"><p style="display: inline;">112,959 shares of Series F redeemable convertible preferred stock at $7.61 per share, and</p></li><li style="padding-left: 31pt;text-indent: 0pt;text-align: left;"><p style="display: inline;">110,018 shares of Series C redeemable convertible preferred stock at $3.27 per share. Each of the above warrants were immediately exercisable and, accordingly, the Company calculated the fair value of the warrants using the Black-Scholes option pricing model and recorded deferred financing costs related to the issuances of the warrants in the respective periods. In April 2014, in connection with the closing of the Company’s IPO, the above warrants to purchase 222,977 shares of preferred stock were converted into warrants to purchase an aggregate of 148,650 shares of common stock. This conversion resulted in the warrant liability of $1,140 being reclassified to additional paid-in capital.</p></li></ol><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company incurred financing costs of $2,899, $68 and $1,345 during the years ended December 31, 2014, 2013 and 2012, respectively, which, along with the fair value of warrants, have been deferred and amortized using the effective interest rate method through the final maturities of the respective credit facilities. Deferred financing costs are recorded in other assets in the accompanying consolidated balance sheets. Amortization expense relating to the deferred financing costs was $528, $1,646 and $687 for the years ended December 31, 2014, 2013 and 2012, respectively, and is included in interest expense in the accompanying consolidated statements of operations.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li style="padding-left: 47pt;text-indent: -16pt;text-align: left;"><p style="display: inline;">Common Stock and Redeemable Convertible Preferred Stock</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">As of December 31, 2014 and 2013, respectively, there were no shares and 26,820,270 shares of redeemable convertible preferred stock issued and outstanding. The redeemable convertible preferred stock, Series A-G (collectively, the “Preferred Stock”), which was outstanding at the time of the Company’s IPO, fully converted to common stock in connection with the IPO (see Note 1). Such Preferred Stock had the following characteristics:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Conversion</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Each share of Preferred Stock was convertible at the option of the holder, at any time, into such number of fully paid shares of the Company’s common stock equal to the applicable original issue price for such share of Preferred Stock divided by the applicable conversion price for such share of Preferred Stock then in effect. As of December 31, 2013, the original issue prices and the conversion prices for each series of Preferred Stock were as follows: $0.50 for Series A, $1.77 for Series B, $3.27 for Series C, $6.87 for Series D, $7.98 for Series E, $7.61 for Series F and $9.00 for Series G (prior to giving effect to a 1-for-1.5 reverse stock split of the Company’s common stock implemented on March 14, 2014 in connection with the IPO). The conversion prices for each series</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">of Preferred Stock were subject to adjustment upon the occurrence of certain events, including stock dividends, stock splits, combinations or other similar recapitalizations, and issuance of capital stock at a price below the conversion price in effect for such series of redeemable convertible preferred stock. The conversion price for the Series G convertible preferred stock was also subject to further adjustment in the event of an IPO with a public offering price of less than $11.88 per share.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Dividends</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The holders of Preferred Stock were entitled to receive, when and as declared by the Board of Directors and out of funds legally available, non-cumulative dividends at a rate determined by the Board of Directors, payable in preference and priority to the payment of any dividends on common stock. Through December 31, 2014, no dividends were declared or paid by the Company.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Liquidation Preference</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In the event of any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, the holders of the then outstanding Preferred Stock would receive, in preference to any payments to the holders of common stock, an amount (i) for the Preferred Stock other than the Series G, equal to the original issue price for such series of Preferred Stock (except that the holders of Series E would receive $1.77 per share in lieu of the original issue price) plus all declared but unpaid dividends and (ii) for the Series G, equal to the original issue price for the Series G, plus an amount per share per annum equal to $0.90 compounded annually (subject to a maximum amount, including the original issue price for the Series G, equal to $12.15), plus all declared but unpaid dividends (“Preferential Payments”).</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">After all Preferential Payments, the remaining assets of the Company would be distributed among the holders of the shares of Series A, Series C, Series D and common stock, pro rata, based on the number of shares held on an “as-if converted” basis (except that the holders of shares of Series C and Series D would not receive more than an aggregate of $6.54 and $10.30, respectively, including Preferential Payments).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Voting</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Each holder of Preferred Stock was entitled to the number of votes equal to the number of shares of common stock into which such holder’s shares of Preferred Stock were convertible at the time of such vote and would vote together with the holders of common stock on any matters presented to the stockholders for their consideration. In addition, the holders of Preferred Stock were entitled to vote separately from the common stock to elect six members of the Board of Directors and to approve certain specified matters. On all matters in which the holders of Preferred Stock were entitled to vote separately, the holders of Series E could not cast more than 28.5% of the votes (the “Series E Reduced Voting”).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Redemption</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Redemption rights issued in connection with the Series C were extended to the holders of the Series A and Series B in February 2006, with the right to require redemption commencing 60 days after receipt by the Company of a notice by the holders of Preferred Stock on or after February 2011. Redemption rights were also issued to the holders of the Series D, with the right to require redemption commencing 60 days after receipt by the Company of a notice by the holders of Preferred Stock on or after August 2012.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Concurrent with the issuance of the Series D, the holders of the Series A, Series B and Series C agreed to modify their redemption rights so that the right to require redemption commenced</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">60 days after receipt by the Company of a notice by the holders of Preferred Stock on or after August 2012. Concurrent with the issuance of the Series F, the holders of Series A, Series B, Series C, Series D and Series E agreed to modify their redemption rights so that the right to require redemption required approval of at least 56% of the outstanding Preferred Stock (subject to the Series E Reduced Voting), commencing 60 days after receipt by the Company of a notice by the holders of Preferred Stock on or after October 15, 2013.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Concurrent with the issuance of the Series G, (i) the holders of Series A, Series B, Series C, Series D, Series E and Series F agreed to modify their redemption rights so that the right to require redemption required approval of at least 56% of the outstanding Series A, Series B, Series C,</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Series D, Series E and Series F (subject to the Series E Reduced Voting), and (ii) the holders of a majority of the Series G were given the right to require redemption, in each case, commencing not less than 75 days and not more than 90 days (subject to certain modifications, as set forth in the Company’s certificate of incorporation) after receipt by the Company of a notice by such holders of Preferred Stock on or after November 10, 2016. Accordingly, (i) at the option of 56% of the holders of Series A, Series B, Series C, Series D, Series E and Series F (subject to the Series E Reduced Voting), each share of Series A, Series B, Series C, Series D, Series E and Series F became redeemable at a price equal to the applicable original issue price per such share of Preferred Stock, plus all declared but unpaid dividends thereon, commencing not less than 75 days and not more than 90 days (subject to certain modifications, as set forth in the Company’s certificate of incorporation) after receipt by the Company of a notice by the holders of such Preferred Stock on or after November 10, 2016, and (ii) at the option of a majority of the holders of Series G, each share of Series G became redeemable at a price equal to the applicable original issue price per share of Series G, plus all declared but unpaid dividends thereon, commencing not less than 75 days and not more than 90 days (subject to certain modifications, as set forth in the Company’s certificate of incorporation) after receipt by the Company of a notice by the holders of Series G on or after November 10, 2016. In addition, for as long as any share of Series G was not redeemed after the date on which the Company had the obligation to redeem such share, interest at the rate of 15%</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">per annum would accrue on the redemption price of such share of Series G, which interest would be payable quarterly in arrears.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company recorded its Preferred Stock outside of permanent equity because the redemption feature was not solely within the control of the Company.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In March 2014, the Company’s Board of Directors and stockholders approved an amendment to the Company’s amended and restated certificate of incorporation effecting a 1-for-1.5 reverse stock split of the Company’s issued and outstanding shares of common stock. The par value of the common stock was not adjusted as a result of the reverse stock split. All issued and outstanding common stock and per share amounts contained in the Company’s consolidated financial statements and related notes thereto have been retroactively adjusted to reflect this reverse stock split for all periods presented. The reverse stock split was effected on March 14, 2014.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In April 2014, in connection with the closing of the Company’s IPO, the Company filed an amended and restated certificate of incorporation with the Secretary of State of the State of Delaware that amended and restated in its entirety the Company’s certificate of incorporation to, among other things, increase the total number of shares of the Company’s common stock that the Company is authorized to issue to 90,000,000, eliminate all references to the various series of preferred stock that were previously authorized (including certain protective measures held by the various series of preferred stock), and to authorize up to 10,000,000 shares of undesignated preferred stock that may be issued from time to time with terms to be set by the Company’s Board of Directors, which rights could be senior to those of the Company’s common stock.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In connection with the IPO, all of the Company’s redeemable convertible preferred stock converted into common shares, which is discussed below in further detail. There was no redeemable convertible preferred stock outstanding at December 31, 2014.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The number of shares of the Company’s redeemable convertible preferred stock was not adjusted in connection with the 1-for-1.5 reverse stock split of common stock referred to above. The Company’s redeemable convertible preferred stock consisted of the following at December 31, 2013:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s40" style="text-indent: 0pt;text-align: right;">                    Shares                    </p><p class="s39" style="padding-top: 1pt;text-indent: 0pt;text-align: right;">Issued and</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s39" style="padding-left: 14pt;text-indent: 0pt;text-align: left;">Stated value,</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s39" style="padding-left: 14pt;text-indent: 0pt;text-align: left;">Liquidation</p><p class="s40" style="text-indent: 0pt;line-height: 8pt;text-align: right;"> Authorized </p><p class="s40" style="padding-left: 9pt;text-indent: 0pt;line-height: 8pt;text-align: left;"> outstanding </p><p class="s40" style="padding-left: 9pt;text-indent: 0pt;line-height: 8pt;text-align: left;">net of expenses</p><p class="s40" style="padding-left: 9pt;text-indent: 0pt;line-height: 8pt;text-align: left;"> preference</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:48.7733pt" cellspacing="0"><tr style="height:11pt"><td style="width:191pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Redeemable convertible preferred stock:</p></td><td style="width:227pt" colspan="4"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:191pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Series A....... ......... ......... ........ </p></td><td style="width:55pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">3,450,000</p></td><td style="width:62pt"><p class="s43" style="padding-right: 10pt;text-indent: 0pt;line-height: 11pt;text-align: right;">3,450,000</p></td><td style="width:59pt"><p class="s43" style="padding-right: 11pt;text-indent: 0pt;line-height: 11pt;text-align: right;">$ 1,053</p></td><td style="width:51pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">$ 1,725</p></td></tr><tr style="height:12pt"><td style="width:191pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Series B ....... ......... ......... ........ </p></td><td style="width:55pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">2,547,252</p></td><td style="width:62pt"><p class="s43" style="padding-right: 10pt;text-indent: 0pt;line-height: 11pt;text-align: right;">2,547,252</p></td><td style="width:59pt"><p class="s43" style="padding-right: 11pt;text-indent: 0pt;line-height: 11pt;text-align: right;">4,413</p></td><td style="width:51pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">4,500</p></td></tr><tr style="height:12pt"><td style="width:191pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Series C ....... ......... ......... ........ </p></td><td style="width:55pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">1,943,651</p></td><td style="width:62pt"><p class="s43" style="padding-right: 10pt;text-indent: 0pt;line-height: 11pt;text-align: right;">1,833,633</p></td><td style="width:59pt"><p class="s43" style="padding-right: 11pt;text-indent: 0pt;line-height: 11pt;text-align: right;">5,882</p></td><td style="width:51pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">6,000</p></td></tr><tr style="height:12pt"><td style="width:191pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Series D....... ......... ......... ........ </p></td><td style="width:55pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">3,934,855</p></td><td style="width:62pt"><p class="s43" style="padding-right: 10pt;text-indent: 0pt;line-height: 11pt;text-align: right;">3,934,855</p></td><td style="width:59pt"><p class="s43" style="padding-right: 11pt;text-indent: 0pt;line-height: 11pt;text-align: right;">25,354</p></td><td style="width:51pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">27,027</p></td></tr><tr style="height:12pt"><td style="width:191pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Series E ....... ......... ......... ........ </p></td><td style="width:55pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">8,930,966</p></td><td style="width:62pt"><p class="s43" style="padding-right: 10pt;text-indent: 0pt;line-height: 11pt;text-align: right;">8,930,966</p></td><td style="width:59pt"><p class="s43" style="padding-right: 11pt;text-indent: 0pt;line-height: 11pt;text-align: right;">71,250</p></td><td style="width:51pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">15,789</p></td></tr><tr style="height:12pt"><td style="width:191pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Series F ....... ......... ......... ........ </p></td><td style="width:55pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">3,064,087</p></td><td style="width:62pt"><p class="s43" style="padding-right: 10pt;text-indent: 0pt;line-height: 11pt;text-align: right;">2,951,128</p></td><td style="width:59pt"><p class="s43" style="padding-right: 11pt;text-indent: 0pt;line-height: 11pt;text-align: right;">22,468</p></td><td style="width:51pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">22,468</p></td></tr><tr style="height:14pt"><td style="width:191pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Series G....... ......... ......... ........ </p></td><td style="width:55pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">  3,333,333</p></td><td style="width:62pt"><p class="s51" style="padding-right: 10pt;text-indent: 0pt;line-height: 11pt;text-align: right;">  3,172,436</p></td><td style="width:59pt"><p class="s51" style="padding-right: 11pt;text-indent: 0pt;line-height: 11pt;text-align: right;">    28,346</p></td><td style="width:51pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">    37,118</p></td></tr><tr style="height:15pt"><td style="width:191pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Total .......... ......... ......... ........ </p></td><td style="width:55pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">27,204,144</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="60" height="1" alt="image" src="NYSE_EVDY_2014/Image_098.png"/></span></p></td><td style="width:62pt"><p class="s51" style="padding-right: 10pt;text-indent: 0pt;text-align: right;">26,820,270</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="60" height="1" alt="image" src="NYSE_EVDY_2014/Image_099.png"/></span></p></td><td style="width:59pt"><p class="s51" style="padding-right: 11pt;text-indent: 0pt;text-align: right;">$158,766</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 10pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="50" height="1" alt="image" src="NYSE_EVDY_2014/Image_100.png"/></span></p></td><td style="width:51pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">$114,627</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 11pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="50" height="1" alt="image" src="NYSE_EVDY_2014/Image_101.png"/></span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Conversion of the Redeemable Convertible Preferred Stock</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In connection with the March 14, 2014 1-for-1.5 reverse stock split, the conversion prices for each series of redeemable convertible preferred stock were subject to a 1-for-1.5 adjustment. As a result, upon the closing of the IPO, the 23,647,834 outstanding shares of Series A, Series B, Series C, Series D, Series E and Series F redeemable convertible preferred stock converted into a total of 15,765,223 shares of common stock. Based on this 1-for-1.5 adjustment, the conversion price for the IPO adjustment specific to the Series G shares increased from $11.88 per share to $17.82 per share. Based on the public offering price of $14.00 per share, the 3,172,436 outstanding shares of Series G convertible preferred stock converted into a total of 2,692,012 shares of common stock, including an</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">additional 577,055 shares of common stock issued as a result of the specific Series G IPO adjustment feature or “ratchet provision.” The ratchet provision, which is treated as a deemed stock dividend for accounting purposes, was calculated as the difference between the number of shares of common stock each holder of Series G would receive upon the automatic conversion of the Series G shares and the number of shares contingently issuable just prior to the automatic conversion based on the initial conversion price multiplied by the IPO price of $14.00 per share, which represents the fair value of the common stock on the date of conversion. In April 2014, the Company recorded a one- time $8,079 non-cash preferred stock deemed dividend related to the issuance of additional common shares resulting from the ratchet provision. Such non-cash preferred stock deemed dividend results in a decrease to net income to arrive at net income attributable to common stockholders and, consequently, results in an adjustment to the Company’s computation of net income per share attributable to common stockholders.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Issuance of Common Stock Warrant</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">In March 2014, the Company issued to one of its website partners a warrant to purchase 100,000 shares of common stock at $0.015 per share, in connection with the website partner agreeing to extend the advertising representation agreement by two years. The warrant was immediately exercisable and, accordingly, the Company calculated the fair value of the warrant using the Black- Scholes option pricing model and recorded $1,131 of deferred costs related to the issuance during</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">the year ended December 31, 2014, which will be amortized to the Company’s operating results over the remaining life of the agreement.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Authorized Capital</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">As of December 31, 2014, the Company was authorized to issue 90,000,000 shares of its common stock and 10,000,000 shares of its preferred stock. As of December 31, 2014, the Company has reserved for issuance no shares under its 2003 Stock Option Plan, 347,371 shares under its 2014 Equity Incentive Plan and 361,816 shares for future issuance under the ESPP.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li style="padding-left: 47pt;text-indent: -16pt;text-align: left;"><p style="display: inline;">Stock-Based Compensation</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Stock Options</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company has historically granted non-statutory stock options to employees, directors and consultants of the Company pursuant to its 2003 Stock Option Plan, as amended (the “2003 Plan”). The Board of Directors and the Company’s stockholders subsequently approved the 2014 Equity Incentive Plan (the “2014 Plan”), which became effective immediately upon the signing of the underwriting agreement related to the IPO on March 27, 2014. Upon the effectiveness of the 2014 Plan, no additional options have been or will be granted under the 2003 Plan. Under the 2014 Plan, options are granted at prices not less than the estimated fair market value of the Company’s common stock on the date of grant. The options generally vest and become exercisable over four years from the date of grant and expire after ten years. Additionally, the Company granted 112,500 performance-based awards in 2014 where such options would vest and become exercisable over approximately nine months from the date of grant, dependent upon the Company meeting certain performance criteria. The performance criteria for these options were met at less than target, which resulted in the vesting of 90,555 of such 112,500 shares on December 31, 2014. The remaining 21,945 shares were cancelled on December 31, 2014.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The aggregate number of shares of the Company’s common stock that may be issued pursuant to the 2014 Plan is the sum of (1) 200,000 shares, (2) the 388,781 shares reserved for issuance under the 2003 Plan at the time the 2014 Plan became effective, and (3) any shares subject to outstanding stock options that would otherwise have returned to the 2003 Plan (such as upon the expiration or termination of stock options prior to vesting). In addition, the number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year from January 1, 2015 through January 1, 2024 by the lesser of (a) 4% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year and</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">(b) a number of shares determined by the Board of Directors. As of December 31, 2014, 347,371 shares have been reserved for future issuance under the 2014 Plan.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The following table summarizes stock option activity for the years ended December 31, 2014, 2013 and 2012:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:28.8244pt" cellspacing="0"><tr style="height:8pt"><td style="width:292pt" colspan="2" rowspan="3"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:58pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt"><p class="s54" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Weighted-</p></td><td style="width:58pt" rowspan="3"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:8pt"><td style="width:58pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:51pt"><p class="s54" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;line-height: 7pt;text-align: center;">average</p></td></tr><tr style="height:8pt"><td style="width:58pt"><p class="s54" style="padding-left: 10pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Weighted-</p></td><td style="width:51pt"><p class="s54" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;line-height: 7pt;text-align: center;">remaining</p></td></tr><tr style="height:8pt"><td style="width:235pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p class="s54" style="padding-left: 7pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Number of</p></td><td style="width:58pt"><p class="s54" style="padding-left: 14pt;text-indent: 0pt;line-height: 7pt;text-align: left;">average</p></td><td style="width:51pt"><p class="s54" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;line-height: 7pt;text-align: center;">contractual</p></td><td style="width:58pt"><p class="s54" style="padding-left: 12pt;text-indent: 0pt;line-height: 7pt;text-align: left;">Aggregate</p></td></tr><tr style="height:11pt"><td style="width:235pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p class="s44" style="padding-left: 5pt;text-indent: 0pt;line-height: 8pt;text-align: left;">     options     </p></td><td style="width:58pt"><p class="s44" style="padding-left: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">exercise price</p></td><td style="width:51pt"><p class="s44" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;line-height: 8pt;text-align: center;">life (years)</p></td><td style="width:58pt"><p class="s44" style="padding-left: 6pt;text-indent: 0pt;line-height: 8pt;text-align: left;">intrinsic value</p></td></tr><tr style="height:14pt"><td style="width:235pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">Outstanding at December 31, 2011 .... ......... ... </p></td><td style="width:57pt"><p class="s43" style="padding-left: 8pt;text-indent: 0pt;text-align: left;">4,163,677</p></td><td style="width:58pt"><p class="s43" style="padding-left: 14pt;text-indent: 0pt;text-align: left;">$ 7.43</p></td><td style="width:51pt"><p class="s43" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: center;">7.25</p></td><td style="width:58pt"><p class="s43" style="padding-left: 14pt;text-indent: 0pt;text-align: left;">$ 3,194</p></td></tr><tr style="height:12pt"><td style="width:235pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Granted......... ......... ......... ......... ... </p></td><td style="width:57pt"><p class="s43" style="padding-left: 8pt;text-indent: 0pt;line-height: 11pt;text-align: left;">1,453,961</p></td><td style="width:58pt"><p class="s43" style="padding-left: 24pt;text-indent: 0pt;line-height: 11pt;text-align: left;">6.78</p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:58pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:235pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Exercised ....... ......... ......... ......... ... </p></td><td style="width:57pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(46,505)</p></td><td style="width:58pt"><p class="s43" style="padding-left: 24pt;text-indent: 0pt;line-height: 11pt;text-align: left;">3.62</p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:58pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:14pt"><td style="width:235pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Cancelled ....... ......... ......... ......... ... </p></td><td style="width:57pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">   (299,426<span class="s43">)</span></p></td><td style="width:58pt"><p class="s43" style="padding-left: 24pt;text-indent: 0pt;line-height: 11pt;text-align: left;">8.36</p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:58pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:14pt"><td style="width:235pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">Outstanding at December 31, 2012 .... ......... ... </p></td><td style="width:57pt"><p class="s43" style="padding-left: 8pt;text-indent: 0pt;text-align: left;">5,271,707</p></td><td style="width:58pt"><p class="s43" style="padding-left: 24pt;text-indent: 0pt;text-align: left;">7.28</p></td><td style="width:51pt"><p class="s43" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: center;">7.01</p></td><td style="width:58pt"><p class="s43" style="padding-left: 19pt;text-indent: 0pt;text-align: left;">10,556</p></td></tr><tr style="height:12pt"><td style="width:235pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Granted......... ......... ......... ......... ... </p></td><td style="width:57pt"><p class="s43" style="padding-left: 16pt;text-indent: 0pt;line-height: 11pt;text-align: left;">901,476</p></td><td style="width:58pt"><p class="s43" style="padding-left: 24pt;text-indent: 0pt;line-height: 11pt;text-align: left;">9.41</p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:58pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:235pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Exercised ....... ......... ......... ......... ... </p></td><td style="width:57pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(183,501)</p></td><td style="width:58pt"><p class="s43" style="padding-left: 24pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4.31</p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:58pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:14pt"><td style="width:235pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Cancelled ....... ......... ......... ......... ... </p></td><td style="width:57pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">   (531,891<span class="s43">)</span></p></td><td style="width:58pt"><p class="s43" style="padding-left: 24pt;text-indent: 0pt;line-height: 11pt;text-align: left;">7.67</p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:58pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:14pt"><td style="width:235pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">Outstanding at December 31, 2013 .... ......... ... </p></td><td style="width:57pt"><p class="s43" style="padding-left: 8pt;text-indent: 0pt;text-align: left;">5,457,791</p></td><td style="width:58pt"><p class="s43" style="padding-left: 24pt;text-indent: 0pt;text-align: left;">7.61</p></td><td style="width:51pt"><p class="s43" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: center;">6.54</p></td><td style="width:58pt"><p class="s43" style="padding-left: 19pt;text-indent: 0pt;text-align: left;">20,396</p></td></tr><tr style="height:12pt"><td style="width:235pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Granted......... ......... ......... ......... ... </p></td><td style="width:57pt"><p class="s43" style="padding-left: 8pt;text-indent: 0pt;line-height: 11pt;text-align: left;">1,945,851</p></td><td style="width:58pt"><p class="s43" style="padding-left: 19pt;text-indent: 0pt;line-height: 11pt;text-align: left;">14.67</p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:58pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:235pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Exercised ....... ......... ......... ......... ... </p></td><td style="width:57pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">(1,139,891)</p></td><td style="width:58pt"><p class="s43" style="padding-left: 24pt;text-indent: 0pt;line-height: 11pt;text-align: left;">6.41</p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:58pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:14pt"><td style="width:235pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">Cancelled ....... ......... ......... ......... ... </p></td><td style="width:57pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">   (370,053<span class="s43">)</span></p></td><td style="width:58pt"><p class="s43" style="padding-left: 19pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.52</p></td><td style="width:51pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:58pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:14pt"><td style="width:235pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">Outstanding at December 31, 2014 .... ......... ... </p></td><td style="width:57pt"><p class="s43" style="padding-left: 8pt;text-indent: 0pt;text-align: left;">5,893,698</p></td><td style="width:58pt"><p class="s43" style="padding-left: 24pt;text-indent: 0pt;text-align: left;">9.94</p></td><td style="width:51pt"><p class="s43" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;text-align: center;">6.48</p></td><td style="width:58pt"><p class="s43" style="padding-left: 19pt;text-indent: 0pt;text-align: left;">29,249</p></td></tr><tr style="height:11pt"><td style="width:235pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">Exercisable at December 31, 2014 ..... ......... ... </p></td><td style="width:57pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">  3,556,287</p></td><td style="width:58pt"><p class="s43" style="padding-left: 24pt;text-indent: 0pt;line-height: 10pt;text-align: left;">7.84</p></td><td style="width:51pt"><p class="s43" style="padding-left: 4pt;padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: center;">4.90</p></td><td style="width:58pt"><p class="s43" style="padding-left: 19pt;text-indent: 0pt;line-height: 10pt;text-align: left;">24,731</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 19pt;text-align: left;">The total intrinsic value of the options exercised during the years ended December 31, 2014, 2013 and 2012 was $8,080, $1,146 and $218, respectively.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Proceeds from the exercise of options were $7,939, $101 and $168 for the years ended December 31, 2014, 2013 and 2012, respectively.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: justify;">The weighted-average fair value per share at date of grant for options granted during the years ended December 31, 2014, 2013 and 2012 was $7.53, $4.80 and $3.32, respectively. The fair value of options granted is estimated on the date of grant using the Black-Scholes option pricing model and recognized in expense over the vesting period of the options using the graded attribution method.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The following table presents the weighted-average assumptions used to estimate the fair value of options granted in the years ended December 31, 2014, 2013 and 2012:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:48.7803pt" cellspacing="0"><tr style="height:11pt"><td style="width:320pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:109pt"><p class="s44" style="padding-left: 5pt;text-indent: 0pt;line-height: 8pt;text-align: left;">  2014 2013 2012  </p></td></tr><tr style="height:14pt"><td style="width:320pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Volatility....... ......... ......... ......... ......... ......... ......... .</p></td><td style="width:109pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">49.28% 50.32% 49.50%</p></td></tr><tr style="height:12pt"><td style="width:320pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Expected life (years) .... ......... ......... ......... ......... ......... .</p></td><td style="width:109pt"><p class="s43" style="padding-left: 10pt;text-indent: 0pt;line-height: 11pt;text-align: left;">6.25 6.25 6.25</p></td></tr><tr style="height:12pt"><td style="width:320pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Risk-free interest rate. . . ......... ......... ......... ......... ......... .</p></td><td style="width:109pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">1.92% 1.54% 1.23%</p></td></tr><tr style="height:11pt"><td style="width:320pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Dividend yield . ......... ......... ......... ......... ......... ......... .</p></td><td style="width:109pt"><p class="s43" style="padding-left: 18pt;text-indent: 0pt;line-height: 10pt;text-align: left;">— — —</p></td></tr></table><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The expected stock price volatilities are estimated based on historical realized volatilities of comparable publicly traded company stock prices over a period of time commensurate with the expected term of the option award. The expected life represents the period of time for which the options granted are expected to be outstanding. The Company used the simplified method for determining expected life for options qualifying for treatment due to the limited history the Company currently has with option exercise activity. The risk-free interest rate is based on the U.S. Treasury yield curve for periods equal to the expected term of the options on the grant date.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Total stock-based compensation expense related to stock options was $7,920, $3,039 and $3,610 (including $0, $70 and $78 from discontinued operations) for the years ended December 31, 2014, 2013 and 2012, respectively.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">At December 31, 2014, there was approximately $6,902 of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.29 years. The total fair value of stock options vested during the years ended</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">December 31, 2014, 2013 and 2012 was $4,328, $3,668 and $3,014, respectively.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">2014 Employee Stock Purchase Plan</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company’s directors adopted, and the stockholders subsequently approved, the ESPP. The ESPP, which became effective immediately upon the signing of the underwriting agreement related to the IPO on March 27, 2014, authorizes the issuance of 500,000 shares of the Company’s common stock pursuant to purchase rights granted to employees. The number of shares of common stock reserved for issuance under the ESPP will automatically increase on January 1 of each calendar year from January 1, 2015 through January 1, 2024 by the least of (a) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (b) 400,000 shares and (c) a number determined by the Board of Directors that is less than (a) and (b). Unless otherwise determined by the Board of Directors, common stock will be purchased for participating employees at a price per share equal to the lower of (a) 85% of the fair market value of a share of the common stock on the first date of an offering, or (b) 85% of the fair market value of a share of the common stock on the date of purchase. Generally, all regular employees may participate in the ESPP and may contribute, through payroll deductions, up to 15% of their earnings toward the purchase of common stock under the ESPP. Under the terms of the ESPP, there are defined limitations as to the amount and value of common stock that can be purchased by each employee.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">For the year ended December 31, 2014, employees purchased 138,184 shares for $1,592 under the ESPP, and charges incurred under the ESPP totaled $1,180. As of December 31, 2014, 361,816 shares of common stock were reserved for future issuance under the ESPP.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li style="padding-left: 47pt;text-indent: -16pt;text-align: left;"><p style="display: inline;">Income Taxes</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">The provision (benefit) from continuing operations for income taxes consists of the following:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:48.7803pt" cellspacing="0"><tr style="height:11pt"><td style="width:302pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:44pt"><p class="s44" style="padding-right: 7pt;text-indent: 0pt;line-height: 8pt;text-align: right;">    2014    </p></td><td style="width:37pt"><p class="s44" style="padding-right: 5pt;text-indent: 0pt;line-height: 8pt;text-align: right;">   2013   </p></td><td style="width:36pt"><p class="s44" style="padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: right;">   2012   </p></td></tr><tr style="height:14pt"><td style="width:302pt"><p class="s43" style="padding-left: 47pt;padding-right: 50pt;text-indent: 0pt;text-align: center;">Federal ....... ......... ......... ......... ......... ......... ....... </p></td><td style="width:44pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;text-align: right;">$ 250</p></td><td style="width:37pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">$ —</p></td><td style="width:36pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">$ —</p></td></tr><tr style="height:12pt"><td style="width:302pt"><p class="s43" style="padding-left: 47pt;padding-right: 50pt;text-indent: 0pt;line-height: 11pt;text-align: center;">State. ......... ......... ......... ......... ......... ......... ....... </p></td><td style="width:44pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">110</p></td><td style="width:37pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">95</p></td><td style="width:36pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">62</p></td></tr><tr style="height:14pt"><td style="width:302pt"><p class="s43" style="padding-left: 47pt;padding-right: 50pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Foreign ....... ......... ......... ......... ......... ......... ....... </p></td><td style="width:44pt"><p class="s51" style="padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">         45</p></td><td style="width:37pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">       45</p></td><td style="width:36pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">       33</p></td></tr><tr style="height:15pt"><td style="width:302pt"><p class="s43" style="padding-left: 47pt;padding-right: 50pt;text-indent: 0pt;text-align: center;">Total current . ......... ......... ......... ......... ......... ....... </p></td><td style="width:44pt"><p class="s51" style="padding-right: 7pt;text-indent: 0pt;text-align: right;">       405</p></td><td style="width:37pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">     140</p></td><td style="width:36pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">       95</p></td></tr><tr style="height:14pt"><td style="width:302pt"><p class="s43" style="padding-left: 47pt;padding-right: 50pt;text-indent: 0pt;text-align: center;">Federal ....... ......... ......... ......... ......... ......... ....... </p></td><td style="width:44pt"><p class="s43" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">(7,058)</p></td><td style="width:37pt"><p class="s43" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">749</p></td><td style="width:36pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">749</p></td></tr><tr style="height:14pt"><td style="width:302pt"><p class="s43" style="padding-left: 47pt;padding-right: 50pt;text-indent: 0pt;line-height: 11pt;text-align: center;">State. ......... ......... ......... ......... ......... ......... ....... </p></td><td style="width:44pt"><p class="s51" style="padding-right: 3pt;text-indent: 0pt;line-height: 11pt;text-align: right;">  (2,013<span class="s43">)</span></p></td><td style="width:37pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;line-height: 11pt;text-align: right;">     213</p></td><td style="width:36pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">     182</p></td></tr><tr style="height:15pt"><td style="width:302pt"><p class="s43" style="padding-left: 47pt;padding-right: 50pt;text-indent: 0pt;text-align: center;">Total deferred ......... ......... ......... ......... ......... ....... </p></td><td style="width:44pt"><p class="s51" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">  (9,071<span class="s43">)</span></p></td><td style="width:37pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">     962</p></td><td style="width:36pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">     931</p></td></tr><tr style="height:15pt"><td style="width:302pt"><p class="s43" style="padding-left: 47pt;padding-right: 50pt;text-indent: 0pt;text-align: center;">Total. ......... ......... ......... ......... ......... ......... ....... </p></td><td style="width:44pt"><p class="s51" style="padding-right: 3pt;text-indent: 0pt;text-align: right;">$(8,666<span class="s43">)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="42" height="1" alt="image" src="NYSE_EVDY_2014/Image_102.png"/></span></p></td><td style="width:37pt"><p class="s51" style="padding-right: 5pt;text-indent: 0pt;text-align: right;">$1,102</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 4pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="37" height="1" alt="image" src="NYSE_EVDY_2014/Image_103.png"/></span></p></td><td style="width:36pt"><p class="s51" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">$1,026</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 6pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="37" height="1" alt="image" src="NYSE_EVDY_2014/Image_104.png"/></span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 19pt;text-align: left;">The current income tax provision for the years ended December 31, 2014, 2013 and 2012 consisted of federal and state income taxes and foreign taxes. For the year ended December 31, 2014, the deferred income tax benefit includes a one-time tax benefit of $10,033 associated with the remeasurement of the valuation allowances against the Company’s deferred tax assets related to the DD acquisition (see Note 3), partially offset by a deferred tax charge relating to the basis differences in indefinite-lived intangible assets that cannot be offset by current year deferred tax</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: justify;">assets. For the years ended December 31, 2013 and 2012, the deferred income tax charge relates to basis differences in indefinite-lived intangible assets that cannot be offset by current and prior year deferred tax assets.</p><p style="padding-top: 7pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">The significant components of the Company’s deferred tax assets (liabilities) were as follows:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s40" style="padding-top: 3pt;padding-left: 381pt;text-indent: 0pt;text-align: left;">         December 31,         </p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:48.7793pt" cellspacing="0"><tr style="height:24pt"><td style="width:328pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Deferred tax assets:</p></td><td style="width:49pt"><p class="s44" style="padding-left: 5pt;text-indent: 0pt;line-height: 8pt;text-align: left;">     2014     </p></td><td style="width:46pt"><p class="s44" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">     2013     </p></td></tr><tr style="height:12pt"><td style="width:328pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Net operating loss carryforwards ........ ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ 40,899</p></td><td style="width:46pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ 44,856</p></td></tr><tr style="height:12pt"><td style="width:328pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Allowance for doubtful accounts ........ ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">258</p></td><td style="width:46pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">148</p></td></tr><tr style="height:12pt"><td style="width:328pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Intangible and other assets ..... ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s43" style="padding-left: 18pt;text-indent: 0pt;line-height: 11pt;text-align: left;">1,595</p></td><td style="width:46pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">1,569</p></td></tr><tr style="height:12pt"><td style="width:328pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Deferred revenue...... ......... ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">190</p></td><td style="width:46pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">304</p></td></tr><tr style="height:12pt"><td style="width:328pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Stock-based compensation ...... ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s43" style="padding-left: 18pt;text-indent: 0pt;line-height: 11pt;text-align: left;">9,504</p></td><td style="width:46pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">7,886</p></td></tr><tr style="height:12pt"><td style="width:328pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Accrued expenses and other.... ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s43" style="padding-left: 18pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4,038</p></td><td style="width:46pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4,348</p></td></tr><tr style="height:12pt"><td style="width:328pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">AMT credit. . . ......... ......... ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s43" style="padding-right: 7pt;text-indent: 0pt;line-height: 11pt;text-align: right;">250</p></td><td style="width:46pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">—</p></td></tr><tr style="height:14pt"><td style="width:328pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Depreciation. . ......... ......... ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">      1,722</p></td><td style="width:46pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">         530</p></td></tr><tr style="height:14pt"><td style="width:328pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Total deferred tax assets........ ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s43" style="padding-left: 13pt;text-indent: 0pt;text-align: left;">58,456</p></td><td style="width:46pt"><p class="s43" style="padding-left: 12pt;text-indent: 0pt;text-align: left;">59,641</p></td></tr><tr style="height:14pt"><td style="width:328pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Valuation allowance . . . ......... ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  (46,577<span class="s43">)</span></p></td><td style="width:46pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  (57,169<span class="s43">)</span></p></td></tr><tr style="height:15pt"><td style="width:328pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Net deferred  tax assets ......... ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">    11,879</p></td><td style="width:46pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">      2,472</p></td></tr><tr style="height:26pt"><td style="width:328pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Deferred tax liabilities:</p><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Depreciation. . ......... ......... ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 4pt;text-indent: 0pt;text-align: right;">(69)</p></td><td style="width:46pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">—</p></td></tr><tr style="height:12pt"><td style="width:328pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Goodwill ..... ......... ......... ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(6,028)</p></td><td style="width:46pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(5,066)</p></td></tr><tr style="height:14pt"><td style="width:328pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Intangible and other assets ..... ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  (11,799<span class="s43">)</span></p></td><td style="width:46pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">    (2,472<span class="s43">)</span></p></td></tr><tr style="height:15pt"><td style="width:328pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Total deferred tax liabilities .... ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">  (17,896<span class="s43">)</span></p></td><td style="width:46pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">    (7,538<span class="s43">)</span></p></td></tr><tr style="height:15pt"><td style="width:328pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Net deferred tax liabilities ...... ......... ......... ......... ......... .... </p></td><td style="width:49pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">$ (6,017<span class="s43">)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="48" height="1" alt="image" src="NYSE_EVDY_2014/Image_105.png"/></span></p></td><td style="width:46pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">$ (5,066<span class="s43">)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 3pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="48" height="1" alt="image" src="NYSE_EVDY_2014/Image_106.png"/></span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company has provided a valuation allowance against deferred tax assets to the extent the Company has determined that it is more likely than not that such net deferred tax assets will not be realized. In determining realizability, the Company considered numerous factors including historical profitability and reversing temporary differences, exclusive of indefinite-lived intangibles. The Company’s net deferred tax liabilities increased by $951 in 2014 due primarily to basis differences in indefinite-lived intangible assets that cannot be offset by current year deferred tax assets.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">At December 31, 2014, the Company had approximately $107,000 of U.S. federal and state net operating loss (“NOL”) carryforwards available to offset future taxable income. The U.S. federal NOL carryforwards will expire from 2020 through 2033. The full utilization of these losses in the future is dependent upon the Company’s ability to generate taxable income and may also be limited due to ownership changes, as defined under the provisions of Section 382 of the Internal Revenue Code, as amended. The Company’s NOL carryforwards at December 31, 2014 include $7,433 of income tax deductions related to equity compensation that are greater than the compensation recognized for financial reporting, which will be reflected as a credit to additional paid-in-capital as realized.</p><p style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The difference between the tax provision computed at the statutory rate and the tax provision recorded by the Company primarily relates to the release of the valuation allowance resulting from the DD acquisition. A reconciliation between the statutory rate and the effective tax rate for the years ended December 31, 2014, 2013 and 2012 is as follows:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s40" style="padding-top: 3pt;padding-left: 348pt;text-indent: 0pt;text-align: left;">     Year Ended December 31,     </p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:48.7793pt" cellspacing="0"><tr style="height:11pt"><td style="width:294pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:44pt"><p class="s44" style="padding-left: 5pt;text-indent: 0pt;line-height: 8pt;text-align: left;">    2014    </p></td><td style="width:44pt"><p class="s44" style="padding-left: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">    2013    </p></td><td style="width:41pt"><p class="s44" style="padding-left: 4pt;text-indent: 0pt;line-height: 8pt;text-align: left;">    2012    </p></td></tr><tr style="height:14pt"><td style="width:294pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Provision (benefit) at statutory rate ........ .......... ......... .. </p></td><td style="width:44pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">$ 1,406</p></td><td style="width:44pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">$(4,163)</p></td><td style="width:41pt"><p class="s43" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">$(6,360)</p></td></tr><tr style="height:12pt"><td style="width:294pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Permanent items ......... ......... ......... .......... ......... .. </p></td><td style="width:44pt"><p class="s43" style="padding-left: 21pt;text-indent: 0pt;line-height: 11pt;text-align: left;">885</p></td><td style="width:44pt"><p class="s43" style="padding-left: 20pt;text-indent: 0pt;line-height: 11pt;text-align: left;">311</p></td><td style="width:41pt"><p class="s43" style="padding-left: 20pt;text-indent: 0pt;line-height: 11pt;text-align: left;">236</p></td></tr><tr style="height:12pt"><td style="width:294pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">State taxes ...... ......... ......... ......... .......... ......... .. </p></td><td style="width:44pt"><p class="s43" style="padding-left: 9pt;text-indent: 0pt;line-height: 11pt;text-align: left;">(1,228)</p></td><td style="width:44pt"><p class="s43" style="padding-left: 20pt;text-indent: 0pt;line-height: 11pt;text-align: left;">210</p></td><td style="width:41pt"><p class="s43" style="padding-left: 20pt;text-indent: 0pt;line-height: 11pt;text-align: left;">159</p></td></tr><tr style="height:14pt"><td style="width:294pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Changes in valuation allowance . . . ......... .......... ......... .. </p></td><td style="width:44pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  (9,729<span class="s43">)</span></p></td><td style="width:44pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">    4,744</p></td><td style="width:41pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 11pt;text-align: left;">    6,991</p></td></tr><tr style="height:15pt"><td style="width:294pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Total (benefit) provision . ......... ......... .......... ......... .. </p></td><td style="width:44pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">$(8,666<span class="s43">)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="41" height="1" alt="image" src="NYSE_EVDY_2014/Image_107.png"/></span></p></td><td style="width:44pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">$ 1,102</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 4pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="41" height="1" alt="image" src="NYSE_EVDY_2014/Image_108.png"/></span></p></td><td style="width:41pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;text-align: left;">$ 1,026</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 4pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="41" height="1" alt="image" src="NYSE_EVDY_2014/Image_109.png"/></span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 51pt;text-indent: 0pt;text-align: left;">As of December 31, 2014, 2013 and 2012, there were no unrecognized tax benefits.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company is subject to taxation in the U.S. and various state, local and foreign jurisdictions. In March 2014, an audit of the Company’s U.S. Federal tax return for the year ended December 31, 2011 commenced. As of December 31, 2014, none of the Company’s other tax returns have been examined by any income taxing authority. The Company files income tax returns in the U.S. and various state and foreign jurisdictions. The Company is not subject to U.S. federal, state or non-U.S. income tax examinations by tax authorities for the years prior to 2010. However, to the extent U.S. federal and state NOL carryforwards are utilized, the use of NOLs could be subject to examination by the tax authorities. The Company believes that it has appropriate support for the income tax positions taken and to be taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on assessment of many factors, including past experience and interpretations of tax law. The Company regularly assesses the adequacy of its income tax contingencies in accordance with ASC 740. As a result, the Company may adjust its income tax contingency liabilities for the impact of new facts and developments, such as changes in interpretations of relevant tax law and assessments from taxing authorities.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li style="padding-left: 47pt;text-indent: -16pt;text-align: left;"><p style="display: inline;">Commitments and Contingencies</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Operating Leases</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company is a party to certain non-cancellable operating leases for office space. The future minimum lease commitments for these leases, which expire on various dates through 2023, net of related aggregate sublease rentals, are as follows as of December 31, 2014:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:68.6786pt" cellspacing="0"><tr style="height:11pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 10pt;text-align: center;">2015 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:43pt"><p class="s43" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$ 4,042</p></td></tr><tr style="height:12pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">2016 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:43pt"><p class="s43" style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: left;">3,782</p></td></tr><tr style="height:12pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">2017 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:43pt"><p class="s43" style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: left;">3,532</p></td></tr><tr style="height:12pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">2018 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:43pt"><p class="s43" style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: left;">3,328</p></td></tr><tr style="height:12pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">2019 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:43pt"><p class="s43" style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: left;">3,419</p></td></tr><tr style="height:12pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Thereafter ...... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:43pt"><p class="s43" style="padding-left: 10pt;text-indent: 0pt;line-height: 11pt;text-align: left;">14,915</p></td></tr><tr style="height:14pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Sublease rentals .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:43pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;line-height: 11pt;text-align: left;">  (2,068<span class="s43">)</span></p></td></tr><tr style="height:15pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;text-align: center;">Net lease commitments. . . ......... ......... ......... ......... ......... .... </p></td><td style="width:43pt"><p class="s51" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">$30,950</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="43" height="1" alt="image" src="NYSE_EVDY_2014/Image_110.png"/></span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 19pt;text-align: left;">Rent expense was approximately $3,625, $3,377 and $3,009, net of sublease income of $427, $102 and $78, for the years ended December 31, 2014, 2013 and 2012, respectively.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Minimum Guaranteed Payments</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company has entered into certain agreements with website partners, pursuant to which the Company is required to pay minimum guaranteed payments over the term of the agreement, regardless of revenue generated by the Company. Future minimum guaranteed payments as of December 31, 2014, are as follows:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:68.6795pt" cellspacing="0"><tr style="height:11pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 10pt;text-align: center;">2015 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: center;">$19,095</p></td></tr><tr style="height:12pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">2016 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s43" style="padding-left: 7pt;text-indent: 0pt;line-height: 11pt;text-align: center;">13,934</p></td></tr><tr style="height:12pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">2017 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s43" style="padding-left: 7pt;text-indent: 0pt;line-height: 11pt;text-align: center;">12,257</p></td></tr><tr style="height:12pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">2018 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s43" style="padding-left: 7pt;text-indent: 0pt;line-height: 11pt;text-align: center;">12,135</p></td></tr><tr style="height:12pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">2019 . . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s43" style="padding-left: 7pt;text-indent: 0pt;line-height: 11pt;text-align: center;">12,322</p></td></tr><tr style="height:14pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Thereafter ...... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: center;">  22,889</p></td></tr><tr style="height:15pt"><td style="width:340pt"><p class="s43" style="padding-left: 39pt;padding-right: 42pt;text-indent: 0pt;text-align: center;">Total . . ......... .......... ......... ......... ......... ......... ......... .... </p></td><td style="width:40pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;text-align: center;">$92,632</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="43" height="1" alt="image" src="NYSE_EVDY_2014/Image_111.png"/></span></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Certain minimum guaranteed payments with respect to these agreements are subject to reductions if specified performance metrics are not maintained by the other party.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Contingency</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company is subject to certain claims that have arisen in the ordinary conduct of business. Based on the advice of counsel and an assessment of the nature and status of any potential claim, and taking into account any accruals the Company may have established for them, the Company currently believes that any liabilities ultimately resulting from such claims will not, individually or in the aggregate, have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li style="padding-left: 47pt;text-indent: -16pt;text-align: left;"><p style="display: inline;">Benefit Plan</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company sponsors a defined contribution 401(k) plan covering all eligible employees, which is subject to the provisions of the Employee Retirement Income Security Act of 1974. Participants of the plan may make annual contributions up to the applicable IRS limit. The Company initiated a matching contribution to the plan commencing in 2011, for which the Company expensed $487, $409 and $339 during the years ended December 31, 2014, 2013 and 2012, respectively.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li style="padding-left: 47pt;text-indent: -16pt;text-align: left;"><p style="display: inline;">Related-Party Transactions</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">During the years ended December 31, 2013 and 2012, a consulting firm wholly-owned by one of the Company’s directors provided sales consulting services to the Company totaling $142 and $554, respectively. During the year ended December 31, 2012, the Company engaged a financial advisory firm to assist with certain financing initiatives for fees totaling $630. One of the Company’s directors was the executive chairman of the financial advisory firm until December 31, 2012.</p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li style="padding-top: 3pt;padding-left: 47pt;text-indent: -16pt;text-align: left;"><p style="display: inline;">Supplemental Disclosure of Cash Flow Information</p></li></ol><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Supplemental information related to the consolidated statements of cash flows is summarized below:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s40" style="padding-left: 379pt;text-indent: 0pt;text-align: left;">   Year Ended December 31,   </p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:28.8234pt" cellspacing="0"><tr style="height:24pt"><td style="width:346pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Supplemental disclosure of cash flow information:</p></td><td style="width:38pt"><p class="s44" style="text-indent: 0pt;line-height: 8pt;text-align: center;">   2014   </p></td><td style="width:39pt"><p class="s44" style="padding-left: 6pt;text-indent: 0pt;line-height: 8pt;text-align: left;">   2013   </p></td><td style="width:36pt"><p class="s44" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: center;">   2012   </p></td></tr><tr style="height:14pt"><td style="width:346pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Interest paid . ......... ......... ......... .......... ......... ......... ........ </p></td><td style="width:38pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: center;">$3,734</p></td><td style="width:39pt"><p class="s51" style="padding-left: 6pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$6,173</p></td><td style="width:36pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: center;">$3,464</p></td></tr><tr style="height:15pt"><td style="width:346pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Income taxes paid .... ......... ......... .......... ......... ......... ........ </p></td><td style="width:38pt"><p class="s51" style="text-indent: 0pt;text-align: center;">     341</p></td><td style="width:39pt"><p class="s51" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">       73</p></td><td style="width:36pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;text-align: center;">       55</p></td></tr><tr style="height:27pt"><td style="width:346pt"><p class="s43" style="padding-left: 2pt;padding-right: 4pt;text-indent: 0pt;text-align: left;">Supplemental disclosure of non-cash investing and financing  activities: Issuance of common stock for acquired business. . ......... ......... ........ </p></td><td style="width:38pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s51" style="text-indent: 0pt;text-align: center;">$ 919</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s51" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">$2,921</p></td><td style="width:36pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s51" style="padding-left: 3pt;text-indent: 0pt;text-align: center;">$ 700</p></td></tr><tr style="height:15pt"><td style="width:346pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Warrants issued in connection with credit facilities ........ ......... ........ </p></td><td style="width:38pt"><p class="s51" style="text-indent: 0pt;text-align: center;">$ —</p></td><td style="width:39pt"><p class="s51" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">$ 149</p></td><td style="width:36pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;text-align: center;">$3,452</p></td></tr><tr style="height:15pt"><td style="width:346pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Warrants issued in connection with website partner agreement ..... ........ </p></td><td style="width:38pt"><p class="s51" style="text-indent: 0pt;text-align: center;">$1,131</p></td><td style="width:39pt"><p class="s51" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">$ —</p></td><td style="width:36pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;text-align: center;">$ —</p></td></tr><tr style="height:15pt"><td style="width:346pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Capital lease obligations incurred ....... .......... ......... ......... ........ </p></td><td style="width:38pt"><p class="s51" style="text-indent: 0pt;text-align: center;">$ 466</p></td><td style="width:39pt"><p class="s51" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">$ 879</p></td><td style="width:36pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;text-align: center;">$ 869</p></td></tr><tr style="height:22pt"><td style="width:346pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Amounts due from stock option exercises ........ ......... ......... ........ </p></td><td style="width:38pt"><p class="s51" style="text-indent: 0pt;text-align: center;">$ 43</p></td><td style="width:39pt"><p class="s51" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">$ 688</p></td><td style="width:36pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;text-align: center;">$ —</p></td></tr><tr style="height:20pt"><td style="width:346pt"><p class="s43" style="padding-top: 7pt;padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">17. Subsequent Events</p></td><td style="width:38pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:36pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 19pt;text-align: left;">The Company has completed an evaluation of all subsequent events through the issuance date of these financial statements and concluded that no subsequent events occurred that required recognition to the financial statements or disclosures in the notes to the consolidated financial statements.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><ol id="l14"><li style="padding-top: 3pt;padding-left: 47pt;text-indent: -16pt;text-align: left;"><p style="display: inline;">Quarterly Financial Data (unaudited)</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The following tables summarize the quarterly financial data for the years ended December 31, 2014 and 2013:</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s40" style="padding-left: 264pt;text-indent: 0pt;text-align: left;">                                                   2014                                                   </p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:28.8244pt" cellspacing="0"><tr style="height:32pt"><td style="width:232pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-top: 7pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Revenues</p></td><td style="width:55pt"><p class="s54" style="padding-right: 2pt;text-indent: 0pt;line-height: 7pt;text-align: center;">First</p><p class="s44" style="padding-right: 2pt;text-indent: 0pt;line-height: 9pt;text-align: center;">     quarter     </p></td><td style="width:59pt"><p class="s54" style="padding-right: 3pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Second</p><p class="s44" style="padding-right: 3pt;text-indent: 0pt;line-height: 9pt;text-align: center;">      quarter      </p></td><td style="width:59pt"><p class="s54" style="padding-right: 3pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Third</p><p class="s44" style="padding-right: 3pt;text-indent: 0pt;line-height: 9pt;text-align: center;">      quarter      </p></td><td style="width:58pt"><p class="s54" style="padding-right: 3pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Fourth</p><p class="s44" style="padding-right: 3pt;text-indent: 0pt;line-height: 9pt;text-align: center;">      quarter      </p></td></tr><tr style="height:12pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Advertising and sponsorship revenues..... ........ </p></td><td style="width:55pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ 32,692</p></td><td style="width:59pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ 36,882</p></td><td style="width:59pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ 37,910</p></td><td style="width:58pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">$ 58,981</p></td></tr><tr style="height:14pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Premium services revenues....... ......... ........ </p></td><td style="width:55pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">         4,813</p></td><td style="width:59pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">           4,565</p></td><td style="width:59pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">           4,414</p></td><td style="width:58pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">           4,068</p></td></tr><tr style="height:15pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Total revenues .......... ......... ......... ........ </p></td><td style="width:55pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">       37,505</p></td><td style="width:59pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">         41,447</p></td><td style="width:59pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">         42,324</p></td><td style="width:58pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">         63,049</p></td></tr><tr style="height:14pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Operating expenses:</p></td><td style="width:55pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:59pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:59pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:58pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Cost of revenues ........ ......... ......... ........ </p></td><td style="width:55pt"><p class="s43" style="padding-left: 20pt;text-indent: 0pt;line-height: 11pt;text-align: left;">11,421</p></td><td style="width:59pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">10,961</p></td><td style="width:59pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">11,006</p></td><td style="width:58pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">15,908</p></td></tr><tr style="height:12pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Sales and marketing..... ......... ......... ........ </p></td><td style="width:55pt"><p class="s43" style="padding-left: 20pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10,220</p></td><td style="width:59pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">12,216</p></td><td style="width:59pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">12,213</p></td><td style="width:58pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">13,956</p></td></tr><tr style="height:12pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Product development.... ......... ......... ........ </p></td><td style="width:55pt"><p class="s43" style="padding-left: 20pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10,762</p></td><td style="width:59pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">10,805</p></td><td style="width:59pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">10,886</p></td><td style="width:58pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">12,088</p></td></tr><tr style="height:14pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">General and administrative....... ......... ........ </p></td><td style="width:55pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">         6,595</p></td><td style="width:59pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">           7,126</p></td><td style="width:59pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">           7,504</p></td><td style="width:58pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">           8,816</p></td></tr><tr style="height:15pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Total operating expenses ......... ......... ........ </p></td><td style="width:55pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">       38,998</p></td><td style="width:59pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">         41,108</p></td><td style="width:59pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">         41,609</p></td><td style="width:58pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">         50,768</p></td></tr><tr style="height:14pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Income (loss) from operations . . . ......... ........ </p></td><td style="width:55pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">(1,493)</p></td><td style="width:59pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">339</p></td><td style="width:59pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">715</p></td><td style="width:58pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">12,281</p></td></tr><tr style="height:12pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Interest expense, net .... ......... ......... ........ </p></td><td style="width:55pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(1,863)</p></td><td style="width:59pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(585)</p></td><td style="width:59pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(500)</p></td><td style="width:58pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(763)</p></td></tr><tr style="height:14pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Other expense .......... ......... ......... ........ </p></td><td style="width:55pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">       (4,114<span class="s43">)</span></p></td><td style="width:59pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">                —</p></td><td style="width:59pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">                —</p></td><td style="width:58pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">                —</p></td></tr><tr style="height:24pt"><td style="width:232pt"><p class="s43" style="padding-top: 2pt;padding-left: 12pt;text-indent: -10pt;line-height: 87%;text-align: left;">Income (loss) from continuing operations before provision for income taxes ..... ......... ........ </p></td><td style="width:55pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">(7,470)</p></td><td style="width:59pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">(246)</p></td><td style="width:59pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">215</p></td><td style="width:58pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">11,518</p></td></tr><tr style="height:14pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Benefit (provision) for income taxes ...... ........ </p></td><td style="width:55pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">          (289<span class="s43">)</span></p></td><td style="width:59pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">            (349<span class="s43">)</span></p></td><td style="width:59pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">            (365<span class="s43">)</span></p></td><td style="width:58pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">           9,669</p></td></tr><tr style="height:14pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Net income (loss) ....... ......... ......... ........ </p></td><td style="width:55pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">(7,759)</p></td><td style="width:59pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">(595)</p></td><td style="width:59pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: right;">(150)</p></td><td style="width:58pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">21,187</p></td></tr><tr style="height:14pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Series G preferred stock deemed dividend ........ </p></td><td style="width:55pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">              —</p></td><td style="width:59pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">         (8,079<span class="s43">)</span></p></td><td style="width:59pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">                —</p></td><td style="width:58pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">                —</p></td></tr><tr style="height:25pt"><td style="width:232pt"><p class="s43" style="padding-top: 2pt;padding-left: 12pt;text-indent: -10pt;line-height: 87%;text-align: left;">Net income (loss) attributable to common stockholders .......... ......... ......... ........ </p></td><td style="width:55pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s51" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">$ (7,759<span class="s43">)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 3pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="60" height="1" alt="image" src="NYSE_EVDY_2014/Image_112.png"/></span></p></td><td style="width:59pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s51" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">$ (8,674<span class="s43">)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 2pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="67" height="1" alt="image" src="NYSE_EVDY_2014/Image_113.png"/></span></p></td><td style="width:59pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s51" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">$ (150<span class="s43">)</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 2pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="67" height="1" alt="image" src="NYSE_EVDY_2014/Image_114.png"/></span></p></td><td style="width:58pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s51" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">$ 21,187</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 2pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="67" height="1" alt="image" src="NYSE_EVDY_2014/Image_115.png"/></span></p></td></tr><tr style="height:25pt"><td style="width:232pt"><p class="s43" style="padding-top: 3pt;padding-left: 12pt;text-indent: -10pt;line-height: 87%;text-align: left;">Net income (loss) attributable to common stockholders per common share:</p></td><td style="width:55pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:59pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:59pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:58pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:14pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Basic . ......... .......... ......... ......... ........ </p></td><td style="width:55pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$ (1.44<span class="s43">)</span></p></td><td style="width:59pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$ (0.29<span class="s43">)</span></p></td><td style="width:59pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$ (0.00<span class="s43">)</span></p></td><td style="width:58pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$ 0.68</p></td></tr><tr style="height:15pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Diluted........ .......... ......... ......... ........ </p></td><td style="width:55pt"><p class="s51" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">$ (1.44<span class="s43">)</span></p></td><td style="width:59pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">$ (0.29<span class="s43">)</span></p></td><td style="width:59pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">$ (0.00<span class="s43">)</span></p></td><td style="width:58pt"><p class="s51" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">$ 0.64</p></td></tr><tr style="height:14pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Weighted-average common shares outstanding:</p></td><td style="width:55pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:59pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:59pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:58pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Basic . ......... .......... ......... ......... ........ </p></td><td style="width:55pt"><p class="s43" style="padding-left: 8pt;text-indent: 0pt;line-height: 11pt;text-align: left;">5,403,846</p></td><td style="width:59pt"><p class="s43" style="padding-left: 7pt;text-indent: 0pt;line-height: 11pt;text-align: left;">29,802,970</p></td><td style="width:59pt"><p class="s43" style="padding-left: 7pt;text-indent: 0pt;line-height: 11pt;text-align: left;">30,404,529</p></td><td style="width:58pt"><p class="s43" style="padding-left: 7pt;text-indent: 0pt;line-height: 11pt;text-align: left;">31,076,588</p></td></tr><tr style="height:11pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Diluted........ .......... ......... ......... ........ </p></td><td style="width:55pt"><p class="s43" style="padding-left: 8pt;text-indent: 0pt;line-height: 10pt;text-align: left;">5,403,846</p></td><td style="width:59pt"><p class="s43" style="padding-left: 7pt;text-indent: 0pt;line-height: 10pt;text-align: left;">29,802,970</p></td><td style="width:59pt"><p class="s43" style="padding-left: 7pt;text-indent: 0pt;line-height: 10pt;text-align: left;">30,404,529</p></td><td style="width:58pt"><p class="s43" style="padding-left: 7pt;text-indent: 0pt;line-height: 10pt;text-align: left;">32,977,544</p></td></tr></table><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s40" style="padding-top: 3pt;padding-left: 265pt;text-indent: 0pt;text-align: left;">                                                   2013                                                   </p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:28.8214pt" cellspacing="0"><tr style="height:32pt"><td style="width:237pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-top: 7pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Revenues</p></td><td style="width:56pt"><p class="s54" style="padding-right: 11pt;text-indent: 0pt;line-height: 7pt;text-align: center;">First</p><p class="s44" style="padding-right: 11pt;text-indent: 0pt;line-height: 9pt;text-align: center;">     quarter     </p></td><td style="width:57pt"><p class="s54" style="padding-right: 11pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Second</p><p class="s44" style="padding-right: 11pt;text-indent: 0pt;line-height: 9pt;text-align: center;">     quarter     </p></td><td style="width:57pt"><p class="s54" style="padding-right: 11pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Third</p><p class="s44" style="padding-right: 11pt;text-indent: 0pt;line-height: 9pt;text-align: center;">     quarter     </p></td><td style="width:56pt"><p class="s54" style="padding-right: 6pt;text-indent: 0pt;line-height: 7pt;text-align: center;">Fourth</p><p class="s44" style="padding-right: 6pt;text-indent: 0pt;line-height: 9pt;text-align: center;">      quarter      </p></td></tr><tr style="height:12pt"><td style="width:237pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Advertising and sponsorship revenues ..... ....... </p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: left;">$ 25,380</p></td><td style="width:57pt"><p class="s43" style="padding-right: 11pt;text-indent: 0pt;line-height: 11pt;text-align: right;">$ 31,819</p></td><td style="width:57pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: left;">$ 29,662</p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: left;">$ 48,032</p></td></tr><tr style="height:14pt"><td style="width:237pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Premium services revenues ....... ......... ....... </p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">         5,124</p></td><td style="width:57pt"><p class="s51" style="padding-right: 11pt;text-indent: 0pt;line-height: 11pt;text-align: right;">         5,379</p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">         5,392</p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">           5,062</p></td></tr><tr style="height:15pt"><td style="width:237pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Total revenues. . ......... ......... ......... ....... </p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;text-align: left;">       30,504</p></td><td style="width:57pt"><p class="s51" style="padding-right: 11pt;text-indent: 0pt;text-align: right;">       37,198</p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;text-align: left;">       35,054</p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;text-align: left;">         53,094</p></td></tr><tr style="height:14pt"><td style="width:237pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Operating expenses:</p></td><td style="width:56pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:56pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:237pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Cost of revenues......... ......... ......... ....... </p></td><td style="width:56pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">9,835</p></td><td style="width:57pt"><p class="s43" style="padding-right: 11pt;text-indent: 0pt;line-height: 11pt;text-align: right;">10,826</p></td><td style="width:57pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">9,620</p></td><td style="width:56pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">13,057</p></td></tr><tr style="height:12pt"><td style="width:237pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Sales and marketing ..... ......... ......... ....... </p></td><td style="width:56pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">9,061</p></td><td style="width:57pt"><p class="s43" style="padding-right: 11pt;text-indent: 0pt;line-height: 11pt;text-align: right;">11,860</p></td><td style="width:57pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10,814</p></td><td style="width:56pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">12,650</p></td></tr><tr style="height:12pt"><td style="width:237pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Product development .... ......... ......... ....... </p></td><td style="width:56pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10,160</p></td><td style="width:57pt"><p class="s43" style="padding-right: 11pt;text-indent: 0pt;line-height: 11pt;text-align: right;">10,700</p></td><td style="width:57pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10,656</p></td><td style="width:56pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">12,243</p></td></tr><tr style="height:14pt"><td style="width:237pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">General and administrative ....... ......... ....... </p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">         6,539</p></td><td style="width:57pt"><p class="s51" style="padding-right: 11pt;text-indent: 0pt;line-height: 11pt;text-align: right;">         6,191</p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">         6,462</p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">           8,270</p></td></tr><tr style="height:14pt"><td style="width:237pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Total operating expenses ......... ......... ....... </p></td><td style="width:56pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;text-align: left;">35,595</p></td><td style="width:57pt"><p class="s43" style="padding-right: 11pt;text-indent: 0pt;text-align: right;">39,577</p></td><td style="width:57pt"><p class="s43" style="padding-left: 17pt;text-indent: 0pt;text-align: left;">37,552</p></td><td style="width:56pt"><p class="s43" style="padding-left: 22pt;text-indent: 0pt;text-align: left;">46,220</p></td></tr><tr style="height:12pt"><td style="width:237pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">(Loss) income from operations . . . ......... ....... </p></td><td style="width:56pt"><p class="s43" style="padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(5,091)</p></td><td style="width:57pt"><p class="s43" style="padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(2,379)</p></td><td style="width:57pt"><p class="s43" style="padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(2,498)</p></td><td style="width:56pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;line-height: 11pt;text-align: right;">6,874</p></td></tr><tr style="height:12pt"><td style="width:237pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Interest expense, net..... ......... ......... ....... </p></td><td style="width:56pt"><p class="s43" style="padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(2,129)</p></td><td style="width:57pt"><p class="s43" style="padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(2,015)</p></td><td style="width:57pt"><p class="s43" style="padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(2,125)</p></td><td style="width:56pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: right;">(2,173)</p></td></tr><tr style="height:14pt"><td style="width:237pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Other expense . . ......... ......... ......... ....... </p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">              —</p></td><td style="width:57pt"><p class="s51" style="padding-right: 11pt;text-indent: 0pt;line-height: 11pt;text-align: right;">              —</p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">              —</p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">            (359<span class="s43">)</span></p></td></tr><tr style="height:24pt"><td style="width:237pt"><p class="s43" style="padding-top: 2pt;padding-left: 12pt;text-indent: -10pt;line-height: 86%;text-align: left;">(Loss) income from continuing operations before provision for income taxes ..... ......... ....... </p></td><td style="width:56pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">(7,220)</p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">(4,394)</p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">(4,623)</p></td><td style="width:56pt"><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s43" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">4,342</p></td></tr><tr style="height:14pt"><td style="width:237pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Provision for income taxes........ ......... ....... </p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">          (264<span class="s43">)</span></p></td><td style="width:57pt"><p class="s51" style="padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: right;">          (247<span class="s43">)</span></p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">          (311<span class="s43">)</span></p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">            (280<span class="s43">)</span></p></td></tr><tr style="height:14pt"><td style="width:237pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">(Loss) income from continuing operations . ....... </p></td><td style="width:56pt"><p class="s43" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">(7,484)</p></td><td style="width:57pt"><p class="s43" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">(4,641)</p></td><td style="width:57pt"><p class="s43" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">(4,934)</p></td><td style="width:56pt"><p class="s43" style="padding-right: 6pt;text-indent: 0pt;text-align: right;">4,062</p></td></tr><tr style="height:14pt"><td style="width:237pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Loss from discontinued operations, net of tax .... </p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">       (1,745<span class="s43">)</span></p></td><td style="width:57pt"><p class="s51" style="padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: right;">       (1,596<span class="s43">)</span></p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">          (397<span class="s43">)</span></p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;line-height: 11pt;text-align: left;">         (1,501<span class="s43">)</span></p></td></tr><tr style="height:15pt"><td style="width:237pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Net income (loss)........ ......... ......... ....... </p></td><td style="width:56pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s51" style="text-indent: 0pt;text-align: left;">$ (9,229<span class="s43">)</span></p></td><td style="width:57pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s51" style="padding-right: 8pt;text-indent: 0pt;text-align: right;">$ (6,237<span class="s43">)</span></p></td><td style="width:57pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s51" style="text-indent: 0pt;text-align: left;">$ (5,331<span class="s43">)</span></p></td><td style="width:56pt;border-bottom-style:solid;border-bottom-width:1pt"><p class="s51" style="text-indent: 0pt;text-align: left;">$ 2,561</p></td></tr><tr style="height:37pt"><td style="width:237pt"><p class="s43" style="padding-top: 3pt;padding-left: 12pt;text-indent: -10pt;line-height: 87%;text-align: left;">Basic net income (loss) attributable to common stockholders per common share:</p><p class="s43" style="padding-left: 22pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Net income (loss) attributable to common</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt;border-top-style:solid;border-top-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt;border-top-style:solid;border-top-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:237pt"><p class="s43" style="padding-right: 11pt;text-indent: 0pt;line-height: 9pt;text-align: right;">stockholders from continuing operations . . .</p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;line-height: 9pt;text-align: left;">$ (1.52)</p></td><td style="width:57pt"><p class="s43" style="padding-right: 8pt;text-indent: 0pt;line-height: 9pt;text-align: right;">$ (0.92)</p></td><td style="width:57pt"><p class="s43" style="text-indent: 0pt;line-height: 9pt;text-align: left;">$ (0.95)</p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;line-height: 9pt;text-align: left;">$ 0.78</p></td></tr><tr style="height:22pt"><td style="width:237pt"><p class="s43" style="padding-top: 1pt;padding-left: 32pt;padding-right: 13pt;text-indent: -10pt;line-height: 10pt;text-align: left;">Net loss attributable to  common stockholders from discontinued operations,</p></td><td style="width:56pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:56pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:237pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 9pt;text-align: right;">net of tax ......... ......... ......... ....... </p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;line-height: 9pt;text-align: left;">         (0.35<span class="s43">)</span></p></td><td style="width:57pt"><p class="s51" style="padding-right: 8pt;text-indent: 0pt;line-height: 9pt;text-align: right;">         (0.32<span class="s43">)</span></p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 9pt;text-align: left;">         (0.08<span class="s43">)</span></p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;line-height: 9pt;text-align: left;">           (0.29<span class="s43">)</span></p></td></tr><tr style="height:15pt"><td style="width:237pt"><p class="s43" style="padding-top: 3pt;padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Net income (loss) attributable to common</p></td><td style="width:56pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:56pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:10pt"><td style="width:237pt"><p class="s43" style="padding-right: 9pt;text-indent: 0pt;line-height: 9pt;text-align: right;">stockholders . . ......... ......... ......... ....... </p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;line-height: 9pt;text-align: left;">$ (1.87<span class="s43">)</span></p></td><td style="width:57pt"><p class="s51" style="padding-right: 8pt;text-indent: 0pt;line-height: 9pt;text-align: right;">$ (1.24<span class="s43">)</span></p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 9pt;text-align: left;">$ (1.02<span class="s43">)</span></p></td><td style="width:56pt"><p class="s51" style="text-indent: 0pt;line-height: 9pt;text-align: left;">$ 0.49</p></td></tr></table><p style="padding-top: 4pt;padding-left: 41pt;text-indent: -10pt;line-height: 86%;text-align: left;">Diluted net income (loss) attributable to common stockholders per common share:</p><p style="padding-left: 51pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Net income (loss) attributable to common</p><p style="padding-left: 61pt;text-indent: 0pt;line-height: 11pt;text-align: left;">stockholders from continuing operations . . . $ (1.52) $ (0.92) $ (0.95) $ 0.16</p><p style="padding-top: 1pt;padding-left: 61pt;text-indent: -10pt;line-height: 86%;text-align: left;">Net loss attributable to common stockholders from discontinued operations,</p><table style="border-collapse:collapse;margin-left:28.8194pt" cellspacing="0"><tr style="height:10pt"><td style="width:232pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 9pt;text-align: right;">net of tax ......... ......... ......... ....... </p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 9pt;text-align: center;">         (0.35<span class="s43">)</span></p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 9pt;text-align: center;">         (0.32<span class="s43">)</span></p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 9pt;text-align: center;">         (0.08<span class="s43">)</span></p></td><td style="width:60pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 9pt;text-align: left;">           (0.29<span class="s43">)</span></p></td></tr><tr style="height:15pt"><td style="width:232pt"><p class="s43" style="padding-top: 3pt;padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Net income (loss) attributable to common</p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:13pt"><td style="width:232pt"><p class="s43" style="padding-right: 4pt;text-indent: 0pt;line-height: 10pt;text-align: right;">stockholders . . ......... ......... ......... ....... </p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 10pt;text-align: center;">$ (1.87<span class="s43">)</span></p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 10pt;text-align: center;">$ (1.24<span class="s43">)</span></p></td><td style="width:57pt"><p class="s51" style="text-indent: 0pt;line-height: 10pt;text-align: center;">$ (1.02<span class="s43">)</span></p></td><td style="width:60pt"><p class="s51" style="padding-left: 4pt;text-indent: 0pt;line-height: 10pt;text-align: left;">$ 0.10</p></td></tr><tr style="height:14pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">Weighted-average common shares outstanding:</p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:57pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:60pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Basic . . ......... ......... ......... ......... ....... </p></td><td style="width:57pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: center;">4,925,306</p></td><td style="width:57pt"><p class="s43" style="padding-left: 1pt;text-indent: 0pt;line-height: 11pt;text-align: center;">5,030,265</p></td><td style="width:57pt"><p class="s43" style="padding-left: 1pt;text-indent: 0pt;line-height: 11pt;text-align: center;">5,213,706</p></td><td style="width:60pt"><p class="s43" style="padding-left: 14pt;text-indent: 0pt;line-height: 11pt;text-align: left;">5,239,463</p></td></tr><tr style="height:11pt"><td style="width:232pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Diluted ......... ......... ......... ......... ....... </p></td><td style="width:57pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 10pt;text-align: center;">4,925,306</p></td><td style="width:57pt"><p class="s43" style="padding-left: 1pt;text-indent: 0pt;line-height: 10pt;text-align: center;">5,030,265</p></td><td style="width:57pt"><p class="s43" style="padding-left: 1pt;text-indent: 0pt;line-height: 10pt;text-align: center;">5,213,706</p></td><td style="width:60pt"><p class="s43" style="padding-left: 9pt;text-indent: 0pt;line-height: 10pt;text-align: left;">25,398,572</p></td></tr></table><p style="padding-top: 2pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">None.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Item 9A. Controls and Procedures.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Evaluation of Disclosure Controls and Procedures</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Our management, with the participation of our chief executive officer and our chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2014. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2014, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Management’s Report on Internal Control over Financial Reporting</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">This annual report does not include a report of management’s assessment regarding internal control over financial reporting or an attestation report of our registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s45" style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Changes in Internal Control over Financial Reporting</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the fourth quarter of 2014 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Item 9B. Other Information.</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">None.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The information required by Part III is omitted from this report because we will file a definitive proxy statement within 120 days after the end of our 2014 fiscal year pursuant to Regulation 14A for our 2015 Annual Meeting of Stockholders, or the 2015 Proxy Statement, and the information to be included in the 2015 Proxy Statement is incorporated herein by reference.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Item 10. Directors, Executive Officers and Corporate Governance.</p><ol id="l15"><li style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;"><p style="display: inline;">The information required by this Item concerning our executive officers and our directors and nominees for director, including information with respect to our audit committee and audit committee financial expert, may be found under the section entitled “Proposal No. 1—Election of Directors” appearing in the 2015 Proxy Statement. Such information is incorporated herein by reference.</p></li><li style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;"><p style="display: inline;">The information required by this Item concerning our code of ethics may be found under the section entitled “Proposal No. 1—Election of Directors—Code of Ethics” appearing in the 2015 Proxy Statement. Such information is incorporated herein by reference.</p></li><li style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: justify;"><p style="display: inline;">The information required by this Item concerning compliance with Section 16(a) of the Securities Exchange Act of 1934 may be found in the section entitled “Section 16(a) Beneficial Ownership Reporting Compliance” appearing in the 2015 Proxy Statement. Such information is incorporated herein by reference.</p></li></ol></li></ol><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Item 11. Executive Compensation.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">The information required by this Item may be found under the sections entitled “Proposal No. 1—Election of Directors—Director Compensation” and “Compensation of Executive Officers” appearing in the 2015 Proxy Statement. Such information is incorporated herein by reference.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 72pt;text-indent: -41pt;text-align: left;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</p><ol id="l16"><li style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;"><p style="display: inline;">The information required by this Item with respect to security ownership of certain beneficial owners and management may be found under the section entitled “Security Ownership of Certain Beneficial Owners and Management” appearing in the 2015 Proxy Statement. Such information is incorporated herein by reference.</p></li><li style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: left;"><p style="display: inline;">The information required by this Item with respect to securities authorized for issuance under our equity compensation plans may be found under the sections entitled “Equity Compensation Plan Information” appearing in the 2015 Proxy Statement. Such information is incorporated herein by reference.</p></li></ol><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Item 13. Certain Relationships and Related Transactions, and Director Independence.</p><ol id="l17"><li style="padding-top: 8pt;padding-left: 31pt;text-indent: 19pt;text-align: left;"><p style="display: inline;">The information required by this Item concerning related party transactions may be found under the section entitled “Certain Relationships and Related Party Transactions” appearing in the 2015 Proxy Statement. Such information is incorporated herein by reference.</p></li><li style="padding-top: 7pt;padding-left: 31pt;text-indent: 19pt;text-align: justify;"><p style="display: inline;">The information required by this Item concerning director independence may be found under the section entitled “Proposal No. 1—Election of Directors” appearing in the 2015 Proxy Statement. Such information is incorporated herein by reference.</p></li></ol><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Item 14. Principal Accounting Fees and Services.</p><p style="padding-top: 8pt;padding-left: 51pt;text-indent: 0pt;text-align: left;">The information required by this Item may be found under the section entitled “Proposal</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">No. 2—Ratification of Appointment of Independent Registered Public Accounting Firm” appearing in the 2015 Proxy Statement. Such information is incorporated herein by reference.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">Item 15. Exhibits, Financial Statement Schedules.</p><ol id="l18"><li style="padding-top: 8pt;padding-left: 47pt;text-indent: -16pt;text-align: left;"><p style="display: inline;">The following documents are filed as part of this report:</p><ol id="l19"><li style="padding-top: 8pt;padding-left: 68pt;text-indent: -17pt;text-align: left;"><p style="display: inline;">Consolidated Financial Statements and Report of Independent Registered Public Accounting Firm</p></li><li style="padding-top: 8pt;padding-left: 68pt;text-indent: -17pt;text-align: left;"><p style="display: inline;">Consolidated Financial Statement Schedules</p><p style="padding-top: 8pt;padding-left: 88pt;text-indent: 0pt;text-align: left;">Financial Statement Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.</p></li><li style="padding-top: 7pt;padding-left: 68pt;text-indent: -17pt;text-align: left;"><p style="display: inline;">Exhibits are incorporated herein by reference or are filed with this report as indicated below (numbered in accordance with Item 601 of Regulation S-K).</p></li></ol></li><li style="padding-top: 8pt;padding-left: 48pt;text-indent: -17pt;text-align: left;"><p style="display: inline;">Exhibits</p></li></ol><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s39" style="padding-top: 5pt;padding-left: 42pt;text-indent: 0pt;text-align: left;">Exhibit</p><p class="s40" style="padding-top: 3pt;padding-left: 42pt;text-indent: 0pt;text-align: left;">                            Incorporated by Reference                            </p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s39" style="padding-top: 5pt;padding-left: 13pt;text-indent: 0pt;text-align: left;">Filed</p><table style="border-collapse:collapse;margin-left:28.824pt" cellspacing="0"><tr style="height:11pt"><td style="width:54pt"><p class="s44" style="padding-left: 2pt;text-indent: 0pt;line-height: 8pt;text-align: left;">         No.         </p></td><td style="width:151pt"><p class="s44" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">                          Description                          </p></td><td style="width:27pt"><p class="s44" style="padding-left: 2pt;padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: center;">Form</p></td><td style="width:56pt"><p class="s44" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">     File No.     </p></td><td style="width:38pt"><p class="s44" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;"> Exhibit </p></td><td style="width:94pt"><p class="s44" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">           Filing Date           </p></td><td style="width:39pt"><p class="s44" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Herewith</p></td></tr><tr style="height:84pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">2.1</p></td><td style="width:151pt"><p class="s43" style="padding-top: 2pt;padding-left: 3pt;text-indent: 0pt;line-height: 87%;text-align: left;">Agreement and Plan of Merger, dated as of November 10, 2014, by and among the Registrant, DRD Acquisition Corp., DoctorDirectory.com, Inc. and Clifford Donnelly, as the Interested Holders Representative.</p></td><td style="width:27pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: center;">8-K</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">001-36371</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">2.1</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">November 12, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:42pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">3.1</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 87%;text-align: left;">Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect.</p></td><td style="width:27pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;line-height: 11pt;text-align: center;">8-K</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">001-36371</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">3.1</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">April 7, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:32pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">3.2</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 87%;text-align: left;">Amended and Restated Bylaws of the Registrant, as currently in effect.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">3.4</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:22pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4.1</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 25pt;text-indent: 0pt;line-height: 87%;text-align: left;">Form of the Registrant Common Stock Certificate.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4.1</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:92pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4.2</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 6pt;text-indent: 0pt;line-height: 87%;text-align: left;">Sixth Amended and Restated Stockholder Rights Agreement, by and between the Registrant and the investors listed on Schedule A thereto,  key holders listed on Schedule B thereto and other holders listed on Schedule C  thereto,  dated as of November 10, 2010.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4.2</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:52pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4.3</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 87%;text-align: left;">Warrant to Purchase Shares of Series F Preferred Stock issued to Compass Horizon Funding Company LLC, dated</p><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 10pt;text-align: left;">October 8, 2009.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4.5</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:51pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4.4</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 87%;text-align: left;">Warrant to Purchase Common Stock issued to Mayo Foundation for Medical Education and Research, dated</p><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 9pt;text-align: left;">March 12, 2014.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">4.13</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><table style="border-collapse:collapse;margin-left:28.824pt" cellspacing="0"><tr style="height:11pt"><td style="width:54pt"><p class="s44" style="padding-left: 2pt;text-indent: 0pt;line-height: 8pt;text-align: left;">         No.         </p></td><td style="width:151pt"><p class="s44" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">                          Description                          </p></td><td style="width:27pt"><p class="s44" style="padding-left: 2pt;padding-right: 2pt;text-indent: 0pt;line-height: 8pt;text-align: center;">Form</p></td><td style="width:56pt"><p class="s44" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">     File No.     </p></td><td style="width:38pt"><p class="s44" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;"> Exhibit </p></td><td style="width:94pt"><p class="s44" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">           Filing Date           </p></td><td style="width:39pt"><p class="s44" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Herewith</p></td></tr><tr style="height:94pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">10.1</p></td><td style="width:151pt"><p class="s43" style="padding-top: 2pt;padding-left: 3pt;padding-right: 4pt;text-indent: 0pt;line-height: 87%;text-align: left;">Amended and Restated Credit Agreement, dated as of November 10, 2014, by and among the Registrant, Silicon Valley Bank, as Administrative Agent, certain of the Registrant’s wholly-owned subsidiaries and the other lenders party thereto.</p></td><td style="width:27pt"><p class="s43" style="padding-right: 2pt;text-indent: 0pt;text-align: center;">8-K</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">001-36371</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">10.1</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">November 12, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:32pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.2*</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 87%;text-align: left;">2003 Stock Option Plan, as amended, and related documents.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.1</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:32pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.2.1*</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 87%;text-align: left;">Amendment to 2003 Stock Option Plan, dated March 22, 2013.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.1.1</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:32pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.2.2*</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 87%;text-align: left;">Amendment to 2003 Stock Option Plan, dated March 12, 2014.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.1.2</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:22pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.3*</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 87%;text-align: left;">2014 Equity Incentive Plan and related documents.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.2</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:22pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.4*</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 87%;text-align: left;">Everyday Health, Inc. 2014 Employee Stock Purchase Plan.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.14</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:72pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.5</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 10pt;text-indent: 0pt;line-height: 87%;text-align: left;">Agreement of Lease between the Registrant and the Rector, Church-Wardens and Vestrymen of the Trinity Church in the City of New York, dated as of August 26, 2009.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.3</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:22pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.5.1</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 87%;text-align: left;">First Amendment to Lease, dated as of February 22, 2010.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.3.1</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:22pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.5.2</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 87%;text-align: left;">Second Amendment to Lease, dated as of May 1, 2010.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.3.2</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:22pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.5.3</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 87%;text-align: left;">Third Amendment to Lease, dated as of May 31, 2011.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.3.3</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:22pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.5.4</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 87%;text-align: left;">Fourth Amendment to Lease, dated as of April 1, 2012.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.3.4</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:42pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.6*</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 87%;text-align: left;">Form of Indemnification Agreement to be entered into with each director of the Registrant.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.4</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:42pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.7*</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 87%;text-align: left;">Employment Agreement between the Registrant and Benjamin Wolin, dated November 22, 2010.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.7</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:42pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.8*</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 87%;text-align: left;">Agreement between the Registrant and Michael Keriakos, dated December 19, 2013.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.8.1</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:42pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.9*</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 25pt;text-indent: 0pt;line-height: 87%;text-align: left;">Employment Agreement between the Registrant and Brian Cooper, dated November 22, 2010.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.9</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:32pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.10*</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 87%;text-align: left;">Offer Letter between the Registrant and Alan Shapiro, dated October 18, 2007.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.10</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:31pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.11*</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Offer Letter between the Registrant and Paul Slavin, dated August 17, 2011.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 2pt;padding-right: 8pt;text-indent: 0pt;line-height: 11pt;text-align: center;">S-1</p></td><td style="width:56pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.11</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:39pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr></table><table style="border-collapse:collapse;margin-left:28.824pt" cellspacing="0"><tr style="height:11pt"><td style="width:54pt"><p class="s44" style="padding-left: 2pt;text-indent: 0pt;line-height: 8pt;text-align: left;">         No.         </p></td><td style="width:151pt"><p class="s44" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">                          Description                          </p></td><td style="width:27pt"><p class="s44" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">Form</p></td><td style="width:56pt"><p class="s44" style="text-indent: 0pt;line-height: 8pt;text-align: center;">     File No.     </p></td><td style="width:38pt"><p class="s44" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;"> Exhibit </p></td><td style="width:94pt"><p class="s44" style="padding-left: 3pt;text-indent: 0pt;line-height: 8pt;text-align: left;">           Filing Date           </p></td><td style="width:40pt"><p class="s44" style="padding-left: 2pt;padding-right: 1pt;text-indent: 0pt;line-height: 8pt;text-align: center;">Herewith</p></td></tr><tr style="height:44pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;text-align: left;">10.11.1*</p></td><td style="width:151pt"><p class="s43" style="padding-top: 2pt;padding-left: 3pt;padding-right: 7pt;text-indent: 0pt;line-height: 87%;text-align: left;">Amendment to Offer Letter between the Registrant and Paul Slavin, dated February 25, 2013.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">S-1</p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;text-align: center;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">10.11.1</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;text-align: left;">February 24, 2014</p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:32pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.12*</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 87%;text-align: left;">Agreement with Myrtle Potter &amp; Company, LLC, dated</p><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 10pt;text-align: left;">May 1, 2011.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">S-1</p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: center;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.13</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:32pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.12.1*</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 87%;text-align: left;">Agreement with Myrtle Potter &amp; Company, LLC, dated September 10, 2012.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">S-1</p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: center;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.13.1</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:32pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.12.2*</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 87%;text-align: left;">Agreement with Myrtle Potter &amp; Company, LLC, dated September 14, 2012.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">S-1</p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: center;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.13.2</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:32pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.13</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 87%;text-align: left;">Loan and Security Agreement with Silicon Valley Bank, dated as of September 22, 2010.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">S-1</p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: center;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.5</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:42pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.13.1</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 10pt;text-indent: 0pt;line-height: 87%;text-align: left;">First Loan Modification Agreement with Silicon Valley Bank, dated as of April 27, 2011.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">S-1</p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: center;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.5.1</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:42pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.13.2</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 6pt;text-indent: 0pt;line-height: 87%;text-align: left;">Joinder Agreement with respect to Loan and Security Agreement with Silicon Valley Bank, dated as of July 8, 2011.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">S-1</p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: center;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.5.2</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:42pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.13.3</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 87%;text-align: left;">Second Loan Modification Agreement with Silicon Valley Bank, dated as of</p><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 10pt;text-align: left;">December 21, 2011.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">S-1</p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: center;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.5.3</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:42pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.13.4</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 87%;text-align: left;">Third Loan Modification Agreement with Silicon Valley Bank, dated as of August 10, 2012.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">S-1</p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: center;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.5.4</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:42pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.13.5</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 87%;text-align: left;">Fourth Loan Modification Agreement with Silicon Valley Bank, dated as of October 22, 2012.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">S-1</p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: center;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.5.5</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:42pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.13.6</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 87%;text-align: left;">Fifth Loan Modification Agreement with Silicon Valley Bank, dated as of</p><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 10pt;text-align: left;">September 23, 2013.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">S-1</p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: center;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.5.6</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:42pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.13.7</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 87%;text-align: left;">Sixth Loan Modification Agreement with Silicon Valley Bank, dated as of</p><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 10pt;text-align: left;">November 14, 2013.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">S-1</p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: center;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.5.7</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:52pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.14</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 9pt;text-indent: 0pt;line-height: 87%;text-align: left;">Subordinated Loan and Security Agreement with Silicon Valley Bank and Silver Lake Waterman Fund, L.P., dated as of October 22, 2012.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">S-1</p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: center;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.6</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:52pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.14.1</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 10pt;text-indent: 0pt;line-height: 87%;text-align: left;">First Loan Modification Agreement with Silicon Valley Bank and Silver  Lake Waterman Fund, L.P., dated as of November 14, 2013.</p></td><td style="width:27pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">S-1</p></td><td style="width:56pt"><p class="s43" style="text-indent: 0pt;line-height: 11pt;text-align: center;">333-194097</p></td><td style="width:38pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">10.6.1</p></td><td style="width:94pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">February 24, 2014</p></td><td style="width:40pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td></tr><tr style="height:12pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">21.1</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;text-indent: 0pt;line-height: 11pt;text-align: left;">List of Subsidiaries.</p></td><td style="width:27pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:56pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:38pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:94pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:40pt"><p class="s43" style="padding-left: 1pt;text-indent: 0pt;line-height: 11pt;text-align: center;">X</p></td></tr><tr style="height:31pt"><td style="width:54pt"><p class="s43" style="padding-left: 2pt;text-indent: 0pt;line-height: 11pt;text-align: left;">23.1</p></td><td style="width:151pt"><p class="s43" style="padding-left: 3pt;padding-right: 8pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Consent of Ernst &amp; Young LLP, independent registered public accounting firm.</p></td><td style="width:27pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:56pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:38pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:94pt"><p style="text-indent: 0pt;text-align: left;"><br/></p></td><td style="width:40pt"><p class="s43" style="padding-left: 1pt;text-indent: 0pt;line-height: 11pt;text-align: center;">X</p></td></tr></table><p class="s40" style="padding-left: 31pt;text-indent: 0pt;line-height: 8pt;text-align: left;">         No. Description<span class="s39"> </span>Form File No. Exhibit Filing Date           </p><ol id="l20"><ol id="l21"><li style="padding-top: 4pt;padding-left: 86pt;text-indent: -55pt;line-height: 87%;text-align: left;"><p style="display: inline;">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002.</p></li><li style="padding-top: 1pt;padding-left: 86pt;text-indent: -55pt;line-height: 87%;text-align: left;"><p style="display: inline;">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002.</p></li></ol></ol><ol id="l22"><ol id="l23"><li style="padding-top: 1pt;padding-left: 86pt;text-indent: -55pt;line-height: 87%;text-align: left;"><p style="display: inline;">+ Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</p></li><li style="padding-top: 1pt;padding-left: 86pt;text-indent: -55pt;line-height: 87%;text-align: left;"><p style="display: inline;">+ Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</p></li></ol></ol><p class="s40" style="padding-left: 18pt;text-indent: 0pt;line-height: 8pt;text-align: center;">Herewith</p><p style="padding-top: 3pt;text-indent: 0pt;text-align: center;">X</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 7pt;text-indent: 0pt;text-align: center;">X</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 7pt;text-indent: 0pt;text-align: center;">X</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;text-indent: 0pt;text-align: center;">X</p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">101.INS XBRL Instance Document. X</p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 11pt;text-align: left;">101.SCH XBRL Taxonomy Extension X</p><p style="padding-left: 86pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Schema.</p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 11pt;text-align: left;">101.CAL XBRL Taxonomy Extension X</p><p style="padding-left: 86pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Calculation Linkbase.</p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 11pt;text-align: left;">101.DEF XBRL Taxonomy Extension X</p><p style="padding-left: 86pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Definition Linkbase.</p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 11pt;text-align: left;">101.LAB XBRL Taxonomy Extension X</p><p style="padding-left: 86pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Label Linkbase.</p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 11pt;text-align: left;">101.PRE XBRL Taxonomy Extension X</p><p style="padding-left: 86pt;text-indent: 0pt;line-height: 11pt;text-align: left;">Presentation Linkbase.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="63" height="1" alt="image" src="NYSE_EVDY_2014/Image_116.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 32pt;text-indent: 0pt;text-align: left;">* Indicates a management contract or compensatory plan or arrangement.</p><p style="padding-top: 8pt;padding-left: 31pt;text-indent: 0pt;text-align: left;">+ These certifications are being furnished solely to accompany this quarterly report pursuant to 18</p><p style="padding-left: 42pt;text-indent: 0pt;text-align: left;">U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p><p style="padding-top: 2pt;padding-left: 223pt;text-indent: 0pt;text-align: left;">SIGNATURES</p><p style="padding-top: 4pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="padding-top: 6pt;padding-left: 258pt;text-indent: 0pt;text-align: left;">E<span class="s60">VERYDAY </span>H<span class="s60">EALTH</span>, I<span class="s60">NC</span>.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Date: March 5, 2015 By:<u> /S/ BENJAMIN WOLIN                        </u></p><p class="s39" style="padding-top: 5pt;text-indent: 0pt;text-align: right;">Benjamin Wolin</p><p class="s39" style="padding-left: 288pt;text-indent: 0pt;text-align: center;">Chief Executive Officer &amp;  Director</p><p class="s61" style="padding-left: 288pt;text-indent: 0pt;text-align: center;">(Principal  Executive Officer)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 31pt;text-indent: 0pt;text-align: left;">Date: March 5, 2015 By:<u> /S/ BRIAN COOPER                          </u></p><p class="s39" style="padding-top: 5pt;text-indent: 0pt;text-align: right;">Brian Cooper</p><p class="s39" style="padding-left: 288pt;text-indent: 0pt;text-align: center;">Executive Vice President &amp; Chief Financial Officer</p><p class="s61" style="padding-left: 288pt;text-indent: 0pt;text-align: center;">(Principal Financial and Accounting  Officer)</p><p style="padding-top: 4pt;padding-left: 31pt;text-indent: 19pt;text-align: left;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><p class="s39" style="padding-top: 2pt;padding-left: 84pt;text-indent: 0pt;text-align: left;">Signature Title Date</p><p class="s57" style="padding-left: 31pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="186" height="1" alt="image" src="NYSE_EVDY_2014/Image_117.png"/></span>	<span><img width="299" height="1" alt="image" src="NYSE_EVDY_2014/Image_118.png"/></span>	<span><img width="84" height="1" alt="image" src="NYSE_EVDY_2014/Image_119.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-bottom: 1pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">/<span class="s60">S</span>/  B<span class="s60">ENJAMIN </span>W<span class="s60">OLIN</span></p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="188" height="1" alt="image" src="NYSE_EVDY_2014/Image_120.png"/></span></p><p class="s39" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">(Benjamin Wolin)</p><p style="padding-top: 3pt;padding-left: 19pt;text-indent: -10pt;text-align: left;">Chief Executive Officer &amp; Director (Principal Executive Officer)</p><p style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">March 5, 2015</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-bottom: 2pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">/<span class="s60">S</span>/  B<span class="s60">RIAN </span>C<span class="s60">OOPER</span></p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="186" height="1" alt="image" src="NYSE_EVDY_2014/Image_121.png"/></span></p><p class="s39" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">(Brian Cooper)</p><p style="padding-top: 3pt;padding-left: 19pt;text-indent: -10pt;text-align: left;">Executive Vice President &amp; Chief Financial Officer (Principal Financial and Accounting Officer)</p><p style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">March 5, 2015</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-bottom: 2pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">/<span class="s60">S</span>/  D<span class="s60">OUGLAS </span>M<span class="s60">C</span>C<span class="s60">ORMICK</span></p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="188" height="1" alt="image" src="NYSE_EVDY_2014/Image_122.png"/></span></p><p class="s39" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">(Douglas McCormick)</p><p style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Director March 5, 2015</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-bottom: 2pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">/<span class="s60">S</span>/  D<span class="s60">ANA  </span>L. E<span class="s60">VAN</span></p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="188" height="1" alt="image" src="NYSE_EVDY_2014/Image_123.png"/></span></p><p class="s39" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">(Dana  L. Evan)</p><p style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Director March 5, 2015</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-bottom: 1pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">/<span class="s60">S</span>/  D<span class="s60">AVID </span>G<span class="s60">OLDEN</span></p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="188" height="1" alt="image" src="NYSE_EVDY_2014/Image_124.png"/></span></p><p class="s39" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">(David Golden)</p><p style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Director March 5, 2015</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-bottom: 2pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">/<span class="s60">S</span>/  H<span class="s60">ABIB </span>K<span class="s60">AIROUZ</span></p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="188" height="1" alt="image" src="NYSE_EVDY_2014/Image_125.png"/></span></p><p class="s39" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">(Habib Kairouz)</p><p style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Director March 5, 2015</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-bottom: 2pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">/<span class="s60">S</span>/  M<span class="s60">YRTLE </span>P<span class="s60">OTTER</span></p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="188" height="1" alt="image" src="NYSE_EVDY_2014/Image_126.png"/></span></p><p class="s39" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">(Myrtle Potter)</p><p style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Director March 5, 2015</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-bottom: 2pt;padding-left: 32pt;text-indent: 0pt;text-align: center;">/<span class="s60">S</span>/  S<span class="s60">HARON </span>W<span class="s60">IENBAR</span></p><p style="padding-left: 31pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="188" height="1" alt="image" src="NYSE_EVDY_2014/Image_127.png"/></span></p><p class="s39" style="padding-left: 32pt;text-indent: 0pt;text-align: center;">(Sharon Wienbar)</p><p style="padding-top: 3pt;padding-left: 9pt;text-indent: 0pt;text-align: left;">Director March 5, 2015</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 143pt;text-indent: 0pt;text-align: left;">[THIS PAGE INTENTIONALLY LEFT BLANK]</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 143pt;text-indent: 0pt;text-align: left;">[THIS PAGE INTENTIONALLY LEFT BLANK]</p><p style="padding-left: 246pt;text-indent: 0pt;text-align: left;"><span><img width="31" height="30" alt="image" src="NYSE_EVDY_2014/Image_128.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s62" style="padding-top: 3pt;padding-left: 76pt;text-indent: 0pt;text-align: left;">everyday  health,  inc.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="1" height="721" alt="image" src="NYSE_EVDY_2014/Image_129.png"/></span></p><p class="s63" style="padding-top: 10pt;padding-left: 49pt;text-indent: 0pt;text-align: left;">directors</p><p class="s64" style="padding-top: 8pt;padding-left: 49pt;text-indent: 0pt;text-align: left;">doug Mccormick, chairman</p><p class="s64" style="padding-left: 49pt;text-indent: 0pt;text-align: left;">Venture Partner</p><p class="s64" style="padding-left: 49pt;text-indent: 0pt;text-align: left;">Rho Capital Partners</p><p class="s64" style="padding-top: 9pt;padding-left: 49pt;text-indent: 0pt;text-align: left;">Ben Wolin</p><p class="s64" style="padding-left: 49pt;text-indent: 0pt;text-align: left;">Chief Executive Officer &amp; Co-Founder</p><p class="s64" style="padding-top: 9pt;padding-left: 49pt;text-indent: 0pt;text-align: left;">dana evan Venture Partner Icon Ventures</p><p class="s64" style="padding-top: 9pt;padding-left: 49pt;text-indent: 0pt;text-align: left;">david Golden Managing Partner Revolution Ventures</p><p class="s64" style="padding-top: 9pt;padding-left: 49pt;text-indent: 0pt;text-align: left;">Habib Kairouz Managing Partner Rho Capital Partners</p><p class="s64" style="padding-top: 9pt;padding-left: 49pt;text-indent: 0pt;text-align: left;">Myrtle Potter</p><p class="s64" style="padding-left: 49pt;text-indent: 0pt;text-align: left;">Chief Executive Officer</p><p class="s64" style="padding-left: 49pt;text-indent: 0pt;text-align: left;">Myrtle Potter &amp; Company, LLC</p><p class="s64" style="padding-top: 9pt;padding-left: 49pt;text-indent: 0pt;text-align: left;">sharon Wienbar</p><p class="s64" style="padding-left: 49pt;text-indent: 0pt;text-align: left;">Partner</p><p class="s64" style="padding-left: 49pt;text-indent: 0pt;text-align: left;">Scale Venture Partners</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s63" style="padding-left: 49pt;text-indent: 0pt;text-align: left;">reGistrar and</p><p class="s63" style="padding-top: 2pt;padding-left: 49pt;text-indent: 0pt;text-align: left;">transfer aGent</p><p class="s64" style="padding-top: 8pt;padding-left: 49pt;text-indent: 0pt;text-align: left;">american stock transfer &amp; trust company, LLc</p><p class="s64" style="padding-left: 49pt;text-indent: 0pt;text-align: left;">6201 15<span class="s65">th </span>Avenue</p><p class="s64" style="padding-left: 49pt;text-indent: 0pt;text-align: left;">Brooklyn, NY 11219</p><p class="s64" style="padding-left: 49pt;text-indent: 0pt;text-align: left;">800.937.5449</p><p style="padding-left: 49pt;text-indent: 0pt;text-align: left;"><a href="http://www.amstock.com/" class="s66">www.amstock.com</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s63" style="padding-left: 49pt;text-indent: 0pt;text-align: left;">auditors</p><p class="s64" style="padding-top: 8pt;padding-left: 49pt;text-indent: 0pt;text-align: left;">ernst &amp; Young LLP</p><p class="s64" style="padding-left: 49pt;text-indent: 0pt;text-align: left;">5 Times Square</p><p class="s64" style="padding-left: 49pt;text-indent: 0pt;text-align: left;">New York, NY 10036</p><p class="s67" style="padding-top: 10pt;padding-left: 47pt;text-indent: 0pt;text-align: left;">corPorate officers</p><p style="text-indent: 0pt;text-align: left;"><span><img width="1" height="721" alt="image" src="NYSE_EVDY_2014/Image_130.png"/></span></p><p class="s64" style="padding-top: 8pt;padding-left: 47pt;text-indent: 0pt;text-align: left;">Ben Wolin</p><p class="s64" style="padding-left: 47pt;text-indent: 0pt;text-align: left;">Chief Executive Officer &amp; Co-Founder</p><p class="s64" style="padding-top: 9pt;padding-left: 47pt;text-indent: 0pt;text-align: left;">Brian cooper</p><p class="s64" style="padding-left: 47pt;text-indent: 0pt;text-align: left;">Executive Vice President &amp; Chief Financial Officer</p><p class="s64" style="padding-top: 9pt;padding-left: 47pt;text-indent: 0pt;text-align: left;">Michael du toit</p><p class="s64" style="padding-left: 47pt;text-indent: 0pt;text-align: left;">President</p><p class="s64" style="padding-top: 9pt;padding-left: 47pt;text-indent: 0pt;text-align: left;">alan shapiro</p><p class="s64" style="padding-left: 47pt;text-indent: 0pt;text-align: left;">Executive Vice President, General Counsel &amp; Chief Privacy Officer</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s67" style="padding-top: 7pt;padding-left: 47pt;text-indent: 0pt;text-align: left;">stocK ListinG</p><p class="s64" style="padding-top: 8pt;padding-left: 47pt;text-indent: 0pt;text-align: left;">Our common stock is traded on the New York Stock Exchange. Our ticker symbol is eVdY.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s67" style="padding-top: 6pt;padding-left: 47pt;text-indent: 0pt;line-height: 113%;text-align: left;">annuaL MeetinG of stocKHoLders</p><p class="s64" style="padding-top: 8pt;padding-left: 47pt;text-indent: 0pt;line-height: 117%;text-align: left;">The annual meeting of stockholders will be held on Tuesday, June 2, 2015 at 10:00 A.M. EDT at the offices of Cooley LLP, 1114 Avenue of the Americas, 46<span class="s65">th </span>Floor, New York, NY 10036</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s67" style="padding-left: 47pt;text-indent: 0pt;text-align: left;">corPorate WeBsite</p><p class="s64" style="padding-top: 8pt;padding-left: 47pt;text-indent: 0pt;text-align: left;">corporate.everydayhealth.com</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s67" style="padding-top: 7pt;padding-left: 47pt;text-indent: 0pt;text-align: left;">inVestor reLations</p><p style="padding-top: 10pt;padding-left: 47pt;text-indent: 0pt;line-height: 117%;text-align: left;"><a href="mailto:ir@everydayhealthinc.com" class="s66" target="_blank">Additional investor information may be obtained by contacting Melanie Goldey, Senior Vice President, Strategic Planning &amp; Investor Relations at ir@everydayhealthinc.com</a></p><p style="text-indent: 0pt;text-align: left;"><span><img width="804" height="1044" alt="image" src="NYSE_EVDY_2014/Image_131.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s68" style="padding-left: 32pt;text-indent: 0pt;line-height: 108%;text-align: left;">We empower and inspire people to live their healthiest lives every day.</p><p style="padding-left: 156pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s69" style="padding-top: 4pt;padding-left: 109pt;text-indent: 0pt;text-align: left;">Everyday Health, Inc. <span class="s70">345 Hudson Street, New York, NY 10014</span></p></body></html>
